{"PMC7441789": [["IntroductionCoronaviruses are positive-sense RNA viruses with non-segmented genomes and overlapping Open reading frame (ORF 1a and 1b) with a size genome structures ranging from 28 to 32 KB.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["KB", "CANCER", 187, 189], ["Coronaviruses", "PROTEIN", 12, 25], ["non-segmented genomes", "DNA", 62, 83], ["Open reading frame", "DNA", 100, 118], ["ORF 1a", "DNA", 120, 126], ["1b", "DNA", 131, 133], ["sense RNA viruses", "PROBLEM", 39, 56], ["non-segmented genomes", "PROBLEM", 62, 83], ["Open reading frame", "TEST", 100, 118], ["ORF 1a", "TEST", 120, 126], ["a size genome structures", "TEST", 140, 164], ["RNA viruses", "OBSERVATION", 45, 56], ["size", "OBSERVATION_MODIFIER", 142, 146], ["genome", "OBSERVATION_MODIFIER", 147, 153], ["structures", "OBSERVATION_MODIFIER", 154, 164], ["ranging", "OBSERVATION_MODIFIER", 165, 172]]], ["The polyproteins are processed into non-structural proteins (NSP) and structural proteins.", [["NSP", "GENE_OR_GENE_PRODUCT", 61, 64], ["polyproteins", "PROTEIN", 4, 16], ["non-structural proteins", "PROTEIN", 36, 59], ["NSP", "PROTEIN", 61, 64], ["structural proteins", "PROTEIN", 70, 89], ["The polyproteins", "PROBLEM", 0, 16], ["polyproteins", "OBSERVATION", 4, 16], ["non-structural proteins", "OBSERVATION", 36, 59]]], ["Coronaviruses regularly undergo recombination after infecting host cells (Lauber et al., 2013).", [["cells", "ANATOMY", 67, 72], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["host cells", "CELL", 62, 72], ["host cells", "CELL_TYPE", 62, 72], ["Coronaviruses", "PROBLEM", 0, 13], ["host cells", "OBSERVATION", 62, 72]]], ["The proteases of novel coronavirus share high percentage of sequence and structure similarity with SARS coronavirus which has the main role in the processing of viral polyprotein.", [["SARS coronavirus", "DISEASE", 99, 115], ["coronavirus", "ORGANISM", 23, 34], ["SARS coronavirus", "ORGANISM", 99, 115], ["proteases", "PROTEIN", 4, 13], ["viral polyprotein", "PROTEIN", 161, 178], ["SARS coronavirus", "SPECIES", 99, 115], ["novel coronavirus", "PROBLEM", 17, 34], ["SARS coronavirus", "PROBLEM", 99, 115], ["viral polyprotein", "PROBLEM", 161, 178], ["SARS coronavirus", "OBSERVATION", 99, 115], ["main", "OBSERVATION_MODIFIER", 130, 134], ["viral polyprotein", "OBSERVATION", 161, 178]]], ["These proteins perform stripping ubiquitin to help in evading immune response of the host (Shanker et al., 2020).", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 33, 42], ["ubiquitin", "PROTEIN", 33, 42], ["stripping ubiquitin", "TREATMENT", 23, 42]]], ["Small molecules and drug inhibitors can be designed to block the cascade signaling pathways to protect the host system.", [["Small molecules", "PROBLEM", 0, 15], ["drug inhibitors", "TREATMENT", 20, 35], ["the cascade signaling pathways", "TREATMENT", 61, 91], ["molecules", "OBSERVATION", 6, 15]]], ["Viral proteins have multiple functional domains such as a largest NSP-3 protein and proteases like protease and papain-like protease (3CLpro and PLpro) are involved in polyprotein processing (B\u00e1ez-Santos et al., 2015).", [["NSP-3", "GENE_OR_GENE_PRODUCT", 66, 71], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 112, 132], ["3CLpro", "GENE_OR_GENE_PRODUCT", 134, 140], ["PLpro", "GENE_OR_GENE_PRODUCT", 145, 150], ["Viral proteins", "PROTEIN", 0, 14], ["NSP-3 protein", "PROTEIN", 66, 79], ["proteases", "PROTEIN", 84, 93], ["protease", "PROTEIN", 99, 107], ["papain-like protease", "PROTEIN", 112, 132], ["3CLpro", "PROTEIN", 134, 140], ["PLpro", "PROTEIN", 145, 150], ["Viral proteins", "PROBLEM", 0, 14], ["multiple functional domains", "PROBLEM", 20, 47], ["a largest NSP", "TEST", 56, 69], ["proteases", "TREATMENT", 84, 93], ["protease", "TREATMENT", 99, 107], ["papain", "TREATMENT", 112, 118], ["protease (3CLpro and PLpro)", "TREATMENT", 124, 151], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["functional domains", "OBSERVATION", 29, 47], ["largest", "OBSERVATION_MODIFIER", 58, 65]]], ["Novel coronavirus infection leads to over activation of CD4 effector T-cells resulting in excessive production of inflammatory cytokines termed as cytokine storm that recruits excess immune cells at the site of infection and reduces tissue capacity which leads to organ failure (Felsenstein et al., 2020).", [["CD4 effector T-cells", "ANATOMY", 56, 76], ["immune cells", "ANATOMY", 183, 195], ["tissue", "ANATOMY", 233, 239], ["organ", "ANATOMY", 264, 269], ["coronavirus infection", "DISEASE", 6, 27], ["infection", "DISEASE", 211, 220], ["organ failure", "DISEASE", 264, 277], ["coronavirus", "ORGANISM", 6, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["immune cells", "CELL", 183, 195], ["tissue", "TISSUE", 233, 239], ["organ", "ORGAN", 264, 269], ["CD4 effector T-cells", "CELL_TYPE", 56, 76], ["inflammatory cytokines", "PROTEIN", 114, 136], ["cytokine", "PROTEIN", 147, 155], ["immune cells", "CELL_TYPE", 183, 195], ["Novel coronavirus infection", "PROBLEM", 0, 27], ["inflammatory cytokines", "PROBLEM", 114, 136], ["cytokine storm", "PROBLEM", 147, 161], ["excess immune cells", "PROBLEM", 176, 195], ["infection", "PROBLEM", 211, 220], ["reduces tissue capacity", "PROBLEM", 225, 248], ["organ failure", "PROBLEM", 264, 277], ["coronavirus", "OBSERVATION_MODIFIER", 6, 17], ["infection", "OBSERVATION", 18, 27], ["excessive", "OBSERVATION_MODIFIER", 90, 99], ["production", "OBSERVATION_MODIFIER", 100, 110], ["inflammatory", "OBSERVATION_MODIFIER", 114, 126], ["excess immune cells", "OBSERVATION", 176, 195], ["infection", "OBSERVATION", 211, 220], ["organ", "ANATOMY", 264, 269], ["failure", "OBSERVATION", 270, 277]]], ["Plant-based immuno-modulatory agents would reduce the severity of hyperactivation of inflammatory response and reduce cytokine storm.", [["cytokine", "PROTEIN", 118, 126], ["Plant-based immuno-modulatory agents", "TREATMENT", 0, 36], ["hyperactivation of inflammatory response", "PROBLEM", 66, 106], ["cytokine storm", "PROBLEM", 118, 132], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97], ["cytokine storm", "OBSERVATION", 118, 132]]], ["Several medicinal plant extracts and their constituents with immuno-modulatory activities proved their ability to reduce the over inflammatory response of cytokines (Liu et al., 2016).", [["extracts", "ANATOMY", 24, 32], ["extracts", "ORGANISM_SUBSTANCE", 24, 32], ["cytokines", "PROTEIN", 155, 164], ["Several medicinal plant extracts", "TREATMENT", 0, 32], ["immuno-modulatory activities", "PROBLEM", 61, 89]]], ["Tinospora cordifolia which is a medicinal plant native to India commonly called as Guduchi, heart-leaved moonseed and used in Ayurvedic formulations as a medicine to treat several diseases.", [["heart", "ANATOMY", 92, 97], ["Tinospora cordifolia", "CHEMICAL", 0, 20], ["Tinospora cordifolia", "ORGANISM", 0, 20], ["heart", "ORGAN", 92, 97], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "PROBLEM", 0, 20], ["Ayurvedic formulations", "TREATMENT", 126, 148], ["a medicine", "TREATMENT", 152, 162], ["several diseases", "PROBLEM", 172, 188], ["heart", "ANATOMY", 92, 97], ["diseases", "OBSERVATION", 180, 188]]], ["Tinospora cordifolia is found to have antineoplastic, antidiabetic, hypolipidemic, antioxidant and anti-inflammatory effects.", [["Tinospora cordifolia", "CHEMICAL", 0, 20], ["Tinospora cordifolia", "ORGANISM", 0, 20], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "PROBLEM", 0, 20], ["antineoplastic", "TREATMENT", 38, 52], ["antidiabetic", "TREATMENT", 54, 66], ["hypolipidemic", "TREATMENT", 68, 81], ["antioxidant", "TREATMENT", 83, 94], ["anti-inflammatory effects", "TREATMENT", 99, 124], ["anti-inflammatory effects", "OBSERVATION", 99, 124]]], ["Phytochemical studies of T. cordifolia showed the presence of numerous components such as tinosponone, tinosporin, berberine, palmitine, choline, tembetarine, isocolumbin and tetrahydropalmatine and other alkaloids, steroids, lactones, glycosides and sesquiterpenoids.", [["tinosponone", "CHEMICAL", 90, 101], ["tinosporin", "CHEMICAL", 103, 113], ["berberine", "CHEMICAL", 115, 124], ["palmitine", "CHEMICAL", 126, 135], ["choline", "CHEMICAL", 137, 144], ["tembetarine", "CHEMICAL", 146, 157], ["isocolumbin", "CHEMICAL", 159, 170], ["tetrahydropalmatine", "CHEMICAL", 175, 194], ["steroids, lactones, glycosides", "CHEMICAL", 216, 246], ["sesquiterpenoids", "CHEMICAL", 251, 267], ["tinosponone", "CHEMICAL", 90, 101], ["tinosporin", "CHEMICAL", 103, 113], ["berberine", "CHEMICAL", 115, 124], ["palmitine", "CHEMICAL", 126, 135], ["choline", "CHEMICAL", 137, 144], ["tembetarine", "CHEMICAL", 146, 157], ["isocolumbin", "CHEMICAL", 159, 170], ["tetrahydropalmatine", "CHEMICAL", 175, 194], ["steroids", "CHEMICAL", 216, 224], ["lactones", "CHEMICAL", 226, 234], ["glycosides", "CHEMICAL", 236, 246], ["sesquiterpenoids", "CHEMICAL", 251, 267], ["T. cordifolia", "ORGANISM", 25, 38], ["tinosponone", "SIMPLE_CHEMICAL", 90, 101], ["tinosporin", "SIMPLE_CHEMICAL", 103, 113], ["berberine", "SIMPLE_CHEMICAL", 115, 124], ["palmitine", "SIMPLE_CHEMICAL", 126, 135], ["choline", "SIMPLE_CHEMICAL", 137, 144], ["tembetarine", "SIMPLE_CHEMICAL", 146, 157], ["isocolumbin", "SIMPLE_CHEMICAL", 159, 170], ["tetrahydropalmatine", "SIMPLE_CHEMICAL", 175, 194], ["alkaloids", "SIMPLE_CHEMICAL", 205, 214], ["steroids", "SIMPLE_CHEMICAL", 216, 224], ["lactones", "SIMPLE_CHEMICAL", 226, 234], ["glycosides", "SIMPLE_CHEMICAL", 236, 246], ["sesquiterpenoids", "SIMPLE_CHEMICAL", 251, 267], ["T. cordifolia", "SPECIES", 25, 38], ["T. cordifolia", "SPECIES", 25, 38], ["Phytochemical studies", "TEST", 0, 21], ["T. cordifolia", "TEST", 25, 38], ["numerous components", "PROBLEM", 62, 81], ["tinosponone", "TREATMENT", 90, 101], ["tinosporin", "TREATMENT", 103, 113], ["berberine", "TREATMENT", 115, 124], ["palmitine", "TREATMENT", 126, 135], ["choline", "TREATMENT", 137, 144], ["tembetarine", "TREATMENT", 146, 157], ["isocolumbin", "TREATMENT", 159, 170], ["tetrahydropalmatine", "TREATMENT", 175, 194], ["other alkaloids", "TREATMENT", 199, 214], ["steroids", "TREATMENT", 216, 224], ["lactones", "TREATMENT", 226, 234], ["glycosides", "TREATMENT", 236, 246], ["sesquiterpenoids", "TREATMENT", 251, 267], ["numerous", "OBSERVATION_MODIFIER", 62, 70], ["components", "OBSERVATION", 71, 81]]], ["Tinospora cordifolia has an effect on the expression of cyclooxygenase-1, tumor necrosis factor-\u03b1, iNOS genes, cytokines (IL-6, IL-1b and PGE2) and NF-kB activation and has the potential to reduce the expression of the COX-2 enzyme and thereby reducing the expression of TNF-\u03b1, synthesis of IL-1B and IL-6 and other pro-inflammatory interleukins (Tiwari et al., 2018).", [["Tinospora cordifolia", "CHEMICAL", 0, 20], ["necrosis", "DISEASE", 80, 88], ["PGE2", "CHEMICAL", 138, 142], ["Tinospora cordifolia", "ORGANISM", 0, 20], ["cyclooxygenase-1", "GENE_OR_GENE_PRODUCT", 56, 72], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 97], ["iNOS", "GENE_OR_GENE_PRODUCT", 99, 103], ["IL-6", "GENE_OR_GENE_PRODUCT", 122, 126], ["IL-1b", "GENE_OR_GENE_PRODUCT", 128, 133], ["PGE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["NF-kB", "GENE_OR_GENE_PRODUCT", 148, 153], ["COX-2", "GENE_OR_GENE_PRODUCT", 219, 224], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 271, 276], ["IL-1B", "GENE_OR_GENE_PRODUCT", 291, 296], ["IL-6", "GENE_OR_GENE_PRODUCT", 301, 305], ["interleukins", "GENE_OR_GENE_PRODUCT", 333, 345], ["cyclooxygenase-1", "PROTEIN", 56, 72], ["iNOS genes", "DNA", 99, 109], ["cytokines", "PROTEIN", 111, 120], ["PGE2", "PROTEIN", 138, 142], ["COX-2 enzyme", "PROTEIN", 219, 231], ["TNF", "PROTEIN", 271, 274], ["IL-1B", "PROTEIN", 291, 296], ["IL-6", "PROTEIN", 301, 305], ["pro-inflammatory interleukins", "PROTEIN", 316, 345], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "SPECIES", 0, 20], ["Tinospora cordifolia", "PROBLEM", 0, 20], ["cyclooxygenase", "TEST", 56, 70], ["tumor necrosis factor", "PROBLEM", 74, 95], ["iNOS genes", "PROBLEM", 99, 109], ["cytokines", "TEST", 111, 120], ["IL", "TEST", 122, 124], ["IL", "TEST", 128, 130], ["PGE2", "TREATMENT", 138, 142], ["NF", "PROBLEM", 148, 150], ["the COX", "TEST", 215, 222], ["TNF", "TEST", 271, 274], ["synthesis", "TEST", 278, 287], ["IL", "TEST", 291, 293], ["IL", "TEST", 301, 303], ["effect", "OBSERVATION_MODIFIER", 28, 34], ["cyclooxygenase", "OBSERVATION_MODIFIER", 56, 70], ["tumor", "OBSERVATION_MODIFIER", 74, 79], ["necrosis", "OBSERVATION", 80, 88]]], ["The phytosterols such as stigmasterol and \u03b2-sitosterol found in T. cordifolia are found to be responsible for the inhibition of cyclooxygenase-2 synthesis and adhesion molecules in TNF-\u03b1 stimulated by cells (Philip et al., 2018).", [["cells", "ANATOMY", 201, 206], ["phytosterols", "CHEMICAL", 4, 16], ["stigmasterol", "CHEMICAL", 25, 37], ["\u03b2-sitosterol", "CHEMICAL", 42, 54], ["phytosterols", "CHEMICAL", 4, 16], ["stigmasterol", "CHEMICAL", 25, 37], ["\u03b2-sitosterol", "CHEMICAL", 42, 54], ["phytosterols", "SIMPLE_CHEMICAL", 4, 16], ["stigmasterol", "SIMPLE_CHEMICAL", 25, 37], ["\u03b2-sitosterol", "SIMPLE_CHEMICAL", 42, 54], ["T. cordifolia", "ORGANISM", 64, 77], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 128, 144], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 181, 186], ["cells", "CELL", 201, 206], ["cyclooxygenase-2", "PROTEIN", 128, 144], ["adhesion molecules", "PROTEIN", 159, 177], ["TNF", "PROTEIN", 181, 184], ["\u03b1", "PROTEIN", 185, 186], ["T. cordifolia", "SPECIES", 64, 77], ["T. cordifolia", "SPECIES", 64, 77], ["The phytosterols", "TREATMENT", 0, 16], ["stigmasterol", "TREATMENT", 25, 37], ["\u03b2-sitosterol", "TREATMENT", 42, 54], ["T. cordifolia", "PROBLEM", 64, 77], ["cyclooxygenase-2 synthesis", "TREATMENT", 128, 154], ["adhesion molecules", "PROBLEM", 159, 177], ["TNF", "TEST", 181, 184]]], ["Stigmasterol inhibits prostaglandin E2 and other matrix degradation mediators (Joshi & Kaur, 2016; Sharma et al., 2019; Singh & Chaudhuri, 2017; Tiwari et al., 2018; Upadhyay et al., 2010; Yanez et al., 2017).", [["matrix", "ANATOMY", 49, 55], ["Stigmasterol", "CHEMICAL", 0, 12], ["prostaglandin E2", "CHEMICAL", 22, 38], ["Stigmasterol", "CHEMICAL", 0, 12], ["prostaglandin E2", "CHEMICAL", 22, 38], ["Stigmasterol", "SIMPLE_CHEMICAL", 0, 12], ["prostaglandin E2", "SIMPLE_CHEMICAL", 22, 38], ["Stigmasterol", "TREATMENT", 0, 12], ["prostaglandin E2", "TREATMENT", 22, 38]]], ["The phytochemicals of medicinal plants have anti-viral properties and hence, in the present study, we explored the inhibitory effect of phytochemicals of T. cordifolia against the SARS-CoV-2 by computational analysis.Protein preparation for docking ::: MethodologyThe main protease (3CLpro) in complex with an inhibitor N3 was selected from PDB for the present study.", [["T. cordifolia", "ORGANISM", 154, 167], ["3CLpro", "SIMPLE_CHEMICAL", 283, 289], ["protease", "PROTEIN", 273, 281], ["3CLpro", "PROTEIN", 283, 289], ["T. cordifolia", "SPECIES", 154, 167], ["T. cordifolia", "SPECIES", 154, 167], ["SARS-CoV", "SPECIES", 180, 188], ["medicinal plants", "TREATMENT", 22, 38], ["anti-viral properties", "TREATMENT", 44, 65], ["T. cordifolia", "PROBLEM", 154, 167], ["the SARS", "TEST", 176, 184], ["CoV", "TEST", 185, 188], ["computational analysis", "TEST", 194, 216], ["The main protease (3CLpro)", "TREATMENT", 264, 290], ["an inhibitor N3", "TREATMENT", 307, 322], ["the present study", "TEST", 349, 366], ["main", "OBSERVATION_MODIFIER", 268, 272]]], ["The ligands bound to the protein were removed using Chimera.", [["Chimera", "PROTEIN", 52, 59]]], ["Structure-based virtual screening was performed using PyRx, Main protease (Mpro, aka 3CLpro, 3-chymotrypsin-like protease, (PDB ID: 6lu7) was used as the macromolecule (receptor).", [["PyRx", "SIMPLE_CHEMICAL", 54, 58], ["Main protease", "GENE_OR_GENE_PRODUCT", 60, 73], ["Mpro", "GENE_OR_GENE_PRODUCT", 75, 79], ["aka 3CLpro", "GENE_OR_GENE_PRODUCT", 81, 91], ["3-chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 93, 121], ["PyRx", "PROTEIN", 54, 58], ["Main protease", "PROTEIN", 60, 73], ["Mpro", "PROTEIN", 75, 79], ["aka 3CLpro, 3-chymotrypsin-like protease", "PROTEIN", 81, 121], ["PDB ID", "PROTEIN", 124, 130], ["6lu7", "PROTEIN", 132, 136], ["based virtual screening", "TEST", 10, 33], ["PyRx", "TREATMENT", 54, 58], ["Main protease", "TREATMENT", 60, 73], ["Mpro", "TEST", 75, 79], ["aka 3CLpro", "TREATMENT", 81, 91], ["chymotrypsin-like protease", "TREATMENT", 95, 121]]], ["The amino acids interacting with the old ligand were considered as the active site in the generated protein and receptor grid (Peele et al., 2020).Ligand preparation and virtual screening ::: MethodologyThe phytochemicals, namely phytosterols, berberine, cardiofolioside B, chasmanthin, columbin, cordifolide A, palmarin, tembetarine, tinosponone, tinosporinone, xanosporic acid of T. cordifolia was downloaded from Indian Medicinal Plants, Phytochemistry and Therapeutics (IMPPAT) database (https://cb.imsc.res.in/imppat/home) in 3D-SDF format.", [["amino acids", "CHEMICAL", 4, 15], ["phytosterols", "CHEMICAL", 230, 242], ["berberine", "CHEMICAL", 244, 253], ["cardiofolioside B", "CHEMICAL", 255, 272], ["chasmanthin", "CHEMICAL", 274, 285], ["columbin", "CHEMICAL", 287, 295], ["cordifolide A", "CHEMICAL", 297, 310], ["palmarin", "CHEMICAL", 312, 320], ["tembetarine", "CHEMICAL", 322, 333], ["tinosponone", "CHEMICAL", 335, 346], ["tinosporinone", "CHEMICAL", 348, 361], ["xanosporic acid of T. cordifolia", "CHEMICAL", 363, 395], ["amino acids", "CHEMICAL", 4, 15], ["phytosterols", "CHEMICAL", 230, 242], ["berberine", "CHEMICAL", 244, 253], ["cardiofolioside B", "CHEMICAL", 255, 272], ["chasmanthin", "CHEMICAL", 274, 285], ["columbin", "CHEMICAL", 287, 295], ["cordifolide A", "CHEMICAL", 297, 310], ["palmarin", "CHEMICAL", 312, 320], ["tembetarine", "CHEMICAL", 322, 333], ["tinosponone", "CHEMICAL", 335, 346], ["tinosporinone", "CHEMICAL", 348, 361], ["xanosporic acid", "CHEMICAL", 363, 378], ["amino acids", "AMINO_ACID", 4, 15], ["phytosterols", "SIMPLE_CHEMICAL", 230, 242], ["berberine", "SIMPLE_CHEMICAL", 244, 253], ["cardiofolioside B", "SIMPLE_CHEMICAL", 255, 272], ["chasmanthin", "SIMPLE_CHEMICAL", 274, 285], ["columbin", "SIMPLE_CHEMICAL", 287, 295], ["cordifolide A", "SIMPLE_CHEMICAL", 297, 310], ["palmarin", "SIMPLE_CHEMICAL", 312, 320], ["tembetarine", "SIMPLE_CHEMICAL", 322, 333], ["tinosponone", "SIMPLE_CHEMICAL", 335, 346], ["tinosporinone", "SIMPLE_CHEMICAL", 348, 361], ["xanosporic acid", "SIMPLE_CHEMICAL", 363, 378], ["T. cordifolia", "ORGANISM", 382, 395], ["T. cordifolia", "SPECIES", 382, 395], ["T. cordifolia", "SPECIES", 382, 395], ["The amino acids", "TREATMENT", 0, 15], ["the old ligand", "TREATMENT", 33, 47], ["virtual screening", "TEST", 170, 187], ["phytosterols", "TREATMENT", 230, 242], ["berberine", "TREATMENT", 244, 253], ["cardiofolioside B", "TREATMENT", 255, 272], ["chasmanthin", "TREATMENT", 274, 285], ["columbin", "TREATMENT", 287, 295], ["cordifolide A", "TREATMENT", 297, 310], ["palmarin", "TREATMENT", 312, 320], ["tembetarine", "TREATMENT", 322, 333], ["tinosponone", "TREATMENT", 335, 346], ["tinosporinone", "TREATMENT", 348, 361], ["T. cordifolia", "PROBLEM", 382, 395], ["amino acids", "OBSERVATION", 4, 15], ["active", "OBSERVATION", 71, 77]]], ["Hydrogen atoms were added before docking and the top-ranked two ligand poses of T. cordifolia phytochemical compounds bound to the active site pocket of main protease were used for further analysis.", [["Hydrogen atoms", "CHEMICAL", 0, 14], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["T. cordifolia", "ORGANISM", 80, 93], ["protease", "PROTEIN", 158, 166], ["T. cordifolia", "SPECIES", 80, 93], ["T. cordifolia", "SPECIES", 80, 93], ["Hydrogen atoms", "TREATMENT", 0, 14], ["docking", "TREATMENT", 33, 40], ["T. cordifolia phytochemical compounds", "TREATMENT", 80, 117], ["main protease", "TREATMENT", 153, 166], ["further analysis", "TEST", 181, 197], ["cordifolia", "OBSERVATION", 83, 93], ["phytochemical compounds", "OBSERVATION", 94, 117], ["active", "OBSERVATION_MODIFIER", 131, 137], ["site", "OBSERVATION_MODIFIER", 138, 142], ["pocket", "OBSERVATION_MODIFIER", 143, 149], ["main protease", "OBSERVATION", 153, 166]]], ["The top hits were analyzed for finding ADME properties using the pkCSM online server (http://biosig.unimelb.edu.au/pkcsm/prediction).Molecular dynamics simulations ::: MethodologyThe complex of main protease and the top-ranking phytochemical drug candidate with best docking score was prepared for MD simulations and run for 10 ns using GROMACS 2020.2 using CHARMM 36 force field.", [["protease", "PROTEIN", 199, 207], ["main protease", "TREATMENT", 194, 207], ["complex", "OBSERVATION_MODIFIER", 183, 190], ["main", "OBSERVATION_MODIFIER", 194, 198], ["protease", "OBSERVATION", 199, 207]]], ["Topology generation and energy minimization of ligand were performed using the CGenFF server.", [["energy minimization of ligand", "TREATMENT", 24, 53]]], ["The random mean square deviation (RMSD) of the complex with respect to time frame was plotted in the graph (Abraham Peele et al., 2020).Molecular docking for phytochemicals of T. cordifolia ::: Results and discussionThe 3CL main protease is essential for SARS-CoV-2 replication and considered as crucial target for developing the drug (Peele et al., 2020; Wu et al., 2020; Zhang et al., 2020).", [["T. cordifolia", "ORGANISM", 176, 189], ["3CL main protease", "PROTEIN", 220, 237], ["T. cordifolia", "SPECIES", 176, 189], ["T. cordifolia", "SPECIES", 176, 189], ["SARS-CoV", "SPECIES", 255, 263], ["The random mean square deviation (RMSD) of the complex", "PROBLEM", 0, 54], ["The 3CL main protease", "TREATMENT", 216, 237], ["SARS", "PROBLEM", 255, 259], ["CoV-2 replication", "TREATMENT", 260, 277], ["random", "OBSERVATION_MODIFIER", 4, 10], ["mean", "OBSERVATION_MODIFIER", 11, 15], ["square deviation", "OBSERVATION", 16, 32]]], ["A total of 11 phytochemicals of T. cordifolia was screened by in silico analysis.", [["T. cordifolia", "ORGANISM", 32, 45], ["T. cordifolia", "SPECIES", 32, 45], ["T. cordifolia", "SPECIES", 32, 45], ["T. cordifolia", "PROBLEM", 32, 45], ["silico analysis", "TEST", 65, 80]]], ["Docking results proved that the top 5 potential phytochemical molecules of T. cordifolia could be considered as 3CLpro inhibitors.", [["T. cordifolia", "ORGANISM", 75, 88], ["3CLpro", "SIMPLE_CHEMICAL", 112, 118], ["T. cordifolia", "SPECIES", 75, 88], ["T. cordifolia", "SPECIES", 75, 88], ["T. cordifolia", "PROBLEM", 75, 88], ["3CLpro inhibitors", "TREATMENT", 112, 129]]], ["The stable docking poses of tinosponone, xanosporic acid cardiofolioside B, tembetarine and berberine with main protease showed the best docking scores, namely \u22127.7, \u22127.5, \u22127.3, \u22126.6 and \u22126.5 kcal/mol, respectively and the interactions were analyzed using 2D diagram.", [["tinosponone", "CHEMICAL", 28, 39], ["xanosporic acid cardiofolioside B", "CHEMICAL", 41, 74], ["tembetarine", "CHEMICAL", 76, 87], ["berberine", "CHEMICAL", 92, 101], ["tinosponone", "CHEMICAL", 28, 39], ["xanosporic acid", "CHEMICAL", 41, 56], ["cardiofolioside B", "CHEMICAL", 57, 74], ["tembetarine", "CHEMICAL", 76, 87], ["berberine", "CHEMICAL", 92, 101], ["tinosponone", "SIMPLE_CHEMICAL", 28, 39], ["xanosporic acid cardiofolioside B", "SIMPLE_CHEMICAL", 41, 74], ["tembetarine", "SIMPLE_CHEMICAL", 76, 87], ["berberine", "SIMPLE_CHEMICAL", 92, 101], ["protease", "PROTEIN", 112, 120], ["tinosponone", "TREATMENT", 28, 39], ["xanosporic acid cardiofolioside B", "TREATMENT", 41, 74], ["tembetarine", "TREATMENT", 76, 87], ["berberine", "TREATMENT", 92, 101], ["main protease", "TREATMENT", 107, 120], ["\u2212", "TEST", 172, 173], ["\u2212", "TEST", 178, 179], ["2D diagram", "TEST", 256, 266], ["stable", "OBSERVATION_MODIFIER", 4, 10]]], ["Based on the lowest docking energy value of docked complex, tinosponone was selected as potent inhibitor molecule (Table 1).", [["tinosponone", "CHEMICAL", 60, 71], ["tinosponone", "CHEMICAL", 60, 71], ["tinosponone", "SIMPLE_CHEMICAL", 60, 71], ["docked complex", "PROTEIN", 44, 58], ["tinosponone", "TREATMENT", 60, 71]]], ["The compound tinosponone showed hydrogen bond interactions with GLU166 and ASN 142 (Figure 1(a,b)).", [["tinosponone", "CHEMICAL", 13, 24], ["ASN 142", "CHEMICAL", 75, 82], ["tinosponone", "CHEMICAL", 13, 24], ["hydrogen", "CHEMICAL", 32, 40], ["GLU166", "CHEMICAL", 64, 70], ["ASN 142", "CHEMICAL", 75, 82], ["tinosponone", "SIMPLE_CHEMICAL", 13, 24], ["hydrogen", "SIMPLE_CHEMICAL", 32, 40], ["GLU166", "SIMPLE_CHEMICAL", 64, 70], ["ASN 142", "SIMPLE_CHEMICAL", 75, 82], ["The compound tinosponone", "TEST", 0, 24], ["hydrogen bond interactions", "PROBLEM", 32, 58], ["GLU166", "TEST", 64, 70], ["ASN", "TEST", 75, 78], ["Figure", "TEST", 84, 90], ["hydrogen bond", "OBSERVATION", 32, 45]]], ["Xanosporic acid showed hydrogen bond interactions with HIS 41, HIS 163 and GLN 189 (Figure 2(a,b)).", [["Xanosporic acid", "CHEMICAL", 0, 15], ["GLN 189", "CHEMICAL", 75, 82], ["Xanosporic acid", "CHEMICAL", 0, 15], ["hydrogen", "CHEMICAL", 23, 31], ["Xanosporic acid", "SIMPLE_CHEMICAL", 0, 15], ["hydrogen", "SIMPLE_CHEMICAL", 23, 31], ["Xanosporic acid", "TEST", 0, 15], ["hydrogen bond interactions", "PROBLEM", 23, 49], ["HIS", "TEST", 55, 58], ["HIS", "TEST", 63, 66], ["GLN", "TEST", 75, 78], ["Figure", "TEST", 84, 90], ["hydrogen bond", "OBSERVATION", 23, 36]]], ["Cardiofolioside B showed interactions of hydrogen bond with SER 46, HIS 41, CYS 145, THR 24 (Figure 3(a,b)).", [["Cardiofolioside B", "CHEMICAL", 0, 17], ["Cardiofolioside B", "CHEMICAL", 0, 17], ["hydrogen", "CHEMICAL", 41, 49], ["Cardiofolioside B", "GENE_OR_GENE_PRODUCT", 0, 17], ["SER", "SIMPLE_CHEMICAL", 60, 63], ["hydrogen bond", "TEST", 41, 54], ["SER", "TEST", 60, 63], ["HIS", "TEST", 68, 71], ["CYS", "TEST", 76, 79], ["THR", "TEST", 85, 88], ["Figure", "TEST", 93, 99]]], ["Tembetarine showed hydrogen bond interactions with GLU166, HIS 163 (Figure 4(a,b)).", [["Tembetarine", "CHEMICAL", 0, 11], ["GLU166", "CHEMICAL", 51, 57], ["Tembetarine", "CHEMICAL", 0, 11], ["hydrogen", "CHEMICAL", 19, 27], ["GLU166", "CHEMICAL", 51, 57], ["Tembetarine", "SIMPLE_CHEMICAL", 0, 11], ["GLU166", "SIMPLE_CHEMICAL", 51, 57], ["hydrogen bond interactions", "PROBLEM", 19, 45], ["GLU166", "TEST", 51, 57], ["HIS", "TEST", 59, 62], ["Figure", "TEST", 68, 74], ["hydrogen bond", "OBSERVATION", 19, 32]]], ["Berberine showed hydrogen bond interactions with PHE 140 and ASN 142 (Figure 5(a,b)).ADME prediction ::: Results and discussionThe top 5 phytochemicals of T. cordifolia shown better binding affinity with 3CL main protease was subjected to ADME analysis.", [["Berberine", "CHEMICAL", 0, 9], ["PHE 140", "CHEMICAL", 49, 56], ["ASN 142", "CHEMICAL", 61, 68], ["Berberine", "CHEMICAL", 0, 9], ["hydrogen", "CHEMICAL", 17, 25], ["PHE", "CHEMICAL", 49, 52], ["ASN 142", "CHEMICAL", 61, 68], ["Berberine", "SIMPLE_CHEMICAL", 0, 9], ["hydrogen", "SIMPLE_CHEMICAL", 17, 25], ["PHE 140", "SIMPLE_CHEMICAL", 49, 56], ["ASN 142", "SIMPLE_CHEMICAL", 61, 68], ["T. cordifolia", "ORGANISM", 155, 168], ["3CL main protease", "PROTEIN", 204, 221], ["T. cordifolia", "SPECIES", 155, 168], ["T. cordifolia", "SPECIES", 155, 168], ["Berberine", "TREATMENT", 0, 9], ["hydrogen bond interactions", "PROBLEM", 17, 43], ["PHE", "TEST", 49, 52], ["ASN", "TEST", 61, 64], ["Figure", "TEST", 70, 76], ["T. cordifolia", "PROBLEM", 155, 168], ["better binding affinity", "PROBLEM", 175, 198], ["3CL main protease", "TREATMENT", 204, 221], ["ADME analysis", "TEST", 239, 252], ["hydrogen bond", "OBSERVATION", 17, 30]]], ["The compound, namely tinasponone has satisfied Lipinski\u2019s rule of five conditions and the data were represented in Table 1.", [["tinasponone", "CHEMICAL", 21, 32], ["tinasponone", "CHEMICAL", 21, 32], ["tinasponone", "SIMPLE_CHEMICAL", 21, 32], ["the data", "TEST", 86, 94], ["compound", "OBSERVATION_MODIFIER", 4, 12]]], ["Tinasponone possessed good pharmacokinetic properties of druggability with better permeability through membranes and does not interfere with the sites of CYP450 metabolism of other drugs.", [["membranes", "ANATOMY", 103, 112], ["Tinasponone", "CHEMICAL", 0, 11], ["Tinasponone", "CHEMICAL", 0, 11], ["Tinasponone", "SIMPLE_CHEMICAL", 0, 11], ["membranes", "CELLULAR_COMPONENT", 103, 112], ["CYP450", "GENE_OR_GENE_PRODUCT", 154, 160], ["CYP450", "PROTEIN", 154, 160], ["good", "OBSERVATION_MODIFIER", 22, 26], ["pharmacokinetic properties", "OBSERVATION", 27, 53], ["druggability", "OBSERVATION_MODIFIER", 57, 69], ["better permeability", "OBSERVATION_MODIFIER", 75, 94]]], ["The physicochemical properties of tinosponone have revealed that the molecular weight 330.38 g/mol with five hydrogen bond acceptors and one hydrogen bond donor, topological polar surface area (TPSA), 76.74\u00c52 and lipophilicity, LogP 2.81.", [["tinosponone", "CHEMICAL", 34, 45], ["tinosponone", "CHEMICAL", 34, 45], ["hydrogen", "CHEMICAL", 109, 117], ["hydrogen", "CHEMICAL", 141, 149], ["tinosponone", "SIMPLE_CHEMICAL", 34, 45], ["the molecular weight", "TEST", 65, 85], ["five hydrogen bond acceptors", "TREATMENT", 104, 132], ["one hydrogen bond donor", "TREATMENT", 137, 160], ["TPSA", "TEST", 194, 198], ["lipophilicity", "TEST", 213, 226], ["LogP", "TEST", 228, 232], ["hydrogen bond", "OBSERVATION", 141, 154], ["polar", "OBSERVATION_MODIFIER", 174, 179], ["surface", "OBSERVATION_MODIFIER", 180, 187]]], ["AMES test for toxicity prediction of tinasponone by pkCSM server has shown that the tinasponone has no toxicity.Molecular dynamics simulations ::: Results and discussionThe nature of binding was studied using molecular dynamics simulation study.", [["toxicity", "DISEASE", 14, 22], ["tinasponone", "CHEMICAL", 37, 48], ["tinasponone", "CHEMICAL", 84, 95], ["toxicity", "DISEASE", 103, 111], ["tinasponone", "CHEMICAL", 37, 48], ["tinasponone", "CHEMICAL", 84, 95], ["tinasponone", "SIMPLE_CHEMICAL", 37, 48], ["pkCSM", "SIMPLE_CHEMICAL", 52, 57], ["tinasponone", "SIMPLE_CHEMICAL", 84, 95], ["AMES test", "TEST", 0, 9], ["toxicity", "PROBLEM", 14, 22], ["toxicity", "PROBLEM", 103, 111], ["molecular dynamics simulation study", "TEST", 209, 244], ["no", "UNCERTAINTY", 100, 102], ["toxicity", "OBSERVATION", 103, 111]]], ["The top-ranked drug, tinosponone with main protease complex has shown the stability conformation throughout the running of simulation for 10 ns and the RMSD value was obtained below 0.2 nm.", [["tinosponone", "CHEMICAL", 21, 32], ["tinosponone", "CHEMICAL", 21, 32], ["tinosponone", "SIMPLE_CHEMICAL", 21, 32], ["protease complex", "PROTEIN", 43, 59], ["main protease complex", "TREATMENT", 38, 59], ["the RMSD value", "TEST", 148, 162], ["stability conformation", "OBSERVATION", 74, 96]]], ["The average deviation was found to be negligible, i.e. 0.12 nm (Figure 6).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["deviation", "OBSERVATION", 12, 21]]], ["Hence, from the present study on in silico approach, it is suggested that the best docked phytochemical compounds could be tested biologically to develop potent drugs against novel coronavirus.ConclusionBased on virtual screening and molecular docking analysis, the phytochemical compounds, namely tinosponone, xanosporic acid, cardiofolioside B, tembetarine and berberine of T. cordifolia were identified as possible lead molecules to fight against SARS-CoV-2.", [["coronavirus", "DISEASE", 181, 192], ["tinosponone", "CHEMICAL", 298, 309], ["xanosporic acid", "CHEMICAL", 311, 326], ["cardiofolioside B", "CHEMICAL", 328, 345], ["tembetarine", "CHEMICAL", 347, 358], ["berberine", "CHEMICAL", 363, 372], ["SARS", "DISEASE", 450, 454], ["tinosponone", "CHEMICAL", 298, 309], ["xanosporic acid", "CHEMICAL", 311, 326], ["cardiofolioside B", "CHEMICAL", 328, 345], ["tembetarine", "CHEMICAL", 347, 358], ["berberine", "CHEMICAL", 363, 372], ["coronavirus", "ORGANISM", 181, 192], ["tinosponone", "SIMPLE_CHEMICAL", 298, 309], ["xanosporic acid", "SIMPLE_CHEMICAL", 311, 326], ["cardiofolioside B", "SIMPLE_CHEMICAL", 328, 345], ["tembetarine", "SIMPLE_CHEMICAL", 347, 358], ["berberine", "SIMPLE_CHEMICAL", 363, 372], ["T. cordifolia", "ORGANISM", 376, 389], ["SARS-CoV-2", "ORGANISM", 450, 460], ["T. cordifolia", "SPECIES", 376, 389], ["T. cordifolia", "SPECIES", 376, 389], ["SARS-CoV", "SPECIES", 450, 458], ["the present study", "TEST", 12, 29], ["potent drugs", "TREATMENT", 154, 166], ["novel coronavirus", "PROBLEM", 175, 192], ["virtual screening", "TEST", 212, 229], ["molecular docking analysis", "TEST", 234, 260], ["the phytochemical compounds", "TEST", 262, 289], ["tinosponone", "TREATMENT", 298, 309], ["xanosporic acid", "TREATMENT", 311, 326], ["cardiofolioside B", "TREATMENT", 328, 345], ["tembetarine", "TREATMENT", 347, 358], ["berberine", "TREATMENT", 363, 372], ["T. cordifolia", "PROBLEM", 376, 389], ["lead molecules", "PROBLEM", 418, 432], ["SARS", "PROBLEM", 450, 454], ["CoV", "TEST", 455, 458]]], ["The present in silico study proved that tinosponone as potent, selective and nontoxic inhibitor of 3CL protease of SARS-CoV-2.", [["tinosponone", "CHEMICAL", 40, 51], ["tinosponone", "CHEMICAL", 40, 51], ["tinosponone", "SIMPLE_CHEMICAL", 40, 51], ["3CL protease", "GENE_OR_GENE_PRODUCT", 99, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["3CL protease", "PROTEIN", 99, 111], ["SARS-CoV", "SPECIES", 115, 123], ["silico study", "TEST", 15, 27], ["tinosponone", "TREATMENT", 40, 51], ["selective and nontoxic inhibitor", "TREATMENT", 63, 95], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123]]]], "9acc3704e1095a8c1d0bd50a696d613a5bc5e919": [["IntroductionThe coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reaches more than 170 countries, resulting in considerable morbidity and mortality.", [["coronavirus disease", "DISEASE", 16, 35], ["acute respiratory syndrome coronavirus", "DISEASE", 62, 100], ["coronavirus", "ORGANISM", 16, 27], ["SARS-CoV-2", "ORGANISM", 104, 114], ["severe acute respiratory syndrome coronavirus", "SPECIES", 55, 100], ["SARS-CoV-2", "SPECIES", 104, 114], ["The coronavirus disease", "PROBLEM", 12, 35], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 51, 100], ["SARS-CoV", "TEST", 104, 112], ["considerable morbidity", "PROBLEM", 162, 184], ["coronavirus disease", "OBSERVATION", 16, 35], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88], ["considerable", "OBSERVATION_MODIFIER", 162, 174], ["morbidity", "OBSERVATION", 175, 184]]], ["Although currently available studies confirmed the presence of myocardial injury and its association with mortality in patients with COVID-19, 1-2 they lack evidence from echocardiography to determine the features of cardiac injury.", [["myocardial", "ANATOMY", 63, 73], ["cardiac", "ANATOMY", 217, 224], ["myocardial injury", "DISEASE", 63, 80], ["cardiac injury", "DISEASE", 217, 231], ["myocardial", "MULTI-TISSUE_STRUCTURE", 63, 73], ["patients", "ORGANISM", 119, 127], ["cardiac", "ORGAN", 217, 224], ["patients", "SPECIES", 119, 127], ["studies", "TEST", 29, 36], ["myocardial injury", "PROBLEM", 63, 80], ["COVID", "TEST", 133, 138], ["echocardiography", "TEST", 171, 187], ["cardiac injury", "PROBLEM", 217, 231], ["myocardial", "ANATOMY", 63, 73], ["injury", "OBSERVATION", 74, 80], ["cardiac", "ANATOMY", 217, 224], ["injury", "OBSERVATION", 225, 231]]], ["As the prevalence of acute respiratory distress syndrome (ARDS) has been reported to be 29% -67% of critically ill patients with COVID-19, 3,4 right ventricular (RV) function is supposed to be more susceptible to impairment due to increased RV afterload.", [["respiratory", "ANATOMY", 27, 38], ["right ventricular", "ANATOMY", 143, 160], ["RV", "ANATOMY", 162, 164], ["RV", "ANATOMY", 241, 243], ["acute respiratory distress syndrome", "DISEASE", 21, 56], ["ARDS", "DISEASE", 58, 62], ["critically ill", "DISEASE", 100, 114], ["COVID-19", "CHEMICAL", 129, 137], ["patients", "ORGANISM", 115, 123], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 143, 160], ["RV", "MULTI-TISSUE_STRUCTURE", 162, 164], ["RV", "ORGAN", 241, 243], ["patients", "SPECIES", 115, 123], ["acute respiratory distress syndrome", "PROBLEM", 21, 56], ["ARDS", "PROBLEM", 58, 62], ["COVID", "TEST", 129, 134], ["increased RV afterload", "PROBLEM", 231, 253], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory distress", "OBSERVATION", 27, 47], ["right ventricular", "ANATOMY", 143, 160], ["RV", "ANATOMY", 162, 164], ["increased", "OBSERVATION_MODIFIER", 231, 240], ["RV afterload", "OBSERVATION", 241, 253]]], ["In clinical practice, RV structure and function are mainly evaluated by echocardiography.", [["RV", "ANATOMY", 22, 24], ["RV", "MULTI-TISSUE_STRUCTURE", 22, 24], ["echocardiography", "TEST", 72, 88], ["RV", "ANATOMY", 22, 24]]], ["The conventional echocardiographic parameter have limited diagnostic value, as they may fail to detect early abnormalities of RV systolic function.", [["RV", "ANATOMY", 126, 128], ["RV systolic", "MULTI-TISSUE_STRUCTURE", 126, 137], ["The conventional echocardiographic parameter", "TEST", 0, 44], ["diagnostic value", "TEST", 58, 74], ["early abnormalities of RV systolic function", "PROBLEM", 103, 146], ["RV systolic", "ANATOMY", 126, 137]]], ["5 Recently, two-dimensional speckle-tracking echocardiography (2D-STE) has been introduced, which evaluates myocardial function accurately and reproducibly.", [["myocardial", "ANATOMY", 108, 118], ["myocardial", "MULTI-TISSUE_STRUCTURE", 108, 118], ["tracking echocardiography", "TEST", 36, 61]]], ["6, 7 Because of its capability to detect subclinical impairment of cardiac function, 2D-STE has been extensively applied to investigate RV function in different clinical settings.", [["cardiac", "ANATOMY", 67, 74], ["RV", "ANATOMY", 136, 138], ["impairment of cardiac function", "DISEASE", 53, 83], ["cardiac", "ORGAN", 67, 74], ["RV", "MULTI-TISSUE_STRUCTURE", 136, 138], ["subclinical impairment of cardiac function", "PROBLEM", 41, 83], ["cardiac", "ANATOMY", 67, 74], ["RV", "ANATOMY", 136, 138]]], ["[8] [9] [10] Moreover, the RV longitudinal strain (RVLS) derived from 2D-STE has been demonstrated to be of prognostic value.", [["the RV longitudinal strain", "PROBLEM", 23, 49]]], ["11 To the best of our knowledge, there are no data regarding the use of RVLS in patients with COVID-19.", [["RVLS", "DISEASE", 72, 76], ["RVLS", "CANCER", 72, 76], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["RVLS", "TREATMENT", 72, 76], ["COVID", "TEST", 94, 99]]], ["In addition, confirming the role of RVLS in these patients may be of additional significance, as most cases exhibit the preserved conventional echocardiographic parameters, among whom detection and risk stratification may be challenging.", [["RVLS", "GENE_OR_GENE_PRODUCT", 36, 40], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Accordingly, the purpose of this study was to evaluate the prognostic value of RVLS in patients with COVID-19.Study PopulationThis observational study was performed at the west branch of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology-a designated hospital to treat patients with COVID-19.", [["RVLS", "DISEASE", 79, 83], ["RVLS", "CANCER", 79, 83], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 304, 312], ["this study", "TEST", 28, 38], ["COVID", "TEST", 101, 106], ["This observational study", "TEST", 126, 150], ["COVID", "TEST", 318, 323]]], ["We included a total of 150 consecutive adult patients with COVID-19 who were diagnosed according to the interim guidance of World Health Organization 12 from Feb 12, 2020 to Mar 15, 2020 .", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Considering the presence of cardiac damage in patients with COVID-19, bedside echocardiography was performed in all patients from 3 wards managed by the investigators for evaluation of cardiac function.", [["cardiac", "ANATOMY", 28, 35], ["cardiac", "ANATOMY", 185, 192], ["cardiac damage", "DISEASE", 28, 42], ["cardiac", "ORGAN", 28, 35], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 116, 124], ["cardiac", "ORGAN", 185, 192], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 116, 124], ["cardiac damage", "PROBLEM", 28, 42], ["COVID", "TEST", 60, 65], ["bedside echocardiography", "TEST", 70, 94], ["evaluation", "TEST", 171, 181], ["cardiac function", "TEST", 185, 201], ["cardiac", "ANATOMY", 28, 35], ["damage", "OBSERVATION", 36, 42], ["cardiac", "ANATOMY", 185, 192]]], ["The median time from admission to echocardiography performed was 7 days (interquartile range [IQR] [3] [4] [5] [6] [7] [8] [9] [10] .", [["[IQR] [3] [4] [5] [6] [7] [8] [9]", "CHEMICAL", 93, 126], ["echocardiography", "TEST", 34, 50]]], ["Patients with known cardiomyopathy, previous myocardial infarction or suboptimal images were excluded.", [["myocardial", "ANATOMY", 45, 55], ["cardiomyopathy", "DISEASE", 20, 34], ["myocardial infarction", "DISEASE", 45, 66], ["Patients", "ORGANISM", 0, 8], ["myocardial", "MULTI-TISSUE_STRUCTURE", 45, 55], ["Patients", "SPECIES", 0, 8], ["known cardiomyopathy", "PROBLEM", 14, 34], ["previous myocardial infarction", "PROBLEM", 36, 66], ["suboptimal images", "TEST", 70, 87], ["cardiomyopathy", "OBSERVATION", 20, 34], ["myocardial", "ANATOMY", 45, 55], ["infarction", "OBSERVATION", 56, 66]]], ["Of these patients, 2 had dilated cardiomyopathy, 4 had old myocardial infarction, and 24 did not have images of sufficient quality for echocardiographic analysis.Study PopulationThe remaining 120 patients were included in our final analysis.", [["myocardial", "ANATOMY", 59, 69], ["dilated cardiomyopathy", "DISEASE", 25, 47], ["myocardial infarction", "DISEASE", 59, 80], ["patients", "ORGANISM", 9, 17], ["myocardial", "MULTI-TISSUE_STRUCTURE", 59, 69], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 196, 204], ["dilated cardiomyopathy", "PROBLEM", 25, 47], ["old myocardial infarction", "PROBLEM", 55, 80], ["images", "TEST", 102, 108], ["echocardiographic analysis", "TEST", 135, 161], ["Study Population", "TEST", 162, 178], ["our final analysis", "TEST", 222, 240], ["dilated", "OBSERVATION_MODIFIER", 25, 32], ["cardiomyopathy", "OBSERVATION", 33, 47], ["myocardial", "ANATOMY", 59, 69], ["infarction", "OBSERVATION", 70, 80]]], ["The control group consisted of 37 healthy volunteers who had no cardiopulmonary disease based on physical check-up, electrocardiogram, chest X-ray and echocardiography.Study PopulationThe study complied with the edicts of the 1975 Declaration of Helsinki 13Clinical DataPatients' demographic characteristics, medical history, laboratory examinations, comorbidities, complication, treatment and outcomes were retrieved from electronic medical records.", [["cardiopulmonary", "ANATOMY", 64, 79], ["cardiopulmonary disease", "DISEASE", 64, 87], ["volunteers", "ORGANISM", 42, 52], ["cardiopulmonary disease", "PROBLEM", 64, 87], ["physical check", "TEST", 97, 111], ["electrocardiogram", "TEST", 116, 133], ["chest X-ray", "TEST", 135, 146], ["echocardiography", "TEST", 151, 167], ["The study", "TEST", 184, 193], ["laboratory examinations", "TEST", 326, 349], ["comorbidities", "PROBLEM", 351, 364], ["complication", "PROBLEM", 366, 378], ["treatment", "TREATMENT", 380, 389], ["no", "UNCERTAINTY", 61, 63], ["cardiopulmonary", "ANATOMY", 64, 79], ["disease", "OBSERVATION", 80, 87], ["chest", "ANATOMY", 135, 140]]], ["Cardiac biomarkers measured on admission included hypersensitive troponin I (hs-TNI), creatine kinase muscle-brain (CK-MB) and B-type natriuretic peptide (BNP).Clinical DataThese data were independently reviewed and entered into the computer database by two analysts (C.W. and W.S.)", [["Cardiac", "ANATOMY", 0, 7], ["creatine", "CHEMICAL", 86, 94], ["creatine", "CHEMICAL", 86, 94], ["Cardiac", "ORGAN", 0, 7], ["troponin I", "GENE_OR_GENE_PRODUCT", 65, 75], ["hs-TNI", "GENE_OR_GENE_PRODUCT", 77, 83], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 86, 101], ["muscle", "ORGAN", 102, 108], ["brain", "ORGAN", 109, 114], ["CK-MB", "GENE_OR_GENE_PRODUCT", 116, 121], ["B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 127, 153], ["BNP", "GENE_OR_GENE_PRODUCT", 155, 158], ["hypersensitive troponin I", "PROTEIN", 50, 75], ["TNI", "PROTEIN", 80, 83], ["creatine kinase", "PROTEIN", 86, 101], ["Cardiac biomarkers", "TEST", 0, 18], ["hypersensitive troponin I", "PROBLEM", 50, 75], ["hs", "TEST", 77, 79], ["TNI", "TEST", 80, 83], ["creatine kinase muscle", "TEST", 86, 108], ["CK-MB", "TEST", 116, 121], ["B-type natriuretic peptide", "TEST", 127, 153], ["BNP", "TEST", 155, 158], ["muscle", "ANATOMY", 102, 108], ["brain", "ANATOMY", 109, 114]]], ["The final follow-up date was April 2, 2020Transthoracic EchocardiographyBedside transthoracic echocardiographic examinations were performed in all patients with the EPIQ7C ultrasound systems (Philips Medical Systems, Andover, MA, USA).", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["Transthoracic Echocardiography", "TEST", 42, 72], ["Bedside transthoracic echocardiographic examinations", "TEST", 72, 124], ["the EPIQ7C ultrasound systems", "TEST", 161, 190]]], ["2D and Doppler echocardiography were acquired based on the guidelines of the American Society of Echocardiography.", [["2D and Doppler echocardiography", "TEST", 0, 31], ["Echocardiography", "TEST", 97, 113]]], ["14 Images were stored and analyzed by two independent observers (Y.C. and L.C.) blinded to clinical data.Conventional Echocardiographic AnalysisLeft ventricular (LV) end-systolic volume (EDV) and end-diastolic volume (ESV), and ejection fraction (EF) were measured by biplane Simpson's method.", [["Left ventricular", "ANATOMY", 144, 160], ["LV", "ANATOMY", 162, 164], ["ventricular", "MULTI-TISSUE_STRUCTURE", 149, 160], ["LV", "MULTI-TISSUE_STRUCTURE", 162, 164], ["Images", "TEST", 3, 9], ["clinical data", "TEST", 91, 104], ["Conventional Echocardiographic Analysis", "TEST", 105, 144], ["end-systolic volume", "TEST", 166, 185], ["EDV", "TEST", 187, 190], ["end-diastolic volume", "TEST", 196, 216], ["ESV", "TEST", 218, 221], ["ejection fraction", "TEST", 228, 245], ["EF", "TEST", 247, 249], ["Left ventricular", "ANATOMY", 144, 160], ["LV", "ANATOMY", 162, 164], ["diastolic volume", "OBSERVATION", 200, 216], ["ejection fraction", "OBSERVATION", 228, 245]]], ["15 LV mass was calculated from parasternal view based on Devereux's formula.", [["LV", "ANATOMY", 3, 5], ["LV", "MULTI-TISSUE_STRUCTURE", 3, 5], ["LV mass", "PROBLEM", 3, 10], ["parasternal view", "TEST", 31, 47], ["Devereux's formula", "TREATMENT", 57, 75], ["LV", "ANATOMY", 3, 5], ["mass", "OBSERVATION", 6, 10]]], ["LV diastolic function was estimated by the early transmitral flow velocity (E) to the late transmitral flow velocity (A) (E/A) ratio, and the transmitral E to the early diastolic medial LV septal tissue velocity (e\u2032) (E/e\u2032) ratio.Conventional Echocardiographic AnalysisRight atrial (RA) and RV size were determined from the apical 4-chamber view.", [["LV", "ANATOMY", 0, 2], ["transmitral", "ANATOMY", 49, 60], ["transmitral", "ANATOMY", 91, 102], ["medial LV septal tissue", "ANATOMY", 179, 202], ["atrial", "ANATOMY", 275, 281], ["RV", "ANATOMY", 291, 293], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["septal tissue", "TISSUE", 189, 202], ["atrial", "MULTI-TISSUE_STRUCTURE", 275, 281], ["LV diastolic function", "TEST", 0, 21], ["the late transmitral flow velocity", "TEST", 82, 116], ["ratio", "TEST", 127, 132], ["the transmitral E", "TEST", 138, 155], ["Conventional Echocardiographic AnalysisRight atrial (RA)", "TEST", 230, 286], ["RV size", "TEST", 291, 298], ["diastolic function", "OBSERVATION", 3, 21], ["early", "OBSERVATION_MODIFIER", 43, 48], ["transmitral flow", "OBSERVATION", 49, 65], ["late", "OBSERVATION_MODIFIER", 86, 90], ["transmitral flow", "OBSERVATION", 91, 107], ["velocity", "OBSERVATION_MODIFIER", 108, 116], ["early", "OBSERVATION_MODIFIER", 163, 168], ["diastolic", "OBSERVATION", 169, 178], ["medial", "ANATOMY_MODIFIER", 179, 185], ["LV septal tissue", "ANATOMY", 186, 202], ["velocity", "OBSERVATION_MODIFIER", 203, 211], ["atrial", "ANATOMY", 275, 281], ["RA", "ANATOMY", 283, 285], ["RV", "ANATOMY", 291, 293], ["size", "OBSERVATION_MODIFIER", 294, 298], ["apical", "ANATOMY_MODIFIER", 324, 330]]], ["Tricuspid annular plane systolic excursion (TAPSE) was measured as the systolic displacement of the tricuspid lateral annulus, recorded on M-mode.", [["tricuspid lateral annulus", "ANATOMY", 100, 125], ["lateral annulus", "MULTI-TISSUE_STRUCTURE", 110, 125], ["Tricuspid annular plane systolic excursion", "TEST", 0, 42], ["TAPSE", "TEST", 44, 49], ["annular", "ANATOMY_MODIFIER", 10, 17], ["excursion", "OBSERVATION_MODIFIER", 33, 42], ["systolic", "OBSERVATION_MODIFIER", 71, 79], ["displacement", "OBSERVATION_MODIFIER", 80, 92], ["tricuspid lateral annulus", "ANATOMY", 100, 125]]], ["RV end-diastolic and end-systolic area were obtained from the apical 4-chamber view.", [["RV", "ANATOMY", 0, 2], ["RV", "TEST", 0, 2], ["diastolic", "ANATOMY_MODIFIER", 7, 16], ["end", "OBSERVATION_MODIFIER", 21, 24], ["systolic area", "OBSERVATION", 25, 38], ["apical", "ANATOMY_MODIFIER", 62, 68]]], ["RV fractional area change (FAC) was calculated as (RV end-diastolic area -RV end-systolic area)/end-diastolic area\u00d7100%.", [["RV fractional area change", "PROBLEM", 0, 25], ["RV", "TEST", 51, 53], ["diastolic area", "TEST", 58, 72], ["RV", "TEST", 74, 76], ["end-diastolic area", "TEST", 96, 114], ["fractional", "OBSERVATION_MODIFIER", 3, 13], ["area", "OBSERVATION", 14, 18], ["RV", "ANATOMY", 74, 76], ["systolic", "OBSERVATION_MODIFIER", 81, 89], ["diastolic", "OBSERVATION_MODIFIER", 100, 109], ["area", "OBSERVATION_MODIFIER", 110, 114]]], ["Tricuspid lateral annular systolic velocity (S') was assessed by tissue Doppler imaging from the apical 4-chamber view.", [["lateral annular", "ANATOMY", 10, 25], ["tissue", "ANATOMY", 65, 71], ["tissue", "TISSUE", 65, 71], ["Tricuspid lateral annular systolic velocity", "TEST", 0, 43], ["tissue Doppler imaging", "TEST", 65, 87], ["lateral", "ANATOMY_MODIFIER", 10, 17], ["annular systolic", "ANATOMY", 18, 34], ["velocity", "OBSERVATION_MODIFIER", 35, 43], ["apical", "ANATOMY_MODIFIER", 97, 103]]], ["Estimation of tricuspid regurgitation (TR) incorporated color-Doppler imaging and contour of the jet in continuous-wave Doppler.", [["tricuspid", "ANATOMY", 14, 23], ["tricuspid regurgitation", "DISEASE", 14, 37], ["tricuspid", "MULTI-TISSUE_STRUCTURE", 14, 23], ["tricuspid regurgitation", "PROBLEM", 14, 37], ["color-Doppler imaging", "TEST", 56, 77], ["continuous-wave Doppler", "TEST", 104, 127], ["tricuspid", "ANATOMY", 14, 23], ["regurgitation", "OBSERVATION", 24, 37], ["contour", "OBSERVATION_MODIFIER", 82, 89], ["jet", "OBSERVATION_MODIFIER", 97, 100]]], ["Moderate to severe TR were defined as moderate, moderate to severe, or severe TR.", [["Moderate to severe TR", "PROBLEM", 0, 21], ["moderate to severe", "PROBLEM", 48, 66], ["severe TR", "PROBLEM", 71, 80], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["TR", "OBSERVATION", 19, 21], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["moderate", "OBSERVATION_MODIFIER", 48, 56], ["to severe", "OBSERVATION_MODIFIER", 57, 66], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["TR", "OBSERVATION", 78, 80]]], ["Pulmonary artery systolic pressure (PASP) was assessed from the peak velocity of the TR jet, using the modified Bernoulli equation plus RA pressure evaluated from the inferior vena cava (IVC) size and its collapsibility.STE analyses was conducted according to the recommendations of the American Society ofEchocardiography and European Association of Cardiovascular Imaging.", [["Pulmonary artery", "ANATOMY", 0, 16], ["inferior vena cava", "ANATOMY", 167, 185], ["IVC", "ANATOMY", 187, 190], ["Cardiovascular", "ANATOMY", 351, 365], ["Pulmonary artery", "MULTI-TISSUE_STRUCTURE", 0, 16], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 167, 185], ["IVC", "MULTI-TISSUE_STRUCTURE", 187, 190], ["Pulmonary artery systolic pressure", "TEST", 0, 34], ["PASP", "TEST", 36, 40], ["the modified Bernoulli equation", "TEST", 99, 130], ["RA pressure", "TEST", 136, 147], ["STE analyses", "TEST", 220, 232], ["Cardiovascular Imaging", "TEST", 351, 373], ["artery systolic", "ANATOMY", 10, 25], ["pressure", "OBSERVATION_MODIFIER", 26, 34], ["peak", "OBSERVATION_MODIFIER", 64, 68], ["velocity", "OBSERVATION_MODIFIER", 69, 77], ["TR jet", "OBSERVATION", 85, 91], ["inferior vena cava", "ANATOMY", 167, 185], ["IVC", "ANATOMY", 187, 190], ["size", "OBSERVATION_MODIFIER", 192, 196], ["collapsibility", "OBSERVATION", 205, 219]]], ["6 All of the images were analyzed by 2D strain software (Image-Arena; TomTec Imaging Systems, Germany) in the apical four-chamber view at frame rate of 50~70 frames/sec ( Figure 1 ).", [["the images", "TEST", 9, 19], ["2D strain software", "TEST", 37, 55], ["Image", "TEST", 57, 62], ["frame rate", "TEST", 138, 148], ["apical", "ANATOMY_MODIFIER", 110, 116]]], ["After tracing the RV endocardial border, the region of interest was automatically generated.", [["RV endocardial border", "ANATOMY", 18, 39], ["RV endocardial", "ANATOMY", 18, 32], ["border", "ANATOMY_MODIFIER", 33, 39]]], ["And then manual corrections were performed to fit RV myocardial wall thickness.", [["RV myocardial wall", "ANATOMY", 50, 68], ["RV myocardial wall", "TISSUE", 50, 68], ["manual corrections", "TEST", 9, 27], ["RV myocardial", "ANATOMY", 50, 63], ["wall", "ANATOMY_MODIFIER", 64, 68], ["thickness", "OBSERVATION_MODIFIER", 69, 78]]], ["RV free wall was automatically divided into three segments-basal, mid and apical segments.", [["RV free wall", "ANATOMY", 0, 12], ["apical segments", "ANATOMY", 74, 89], ["apical segments", "MULTI-TISSUE_STRUCTURE", 74, 89], ["free wall", "ANATOMY", 3, 12], ["three segments", "ANATOMY_MODIFIER", 44, 58], ["basal", "ANATOMY_MODIFIER", 59, 64], ["mid", "ANATOMY_MODIFIER", 66, 69], ["apical", "ANATOMY_MODIFIER", 74, 80], ["segments", "ANATOMY_MODIFIER", 81, 89]]], ["RVLS was calculated as the mean of the strain values in the three segments of RV free wall.", [["RV free wall", "ANATOMY", 78, 90], ["RVLS", "TEST", 0, 4], ["three", "ANATOMY_MODIFIER", 60, 65], ["segments", "ANATOMY_MODIFIER", 66, 74], ["RV", "ANATOMY_MODIFIER", 78, 80], ["free", "ANATOMY_MODIFIER", 81, 85], ["wall", "ANATOMY_MODIFIER", 86, 90]]], ["We took the absolute value for a simpler interpretation, as RVLS is a negative value.Interobserver and Intraobserver reproducibilityIntraobserver and interobserver variability of RVLS were estimated in 20 randomly selected subjects and evaluated by intra-class correlation coefficient (ICC) and Bland-Altman analysis.Interobserver and Intraobserver reproducibilityIntraobserver variability was assessed by having one observer remeasure after two weeks.Interobserver and Intraobserver reproducibilityInterobserver variability was evaluated by a second observer who was blinded to the first observer's measurements.Statistical AnalysisContinuous numeric variables were expressed as mean \u00b1 SD or medians (IQR), and compared with a two-sample t test and one-way analysis of variance (for normally distributed data), or Mann-Whitney test and Kruskal-Wallis test (for non-normal distribution of data).Statistical AnalysisCategorical variables were expressed as frequency number (%), and compared using \u03c7 2 test or Fisher's exact test.", [["Interobserver", "TEST", 85, 98], ["Intraobserver reproducibility", "TEST", 103, 132], ["Intraobserver", "TEST", 132, 145], ["RVLS", "TEST", 179, 183], ["Bland-Altman analysis", "TEST", 295, 316], ["Interobserver", "TEST", 317, 330], ["Intraobserver reproducibility", "TEST", 335, 364], ["Intraobserver variability", "TEST", 364, 389], ["Interobserver", "TEST", 452, 465], ["Intraobserver reproducibility", "TEST", 470, 499], ["Statistical AnalysisContinuous numeric variables", "PROBLEM", 613, 661], ["sample t test", "TEST", 732, 745], ["Whitney test", "TEST", 820, 832], ["Kruskal-Wallis test", "TEST", 837, 856], ["Statistical AnalysisCategorical variables", "PROBLEM", 895, 936], ["Fisher's exact test", "TEST", 1008, 1027], ["negative", "OBSERVATION", 70, 78]]], ["To determine the optimal cutoff value (maximum Youden index) of prognostic RV function parameters for detecting increased mortality, receiver operator characteristic (ROC) curves were used.", [["RV", "ANATOMY", 75, 77], ["RV", "MULTI-TISSUE_STRUCTURE", 75, 77], ["the optimal cutoff value", "TEST", 13, 37], ["prognostic RV function parameters", "TEST", 64, 97], ["increased mortality", "PROBLEM", 112, 131]]], ["Survival curves were obtained by the Kaplan-Meier analysis and compared using log-rank test.", [["Survival curves", "TEST", 0, 15], ["Meier analysis", "TEST", 44, 58], ["log-rank test", "TEST", 78, 91]]], ["Estimations of the predictor of mortality were performed using univariate and multivariate Cox regression models.", [["multivariate Cox regression models", "TREATMENT", 78, 112]]], ["All potential predictors of higher mortality were entered into univariate analyses, including sex, age, cardiac injury and inflammatory marker, LVEF, PASP, RV function echocardiographic parameters, acute respiratory distress syndrome (ARDS), and comorbidities (diabetes mellitus, hypertension, cardiovascular artery disease, malignancy and arrhythmia).", [["cardiac", "ANATOMY", 104, 111], ["cardiovascular artery", "ANATOMY", 294, 315], ["cardiac injury", "DISEASE", 104, 118], ["acute respiratory distress syndrome", "DISEASE", 198, 233], ["ARDS", "DISEASE", 235, 239], ["diabetes mellitus", "DISEASE", 261, 278], ["hypertension", "DISEASE", 280, 292], ["cardiovascular artery disease", "DISEASE", 294, 323], ["malignancy", "DISEASE", 325, 335], ["arrhythmia", "DISEASE", 340, 350], ["cardiac", "ORGAN", 104, 111], ["cardiovascular artery", "MULTI-TISSUE_STRUCTURE", 294, 315], ["cardiac injury", "PROBLEM", 104, 118], ["inflammatory marker", "TEST", 123, 142], ["LVEF", "TEST", 144, 148], ["PASP", "TEST", 150, 154], ["echocardiographic parameters", "TEST", 168, 196], ["acute respiratory distress syndrome", "PROBLEM", 198, 233], ["ARDS)", "PROBLEM", 235, 240], ["comorbidities (diabetes mellitus", "PROBLEM", 246, 278], ["hypertension", "PROBLEM", 280, 292], ["cardiovascular artery disease", "PROBLEM", 294, 323], ["malignancy", "PROBLEM", 325, 335], ["arrhythmia", "PROBLEM", 340, 350], ["cardiac", "ANATOMY", 104, 111], ["injury", "OBSERVATION", 112, 118], ["inflammatory", "OBSERVATION_MODIFIER", 123, 135], ["RV", "ANATOMY", 156, 158], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["respiratory distress", "OBSERVATION", 204, 224], ["cardiovascular artery", "ANATOMY", 294, 315], ["malignancy", "OBSERVATION", 325, 335]]], ["Variables with P < 0.05 at univariate analysis entered into multivariate Cox regression models.Clinical CharacteristicsClinical characteristics of patients with COVID-19 according to tertiles of RVLS were shown in Table 1 .The mean age of COVID-19 patients were 61\u00b114 years, 57(48%) patients were men.", [["patients", "ORGANISM", 147, 155], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 283, 291], ["men", "ORGANISM", 297, 300], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 283, 291], ["men", "SPECIES", 297, 300], ["P", "TEST", 15, 16], ["univariate analysis", "TEST", 27, 46], ["COVID", "TEST", 161, 166], ["COVID", "TEST", 239, 244]]], ["Chronic obstructive pulmonary disease was found in 6 patients with COVID-19.", [["pulmonary", "ANATOMY", 20, 29], ["Chronic obstructive pulmonary disease", "DISEASE", 0, 37], ["COVID-19", "CHEMICAL", 67, 75], ["pulmonary", "ORGAN", 20, 29], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Chronic obstructive pulmonary disease", "PROBLEM", 0, 37], ["COVID", "TEST", 67, 72], ["obstructive", "OBSERVATION_MODIFIER", 8, 19], ["pulmonary", "ANATOMY", 20, 29], ["disease", "OBSERVATION", 30, 37]]], ["None of the patients had the history of pulmonary embolism.", [["pulmonary", "ANATOMY", 40, 49], ["pulmonary embolism", "DISEASE", 40, 58], ["patients", "ORGANISM", 12, 20], ["pulmonary", "ORGAN", 40, 49], ["patients", "SPECIES", 12, 20], ["pulmonary embolism", "PROBLEM", 40, 58], ["pulmonary", "ANATOMY", 40, 49], ["embolism", "OBSERVATION", 50, 58]]], ["No patient was diagnosed with pulmonary embolism.", [["pulmonary", "ANATOMY", 30, 39], ["pulmonary embolism", "DISEASE", 30, 48], ["patient", "ORGANISM", 3, 10], ["pulmonary", "ORGAN", 30, 39], ["patient", "SPECIES", 3, 10], ["pulmonary embolism", "PROBLEM", 30, 48], ["pulmonary", "ANATOMY", 30, 39], ["embolism", "OBSERVATION", 40, 48]]], ["Compared with patients in the highest tertiles, those in the lowest RVLS tertile were more likely to have a higher heart rate, D-dimer and C-reactive protein, high-flow oxygen and invasive mechanical ventilation therapy, higher incidence of acute heart injury, ARDS and deep vein thrombosis, and higher mortality.", [["heart", "ANATOMY", 115, 120], ["heart", "ANATOMY", 247, 252], ["deep vein", "ANATOMY", 270, 279], ["oxygen", "CHEMICAL", 169, 175], ["heart injury", "DISEASE", 247, 259], ["ARDS", "DISEASE", 261, 265], ["deep vein thrombosis", "DISEASE", 270, 290], ["oxygen", "CHEMICAL", 169, 175], ["patients", "ORGANISM", 14, 22], ["heart", "ORGAN", 115, 120], ["D-dimer", "SIMPLE_CHEMICAL", 127, 134], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 139, 157], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["heart", "ORGAN", 247, 252], ["vein", "MULTI-TISSUE_STRUCTURE", 275, 279], ["D-dimer", "PROTEIN", 127, 134], ["C-reactive protein", "PROTEIN", 139, 157], ["patients", "SPECIES", 14, 22], ["a higher heart rate", "PROBLEM", 106, 125], ["C-reactive protein", "PROBLEM", 139, 157], ["high-flow oxygen", "TREATMENT", 159, 175], ["invasive mechanical ventilation therapy", "TREATMENT", 180, 219], ["acute heart injury", "PROBLEM", 241, 259], ["ARDS", "PROBLEM", 261, 265], ["deep vein thrombosis", "PROBLEM", 270, 290], ["higher mortality", "PROBLEM", 296, 312], ["reactive protein", "OBSERVATION", 141, 157], ["flow oxygen", "OBSERVATION", 164, 175], ["invasive", "OBSERVATION_MODIFIER", 180, 188], ["mechanical ventilation therapy", "OBSERVATION", 189, 219], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["heart", "ANATOMY", 247, 252], ["injury", "OBSERVATION", 253, 259], ["ARDS", "OBSERVATION", 261, 265], ["deep vein thrombosis", "OBSERVATION", 270, 290], ["higher", "OBSERVATION_MODIFIER", 296, 302], ["mortality", "OBSERVATION_MODIFIER", 303, 312]]], ["There were no significant differences in age, gender, systemic arterial pressure, comorbidities, lymphocyte count, CK-MB, hs-TNI, BNP, partial pressure of oxygen: fraction of inspiration oxygen, procalcitonin, and antiviral, antibiotic, glucocorticoid and angiotensin-converting enzyme inhibitors (ACE-I)/ angiotonin II receptor blockers(ARB) use, the number of intensive care unit admission, and acute kidney injury between the tertiles.Echocardiographic CharacteristicsEchocardiographic characteristics of patients with COVID-19 according to tertiles of RVLS were described in Tables 2 and 3 .", [["arterial", "ANATOMY", 63, 71], ["lymphocyte", "ANATOMY", 97, 107], ["kidney", "ANATOMY", 403, 409], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 187, 193], ["angiotensin", "CHEMICAL", 256, 267], ["ACE-I", "CHEMICAL", 298, 303], ["angiotonin II", "CHEMICAL", 306, 319], ["ARB", "CHEMICAL", 338, 341], ["acute kidney injury", "DISEASE", 397, 416], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 187, 193], ["arterial", "MULTI-TISSUE_STRUCTURE", 63, 71], ["lymphocyte", "CELL", 97, 107], ["CK-MB", "GENE_OR_GENE_PRODUCT", 115, 120], ["hs-TNI", "SIMPLE_CHEMICAL", 122, 128], ["BNP", "GENE_OR_GENE_PRODUCT", 130, 133], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["oxygen", "SIMPLE_CHEMICAL", 187, 193], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 195, 208], ["glucocorticoid", "SIMPLE_CHEMICAL", 237, 251], ["angiotensin-converting enzyme inhibitors", "SIMPLE_CHEMICAL", 256, 296], ["ACE-I", "SIMPLE_CHEMICAL", 298, 303], ["angiotonin II receptor blockers", "SIMPLE_CHEMICAL", 306, 337], ["ARB", "SIMPLE_CHEMICAL", 338, 341], ["kidney", "ORGAN", 403, 409], ["patients", "ORGANISM", 508, 516], ["CK", "PROTEIN", 115, 117], ["angiotonin II receptor", "PROTEIN", 306, 328], ["patients", "SPECIES", 508, 516], ["systemic arterial pressure", "TEST", 54, 80], ["comorbidities", "PROBLEM", 82, 95], ["lymphocyte count", "TEST", 97, 113], ["CK", "TEST", 115, 117], ["MB", "TEST", 118, 120], ["hs", "TEST", 122, 124], ["TNI", "TEST", 125, 128], ["BNP", "TEST", 130, 133], ["partial pressure of oxygen", "TREATMENT", 135, 161], ["inspiration oxygen", "TREATMENT", 175, 193], ["procalcitonin", "TREATMENT", 195, 208], ["antiviral", "TREATMENT", 214, 223], ["antibiotic", "TREATMENT", 225, 235], ["glucocorticoid", "TREATMENT", 237, 251], ["angiotensin", "TREATMENT", 256, 267], ["converting enzyme inhibitors", "TREATMENT", 268, 296], ["ACE-I", "TREATMENT", 298, 303], ["angiotonin II receptor blockers", "TREATMENT", 306, 337], ["ARB", "TREATMENT", 338, 341], ["acute kidney injury", "PROBLEM", 397, 416], ["Echocardiographic Characteristics", "TEST", 438, 471], ["COVID", "TEST", 522, 527], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["systemic arterial", "ANATOMY", 54, 71], ["lymphocyte count", "OBSERVATION", 97, 113], ["partial", "OBSERVATION_MODIFIER", 135, 142], ["pressure", "OBSERVATION_MODIFIER", 143, 151], ["oxygen", "OBSERVATION_MODIFIER", 155, 161], ["acute", "OBSERVATION_MODIFIER", 397, 402], ["kidney", "ANATOMY", 403, 409], ["injury", "OBSERVATION", 410, 416]]], ["Compared with patients in the highest RVLS tertiles, those in the lowest tertile had similar left atrial and LV size, LV mass, E/A, E/e', LVEDV, LVESV, and LVEF.", [["left atrial", "ANATOMY", 93, 104], ["LV", "ANATOMY", 109, 111], ["LV", "ANATOMY", 118, 120], ["patients", "ORGANISM", 14, 22], ["atrial", "MULTI-TISSUE_STRUCTURE", 98, 104], ["LV", "MULTI-TISSUE_STRUCTURE", 109, 111], ["LV", "MULTI-TISSUE_STRUCTURE", 118, 120], ["patients", "SPECIES", 14, 22], ["similar left atrial and LV size", "PROBLEM", 85, 116], ["LV mass", "PROBLEM", 118, 125], ["E/A", "TEST", 127, 130], ["LVEDV", "TEST", 138, 143], ["LVESV", "TEST", 145, 150], ["LVEF", "TEST", 156, 160], ["left atrial", "ANATOMY", 93, 104], ["LV", "ANATOMY", 109, 111], ["size", "OBSERVATION_MODIFIER", 112, 116], ["LV", "ANATOMY", 118, 120], ["mass", "OBSERVATION", 121, 125], ["LVEDV", "OBSERVATION", 138, 143], ["LVESV", "OBSERVATION", 145, 150], ["LVEF", "OBSERVATION", 156, 160]]], ["Distribution of RVLS in patients with COVID-19 was presented in Figure 2 .Echocardiographic CharacteristicsPatients in the lowest RVLS tertile exhibited dilated right atrium, lower RVLS, RVFAC and TAPSE, more moderate-severe TR, and higher PASP.", [["right atrium", "ANATOMY", 161, 173], ["RVLS", "DISEASE", 16, 20], ["TAPSE", "DISEASE", 197, 202], ["RVLS", "CANCER", 16, 20], ["patients", "ORGANISM", 24, 32], ["right atrium", "MULTI-TISSUE_STRUCTURE", 161, 173], ["PASP", "PROTEIN", 240, 244], ["patients", "SPECIES", 24, 32], ["RVLS", "TEST", 16, 20], ["COVID", "TEST", 38, 43], ["Echocardiographic CharacteristicsPatients", "TEST", 74, 115], ["dilated right atrium", "PROBLEM", 153, 173], ["lower RVLS", "PROBLEM", 175, 185], ["RVFAC", "TEST", 187, 192], ["TAPSE", "TEST", 197, 202], ["more moderate-severe TR", "PROBLEM", 204, 227], ["higher PASP", "PROBLEM", 233, 244], ["dilated", "OBSERVATION", 153, 160], ["right atrium", "ANATOMY", 161, 173], ["lower RVLS", "ANATOMY", 175, 185], ["TAPSE", "OBSERVATION", 197, 202], ["moderate", "OBSERVATION_MODIFIER", 209, 217], ["severe", "OBSERVATION_MODIFIER", 218, 224], ["TR", "OBSERVATION", 225, 227], ["higher", "OBSERVATION_MODIFIER", 233, 239], ["PASP", "OBSERVATION", 240, 244]]], ["While RV, pulmonary artery and IVC dimension or S' did not differ between the tertiles.", [["RV", "ANATOMY", 6, 8], ["pulmonary artery", "ANATOMY", 10, 26], ["IVC", "ANATOMY", 31, 34], ["RV", "MULTI-TISSUE_STRUCTURE", 6, 8], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 10, 26], ["IVC", "MULTI-TISSUE_STRUCTURE", 31, 34], ["RV", "ANATOMY", 6, 8], ["pulmonary artery", "ANATOMY", 10, 26], ["IVC", "ANATOMY", 31, 34]]], ["RVLS was lower in ARDS than non-ARDS patients (21.3\u00b14.6% VS 24.6\u00b14.4%, P < 0.001).", [["ARDS", "DISEASE", 18, 22], ["non-ARDS", "DISEASE", 28, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["RVLS", "TEST", 0, 4], ["ARDS", "PROBLEM", 18, 22], ["VS", "TEST", 57, 59], ["\u00b1", "TEST", 64, 65], ["P", "TEST", 71, 72], ["lower", "OBSERVATION_MODIFIER", 9, 14], ["ARDS", "OBSERVATION", 18, 22]]], ["Among the patients, when separated by tertiles, mortality was highest in patients with a RVLS \u2264 20.5%, followed by RVLS in the range between 20.6% and 25.4%, and lowest among patients with RVLS \u2265 25.5% (P < 0.001) (Central Illustration).", [["RVLS", "DISEASE", 89, 93], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 175, 183], ["a RVLS", "TEST", 87, 93], ["RVLS", "TEST", 115, 119], ["RVLS", "TEST", 189, 193]]], ["When stratified by cutoff values, a RVLS lower than 23% was associated with higher mortality (P < 0.001) (Central Illustration).", [["cutoff values", "TEST", 19, 32], ["a RVLS", "TEST", 34, 40]]], ["It also clearly revealed that survival significantly declined with worsening TAPSE and RVFAC ( Figure 4A and 4B).", [["worsening TAPSE", "PROBLEM", 67, 82], ["RVFAC", "TEST", 87, 92]]], ["(Table 4)ReproducibilityThe intraobserver and interobserver reproducibility of RVLS was excellent, as reflected by high ICC (intraobserver: 0.95; interobserver: 0.91).", [["The intraobserver", "TEST", 24, 41], ["RVLS", "TEST", 79, 83], ["interobserver", "TEST", 146, 159]]], ["Bland-Altman analysis demonstrated good intraobserver and interobserver agreement, with small bias (intraobserver:-0.33; interobserver: 0.70) and narrow limits of agreement (intraobserver:-2.19\uff5e1.54; interobserver: -3.08\uff5e4.49).DISCUSSIONTo our knowledge, this is the first study to comprehensively evaluate the prognostic value of RV function using the conventional echocardiography and 2D-STE in patients with COVID-19.", [["RV", "ANATOMY", 331, 333], ["RV", "MULTI-TISSUE_STRUCTURE", 331, 333], ["patients", "ORGANISM", 397, 405], ["patients", "SPECIES", 397, 405], ["Altman analysis", "TEST", 6, 21], ["intraobserver", "TEST", 100, 113], ["interobserver", "TEST", 121, 134], ["intraobserver", "TEST", 174, 187], ["interobserver", "TEST", 200, 213], ["the conventional echocardiography", "TEST", 349, 382], ["COVID", "TEST", 411, 416], ["good", "OBSERVATION_MODIFIER", 35, 39], ["RV", "ANATOMY", 331, 333]]], ["Patients with the greatest degree of RV strain impairment were more likely to have a higher heart rate, high-flow oxygen and invasive mechanical ventilation therapy, higher incidence of acute heart injury, ARDS and deep vein thrombosis, and higher mortality.DISCUSSIONCompared with survivors, non-survivors presented enlarged right-heart chamber, diminished RV function, and elevated PASP.", [["heart", "ANATOMY", 92, 97], ["heart", "ANATOMY", 192, 197], ["deep vein", "ANATOMY", 215, 224], ["right-heart chamber", "ANATOMY", 326, 345], ["RV", "ANATOMY", 358, 360], ["RV strain impairment", "DISEASE", 37, 57], ["oxygen", "CHEMICAL", 114, 120], ["heart injury", "DISEASE", 192, 204], ["ARDS", "DISEASE", 206, 210], ["deep vein thrombosis", "DISEASE", 215, 235], ["oxygen", "CHEMICAL", 114, 120], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 92, 97], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["heart", "ORGAN", 192, 197], ["vein", "MULTI-TISSUE_STRUCTURE", 220, 224], ["heart", "ORGAN", 332, 337], ["RV", "MULTI-TISSUE_STRUCTURE", 358, 360], ["PASP", "PROTEIN", 384, 388], ["Patients", "SPECIES", 0, 8], ["RV strain impairment", "PROBLEM", 37, 57], ["a higher heart rate", "PROBLEM", 83, 102], ["high-flow oxygen", "TREATMENT", 104, 120], ["invasive mechanical ventilation therapy", "TREATMENT", 125, 164], ["acute heart injury", "PROBLEM", 186, 204], ["ARDS", "PROBLEM", 206, 210], ["deep vein thrombosis", "PROBLEM", 215, 235], ["higher mortality", "PROBLEM", 241, 257], ["enlarged right-heart chamber", "PROBLEM", 317, 345], ["diminished RV function", "PROBLEM", 347, 369], ["elevated PASP", "PROBLEM", 375, 388], ["RV", "ANATOMY", 37, 39], ["strain", "OBSERVATION", 40, 46], ["heart", "ANATOMY", 92, 97], ["flow oxygen", "OBSERVATION", 109, 120], ["invasive", "OBSERVATION_MODIFIER", 125, 133], ["mechanical ventilation therapy", "OBSERVATION", 134, 164], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["heart", "ANATOMY", 192, 197], ["injury", "OBSERVATION", 198, 204], ["ARDS", "OBSERVATION", 206, 210], ["deep vein thrombosis", "OBSERVATION", 215, 235], ["higher", "OBSERVATION_MODIFIER", 241, 247], ["mortality", "OBSERVATION_MODIFIER", 248, 257], ["enlarged", "OBSERVATION", 317, 325], ["right", "ANATOMY_MODIFIER", 326, 331], ["heart", "ANATOMY", 332, 337], ["chamber", "ANATOMY_MODIFIER", 338, 345], ["diminished", "OBSERVATION_MODIFIER", 347, 357], ["RV function", "OBSERVATION", 358, 369], ["elevated", "OBSERVATION_MODIFIER", 375, 383], ["PASP", "OBSERVATION", 384, 388]]], ["More importantly, RVLS was able to predict higher risk of mortality in COVID-19 patients, independently of, and incrementally to other echocardiographic parameters.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["echocardiographic parameters", "TEST", 135, 163]]], ["Therefore, comprehensive assessment of RV function using 2D-STE may be essential for risk stratification in COVID-19 patients.Prognosis of RV Function in COVID-19 PatientsIt is significant to recognize patients with COVID-19 at higher risk for poor outcomes who might benefit from vigilant monitoring.", [["RV", "ANATOMY", 39, 41], ["RV", "ANATOMY", 139, 141], ["RV", "MULTI-TISSUE_STRUCTURE", 39, 41], ["patients", "ORGANISM", 117, 125], ["RV", "ORGAN", 139, 141], ["Patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 117, 125], ["Patients", "SPECIES", 163, 171], ["patients", "SPECIES", 202, 210], ["comprehensive assessment", "TEST", 11, 35], ["RV function", "TEST", 39, 50], ["COVID", "TEST", 108, 113], ["RV Function", "TEST", 139, 150], ["COVID", "TEST", 154, 159], ["COVID", "TEST", 216, 221], ["vigilant monitoring", "TEST", 281, 300], ["RV", "ANATOMY", 39, 41], ["RV", "ANATOMY", 139, 141]]], ["Several risk factors of poor prognosis have been identified in SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 63, 83], ["SARS-CoV-2", "ORGANISM", 63, 73], ["SARS-CoV-2", "SPECIES", 63, 73], ["poor prognosis", "PROBLEM", 24, 38], ["SARS", "PROBLEM", 63, 67], ["2 infection", "PROBLEM", 72, 83], ["infection", "OBSERVATION", 74, 83]]], ["16, 17 The role of the previously described prognostic markers, in particular ARDS and male sex, was confirmed in the present study.", [["ARDS", "DISEASE", 78, 82], ["ARDS", "PROBLEM", 78, 82], ["the present study", "TEST", 114, 131]]], ["Furthermore, our study revealed important additional prognostic value of RV dysfunction.", [["RV", "ANATOMY", 73, 75], ["RV dysfunction", "DISEASE", 73, 87], ["RV", "ORGAN", 73, 75], ["our study", "TEST", 13, 22], ["RV dysfunction", "PROBLEM", 73, 87], ["RV", "ANATOMY", 73, 75], ["dysfunction", "OBSERVATION", 76, 87]]], ["Most notably, the additional prognostic value of RVLS was substantial independent of LV systolic functional index, which failed to predict mortality in patients with COVID-19.", [["LV", "ANATOMY", 85, 87], ["COVID-19", "CHEMICAL", 166, 174], ["RVLS", "CANCER", 49, 53], ["LV", "MULTI-TISSUE_STRUCTURE", 85, 87], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["COVID", "TEST", 166, 171], ["LV systolic", "ANATOMY", 85, 96], ["functional index", "OBSERVATION", 97, 113]]], ["This is consistent with a previous study of LV performance in severe acute respiratory syndrome (SARS), showing that only subclinical LV diastolic impairment was observed in patients with SARS.", [["LV", "ANATOMY", 44, 46], ["LV", "ANATOMY", 134, 136], ["acute respiratory syndrome", "DISEASE", 69, 95], ["SARS", "DISEASE", 97, 101], ["LV diastolic impairment", "DISEASE", 134, 157], ["SARS", "DISEASE", 188, 192], ["LV", "MULTI-TISSUE_STRUCTURE", 44, 46], ["LV", "MULTI-TISSUE_STRUCTURE", 134, 136], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["a previous study", "TEST", 24, 40], ["LV performance", "TEST", 44, 58], ["severe acute respiratory syndrome", "PROBLEM", 62, 95], ["subclinical LV diastolic impairment", "PROBLEM", 122, 157], ["SARS", "PROBLEM", 188, 192], ["consistent with", "UNCERTAINTY", 8, 23], ["LV", "ANATOMY", 44, 46], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory syndrome", "OBSERVATION", 75, 95], ["subclinical", "OBSERVATION_MODIFIER", 122, 133], ["LV diastolic", "ANATOMY", 134, 146], ["impairment", "OBSERVATION", 147, 157]]], ["18 Nevertheless, the prognostic value of RV function was not yet explored in the study of SARS.Prognosis of RV Function in COVID-19 PatientsRV dysfunction is related to significant morbidity and mortality in a variety of cardiovascular diseases.", [["RV", "ANATOMY", 41, 43], ["RV", "ANATOMY", 108, 110], ["cardiovascular", "ANATOMY", 221, 235], ["SARS", "DISEASE", 90, 94], ["PatientsRV dysfunction", "DISEASE", 132, 154], ["cardiovascular diseases", "DISEASE", 221, 244], ["RV", "MULTI-TISSUE_STRUCTURE", 41, 43], ["RV", "ORGAN", 108, 110], ["cardiovascular", "ANATOMICAL_SYSTEM", 221, 235], ["RV function", "TEST", 41, 52], ["the study", "TEST", 77, 86], ["SARS", "PROBLEM", 90, 94], ["RV Function", "TEST", 108, 119], ["COVID", "TEST", 123, 128], ["PatientsRV dysfunction", "PROBLEM", 132, 154], ["significant morbidity", "PROBLEM", 169, 190], ["cardiovascular diseases", "PROBLEM", 221, 244], ["RV", "ANATOMY", 108, 110], ["Function", "OBSERVATION", 111, 119], ["significant", "OBSERVATION_MODIFIER", 169, 180], ["morbidity", "OBSERVATION", 181, 190], ["cardiovascular diseases", "OBSERVATION", 221, 244]]], ["[9] [10] [19] [20] Indeed, in the present study, non-survivors displayed RV dilation and dysfunction.", [["RV", "ANATOMY", 73, 75], ["RV dilation", "DISEASE", 73, 84], ["[9] [10] [19] [20", "SIMPLE_CHEMICAL", 0, 17], ["RV", "MULTI-TISSUE_STRUCTURE", 73, 75], ["RV dilation", "PROBLEM", 73, 84], ["dysfunction", "PROBLEM", 89, 100], ["RV", "ANATOMY", 73, 75], ["dilation", "OBSERVATION", 76, 84], ["dysfunction", "OBSERVATION", 89, 100]]], ["It has been reported that SARS-CoV-2 infection could cause both pulmonary and systemic inflammations, which may contribute to RV failure through RV overload and direct damage to cardiomyocyte.", [["pulmonary", "ANATOMY", 64, 73], ["RV", "ANATOMY", 126, 128], ["RV", "ANATOMY", 145, 147], ["cardiomyocyte", "ANATOMY", 178, 191], ["infection", "DISEASE", 37, 46], ["inflammations", "DISEASE", 87, 100], ["RV failure", "DISEASE", 126, 136], ["RV overload", "DISEASE", 145, 156], ["SARS-CoV-2", "ORGANISM", 26, 36], ["pulmonary", "ORGAN", 64, 73], ["RV", "ORGAN", 126, 128], ["RV", "MULTI-TISSUE_STRUCTURE", 145, 147], ["cardiomyocyte", "CELL", 178, 191], ["SARS-CoV-2", "SPECIES", 26, 36], ["SARS", "PROBLEM", 26, 30], ["CoV-2 infection", "PROBLEM", 31, 46], ["pulmonary and systemic inflammations", "PROBLEM", 64, 100], ["RV failure", "PROBLEM", 126, 136], ["RV overload", "PROBLEM", 145, 156], ["direct damage to cardiomyocyte", "PROBLEM", 161, 191], ["SARS", "OBSERVATION", 26, 30], ["infection", "OBSERVATION", 37, 46], ["pulmonary", "ANATOMY", 64, 73], ["systemic", "OBSERVATION_MODIFIER", 78, 86], ["inflammations", "OBSERVATION", 87, 100], ["RV", "ANATOMY", 126, 128], ["failure", "OBSERVATION", 129, 136], ["RV", "ANATOMY", 145, 147], ["overload", "OBSERVATION", 148, 156], ["cardiomyocyte", "ANATOMY", 178, 191]]], ["17, 21 Similarly, in 42 patients with moderate-to-severe ARDS, Lazzeri et al demonstrated that troponin release can be related to RV dysfunction, thus emphasizing the clinical role of RV function.", [["RV", "ANATOMY", 130, 132], ["RV", "ANATOMY", 184, 186], ["ARDS", "DISEASE", 57, 61], ["RV dysfunction", "DISEASE", 130, 144], ["patients", "ORGANISM", 24, 32], ["troponin", "GENE_OR_GENE_PRODUCT", 95, 103], ["RV", "MULTI-TISSUE_STRUCTURE", 130, 132], ["RV", "MULTI-TISSUE_STRUCTURE", 184, 186], ["troponin", "PROTEIN", 95, 103], ["patients", "SPECIES", 24, 32], ["moderate-to-severe ARDS", "PROBLEM", 38, 61], ["Lazzeri et al", "TREATMENT", 63, 76], ["troponin release", "PROBLEM", 95, 111], ["RV dysfunction", "PROBLEM", 130, 144], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["ARDS", "OBSERVATION", 57, 61], ["RV", "ANATOMY", 130, 132], ["dysfunction", "OBSERVATION", 133, 144], ["RV", "ANATOMY", 184, 186]]], ["22 Moreover, although sharing considerable similarities, myocardial injury and cardiac insufficiency were more frequently reported in patients with COVID-19 than in those with SARS.", [["myocardial", "ANATOMY", 57, 67], ["cardiac", "ANATOMY", 79, 86], ["myocardial injury", "DISEASE", 57, 74], ["cardiac insufficiency", "DISEASE", 79, 100], ["SARS", "DISEASE", 176, 180], ["myocardial", "MULTI-TISSUE_STRUCTURE", 57, 67], ["cardiac", "ORGAN", 79, 86], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["myocardial injury", "PROBLEM", 57, 74], ["cardiac insufficiency", "PROBLEM", 79, 100], ["COVID", "TEST", 148, 153], ["SARS", "PROBLEM", 176, 180], ["myocardial", "ANATOMY", 57, 67], ["injury", "OBSERVATION", 68, 74], ["cardiac", "ANATOMY", 79, 86], ["insufficiency", "OBSERVATION", 87, 100]]], ["17, 23 Therefore, assessment of RV function and recognition its prognostic significance is necessary in patients with COVID-19.", [["RV", "ANATOMY", 32, 34], ["RV", "MULTI-TISSUE_STRUCTURE", 32, 34], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["assessment of RV function", "TEST", 18, 43], ["COVID", "TEST", 118, 123], ["RV", "ANATOMY", 32, 34]]], ["RV dysfunction is not only a sign of increased pulmonary pressures, but also directly contribute to cardiac insufficiency.Evaluation of RV Function using EchocardiographyAlthough cardiac magnetic resonance (CMR) imaging remains the gold standard for quantifying RV function, 24 in our study, the highly contagious nature of Covid-19 and patients' inability to hold breath for a short time limit the application of CMR.Evaluation of RV Function using EchocardiographyEchocardiography is more widely used in daily practice.", [["RV", "ANATOMY", 0, 2], ["pulmonary", "ANATOMY", 47, 56], ["cardiac", "ANATOMY", 100, 107], ["RV", "ANATOMY", 262, 264], ["RV dysfunction", "DISEASE", 0, 14], ["cardiac insufficiency", "DISEASE", 100, 121], ["RV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["pulmonary", "ORGAN", 47, 56], ["cardiac", "ORGAN", 100, 107], ["RV", "MULTI-TISSUE_STRUCTURE", 136, 138], ["RV", "MULTI-TISSUE_STRUCTURE", 262, 264], ["patients", "ORGANISM", 337, 345], ["RV", "MULTI-TISSUE_STRUCTURE", 432, 434], ["patients", "SPECIES", 337, 345], ["RV dysfunction", "PROBLEM", 0, 14], ["increased pulmonary pressures", "PROBLEM", 37, 66], ["cardiac insufficiency", "PROBLEM", 100, 121], ["Evaluation of RV Function", "TEST", 122, 147], ["Echocardiography", "TEST", 154, 170], ["cardiac magnetic resonance", "TEST", 179, 205], ["CMR", "TEST", 207, 210], ["imaging", "TEST", 212, 219], ["our study", "TEST", 281, 290], ["Covid", "TEST", 324, 329], ["patients' inability to hold breath", "PROBLEM", 337, 371], ["CMR", "TEST", 414, 417], ["Evaluation of RV Function", "TEST", 418, 443], ["Echocardiography", "TEST", 450, 466], ["Echocardiography", "TEST", 466, 482], ["dysfunction", "OBSERVATION", 3, 14], ["not only a sign of", "UNCERTAINTY", 18, 36], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["pulmonary pressures", "OBSERVATION", 47, 66], ["cardiac", "ANATOMY", 100, 107], ["insufficiency", "OBSERVATION", 108, 121], ["RV", "ANATOMY", 136, 138], ["RV", "ANATOMY", 262, 264], ["contagious", "OBSERVATION_MODIFIER", 303, 313], ["RV", "ANATOMY", 432, 434]]], ["In clinical practice, it is routine to evaluate RV function using conventional echocardiogram parameters recommended by guidelines, 14Clinical ImplicationsOur data demonstrated that RVLS was a powerful and independent predictor of higher mortality, providing additive predictive value over other echocardiographic parameters in patients with COVID-19.", [["RV", "ANATOMY", 48, 50], ["COVID-19", "CHEMICAL", 342, 350], ["RV", "MULTI-TISSUE_STRUCTURE", 48, 50], ["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 328, 336], ["conventional echocardiogram parameters", "TEST", 66, 104], ["echocardiographic parameters", "TEST", 296, 324], ["COVID", "TEST", 342, 347]]], ["Accordingly, the present study revealed the important clinical implication of RVLS, as it can be easily obtained from bedside echocardiography.", [["RVLS", "SIMPLE_CHEMICAL", 78, 82], ["the present study", "TEST", 13, 30], ["bedside echocardiography", "TEST", 118, 142]]], ["This suggests that evaluation of RV function by conventional echocardiography measurements (ie, FAC or TAPSE) need to be complemented by LS analysis to identify patients at higher risk of poor outcome.LimitationsAlthough our study was a cohort of homogenous and consecutive patients who were hospitalized with COVID-19, it is limited by being a single-center study with a relatively limited sample size.", [["RV", "ANATOMY", 33, 35], ["RV", "MULTI-TISSUE_STRUCTURE", 33, 35], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 274, 282], ["evaluation of RV function", "TEST", 19, 44], ["conventional echocardiography measurements", "TEST", 48, 90], ["LS analysis", "TEST", 137, 148], ["poor outcome", "PROBLEM", 188, 200], ["our study", "TEST", 221, 230], ["COVID", "TEST", 310, 315], ["RV", "ANATOMY", 33, 35], ["size", "OBSERVATION_MODIFIER", 398, 402]]], ["Our hospital is one of hardest-hit hospitals by the COVID-19 in Wuhan, the patients we included may not represent the population in other areas.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["may not represent", "UNCERTAINTY", 96, 113], ["population", "OBSERVATION", 118, 128]]], ["Moreover, we enrolled patients who were hospitalized with COVID-19, and the asymptomatic patients who had not been admitted to hospital were not included.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 89, 97]]], ["Considering the wide clinical spectrum of SARS-CoV-2 infection, our findings may not be applicable to the entire COVID-19 population.", [["SARS-CoV-2 infection", "DISEASE", 42, 62], ["SARS-CoV-2", "ORGANISM", 42, 52], ["COVID-19 population", "CELL_LINE", 113, 132], ["SARS-CoV-2", "SPECIES", 42, 52], ["SARS", "PROBLEM", 42, 46], ["CoV-2 infection", "PROBLEM", 47, 62], ["wide", "OBSERVATION_MODIFIER", 16, 20], ["SARS", "OBSERVATION", 42, 46], ["infection", "OBSERVATION", 53, 62]]], ["Therefore, future studies with multi-center and a larger sample size studies are needed to determine the prognosis value of RVLS in COVID-19 patients.", [["RVLS", "DISEASE", 124, 128], ["RVLS", "CANCER", 124, 128], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["future studies", "TEST", 11, 25], ["a larger sample size studies", "TEST", 48, 76], ["RVLS", "TEST", 124, 128]]], ["Beside, we excluded 24 patients owing to poor image quality precluding strain analysis, which limits the generalizability of our results.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["strain analysis", "TEST", 71, 86]]], ["And the results pertain only to the software used in our study and may not apply to other software algorithms because the 2D-STE parameters are hampered by the intervendor variability. we used RV free-wall LS instead of global RV strain because a simultaneous echocardiographic-catheterization study demonstrated that free-wall LS might better reflect RV function than global RV strain.", [["RV", "ANATOMY", 352, 354], ["RV", "MULTI-TISSUE_STRUCTURE", 352, 354], ["our study", "TEST", 53, 62], ["software algorithms", "TEST", 90, 109], ["the 2D-STE parameters", "TEST", 118, 139], ["global RV strain", "PROBLEM", 220, 236], ["a simultaneous echocardiographic", "TEST", 245, 277], ["catheterization study", "TEST", 278, 299], ["free-wall LS", "TEST", 318, 330], ["global RV strain", "PROBLEM", 369, 385], ["wall", "ANATOMY_MODIFIER", 201, 205], ["global RV", "ANATOMY", 220, 229], ["RV", "ANATOMY", 352, 354], ["function", "OBSERVATION", 355, 363], ["RV strain", "OBSERVATION", 376, 385]]], ["27 Moreover, the relationship between LV and RV function could not be explored in the present study, as RV function could be affected by subclinical LV dysfunction.", [["LV", "ANATOMY", 38, 40], ["RV", "ANATOMY", 45, 47], ["RV", "ANATOMY", 104, 106], ["LV", "ANATOMY", 149, 151], ["LV dysfunction", "DISEASE", 149, 163], ["LV", "MULTI-TISSUE_STRUCTURE", 38, 40], ["RV", "MULTI-TISSUE_STRUCTURE", 45, 47], ["RV", "MULTI-TISSUE_STRUCTURE", 104, 106], ["LV", "MULTI-TISSUE_STRUCTURE", 149, 151], ["the present study", "TEST", 82, 99], ["RV function", "TEST", 104, 115], ["subclinical LV dysfunction", "PROBLEM", 137, 163], ["LV", "ANATOMY", 38, 40], ["RV", "ANATOMY", 45, 47], ["subclinical LV dysfunction", "OBSERVATION", 137, 163]]], ["Furthermore, obesity patients were uncommon in our study, as obesity is preliminarily considered as a high risk factor.CONCLUSIONSOur study demonstrates that RVLS is an independent determinant of outcomes in patients with COVID-19.", [["obesity", "DISEASE", 13, 20], ["obesity", "DISEASE", 61, 68], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 208, 216], ["obesity", "PROBLEM", 13, 20], ["our study", "TEST", 47, 56], ["obesity", "PROBLEM", 61, 68], ["a high risk factor", "PROBLEM", 100, 118], ["CONCLUSIONSOur study", "TEST", 119, 139], ["COVID", "TEST", 222, 227], ["obesity", "OBSERVATION", 13, 20]]], ["Importantly, this index may have an additional predictive value over other echocardiographic parameters.", [["this index", "TEST", 13, 23], ["echocardiographic parameters", "TEST", 75, 103]]], ["Therefore, evaluation of RV function should be implemented by investigation of RVLS for risk stratification in COVID-19 patients.COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Right ventricularlongitudinal strain is a powerful and independent predictor of higher mortality, providing additive predictive value over other echocardiographic parameters in patients with COVID-19.", [["RV", "ANATOMY", 25, 27], ["COVID-19", "CHEMICAL", 370, 378], ["RV", "MULTI-TISSUE_STRUCTURE", 25, 27], ["RVLS", "CANCER", 79, 83], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 356, 364], ["evaluation of RV function", "TEST", 11, 36], ["COVID", "TEST", 111, 116], ["Right ventricularlongitudinal strain", "PROBLEM", 179, 215], ["echocardiographic parameters", "TEST", 324, 352], ["COVID", "TEST", 370, 375], ["RV", "ANATOMY", 25, 27], ["Right", "ANATOMY_MODIFIER", 179, 184]]], ["Our study demonstrated comprehensive assessment of RV function by 2D-STE may be essential for risk stratification in COVID-19 patients.TRANSLATIONAL OUTLOOK:Future studies are needed to verify the value of 2D-STE using different software in multicenter design for risk stratification of COVID-19 patients.", [["RV", "ANATOMY", 51, 53], ["RV", "MULTI-TISSUE_STRUCTURE", 51, 53], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 296, 304], ["Our study", "TEST", 0, 9], ["comprehensive assessment", "TEST", 23, 47], ["COVID", "TEST", 117, 122], ["Future studies", "TEST", 157, 171], ["COVID", "TEST", 287, 292], ["RV", "ANATOMY", 51, 53]]]], "PMC7223103": [["IntroductionDeath of a paediatric malignancy patient is not just a physical but also a huge psycho-social loss for the family.", [["malignancy", "DISEASE", 34, 44], ["psycho-social loss", "DISEASE", 92, 110], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["a paediatric malignancy", "PROBLEM", 21, 44], ["malignancy", "OBSERVATION", 34, 44]]], ["Decisions regarding the expected death of a child, like end of life care plan, hospital- or home-based care, are often taken into isolation by care givers and are seldom discussed with the child [1].", [["death", "DISEASE", 33, 38]]], ["Pattern of end of life palliation opted by family has a variable spectrum.", [["life palliation", "TREATMENT", 18, 33]]], ["A study from Germany noted that 40% of advanced cancer cases opted for chemotherapy-based palliation, but majority regretted it in hindsight.", [["cancer", "ANATOMY", 48, 54], ["cancer", "DISEASE", 48, 54], ["cancer", "CANCER", 48, 54], ["A study", "TEST", 0, 7], ["advanced cancer cases", "TREATMENT", 39, 60], ["chemotherapy", "TREATMENT", 71, 83], ["based palliation", "TREATMENT", 84, 100], ["cancer", "OBSERVATION", 48, 54], ["palliation", "OBSERVATION", 90, 100]]], ["Studies have elaborated the symptoms encountered by the dying child as loneliness, fear of death, irritability and dullness.", [["loneliness", "DISEASE", 71, 81], ["death", "DISEASE", 91, 96], ["irritability", "DISEASE", 98, 110], ["dullness", "DISEASE", 115, 123], ["the symptoms", "PROBLEM", 24, 36], ["death", "PROBLEM", 91, 96], ["irritability", "PROBLEM", 98, 110], ["dullness", "PROBLEM", 115, 123], ["dullness", "OBSERVATION", 115, 123]]], ["Despite interventions, satisfactory control was seldom achieved [4, 5].IntroductionData regarding impact of socio-economic background and literacy are sparse.", [["interventions", "TREATMENT", 8, 21]]], ["The Paediatric Oncology Division of Cancer Research Institute, Dehradun, India, caters to the population from sub-Himalayan terrain and neighbouring states.", [["Cancer", "DISEASE", 36, 42], ["Cancer", "OBSERVATION", 36, 42], ["sub", "OBSERVATION_MODIFIER", 110, 113]]], ["Our enlistment is mainly lower or low-middle class population with poor social support.", [["Our enlistment", "TEST", 0, 14], ["mainly", "OBSERVATION_MODIFIER", 18, 24], ["lower", "OBSERVATION_MODIFIER", 25, 30], ["low", "OBSERVATION_MODIFIER", 34, 37], ["middle class", "OBSERVATION_MODIFIER", 38, 50], ["poor", "OBSERVATION_MODIFIER", 67, 71], ["social support", "OBSERVATION", 72, 86]]], ["This centre is a teaching medical school run by a trust and it delivers low-cost treatments to all conditions.", [["low-cost treatments", "TREATMENT", 72, 91]]], ["The pattern of choice of palliation is probably different in such population.", [["palliation", "TREATMENT", 25, 35], ["palliation", "OBSERVATION", 25, 35], ["probably", "UNCERTAINTY", 39, 47], ["different", "OBSERVATION_MODIFIER", 48, 57]]], ["Thus, this study was conducted to analyse the choices opted for end of life care plan in paediatric oncology patients, and to understand the end of life care needs, regrets and understanding of prognosis of the child by the care givers.MethodThis study was conducted at the Paediatric Oncology Division, Cancer Research Institute, Dehradun, India.", [["Cancer", "DISEASE", 304, 310], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["this study", "TEST", 6, 16], ["This study", "TEST", 242, 252], ["Cancer", "OBSERVATION", 304, 310]]], ["The study population included paediatric oncology patients labelled as relapsed/refractory who died during the time period January 2016 to January 2018.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Families of deceased children were contacted telephonically and requested for an interview.", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29]]], ["One parent of the child was interviewed and decision to enrol mother or father was entirely of family.", [["child", "ORGANISM", 18, 23], ["child", "SPECIES", 18, 23]]], ["The interview constituted of six structured sections in a pre-formed questionnaire, created by experts in the field, using a separate feedback obtained from an open discussion with ten families who lost their children due to progressive terminal cancer and some articles from previously published studies [6].", [["terminal cancer", "ANATOMY", 237, 252], ["terminal cancer", "DISEASE", 237, 252], ["children", "ORGANISM", 209, 217], ["terminal cancer", "CANCER", 237, 252], ["children", "SPECIES", 209, 217], ["progressive terminal cancer", "PROBLEM", 225, 252], ["progressive", "OBSERVATION_MODIFIER", 225, 236], ["terminal", "OBSERVATION_MODIFIER", 237, 245], ["cancer", "OBSERVATION", 246, 252]]], ["Interviews were conducted either in person or telephonically.MethodSections of interview were designed to incorporate various aspects of terminal care (Table 1).MethodThis was an open-ended interview in the language (Hindi) of the family member.", [["person", "SPECIES", 36, 42], ["terminal care", "TREATMENT", 137, 150]]], ["Patients\u2019 hospital records were surveyed to record the timing of declaration of in-curability by the treating team, options of EOLC discussion, treatment options offered and consent for opting or declining intensive care in such a situation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["treatment options", "TREATMENT", 144, 161]]], ["Demographic profile of the patients and family, disease details, treatment received and family structure were noted as well.MethodThis study was duly approved by institutional ethical committee (HIMS/RC/2018/199) and written informed consent was taken from each participant before enrolment in the study.AnalysisThe data was entered in Excel sheet and analysed using SPSS software.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["treatment", "TREATMENT", 65, 74], ["MethodThis study", "TEST", 124, 140], ["the study", "TEST", 294, 303], ["Analysis", "TEST", 304, 312], ["The data", "TEST", 312, 320], ["SPSS software", "TEST", 367, 380]]], ["Two-tailed Fisher exact test was used for dichotomised data while chi-square and Student\u2019s t test was used for individual variables.", [["dichotomised data", "TEST", 42, 59], ["Student\u2019s t test", "TEST", 81, 97]]], ["P value of < 0.05 was considered significant.The demographic and disease details of the study group ::: ResultThe mean age of children was 12.04 years (range = 4\u201318, \u00b1 4.61 SD).", [["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["P value", "TEST", 0, 7]]], ["The number of months lapsed between the demise of child and the interview was noted, the mean time from death was 17.88 months (range = 15\u201322, \u00b1 1.53 SD).", [["death", "DISEASE", 104, 109]]], ["The demographic details and disease parameters of deceased children are detailed in Table 2.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]], ["The mean income of the families was Rs 18,080 per month (range = 8000\u201336,000, \u00b1 7330.98 SD).The terminal month of the child ::: ResultThe median lag time between the declaration of in-curability and family\u2019s acceptance of the same was 3 months.", [["terminal", "OBSERVATION_MODIFIER", 96, 104]]], ["After declaration of in-curability, 30% families opted for alternative chemotherapy while 20% opted for salvage regimen (chemotherapy for relapse/refractory cases) initially with belief of improvement and cure.", [["alternative chemotherapy", "TREATMENT", 59, 83], ["salvage regimen", "TREATMENT", 104, 119], ["chemotherapy", "TREATMENT", 121, 133], ["relapse/refractory cases", "TREATMENT", 138, 162]]], ["However, only 3 patients were continuing these modalities even at the terminal week.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["The most disturbing symptom noted by the family during the terminal months of the children was pain followed by breathing difficulty (Table 3).", [["pain", "DISEASE", 95, 99], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["The most disturbing symptom", "PROBLEM", 0, 27], ["pain", "PROBLEM", 95, 99], ["breathing difficulty", "PROBLEM", 112, 132]]], ["Concerns about food intake and presence of altered sensorium were noted by almost every family.", [["sensorium", "DISEASE", 51, 60], ["altered sensorium", "PROBLEM", 43, 60], ["altered", "OBSERVATION_MODIFIER", 43, 50], ["sensorium", "OBSERVATION", 51, 60]]], ["Median scale of severity of child\u2019s distress on 0 to 5 scale was 3; it was same for admitted and non-admitted patients.Choice of EOLC plan ::: ResultOnly 30% families chose hospital-based terminal care for their child.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["distress", "PROBLEM", 36, 44]]], ["The reasons for their choice were quoted as cost of care, distance from home, more children to attend at home, relative\u2019s pressure and fear of persistent symptoms (Table 4).", [["children", "SPECIES", 83, 91], ["persistent symptoms", "PROBLEM", 143, 162]]], ["None of the families consulted the child for his or her choice regarding the place of EOLC plan.", [["child", "ORGANISM", 35, 40], ["EOLC plan", "TREATMENT", 86, 95]]], ["A total of 12 (46%) families regretted their choice of EOLC plan in retrospect.", [["EOLC plan", "TREATMENT", 55, 64]]], ["This retrospective regret was more common with families opting hospital as EOLC place (P = 0.03) and also in families with self-financed treatment (P = 0.179) (Tables 5).", [["self-financed treatment", "TREATMENT", 123, 146]]], ["Pain was noted to be significantly more observed symptoms in the home-based EOLC group (P = 0.020) and respiratory distress was the most bothersome symptom among the admitted group (Table 6).", [["respiratory", "ANATOMY", 103, 114], ["Pain", "DISEASE", 0, 4], ["respiratory distress", "DISEASE", 103, 123], ["Pain", "PROBLEM", 0, 4], ["significantly more observed symptoms", "PROBLEM", 21, 57], ["respiratory distress", "PROBLEM", 103, 123], ["the most bothersome symptom", "PROBLEM", 128, 155], ["respiratory", "ANATOMY", 103, 114], ["distress", "OBSERVATION", 115, 123]]], ["Admitted children had easy access to medicinal remedies for their symptoms and 54% parent expressed their perception as near satisfactory for the control of symptoms temporarily.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["medicinal remedies", "TREATMENT", 37, 55], ["their symptoms", "PROBLEM", 60, 74], ["symptoms", "PROBLEM", 157, 165]]], ["The hospital-based EOLC group regretted its decision with reasons\u2014uncontrolled pain, fearfulness of child regarding the hospital environment and child\u2019s unfulfilled desire to be at home.", [["pain", "DISEASE", 79, 83], ["\u2014uncontrolled pain", "PROBLEM", 65, 83]]], ["The home-based EOLC group regretted its decision with reasons\u2014uncontrolled pain and non-availability of medical help at home (Table 7).", [["pain", "DISEASE", 75, 79], ["uncontrolled pain", "PROBLEM", 62, 79]]], ["Only 3 patients that opted for home-based EOLC were visited by health care worker during terminal care.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["On univariate analysis using the Pearson chi-square test, only living in a rental house was significantly associated with the choice of home-based EOLC (Table 8).DiscussionPaediatric oncology as a separate speciality was unrecognised for a long time in India.", [["univariate analysis", "TEST", 3, 22], ["the Pearson chi-square test", "TEST", 29, 56]]], ["Surveys showed that majority of paediatric cancer patients were sub-optimally treated with either adult medical oncologist or self-trained paediatricians.", [["cancer", "ANATOMY", 43, 49], ["cancer", "DISEASE", 43, 49], ["cancer", "CANCER", 43, 49], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["paediatric cancer", "PROBLEM", 32, 49], ["majority", "OBSERVATION_MODIFIER", 20, 28], ["paediatric", "OBSERVATION_MODIFIER", 32, 42], ["cancer", "OBSERVATION", 43, 49]]], ["Resource allocation in such a large country has severe imbalance.", [["Resource allocation", "TREATMENT", 0, 19], ["severe imbalance", "PROBLEM", 48, 64], ["large", "OBSERVATION_MODIFIER", 30, 35], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["imbalance", "OBSERVATION", 55, 64]]], ["While centres in metropolitan cities have specialised paediatric oncology services and collaborative trials have started, rural India lacks the basic diagnostic facilities for such ailments and under reporting of cancers is common.", [["cancers", "ANATOMY", 213, 220], ["cancers", "DISEASE", 213, 220], ["cancers", "CANCER", 213, 220], ["such ailments", "PROBLEM", 176, 189], ["cancers", "PROBLEM", 213, 220], ["cancers", "OBSERVATION", 213, 220]]], ["India has also witnessed a remarkable improvement in paediatric cancer survivorship and at dedicated centres; its rate is approaching comparable with western data.DiscussionWith advancement in understanding of supportive care, paediatric cancers are curable in majority, yet long period of in-curable disease and eventual mortality is a fact faced by many patients.", [["cancer", "ANATOMY", 64, 70], ["cancers", "ANATOMY", 238, 245], ["cancer", "DISEASE", 64, 70], ["cancers", "DISEASE", 238, 245], ["cancer", "CANCER", 64, 70], ["cancers", "CANCER", 238, 245], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 356, 364], ["paediatric cancer survivorship", "PROBLEM", 53, 83], ["supportive care", "TREATMENT", 210, 225], ["paediatric cancers", "PROBLEM", 227, 245], ["remarkable", "OBSERVATION_MODIFIER", 27, 37], ["improvement", "OBSERVATION_MODIFIER", 38, 49], ["cancer", "OBSERVATION", 64, 70], ["cancers", "OBSERVATION", 238, 245]]], ["EOLC is needed in about 675,000 cancer cases and 25% of diagnosed paediatric cancer cases [11, 12].", [["cancer", "ANATOMY", 32, 38], ["cancer", "ANATOMY", 77, 83], ["cancer", "DISEASE", 32, 38], ["cancer", "DISEASE", 77, 83], ["cancer", "CANCER", 32, 38], ["cancer", "CANCER", 77, 83], ["diagnosed paediatric cancer cases", "PROBLEM", 56, 89], ["cancer", "OBSERVATION", 77, 83]]], ["Approach for care at time of impending death and beyond leads to the concept of end of life palliative care.", [["death", "DISEASE", 39, 44], ["impending death", "PROBLEM", 29, 44], ["life palliative care", "TREATMENT", 87, 107]]], ["By the 1980s, this concept got attention in developed and developing world with people expecting a good quality of life even when death is anticipated [13\u201315].", [["death", "DISEASE", 130, 135], ["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["India which hosts about one million of the cancer population is severely lacking in all aspects of palliative care and capacity building for it as well [16].", [["cancer", "ANATOMY", 43, 49], ["cancer", "DISEASE", 43, 49], ["cancer", "CANCER", 43, 49], ["palliative care", "TREATMENT", 99, 114], ["cancer", "OBSERVATION", 43, 49], ["severely", "OBSERVATION_MODIFIER", 64, 72]]], ["Paediatric palliative care need is different, as a child is not the decision-maker in majority of cases.", [["Paediatric palliative care", "TREATMENT", 0, 26]]], ["His expression of symptoms and fear may not be adequately perceived or addressed by the care givers.", [["symptoms", "PROBLEM", 18, 26]]], ["However, recent era has witnessed concerns among medical fraternity for the need of paediatric palliative care guidelines.DiscussionThe present study noted that about 16% patients needed palliative and end of life care.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["paediatric palliative care guidelines", "TREATMENT", 84, 121], ["The present study", "TEST", 132, 149], ["palliative and end of life care", "TREATMENT", 187, 218]]], ["Hospital was opted as the EOLC place by 8/26 while home was preferred by 18/26 patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["Study at Cipla Palliative Care Institute noted that 83% Indian cancer patients opt for home-based terminal care and the main reason was financial [17, 18].", [["cancer", "ANATOMY", 63, 69], ["cancer", "DISEASE", 63, 69], ["cancer", "CANCER", 63, 69], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["home-based terminal care", "TREATMENT", 87, 111]]], ["The study also noted majority of self-financed family opted for home-based palliation and they acknowledge financial constrains responsible for their choice.DiscussionIn our study, child\u2019s distress and discomfort score, as perceived by parent, was of same grade in hospital- and home-based EOLC.", [["The study", "TEST", 0, 9], ["home-based palliation", "TREATMENT", 64, 85], ["our study", "TEST", 170, 179], ["distress", "PROBLEM", 189, 197], ["discomfort score", "PROBLEM", 202, 218]]], ["However, temporary relief with medication was noted in a significant proportion of admitted patients, 3/7 participants still regretted the decision of opting hospital as terminal care site and majority were concerned with the restrictive atmosphere, non-segregation, lack of privacy and fear of death in child due to frequent medical and nursing interventions.", [["death", "DISEASE", 295, 300], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["participants", "SPECIES", 106, 118], ["medication", "TREATMENT", 31, 41], ["death", "PROBLEM", 295, 300], ["frequent medical and nursing interventions", "TREATMENT", 317, 359]]], ["The 2 families, who opted for ICU care and resuscitation, regretted it later as ventilation and sedation caused separation from their child at the terminal time.", [["ICU care", "TREATMENT", 30, 38], ["resuscitation", "TREATMENT", 43, 56], ["ventilation", "TREATMENT", 80, 91], ["sedation", "TREATMENT", 96, 104]]], ["Regret was less among home-based EOLC-based parents and mainly limited to unavailability of medical aids for symptom relief.", [["medical aids", "TREATMENT", 92, 104], ["symptom relief", "PROBLEM", 109, 123]]], ["Intensive care supports for terminally ill oncological patients are not uniformly promoted.", [["terminally ill", "DISEASE", 28, 42], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Intensive care supports", "TREATMENT", 0, 23]]], ["Lack of consensus among medical fraternity in India has been noted regarding ICU care, ventilator support, withdrawal and policy of no escalation of advanced life support treatment in such cases [19].DiscussionIndia has a diverse population and many religions.", [["ICU care", "TREATMENT", 77, 85], ["ventilator support", "TREATMENT", 87, 105], ["withdrawal", "PROBLEM", 107, 117], ["advanced life support treatment", "TREATMENT", 149, 180]]], ["Each religion has defined good or desirable death as different.", [["death", "DISEASE", 44, 49], ["good", "OBSERVATION_MODIFIER", 26, 30]]], ["The common concept of Karma responsible for all sufferings and sufferings are purging for old sins are accepted by almost all religions.", [["Karma", "OBSERVATION", 22, 27]]], ["While extensive use of pain-alleviating medications is not accepted in Islam and Jainism, these decisions do changes with the paediatric population [20, 21].", [["pain", "DISEASE", 23, 27], ["pain-alleviating medications", "TREATMENT", 23, 51]]], ["A western model of opting hospice is not regularly cherished in Indian society.", [["opting hospice", "TREATMENT", 19, 33]]], ["However, unavailability of community-based EOLC support and non-existent home care assistance lead to regret by family [22].DiscussionPain was noticed as the most disturbing symptom in this study and same was noted in the literature as well.", [["community-based EOLC support", "TREATMENT", 27, 55], ["non-existent home care assistance", "TREATMENT", 60, 93], ["the most disturbing symptom", "PROBLEM", 154, 181], ["this study", "TEST", 185, 195]]], ["Ease of getting morphine is other area of concern.", [["morphine", "CHEMICAL", 16, 24], ["morphine", "CHEMICAL", 16, 24], ["morphine", "SIMPLE_CHEMICAL", 16, 24], ["morphine", "TREATMENT", 16, 24]]], ["In India, availability of morphine to a home-based terminal care patient is almost non-existent.", [["morphine", "CHEMICAL", 26, 34], ["morphine", "CHEMICAL", 26, 34], ["morphine", "SIMPLE_CHEMICAL", 26, 34], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["morphine", "TREATMENT", 26, 34], ["a home-based terminal care", "TREATMENT", 38, 64]]], ["Data regarding supply of morphine showed dismal figure [23, 24].", [["morphine", "CHEMICAL", 25, 33], ["morphine", "CHEMICAL", 25, 33], ["morphine", "SIMPLE_CHEMICAL", 25, 33], ["morphine", "TREATMENT", 25, 33], ["dismal figure", "PROBLEM", 41, 54]]], ["Home-based palliation is often remembered as the terminal period without medical intervention by parents in this study [26].DiscussionThis study noted interesting facts about choice of EOLC among paediatric cancer patients.", [["cancer", "ANATOMY", 207, 213], ["EOLC", "CHEMICAL", 185, 189], ["cancer", "DISEASE", 207, 213], ["EOLC", "CANCER", 185, 189], ["cancer", "CANCER", 207, 213], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["Home-based palliation", "TREATMENT", 0, 21], ["medical intervention", "TREATMENT", 73, 93], ["this study", "TEST", 108, 118], ["This study", "TEST", 134, 144], ["palliation", "OBSERVATION", 11, 21], ["cancer", "OBSERVATION", 207, 213]]], ["Firstly, this study was likely to harbour bias as families not opting to take the interview may be more disturbed and might have experienced more stressful terminal time.", [["this study", "TEST", 9, 19]]], ["Secondly, the child\u2019s stress perception made by parents might not be accurate.", [["child", "ORGANISM", 14, 19]]], ["Moreover, the small number of participants limits the conclusions to be generalised.DiscussionThis study emphasises the need of palliative care facility at community level and availability of medical help at home level for dying children.", [["children", "ORGANISM", 229, 237], ["participants", "SPECIES", 30, 42], ["children", "SPECIES", 229, 237], ["This study", "TEST", 94, 104], ["palliative care facility", "TREATMENT", 128, 152], ["small", "OBSERVATION_MODIFIER", 14, 19], ["number", "OBSERVATION_MODIFIER", 20, 26]]], ["A dedicated palliative team is desired to cope with the regret and distress noted by families after demise of children during the bereavement period.", [["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["distress", "PROBLEM", 67, 75]]]], "1e88cb920c1bbd12e242e02a24dd948e47f3d0cc": [["The nuclear receptor heterodimers of liver X receptors (LXRs) are recently identified as key transcriptional regulators of genes involved in lipid homeostasis and inflammation.", [["nuclear", "ANATOMY", 4, 11], ["inflammation", "DISEASE", 163, 175], ["liver X receptors", "GENE_OR_GENE_PRODUCT", 37, 54], ["LXRs", "GENE_OR_GENE_PRODUCT", 56, 60], ["lipid", "SIMPLE_CHEMICAL", 141, 146], ["nuclear receptor heterodimers", "PROTEIN", 4, 33], ["liver X receptors", "PROTEIN", 37, 54], ["LXRs", "PROTEIN", 56, 60], ["transcriptional regulators", "PROTEIN", 93, 119], ["lipid homeostasis", "PROBLEM", 141, 158], ["inflammation", "PROBLEM", 163, 175], ["liver", "ANATOMY", 37, 42], ["lipid homeostasis", "OBSERVATION", 141, 158], ["inflammation", "OBSERVATION", 163, 175]]], ["LXRs and their ligands are negative regulators of macrophage inflammatory gene expression.", [["macrophage", "ANATOMY", 50, 60], ["LXRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophage", "CELL", 50, 60], ["LXRs", "PROTEIN", 0, 4], ["macrophage inflammatory gene expression", "PROBLEM", 50, 89], ["macrophage", "OBSERVATION_MODIFIER", 50, 60], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73]]], ["Multiple sclerosis (MS), a demyelinating disease of the central nervous system of unknown cause, is characterized by recurrent inflammation involving macrophages and their inflammatory mediators.", [["central nervous system", "ANATOMY", 56, 78], ["macrophages", "ANATOMY", 150, 161], ["Multiple sclerosis", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["demyelinating disease of the central nervous system", "DISEASE", 27, 78], ["inflammation", "DISEASE", 127, 139], ["central nervous system", "ANATOMICAL_SYSTEM", 56, 78], ["macrophages", "CELL", 150, 161], ["macrophages", "CELL_TYPE", 150, 161], ["inflammatory mediators", "PROTEIN", 172, 194], ["Multiple sclerosis (MS)", "PROBLEM", 0, 23], ["a demyelinating disease of the central nervous system", "PROBLEM", 25, 78], ["recurrent inflammation involving macrophages", "PROBLEM", 117, 161], ["sclerosis", "OBSERVATION", 9, 18], ["demyelinating disease", "OBSERVATION", 27, 48], ["central", "ANATOMY_MODIFIER", 56, 63], ["nervous system", "ANATOMY", 64, 78], ["recurrent", "OBSERVATION_MODIFIER", 117, 126], ["inflammation", "OBSERVATION", 127, 139], ["macrophages", "OBSERVATION_MODIFIER", 150, 161], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["Sweden belongs to the countries with a high MS incidence.", [["MS", "DISEASE", 44, 46], ["a high MS incidence", "PROBLEM", 37, 56]]], ["In Italy, incidence is lower, with an exception for Sardinia where the incidence is even higher than that in Sweden.", [["lower", "OBSERVATION_MODIFIER", 23, 28], ["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["We studied LXRs and their related molecules of blood mononuclear cells (MNCs) from female patients with untreated relapsing-remitting MS from Sassari, Sardinia and Stockholm, Sweden.", [["blood mononuclear cells", "ANATOMY", 47, 70], ["MNCs", "ANATOMY", 72, 76], ["relapsing-remitting MS", "DISEASE", 114, 136], ["LXRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["blood mononuclear cells", "CELL", 47, 70], ["MNCs", "CELL", 72, 76], ["patients", "ORGANISM", 90, 98], ["LXRs", "PROTEIN", 11, 15], ["blood mononuclear cells", "CELL_TYPE", 47, 70], ["MNCs", "CELL_TYPE", 72, 76], ["patients", "SPECIES", 90, 98], ["blood mononuclear cells", "PROBLEM", 47, 70], ["untreated relapsing-remitting MS", "PROBLEM", 104, 136], ["blood mononuclear cells", "OBSERVATION", 47, 70], ["relapsing", "OBSERVATION_MODIFIER", 114, 123]]], ["Sex-and age-matched healthy controls (HCs) were from both areas. mRNA expression was evaluated by real-time PCR.", [["controls", "ORGANISM", 28, 36], ["mRNA", "RNA", 65, 69], ["mRNA expression", "PROBLEM", 65, 80]]], ["LXR-a was lower (P < 0.05) in MS (mean AE SEM: 3.1 AE 0.2; n \u00bc 37) compared to HC (3.6 AE 0.1; n \u00bc 37).", [["MS", "DISEASE", 30, 32], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["MS", "TEST", 30, 32], ["mean AE SEM", "TEST", 34, 45], ["AE", "TEST", 51, 53], ["n \u00bc", "TEST", 59, 62], ["HC", "TEST", 79, 81]]], ["LXR-a was lower in MS from Stockholm (2.6 AE 0.2; n \u00bc 22) compared to corresponding HC (3.4 AE 0.1; n \u00bc 22; P < 0.01) and compared to MS (3.8 AE 0.2; n \u00bc 15; P < 0.001) and HC (4 AE 0.2; n \u00bc 15; P < 0.001) from Sardinia.", [["MS", "DISEASE", 19, 21], ["MS", "DISEASE", 134, 136], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["AE", "TEST", 42, 44], ["HC", "TEST", 84, 86], ["AE", "TEST", 92, 94], ["n \u00bc", "TEST", 100, 103], ["P", "TEST", 108, 109], ["MS", "TEST", 134, 136], ["AE", "TEST", 142, 144], ["n", "TEST", 150, 151], ["\u00bc", "TEST", 152, 153], ["P", "TEST", 158, 159], ["HC", "TEST", 173, 175], ["AE", "TEST", 179, 181], ["n \u00bc", "TEST", 187, 190], ["P", "TEST", 195, 196], ["Sardinia", "PROBLEM", 211, 219], ["lower", "OBSERVATION_MODIFIER", 10, 15]]], ["MS patients from Stockholm, but not from Sassari, also expressed lower (P < 0.05) LXR-b (\u00c04.1 AE 0.4) compared to corresponding HC (\u00c02.9 AE 0.3).", [["MS", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["LXR-b", "GENE_OR_GENE_PRODUCT", 82, 87], ["LXR", "PROTEIN", 82, 85], ["patients", "SPECIES", 3, 11], ["LXR-b (\u00c04.1 AE", "TEST", 82, 96], ["HC", "TEST", 128, 130]]], ["MS from Stockholm was associated with higher ABCA-1 (6.1 AE 0.4 versus 5.0 AE 0.3; P < 0.05) and higher estrogen receptor-b-Cx (2.4 AE 0.4 versus 0.8 AE 0.4; P < 0.01) compared to corresponding HC.", [["MS", "DISEASE", 0, 2], ["estrogen", "CHEMICAL", 104, 112], ["estrogen", "CHEMICAL", 104, 112], ["ABCA-1", "GENE_OR_GENE_PRODUCT", 45, 51], ["estrogen receptor-b-Cx", "GENE_OR_GENE_PRODUCT", 104, 126], ["estrogen receptor", "PROTEIN", 104, 121], ["ABCA", "TEST", 45, 49], ["AE", "TEST", 57, 59], ["AE", "TEST", 75, 77], ["P", "TEST", 83, 84], ["higher estrogen receptor", "TEST", 97, 121], ["Cx", "TEST", 124, 126], ["AE", "TEST", 132, 134], ["AE", "TEST", 150, 152], ["P", "TEST", 158, 159]]], ["The HC from Sassari had higher androgen receptor (2.9 AE 0.2) compared to MS from Sassari (1.4 AE 0.3; P < 0.01), MS (1.3 AE 0.4; P < 0.01) and HC from Stockholm (1.2 AE 0.3; P < 0.01).", [["MS", "DISEASE", 74, 76], ["MS", "DISEASE", 114, 116], ["androgen", "CHEMICAL", 31, 39], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 31, 48], ["androgen receptor", "PROTEIN", 31, 48], ["The HC", "TEST", 0, 6], ["Sassari", "TEST", 12, 19], ["higher androgen receptor", "PROBLEM", 24, 48], ["MS", "TEST", 74, 76], ["Sassari", "TEST", 82, 89], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["MS", "TEST", 114, 116], ["AE", "TEST", 122, 124], ["P", "TEST", 130, 131], ["HC", "TEST", 144, 146], ["Stockholm", "TEST", 152, 161], ["AE", "TEST", 167, 169], ["P", "TEST", 175, 176]]], ["MS from Sassari had lower cyclooxygenase-1 compared to corresponding HC (5.1 AE 0.4 versus 6.6 AE 0.3; P < 0.01) and lower prostaglandin-E (\u00c00.03 AE 0.5) compared to the HC (1.4 AE 0.5; P < 0.05) and MS (2.7 AE 0.4; P < 0.05) and HC from Stockholm (1.9 AE 0.4, P < 0.001).", [["MS", "DISEASE", 0, 2], ["prostaglandin-E", "CHEMICAL", 123, 138], ["prostaglandin-E", "CHEMICAL", 123, 138], ["cyclooxygenase-1", "GENE_OR_GENE_PRODUCT", 26, 42], ["prostaglandin-E", "SIMPLE_CHEMICAL", 123, 138], ["cyclooxygenase-1", "PROTEIN", 26, 42], ["lower cyclooxygenase", "PROBLEM", 20, 40], ["HC", "TEST", 69, 71], ["AE", "TEST", 77, 79], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["lower prostaglandin", "TEST", 117, 136], ["AE", "TEST", 146, 148], ["the HC", "TEST", 166, 172], ["AE", "TEST", 178, 180], ["P", "TEST", 186, 187], ["MS", "TEST", 200, 202], ["AE", "TEST", 208, 210], ["P", "TEST", 216, 217], ["HC", "TEST", 230, 232], ["Stockholm", "TEST", 238, 247], ["AE", "TEST", 253, 255], ["P", "TEST", 261, 262]]], ["Our findings identify LXRs and their related molecules as being involved in MS from Stockholm but not from Sassari, while sex hormone receptors seem to be involved in MS in Sassari.A U T O I M M U N I T Y 5Multiple Sclerosis: IFN-b Induces CD123 + BDCA2 -Dendritic Cells that Produce IL-6 and IL-10 and have No Enhanced Type I Interferon Production Y. M. Huang, 1 S. Adikari, 1 U. B\u00e5ve, 2 A. Sanna 1,3 & G. Alm 4 DC antigens (BDCA) and investigate their ability to produce Type I IFN in response to virus stimulation.", [["Cells", "ANATOMY", 265, 270], ["MS", "DISEASE", 76, 78], ["MS", "DISEASE", 167, 169], ["Sclerosis", "DISEASE", 215, 224], ["LXRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["sex hormone receptors", "GENE_OR_GENE_PRODUCT", 122, 143], ["CD123", "GENE_OR_GENE_PRODUCT", 240, 245], ["IL-6", "GENE_OR_GENE_PRODUCT", 284, 288], ["IL-10", "GENE_OR_GENE_PRODUCT", 293, 298], ["Alm 4 DC antigens", "GENE_OR_GENE_PRODUCT", 407, 424], ["BDCA", "CELL", 426, 430], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 473, 483], ["LXRs", "PROTEIN", 22, 26], ["sex hormone receptors", "PROTEIN", 122, 143], ["IFN", "PROTEIN", 226, 229], ["CD123", "PROTEIN", 240, 245], ["BDCA2", "PROTEIN", 248, 253], ["Dendritic Cells", "CELL_TYPE", 255, 270], ["IL-6", "PROTEIN", 284, 288], ["IL", "PROTEIN", 293, 295], ["DC antigens", "PROTEIN", 413, 424], ["BDCA", "PROTEIN", 426, 430], ["Type I IFN", "PROTEIN", 473, 483], ["Sassari", "TREATMENT", 107, 114], ["Sclerosis", "PROBLEM", 215, 224], ["IFN-b", "TEST", 226, 231], ["CD123", "TEST", 240, 245], ["BDCA2", "TEST", 248, 253], ["Dendritic Cells", "PROBLEM", 255, 270], ["IL", "TEST", 284, 286], ["IL", "TEST", 293, 295], ["Adikari", "TEST", 367, 374], ["Sanna", "TEST", 392, 397], ["Type I IFN", "PROBLEM", 473, 483], ["virus stimulation", "TREATMENT", 499, 516], ["Sclerosis", "OBSERVATION", 215, 224], ["Dendritic Cells", "OBSERVATION", 255, 270], ["No", "UNCERTAINTY", 308, 310]]], ["We show that IFN-b induces development of CD123 \u00fe DC from human blood monocytes, which coexpress BDCA4 \u00fe but are negative for BDCA2 -, a specific marker for plasmacytoid DC.", [["CD123 \u00fe DC", "ANATOMY", 42, 52], ["blood monocytes", "ANATOMY", 64, 79], ["plasmacytoid DC", "ANATOMY", 157, 172], ["IFN-b", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD123 \u00fe DC", "CELL", 42, 52], ["human", "ORGANISM", 58, 63], ["blood monocytes", "CELL", 64, 79], ["BDCA4", "GENE_OR_GENE_PRODUCT", 97, 102], ["BDCA2", "GENE_OR_GENE_PRODUCT", 126, 131], ["plasmacytoid DC", "CELL", 157, 172], ["IFN", "PROTEIN", 13, 16], ["CD123 \u00fe DC", "CELL_TYPE", 42, 52], ["human blood monocytes", "CELL_TYPE", 58, 79], ["BDCA4", "PROTEIN", 97, 102], ["BDCA2", "PROTEIN", 126, 131], ["plasmacytoid DC", "CELL_TYPE", 157, 172], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["human blood monocytes", "TEST", 58, 79], ["BDCA2", "PROBLEM", 126, 131], ["plasmacytoid DC", "TREATMENT", 157, 172]]], ["Such IFN-b-modulated DC produce large amounts of IL-6 and IL-10, but no IL-12p40 and have no enhanced IFN-b and IFN-b production.", [["DC", "ANATOMY", 21, 23], ["IFN", "CHEMICAL", 5, 8], ["IFN-b-", "GENE_OR_GENE_PRODUCT", 5, 11], ["DC", "CELL", 21, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 72, 80], ["IFN-b", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN-b", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN", "PROTEIN", 5, 8], ["DC", "CELL_TYPE", 21, 23], ["IL-12p40", "PROTEIN", 72, 80], ["IFN", "PROTEIN", 102, 105], ["IFN", "PROTEIN", 112, 115], ["IL", "TEST", 49, 51], ["IL", "TEST", 58, 60], ["IL", "TEST", 72, 74], ["enhanced IFN", "PROBLEM", 93, 105], ["IFN", "PROBLEM", 112, 115], ["large", "OBSERVATION_MODIFIER", 32, 37], ["amounts", "OBSERVATION_MODIFIER", 38, 45], ["no", "UNCERTAINTY", 90, 92]]], ["The findings indicate that IFN-bmodulated DC represent a myeloid DC subset with diminished CD11c, BDCA-1 and CD1a expression, having potent Th2-promoting function but lacking antiviral capacity.", [["DC", "ANATOMY", 42, 44], ["myeloid DC", "ANATOMY", 57, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["DC", "CELL", 42, 44], ["myeloid DC", "CELL", 57, 67], ["CD11c", "GENE_OR_GENE_PRODUCT", 91, 96], ["BDCA-1", "GENE_OR_GENE_PRODUCT", 98, 104], ["CD1a", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFN", "PROTEIN", 27, 30], ["bmodulated DC", "CELL_TYPE", 31, 44], ["myeloid DC subset", "CELL_TYPE", 57, 74], ["CD11c", "PROTEIN", 91, 96], ["BDCA", "PROTEIN", 98, 102], ["CD1a", "PROTEIN", 109, 113], ["IFN", "PROBLEM", 27, 30], ["diminished CD11c", "PROBLEM", 80, 96], ["BDCA", "TEST", 98, 102], ["lacking antiviral capacity", "PROBLEM", 167, 193], ["myeloid", "OBSERVATION", 57, 64], ["diminished", "OBSERVATION_MODIFIER", 80, 90], ["CD11c", "OBSERVATION", 91, 96], ["antiviral capacity", "OBSERVATION", 175, 193]]], ["The association of psoriasis with throat infections by streptococcus pyogenes suggests a potential antigenic target for the T cells that are known to infiltrate dermis and epidermis of psoriatic skin.", [["throat", "ANATOMY", 34, 40], ["T cells", "ANATOMY", 124, 131], ["infiltrate dermis", "ANATOMY", 150, 167], ["epidermis", "ANATOMY", 172, 181], ["psoriatic skin", "ANATOMY", 185, 199], ["psoriasis", "DISEASE", 19, 28], ["throat infections", "DISEASE", 34, 51], ["streptococcus pyogenes", "DISEASE", 55, 77], ["throat", "ORGANISM_SUBDIVISION", 34, 40], ["streptococcus pyogenes", "ORGANISM", 55, 77], ["T cells", "CELL", 124, 131], ["dermis", "TISSUE", 161, 167], ["epidermis", "TISSUE", 172, 181], ["skin", "ORGAN", 195, 199], ["T cells", "CELL_TYPE", 124, 131], ["streptococcus pyogenes", "SPECIES", 55, 77], ["streptococcus pyogenes", "SPECIES", 55, 77], ["psoriasis", "PROBLEM", 19, 28], ["throat infections", "PROBLEM", 34, 51], ["streptococcus pyogenes", "PROBLEM", 55, 77], ["the T cells", "PROBLEM", 120, 131], ["infiltrate dermis", "PROBLEM", 150, 167], ["epidermis of psoriatic skin", "PROBLEM", 172, 199], ["psoriasis", "OBSERVATION", 19, 28], ["throat", "ANATOMY", 34, 40], ["infections", "OBSERVATION", 41, 51], ["streptococcus pyogenes", "OBSERVATION", 55, 77], ["known to", "UNCERTAINTY", 141, 149], ["infiltrate", "OBSERVATION", 150, 160], ["epidermis", "OBSERVATION_MODIFIER", 172, 181], ["psoriatic", "OBSERVATION_MODIFIER", 185, 194], ["skin", "ANATOMY", 195, 199]]], ["Streptococcal M protein shares an extensive sequence homology with human epidermal keratins.", [["epidermal keratins", "ANATOMY", 73, 91], ["Streptococcal M protein", "GENE_OR_GENE_PRODUCT", 0, 23], ["human", "ORGANISM", 67, 72], ["epidermal keratins", "GENE_OR_GENE_PRODUCT", 73, 91], ["Streptococcal M protein", "PROTEIN", 0, 23], ["human epidermal keratins", "PROTEIN", 67, 91], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Streptococcal M protein", "TEST", 0, 23], ["human epidermal keratins", "TREATMENT", 67, 91], ["epidermal keratins", "OBSERVATION", 73, 91]]], ["Keratins 16 (K16) and 17 (K17) are mostly absent from uninvolved skin but are upregulated in psoriatic lesions.", [["skin", "ANATOMY", 65, 69], ["psoriatic lesions", "ANATOMY", 93, 110], ["psoriatic lesions", "DISEASE", 93, 110], ["Keratins 16", "GENE_OR_GENE_PRODUCT", 0, 11], ["K16", "GENE_OR_GENE_PRODUCT", 13, 16], ["17", "GENE_OR_GENE_PRODUCT", 22, 24], ["K17", "GENE_OR_GENE_PRODUCT", 26, 29], ["skin", "ORGAN", 65, 69], ["psoriatic lesions", "PATHOLOGICAL_FORMATION", 93, 110], ["K16", "PROTEIN", 13, 16], ["K17", "PROTEIN", 26, 29], ["Keratins", "TEST", 0, 8], ["psoriatic lesions", "PROBLEM", 93, 110], ["skin", "ANATOMY", 65, 69], ["upregulated", "OBSERVATION_MODIFIER", 78, 89], ["psoriatic", "OBSERVATION_MODIFIER", 93, 102], ["lesions", "OBSERVATION", 103, 110]]], ["There is increasing evidence that CD8 \u00fe T cells play an important effector role in psoriasis and M proteinprimed T cells may recognize these shared epitopes in skin via molecular mimicry.", [["CD8 \u00fe T cells", "ANATOMY", 34, 47], ["T cells", "ANATOMY", 113, 120], ["skin", "ANATOMY", 160, 164], ["psoriasis", "DISEASE", 83, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["T cells", "CELL", 40, 47], ["M proteinprimed T cells", "CELL", 97, 120], ["skin", "ORGAN", 160, 164], ["CD8 \u00fe T cells", "CELL_TYPE", 34, 47], ["T cells", "CELL_TYPE", 113, 120], ["CD8 \u00fe T cells", "PROBLEM", 34, 47], ["psoriasis", "PROBLEM", 83, 92], ["M proteinprimed T cells", "TREATMENT", 97, 120], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["skin", "ANATOMY", 160, 164], ["molecular mimicry", "OBSERVATION", 169, 186]]], ["To identify candidate epitopes, peptides with sequences from K17 were selected on the basis of predicted binding to HLA-Cw6 and sequence similarities with M6 protein.", [["K17", "GENE_OR_GENE_PRODUCT", 61, 64], ["HLA-Cw6", "GENE_OR_GENE_PRODUCT", 116, 123], ["K17", "DNA", 61, 64], ["Cw6", "DNA", 120, 123], ["M6 protein", "PROTEIN", 155, 165], ["sequences from K17", "TEST", 46, 64], ["HLA", "TEST", 116, 119]]], ["Matched peptides from the sequence of M6 protein and a set of peptides with poor predicted binding were also selected.", [["M6 protein", "PROTEIN", 38, 48], ["Matched peptides", "PROBLEM", 0, 16], ["M6 protein", "TEST", 38, 48], ["poor predicted binding", "PROBLEM", 76, 98]]], ["Cw6 \u00fe individuals with psoriasis and Cw6 \u00fe healthy controls, having a family history of psoriasis, were recruited.", [["psoriasis", "DISEASE", 23, 32], ["psoriasis", "DISEASE", 88, 97], ["Cw6", "GENE_OR_GENE_PRODUCT", 0, 3], ["psoriasis", "PROBLEM", 23, 32], ["psoriasis", "PROBLEM", 88, 97], ["psoriasis", "OBSERVATION", 23, 32], ["psoriasis", "OBSERVATION", 88, 97]]], ["PBMCs were incubated with the peptide antigens.", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["PBMCs", "CELL_TYPE", 0, 5], ["PBMCs", "TREATMENT", 0, 5], ["the peptide antigens", "TEST", 26, 46]]], ["T-cell activation in the CD4 \u00fe , CD8 \u00fe and later the skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells was evaluated by CD69 expression and intracellular IFN-g accumulation using flow cytometry.", [["T-cell", "ANATOMY", 0, 6], ["CD4 \u00fe", "ANATOMY", 25, 30], ["CD8 \u00fe", "ANATOMY", 33, 38], ["skin", "ANATOMY", 53, 57], ["CD8 \u00fe T cells", "ANATOMY", 131, 144], ["intracellular", "ANATOMY", 182, 195], ["T-cell", "CELL", 0, 6], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["skin", "ORGAN", 53, 57], ["cutaneous lymphocyteassociated antigen", "GENE_OR_GENE_PRODUCT", 65, 103], ["CLA", "GENE_OR_GENE_PRODUCT", 105, 108], ["CD8", "GENE_OR_GENE_PRODUCT", 131, 134], ["CD69", "GENE_OR_GENE_PRODUCT", 162, 166], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["IFN-g", "GENE_OR_GENE_PRODUCT", 196, 201], ["CD4", "PROTEIN", 25, 28], ["CD8", "PROTEIN", 33, 36], ["skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells", "CELL_TYPE", 53, 144], ["CD69", "PROTEIN", 162, 166], ["IFN", "PROTEIN", 196, 199], ["T-cell activation", "TEST", 0, 17], ["the CD4", "TEST", 21, 28], ["CD8", "TEST", 33, 36], ["homing cutaneous lymphocyteassociated antigen", "PROBLEM", 58, 103], ["T cells", "PROBLEM", 137, 144], ["CD69 expression", "TEST", 162, 177], ["intracellular IFN", "TEST", 182, 199], ["flow cytometry", "TEST", 221, 235], ["cell activation", "OBSERVATION", 2, 17], ["CD4", "ANATOMY", 25, 28], ["skin", "ANATOMY", 53, 57], ["homing", "ANATOMY_MODIFIER", 58, 64], ["cutaneous", "ANATOMY", 65, 74], ["flow cytometry", "OBSERVATION", 221, 235]]], ["We demonstrate that Cw6 \u00fe psoriasis patients had significant CD8 \u00fe T-cell IFN-g responses to peptides from K17 and M6 protein selected on the basis of sequence homology and predicted HLA-Cw1501 and HLA-B1501 and HLA-B0204 was measured by a radioimmunoassay (RIA).", [["CD8 \u00fe T-cell", "ANATOMY", 61, 73], ["psoriasis", "DISEASE", 26, 35], ["Cw6", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 36, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["K17", "GENE_OR_GENE_PRODUCT", 107, 110], ["HLA-B1501", "GENE_OR_GENE_PRODUCT", 198, 207], ["HLA-B0204", "GENE_OR_GENE_PRODUCT", 212, 221], ["CD8", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 74, 77], ["M6 protein", "PROTEIN", 115, 125], ["HLA-Cw1501", "DNA", 183, 193], ["HLA-B1501 and HLA-B0204", "DNA", 198, 221], ["patients", "SPECIES", 36, 44], ["Cw6 \u00fe psoriasis", "PROBLEM", 20, 35], ["IFN", "TEST", 74, 77], ["peptides", "TEST", 93, 101], ["K17", "TEST", 107, 110], ["M6 protein", "TEST", 115, 125], ["sequence homology", "TEST", 151, 168], ["HLA", "TEST", 183, 186], ["HLA", "TEST", 198, 201], ["HLA", "TEST", 212, 215], ["a radioimmunoassay (RIA", "TEST", 238, 261]]], ["This data was used to develop multiple first generation ANNs, which formed a virtual committee.", [["multiple first generation ANNs", "PROBLEM", 30, 60]]], ["This committee was used to screen (or 'queried') for peptides, where the ANNs agreed ('low-QBC'), or disagreed ('high-QBC'), on their HLA-binding potential.", [["peptides", "PROBLEM", 53, 61]]], ["Seventeen low-QBC peptides and 17 high-QBC peptides were synthesized and tested.", [["QBC peptides", "TEST", 14, 26]]], ["The high-or low-QBC data were added to the original data, and new high-or low-QBC second generation ANNs were developed, respectively.", [["the original data", "TEST", 39, 56], ["new high-or low-QBC second generation ANNs", "PROBLEM", 62, 104], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["This procedure was repeated 40 times.Results:The high-QBC-enriched ANN performed significantly better than the low-QBC-enriched ANN in 37 of the 40 tests.", [["QBC", "DNA", 115, 118], ["This procedure", "TREATMENT", 0, 14], ["the 40 tests", "TEST", 141, 153]]], ["Conclusion: These results demonstrate that high-QBCenriched networks perform better than low-QBC-enriched networks in selecting informative data for developing peptide-MHC-binding predictors.", [["QBC", "PROTEIN", 93, 96], ["MHC", "PROTEIN", 168, 171], ["high-QBCenriched networks", "PROBLEM", 43, 68]]], ["This improvement in selecting data is not due to differences in network training performance but due to the difference in information content in the high-QBC experiment and in the low-QBC experiment.", [["selecting data", "TEST", 20, 34], ["the difference in information content", "PROBLEM", 104, 141]]], ["Finally, it should be noted that this strategy could be used in many contexts where generation of data is difficult and costly.", [["this strategy", "TREATMENT", 33, 46]]], ["Interleukin-18 (IL-18), a pro-inflammatory cytokine that is produced by both lymphoid and nonlymphoid cells, has a critical role in modulation of innate and adaptive immunity.", [["lymphoid", "ANATOMY", 77, 85], ["nonlymphoid cells", "ANATOMY", 90, 107], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 0, 14], ["IL-18", "GENE_OR_GENE_PRODUCT", 16, 21], ["lymphoid", "CELL", 77, 85], ["nonlymphoid cells", "CELL", 90, 107], ["Interleukin-18 (IL-18", "PROTEIN", 0, 21], ["pro-inflammatory cytokine", "PROTEIN", 26, 51], ["lymphoid and nonlymphoid cells", "CELL_TYPE", 77, 107], ["Interleukin", "TEST", 0, 11], ["IL", "TEST", 16, 18], ["a pro-inflammatory cytokine", "TEST", 24, 51], ["innate and adaptive immunity", "TREATMENT", 146, 174], ["both lymphoid", "OBSERVATION", 72, 85], ["nonlymphoid cells", "OBSERVATION", 90, 107]]], ["Its primary function in stimulation of IFN-g production and stimulation of NK-cell-cytotoxic activities makes this cytokine a candidate for cancer immunotherapy.", [["NK", "ANATOMY", 75, 77], ["cell", "ANATOMY", 78, 82], ["cancer", "ANATOMY", 140, 146], ["cancer", "DISEASE", 140, 146], ["IFN-g", "GENE_OR_GENE_PRODUCT", 39, 44], ["NK-cell", "CELL", 75, 82], ["cancer", "CANCER", 140, 146], ["IFN", "PROTEIN", 39, 42], ["cytokine", "PROTEIN", 115, 123], ["IFN-g production", "TREATMENT", 39, 55], ["NK", "TEST", 75, 77], ["cytotoxic activities", "PROBLEM", 83, 103], ["cancer immunotherapy", "TREATMENT", 140, 160]]], ["In oral cavity, this cytokine is produced by oral epithelia and carcinoma cells and is related to tumour regression in nude mice bearing salivary adenocarcinoma.", [["oral cavity", "ANATOMY", 3, 14], ["oral epithelia", "ANATOMY", 45, 59], ["carcinoma cells", "ANATOMY", 64, 79], ["tumour", "ANATOMY", 98, 104], ["salivary adenocarcinoma", "ANATOMY", 137, 160], ["carcinoma", "DISEASE", 64, 73], ["tumour", "DISEASE", 98, 104], ["salivary adenocarcinoma", "DISEASE", 137, 160], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 3, 14], ["oral epithelia", "CELL", 45, 59], ["carcinoma cells", "CELL", 64, 79], ["tumour", "CANCER", 98, 104], ["nude mice", "ORGANISM", 119, 128], ["salivary adenocarcinoma", "CANCER", 137, 160], ["cytokine", "PROTEIN", 21, 29], ["carcinoma cells", "CELL_TYPE", 64, 79], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["oral epithelia", "PROBLEM", 45, 59], ["carcinoma cells", "PROBLEM", 64, 79], ["tumour regression in nude mice bearing salivary adenocarcinoma", "PROBLEM", 98, 160], ["oral cavity", "ANATOMY", 3, 14], ["carcinoma cells", "OBSERVATION", 64, 79], ["related to", "UNCERTAINTY", 87, 97], ["tumour regression", "OBSERVATION", 98, 115], ["salivary adenocarcinoma", "OBSERVATION", 137, 160]]], ["However, direct effects of this cytokine on oral cancer cells have not been elucidated.", [["oral cancer cells", "ANATOMY", 44, 61], ["oral cancer", "DISEASE", 44, 55], ["oral cancer cells", "CELL", 44, 61], ["cytokine", "PROTEIN", 32, 40], ["oral cancer cells", "CELL_TYPE", 44, 61], ["this cytokine", "TREATMENT", 27, 40], ["oral cancer cells", "PROBLEM", 44, 61]]], ["In this project, we investigated IL-18 effect on an oral carcinoma (KB) cell line.", [["oral carcinoma (KB) cell line", "ANATOMY", 52, 81], ["oral carcinoma", "DISEASE", 52, 66], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["oral carcinoma (KB) cell line", "CELL", 52, 81], ["IL-18", "PROTEIN", 33, 38], ["oral carcinoma (KB) cell line", "CELL_LINE", 52, 81], ["IL", "TEST", 33, 35], ["an oral carcinoma", "PROBLEM", 49, 66], ["cell line", "TREATMENT", 72, 81], ["oral", "ANATOMY", 52, 56], ["carcinoma", "OBSERVATION", 57, 66], ["cell line", "OBSERVATION", 72, 81]]], ["With RT-PCR technique, KB-cell line was found to express IL-18 receptors (IL-18Ra and IL-18Rb), indicating that this oral carcinoma line is a target for IL-18 study.", [["KB-cell line", "ANATOMY", 23, 35], ["oral carcinoma line", "ANATOMY", 117, 136], ["oral carcinoma", "DISEASE", 117, 131], ["KB-cell line", "CELL", 23, 35], ["IL-18 receptors", "GENE_OR_GENE_PRODUCT", 57, 72], ["IL-18Ra", "GENE_OR_GENE_PRODUCT", 74, 81], ["IL-18Rb", "GENE_OR_GENE_PRODUCT", 86, 93], ["oral carcinoma line", "CELL", 117, 136], ["IL-18", "GENE_OR_GENE_PRODUCT", 153, 158], ["KB-cell line", "CELL_LINE", 23, 35], ["IL-18 receptors", "PROTEIN", 57, 72], ["IL", "PROTEIN", 74, 76], ["18Ra", "PROTEIN", 77, 81], ["IL", "PROTEIN", 86, 88], ["18Rb", "PROTEIN", 89, 93], ["oral carcinoma line", "CELL_LINE", 117, 136], ["IL", "PROTEIN", 153, 155], ["RT-PCR technique", "TREATMENT", 5, 21], ["KB-cell line", "TREATMENT", 23, 35], ["IL", "TEST", 57, 59], ["IL", "TEST", 74, 76], ["IL", "TREATMENT", 86, 88], ["this oral carcinoma line", "PROBLEM", 112, 136], ["IL-18 study", "TEST", 153, 164], ["cell line", "OBSERVATION", 26, 35], ["carcinoma", "OBSERVATION", 122, 131]]], ["We showed that recombinant human IL-18 inhibited KB-cell proliferation by 17% at concentration of 100 ng/ml (P < 0.05), whereas LDH release by these cells in treatment group and control groups was comparable, indicating that IL-18 suppression of cell proliferation was not mediated by the induction of cell death.", [["KB-cell", "ANATOMY", 49, 56], ["cells", "ANATOMY", 149, 154], ["cell", "ANATOMY", 246, 250], ["cell", "ANATOMY", 302, 306], ["death", "DISEASE", 307, 312], ["human", "ORGANISM", 27, 32], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["KB-cell", "CELL", 49, 56], ["LDH", "SIMPLE_CHEMICAL", 128, 131], ["cells", "CELL", 149, 154], ["IL-18", "GENE_OR_GENE_PRODUCT", 225, 230], ["cell", "CELL", 246, 250], ["cell", "CELL", 302, 306], ["recombinant human IL-18", "PROTEIN", 15, 38], ["KB-cell", "CELL_LINE", 49, 56], ["LDH", "PROTEIN", 128, 131], ["IL-18", "PROTEIN", 225, 230], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["recombinant human IL", "TEST", 15, 35], ["KB", "TEST", 49, 51], ["cell proliferation", "TEST", 52, 70], ["LDH release", "TEST", 128, 139], ["treatment group and control groups", "TREATMENT", 158, 192], ["IL", "TEST", 225, 227], ["cell proliferation", "PROBLEM", 246, 264], ["cell death", "PROBLEM", 302, 312], ["cell proliferation", "OBSERVATION", 52, 70], ["cell proliferation", "OBSERVATION", 246, 264]]], ["To further address this hypothesis, we found that IL-18 treatment did not induce apoptotic cell death, as studied by DNA laddering and TUNEL assays.", [["cell", "ANATOMY", 91, 95], ["IL-18", "GENE_OR_GENE_PRODUCT", 50, 55], ["cell", "CELL", 91, 95], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["IL", "PROTEIN", 50, 52], ["IL-18 treatment", "TREATMENT", 50, 65], ["apoptotic cell death", "PROBLEM", 81, 101], ["TUNEL assays", "TEST", 135, 147], ["apoptotic cell death", "OBSERVATION", 81, 101]]], ["In addition, expression pattern of cell death-controlling genes (bcl-2 and bax) was not altered by this cytokine.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["bcl-2", "GENE_OR_GENE_PRODUCT", 65, 70], ["bax", "GENE_OR_GENE_PRODUCT", 75, 78], ["bcl", "DNA", 65, 68], ["bax", "DNA", 75, 78], ["cytokine", "PROTEIN", 104, 112], ["cell death", "PROBLEM", 35, 45], ["bcl", "TEST", 65, 68], ["cell death", "OBSERVATION", 35, 45]]], ["Findings in these studies indicated that suppression of KB-cell proliferation may be attributed to control of cell cycle, growth arrest or induction of cell differentiation.", [["KB-cell", "ANATOMY", 56, 63], ["cell", "ANATOMY", 110, 114], ["cell", "ANATOMY", 152, 156], ["KB-cell", "CELL", 56, 63], ["cell", "CELL", 110, 114], ["cell", "CELL", 152, 156], ["these studies", "TEST", 12, 25], ["KB-cell proliferation", "PROBLEM", 56, 77], ["cell cycle", "PROBLEM", 110, 120], ["growth arrest", "PROBLEM", 122, 135], ["cell differentiation", "PROBLEM", 152, 172], ["cell proliferation", "OBSERVATION", 59, 77], ["cell cycle", "OBSERVATION", 110, 120], ["cell differentiation", "OBSERVATION", 152, 172]]], ["The data presented in this project could provide an insight of how cancer cell directly responds to IL-18, as this cytokine is an important regulator of anticancer mechanisms.Results:Aloe emodin (AE) is a naturally occurring compound with wide spectrum of biological properties, including antimicrobial, vasorelaxant, immunosuppressive and anticancer actions.", [["cancer cell", "ANATOMY", 67, 78], ["anticancer", "ANATOMY", 153, 163], ["anticancer", "ANATOMY", 340, 350], ["cancer", "DISEASE", 67, 73], ["Aloe emodin", "CHEMICAL", 183, 194], ["AE", "CHEMICAL", 196, 198], ["emodin", "CHEMICAL", 188, 194], ["cancer cell", "CELL", 67, 78], ["IL-18", "GENE_OR_GENE_PRODUCT", 100, 105], ["anticancer", "CANCER", 153, 163], ["Aloe emodin", "SIMPLE_CHEMICAL", 183, 194], ["AE", "SIMPLE_CHEMICAL", 196, 198], ["anticancer", "CANCER", 340, 350], ["cancer cell", "CELL_TYPE", 67, 78], ["IL-18", "PROTEIN", 100, 105], ["cytokine", "PROTEIN", 115, 123], ["how cancer cell", "PROBLEM", 63, 78], ["Aloe emodin", "TREATMENT", 183, 194], ["antimicrobial", "TREATMENT", 289, 302], ["vasorelaxant", "TREATMENT", 304, 316], ["immunosuppressive", "TREATMENT", 318, 335], ["anticancer actions", "TREATMENT", 340, 358], ["Aloe emodin", "OBSERVATION_MODIFIER", 183, 194]]], ["This anthraquinone induces apoptosis in several tumour cell lines with special affinity to tumours of neuroectodermal origin.", [["tumour cell lines", "ANATOMY", 48, 65], ["tumours", "ANATOMY", 91, 98], ["neuroectodermal", "ANATOMY", 102, 117], ["anthraquinone", "CHEMICAL", 5, 18], ["tumour", "DISEASE", 48, 54], ["anthraquinone", "CHEMICAL", 5, 18], ["anthraquinone", "SIMPLE_CHEMICAL", 5, 18], ["tumour cell lines", "CELL", 48, 65], ["tumours", "CANCER", 91, 98], ["neuroectodermal", "CANCER", 102, 117], ["tumour cell lines", "CELL_LINE", 48, 65], ["This anthraquinone", "TREATMENT", 0, 18], ["apoptosis", "PROBLEM", 27, 36], ["several tumour cell lines", "TREATMENT", 40, 65], ["apoptosis", "OBSERVATION_MODIFIER", 27, 36], ["several", "OBSERVATION_MODIFIER", 40, 47], ["tumour cell lines", "OBSERVATION", 48, 65], ["neuroectodermal origin", "OBSERVATION", 102, 124]]], ["High amounts of nitric oxide (NO) released by activated macrophages induce tumour cell death.", [["macrophages", "ANATOMY", 56, 67], ["tumour cell", "ANATOMY", 75, 86], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["tumour", "DISEASE", 75, 81], ["death", "DISEASE", 87, 92], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["nitric oxide", "SIMPLE_CHEMICAL", 16, 28], ["NO", "SIMPLE_CHEMICAL", 30, 32], ["macrophages", "CELL", 56, 67], ["tumour cell", "CELL", 75, 86], ["activated macrophages", "CELL_TYPE", 46, 67], ["nitric oxide", "TREATMENT", 16, 28], ["tumour cell death", "PROBLEM", 75, 92], ["tumour cell death", "OBSERVATION", 75, 92]]], ["Therefore, we explored the capacity of AE to modulate NO-mediated antitumour response in vitro.", [["NO", "CHEMICAL", 54, 56], ["NO", "CHEMICAL", 54, 56], ["AE", "SIMPLE_CHEMICAL", 39, 41], ["NO", "SIMPLE_CHEMICAL", 54, 56], ["antitumour", "CANCER", 66, 76]]], ["Interestingly, while AE markedly suppressed NO release from macrophages alone, it significantly potentiated NO production in cocultures of macrophages and C6 cells, after 48 h of cultivation.", [["macrophages", "ANATOMY", 60, 71], ["macrophages", "ANATOMY", 139, 150], ["C6 cells", "ANATOMY", 155, 163], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["AE", "SIMPLE_CHEMICAL", 21, 23], ["NO", "SIMPLE_CHEMICAL", 44, 46], ["macrophages", "CELL", 60, 71], ["NO", "SIMPLE_CHEMICAL", 108, 110], ["macrophages", "CELL", 139, 150], ["C6 cells", "CELL", 155, 163], ["macrophages", "CELL_TYPE", 60, 71], ["macrophages", "CELL_TYPE", 139, 150], ["C6 cells", "CELL_LINE", 155, 163], ["macrophages", "PROBLEM", 139, 150], ["C6 cells", "PROBLEM", 155, 163], ["cultivation", "TREATMENT", 179, 190], ["macrophages", "OBSERVATION", 60, 71]]], ["Accordingly, the viability of C6 cells cocultivated with macrophages was reduced in the presence of AE.", [["C6 cells", "ANATOMY", 30, 38], ["macrophages", "ANATOMY", 57, 68], ["C6 cells", "CELL", 30, 38], ["macrophages", "CELL", 57, 68], ["C6 cells", "CELL_LINE", 30, 38], ["macrophages", "CELL_TYPE", 57, 68], ["the viability of C6 cells", "TEST", 13, 38], ["macrophages", "PROBLEM", 57, 68], ["C6 cells", "OBSERVATION", 30, 38], ["macrophages", "OBSERVATION", 57, 68]]], ["Moreover, the observed AE-imposed potentiation of NO production in macrophages was closely related to macrophage culture cell density.", [["macrophages", "ANATOMY", 67, 78], ["macrophage culture cell", "ANATOMY", 102, 125], ["NO", "CHEMICAL", 50, 52], ["NO", "CHEMICAL", 50, 52], ["NO", "SIMPLE_CHEMICAL", 50, 52], ["macrophages", "CELL", 67, 78], ["macrophage culture cell", "CELL", 102, 125], ["macrophages", "CELL_TYPE", 67, 78], ["production in macrophages", "PROBLEM", 53, 78], ["macrophage culture cell density", "TEST", 102, 133], ["NO", "UNCERTAINTY", 50, 52], ["production", "OBSERVATION_MODIFIER", 53, 63], ["cell density", "OBSERVATION", 121, 133]]], ["According to these data, we proposed that NO modulator capacity of AE strongly depended on intercellular contact, indicating that macrophage antitumour response was not compromised but even potentiated by AE.Results:Immunotherapy represents an attractive fourth-modality therapeutic approach, especially in the light of the shortcomings of conventional surgery, radiation and chemotherapies in the management of metastatic cancer.", [["intercellular", "ANATOMY", 91, 104], ["macrophage", "ANATOMY", 130, 140], ["metastatic cancer", "ANATOMY", 412, 429], ["NO", "CHEMICAL", 42, 44], ["cancer", "DISEASE", 423, 429], ["NO", "CHEMICAL", 42, 44], ["NO", "SIMPLE_CHEMICAL", 42, 44], ["AE", "SIMPLE_CHEMICAL", 67, 69], ["macrophage", "CELL", 130, 140], ["metastatic cancer", "CANCER", 412, 429], ["Immunotherapy", "TREATMENT", 216, 229], ["an attractive fourth-modality therapeutic approach", "TREATMENT", 241, 291], ["conventional surgery", "TREATMENT", 340, 360], ["radiation", "TREATMENT", 362, 371], ["chemotherapies", "TREATMENT", 376, 390], ["the management", "TREATMENT", 394, 408], ["metastatic cancer", "PROBLEM", 412, 429], ["metastatic", "OBSERVATION_MODIFIER", 412, 422], ["cancer", "OBSERVATION", 423, 429]]], ["To this end, a large number of peptide antigens derived from TAA have been applied in immunotherapeutic trials for the treatment of various malignancies, e.g. cancers of the breast, prostate and kidney, in addition to haematological cancers.", [["malignancies", "ANATOMY", 140, 152], ["cancers", "ANATOMY", 159, 166], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological cancers", "ANATOMY", 218, 240], ["TAA", "DISEASE", 61, 64], ["malignancies", "DISEASE", 140, 152], ["cancers of the breast, prostate and kidney", "DISEASE", 159, 201], ["haematological cancers", "DISEASE", 218, 240], ["TAA", "SIMPLE_CHEMICAL", 61, 64], ["malignancies", "CANCER", 140, 152], ["cancers", "CANCER", 159, 166], ["breast", "CANCER", 174, 180], ["prostate", "CANCER", 182, 190], ["kidney", "ORGAN", 195, 201], ["haematological cancers", "CANCER", 218, 240], ["peptide antigens", "PROTEIN", 31, 47], ["peptide antigens", "TREATMENT", 31, 47], ["TAA", "TREATMENT", 61, 64], ["immunotherapeutic trials", "TREATMENT", 86, 110], ["the treatment", "TREATMENT", 115, 128], ["various malignancies", "PROBLEM", 132, 152], ["e.g. cancers of the breast, prostate and kidney", "PROBLEM", 154, 201], ["haematological cancers", "PROBLEM", 218, 240], ["large", "OBSERVATION_MODIFIER", 15, 20], ["various", "OBSERVATION_MODIFIER", 132, 139], ["malignancies", "OBSERVATION", 140, 152], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological", "ANATOMY", 218, 232], ["cancers", "OBSERVATION", 233, 240]]], ["In some cases the response rates have been impressive and no adverse autoimmunity have been observed.", [["autoimmunity", "DISEASE", 69, 81], ["adverse autoimmunity", "PROBLEM", 61, 81], ["no", "UNCERTAINTY", 58, 60]]], ["A major strategic difficulty associated with these trials relates to the choice of best-suited peptide antigens.", [["A major strategic difficulty", "PROBLEM", 0, 28]]], ["The vast majority of the antigens described thus far is not vital for survival and growth of the tumour cells, and immunoselection of antigen-loss variants may therefore prove to be an additional obstacle for the clinical applicability of most of the known peptide epitopes.", [["tumour cells", "ANATOMY", 97, 109], ["tumour", "DISEASE", 97, 103], ["tumour cells", "CELL", 97, 109], ["antigen", "GENE_OR_GENE_PRODUCT", 134, 141], ["antigens", "PROTEIN", 25, 33], ["tumour cells", "CELL_TYPE", 97, 109], ["the tumour cells", "PROBLEM", 93, 109], ["antigen-loss variants", "PROBLEM", 134, 155], ["the known peptide epitopes", "PROBLEM", 247, 273], ["tumour cells", "OBSERVATION", 97, 109]]], ["In this respect, the development of acquired antigen loss during immunotherapy has been demonstrated in several cases.", [["antigen loss", "DISEASE", 45, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 45, 52], ["acquired antigen loss", "PROBLEM", 36, 57], ["immunotherapy", "TREATMENT", 65, 78], ["antigen loss", "OBSERVATION", 45, 57]]], ["Obviously, the development of loss-variant tumour cells implies that these cells acquire a pronounced growth advantage and are left unaffected by further treatment.", [["loss-variant tumour cells", "ANATOMY", 30, 55], ["cells", "ANATOMY", 75, 80], ["tumour", "DISEASE", 43, 49], ["tumour cells", "CELL", 43, 55], ["cells", "CELL", 75, 80], ["loss-variant tumour cells", "CELL_TYPE", 30, 55], ["loss-variant tumour cells", "PROBLEM", 30, 55], ["these cells", "PROBLEM", 69, 80], ["a pronounced growth advantage", "PROBLEM", 89, 118], ["further treatment", "TREATMENT", 146, 163], ["loss", "OBSERVATION", 30, 34], ["variant", "OBSERVATION_MODIFIER", 35, 42], ["tumour cells", "OBSERVATION", 43, 55], ["pronounced", "OBSERVATION_MODIFIER", 91, 101], ["growth", "OBSERVATION_MODIFIER", 102, 108], ["left", "ANATOMY_MODIFIER", 127, 131]]], ["Ideally, target antigens should be derived from proteins required for survival and growth of tumour cells, as antigens with these characteristics would not be inflicted by the development of loss-variant tumour cells.", [["tumour cells", "ANATOMY", 93, 105], ["loss-variant tumour cells", "ANATOMY", 191, 216], ["tumour", "DISEASE", 93, 99], ["tumour", "DISEASE", 204, 210], ["tumour cells", "CELL", 93, 105], ["tumour cells", "CELL", 204, 216], ["tumour cells", "CELL_TYPE", 93, 105], ["loss-variant tumour cells", "CELL_TYPE", 191, 216], ["survival", "TREATMENT", 70, 78], ["tumour cells", "PROBLEM", 93, 105], ["loss-variant tumour cells", "PROBLEM", 191, 216], ["tumour cells", "OBSERVATION", 93, 105], ["tumour cells", "OBSERVATION", 204, 216]]], ["In this respect, several inhibitors of apoptosis proteins (IAPs) are universally expressed among tumours and play an important role in tumour cell escape from apoptosis.", [["tumours", "ANATOMY", 97, 104], ["tumour cell", "ANATOMY", 135, 146], ["tumour", "DISEASE", 135, 141], ["IAPs", "GENE_OR_GENE_PRODUCT", 59, 63], ["tumours", "CANCER", 97, 104], ["tumour cell", "CELL", 135, 146], ["apoptosis proteins", "PROTEIN", 39, 57], ["IAPs", "PROTEIN", 59, 63], ["apoptosis proteins", "PROBLEM", 39, 57], ["apoptosis", "PROBLEM", 159, 168], ["tumour cell escape", "OBSERVATION", 135, 153]]], ["We have characterized spontaneous T-cell reactivity against IAPderived peptides in cancer patients.", [["T-cell", "ANATOMY", 34, 40], ["cancer", "ANATOMY", 83, 89], ["cancer", "DISEASE", 83, 89], ["T-cell", "CELL", 34, 40], ["cancer", "CANCER", 83, 89], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["spontaneous T-cell reactivity", "PROBLEM", 22, 51], ["IAPderived peptides in cancer patients", "PROBLEM", 60, 98], ["spontaneous", "OBSERVATION_MODIFIER", 22, 33], ["T-cell reactivity", "OBSERVATION", 34, 51], ["cancer", "OBSERVATION", 83, 89]]], ["From the IAP survivin, we have characterized peptides restricted to the Class I molecules HLA-A1, A2, A3, A11, B7 and B35.", [["IAP", "GENE_OR_GENE_PRODUCT", 9, 12], ["survivin", "GENE_OR_GENE_PRODUCT", 13, 21], ["HLA-A1", "GENE_OR_GENE_PRODUCT", 90, 96], ["A2", "GENE_OR_GENE_PRODUCT", 98, 100], ["A3", "GENE_OR_GENE_PRODUCT", 102, 104], ["A11", "GENE_OR_GENE_PRODUCT", 106, 109], ["B7", "GENE_OR_GENE_PRODUCT", 111, 113], ["B35", "GENE_OR_GENE_PRODUCT", 118, 121], ["IAP survivin", "PROTEIN", 9, 21], ["Class I molecules", "PROTEIN", 72, 89], ["HLA", "PROTEIN", 90, 93], ["A1", "PROTEIN", 94, 96], ["A2", "PROTEIN", 98, 100], ["A3", "PROTEIN", 102, 104], ["A11", "PROTEIN", 106, 109], ["B7", "PROTEIN", 111, 113], ["B35", "PROTEIN", 118, 121], ["the IAP survivin", "TREATMENT", 5, 21], ["HLA", "TEST", 90, 93], ["A2", "TEST", 98, 100], ["A11", "TEST", 106, 109], ["A2", "ANATOMY", 98, 100], ["A3", "ANATOMY", 102, 104]]], ["Furthermore, we have demonstrated that survivin-specific T cells infiltrate metastatic lesions and that isolated survivinspecific CTLs are capable of killing HLA-matched tumour cells.", [["T cells", "ANATOMY", 57, 64], ["metastatic lesions", "ANATOMY", 76, 94], ["CTLs", "ANATOMY", 130, 134], ["tumour cells", "ANATOMY", 170, 182], ["tumour", "DISEASE", 170, 176], ["survivin", "GENE_OR_GENE_PRODUCT", 39, 47], ["T cells", "CELL", 57, 64], ["metastatic lesions", "CANCER", 76, 94], ["CTLs", "CELL", 130, 134], ["tumour cells", "CELL", 170, 182], ["survivin", "PROTEIN", 39, 47], ["T cells", "CELL_TYPE", 57, 64], ["survivinspecific CTLs", "CELL_TYPE", 113, 134], ["HLA-matched tumour cells", "CELL_TYPE", 158, 182], ["survivin-specific T cells infiltrate metastatic lesions", "PROBLEM", 39, 94], ["isolated survivinspecific CTLs", "PROBLEM", 104, 134], ["killing HLA-matched tumour cells", "PROBLEM", 150, 182], ["metastatic", "OBSERVATION_MODIFIER", 76, 86], ["tumour cells", "OBSERVATION", 170, 182]]], ["Survivin-derived peptides are now in clinical trial, and continued work in our lab has demonstrated that other IAPs are targets for spontaneous T-cell reactivity in cancer patients.", [["T-cell", "ANATOMY", 144, 150], ["cancer", "ANATOMY", 165, 171], ["cancer", "DISEASE", 165, 171], ["Survivin", "GENE_OR_GENE_PRODUCT", 0, 8], ["IAPs", "GENE_OR_GENE_PRODUCT", 111, 115], ["T-cell", "CELL", 144, 150], ["cancer", "CANCER", 165, 171], ["patients", "ORGANISM", 172, 180], ["Survivin", "PROTEIN", 0, 8], ["IAPs", "PROTEIN", 111, 115], ["patients", "SPECIES", 172, 180], ["Survivin", "TREATMENT", 0, 8], ["other IAPs", "TEST", 105, 115], ["spontaneous T-cell reactivity", "PROBLEM", 132, 161]]], ["We previously reported that in mice with large progressing T-cell lymphoma tumours, dysfunctions in the antitumour CTL activity occur, associated with an accumulation of splenic arginase-producing myeloid suppressor cells (MSCs).", [["T-cell lymphoma tumours", "ANATOMY", 59, 82], ["splenic", "ANATOMY", 170, 177], ["myeloid suppressor cells", "ANATOMY", 197, 221], ["MSCs", "ANATOMY", 223, 227], ["T-cell lymphoma tumours", "DISEASE", 59, 82], ["mice", "ORGANISM", 31, 35], ["T-cell lymphoma tumours", "CANCER", 59, 82], ["antitumour", "CANCER", 104, 114], ["arginase", "GENE_OR_GENE_PRODUCT", 178, 186], ["myeloid suppressor cells", "CELL", 197, 221], ["MSCs", "CELL", 223, 227], ["splenic arginase-producing myeloid suppressor cells", "CELL_TYPE", 170, 221], ["MSCs", "CELL_TYPE", 223, 227], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["large progressing T-cell lymphoma tumours", "PROBLEM", 41, 82], ["dysfunctions", "PROBLEM", 84, 96], ["the antitumour CTL activity", "PROBLEM", 100, 127], ["an accumulation of splenic arginase", "PROBLEM", 151, 186], ["myeloid suppressor cells", "PROBLEM", 197, 221], ["large", "OBSERVATION_MODIFIER", 41, 46], ["progressing", "OBSERVATION_MODIFIER", 47, 58], ["T-cell lymphoma tumours", "OBSERVATION", 59, 82], ["antitumour CTL activity", "OBSERVATION", 104, 127], ["accumulation", "OBSERVATION_MODIFIER", 154, 166], ["splenic", "ANATOMY", 170, 177], ["arginase", "OBSERVATION", 178, 186], ["myeloid suppressor cells", "OBSERVATION", 197, 221]]], ["In this study, we first demonstrate that both the presence and the activation state of these MSC depends on tumour evolution.", [["MSC", "ANATOMY", 93, 96], ["tumour", "ANATOMY", 108, 114], ["tumour", "DISEASE", 108, 114], ["MSC", "CELL", 93, 96], ["tumour", "CANCER", 108, 114], ["MSC", "CELL_TYPE", 93, 96], ["this study", "TEST", 3, 13], ["tumour", "OBSERVATION", 108, 114]]], ["While in tumour regressors hardly any arginase-producing MSC can be found, both the amount and the arginase activity of this population expands from early over late progressors.", [["tumour", "ANATOMY", 9, 15], ["MSC", "ANATOMY", 57, 60], ["tumour", "DISEASE", 9, 15], ["tumour", "CANCER", 9, 15], ["arginase", "GENE_OR_GENE_PRODUCT", 38, 46], ["MSC", "CELL", 57, 60], ["arginase", "GENE_OR_GENE_PRODUCT", 99, 107], ["arginase", "PROTEIN", 38, 46], ["MSC", "CELL_TYPE", 57, 60], ["arginase", "PROTEIN", 99, 107], ["any arginase", "PROBLEM", 34, 46], ["MSC", "PROBLEM", 57, 60], ["arginase activity", "OBSERVATION", 99, 116]]], ["This gradual induction of MSCs is paralleled by an increasing suppression of CTL activity and Th1, but not Th2, cytokine production.", [["MSCs", "ANATOMY", 26, 30], ["MSCs", "CELL", 26, 30], ["CTL", "GENE_OR_GENE_PRODUCT", 77, 80], ["Th1", "GENE_OR_GENE_PRODUCT", 94, 97], ["Th2", "GENE_OR_GENE_PRODUCT", 107, 110], ["MSCs", "CELL_TYPE", 26, 30], ["cytokine", "PROTEIN", 112, 120], ["This gradual induction of MSCs", "TREATMENT", 0, 30], ["MSCs", "OBSERVATION", 26, 30]]], ["Upon analysing the molecular repertoire of MSC in vitro, we found, besides arginase1, a well-established marker for alternatively activated myeloid cells or M2, a strong upregulation of FIZZ1 and Ym, two additional recently identified markers for M2.", [["MSC", "ANATOMY", 43, 46], ["myeloid cells", "ANATOMY", 140, 153], ["MSC", "CELL", 43, 46], ["arginase1", "GENE_OR_GENE_PRODUCT", 75, 84], ["myeloid cells", "CELL", 140, 153], ["M2", "CELL", 157, 159], ["FIZZ1", "GENE_OR_GENE_PRODUCT", 186, 191], ["Ym", "GENE_OR_GENE_PRODUCT", 196, 198], ["M2", "GENE_OR_GENE_PRODUCT", 247, 249], ["MSC", "CELL_TYPE", 43, 46], ["arginase1", "PROTEIN", 75, 84], ["myeloid cells", "CELL_TYPE", 140, 153], ["M2", "PROTEIN", 157, 159], ["FIZZ1", "PROTEIN", 186, 191], ["Ym", "PROTEIN", 196, 198], ["M2", "PROTEIN", 247, 249], ["activated myeloid cells", "PROBLEM", 130, 153], ["myeloid cells", "OBSERVATION", 140, 153]]], ["Further evaluation of molecular markers by microarray analysis in MSC yielded genes involved in wound healing (e.g. coagulation factor XIIIa), anti-inflammation (e.g. selenoprotein P), immunomodulation (e.g. PD-L2) and fat and sugar metabolism (e.g. leptin receptor).", [["MSC", "ANATOMY", 66, 69], ["wound", "ANATOMY", 96, 101], ["fat", "ANATOMY", 219, 222], ["sugar", "CHEMICAL", 227, 232], ["MSC", "CELL", 66, 69], ["wound", "PATHOLOGICAL_FORMATION", 96, 101], ["coagulation factor XIIIa", "GENE_OR_GENE_PRODUCT", 116, 140], ["selenoprotein P", "GENE_OR_GENE_PRODUCT", 167, 182], ["PD-L2", "GENE_OR_GENE_PRODUCT", 208, 213], ["fat", "TISSUE", 219, 222], ["sugar", "SIMPLE_CHEMICAL", 227, 232], ["leptin receptor", "GENE_OR_GENE_PRODUCT", 250, 265], ["MSC", "CELL_TYPE", 66, 69], ["coagulation factor XIIIa", "PROTEIN", 116, 140], ["selenoprotein P", "PROTEIN", 167, 182], ["leptin receptor", "PROTEIN", 250, 265], ["Further evaluation", "TEST", 0, 18], ["molecular markers", "TEST", 22, 39], ["microarray analysis", "TEST", 43, 62], ["wound healing", "PROBLEM", 96, 109], ["coagulation factor XIIIa", "TEST", 116, 140], ["anti-inflammation", "PROBLEM", 143, 160], ["immunomodulation (e.g. PD", "TEST", 185, 210], ["fat and sugar metabolism", "PROBLEM", 219, 243], ["leptin receptor", "TREATMENT", 250, 265], ["wound healing", "OBSERVATION_MODIFIER", 96, 109], ["fat", "ANATOMY", 219, 222]]], ["Of note, many of these genes are regulated by type 2 cytokines (IL-4, IL-13 and IL-10) and are therefore rather M2 associated.", [["IL-4", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-13", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["M2", "GENE_OR_GENE_PRODUCT", 112, 114], ["type 2 cytokines", "PROTEIN", 46, 62], ["IL", "PROTEIN", 64, 66], ["IL", "PROTEIN", 70, 72], ["IL", "PROTEIN", 80, 82], ["M2", "PROTEIN", 112, 114], ["IL", "TEST", 64, 66], ["IL", "TEST", 70, 72], ["rather M2", "OBSERVATION_MODIFIER", 105, 114]]], ["Overall, our data provide new markers for MSC in cancer and further establish their M2 activation state. study.", [["MSC", "ANATOMY", 42, 45], ["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["MSC", "CELL", 42, 45], ["cancer", "CANCER", 49, 55], ["M2", "GENE_OR_GENE_PRODUCT", 84, 86], ["MSC", "CELL_TYPE", 42, 45], ["M2", "PROTEIN", 84, 86], ["our data", "TEST", 9, 17], ["new markers", "TEST", 26, 37], ["MSC in cancer", "PROBLEM", 42, 55], ["study", "TEST", 105, 110], ["cancer", "OBSERVATION", 49, 55]]], ["Only SP-A showed a significant expression in normal mucosa which was downregulated in CRC.", [["mucosa", "ANATOMY", 52, 58], ["CRC", "ANATOMY", 86, 89], ["CRC", "DISEASE", 86, 89], ["SP-A", "GENE_OR_GENE_PRODUCT", 5, 9], ["mucosa", "MULTI-TISSUE_STRUCTURE", 52, 58], ["CRC", "CANCER", 86, 89], ["SP", "PROTEIN", 5, 7], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["expression", "OBSERVATION", 31, 41], ["normal mucosa", "OBSERVATION", 45, 58], ["CRC", "OBSERVATION", 86, 89]]], ["As the absolute signal level was below the noise threshold, these results have to be interpreted with caution and require confirmation by direct measurenment of the proteins.", [["the absolute signal level", "TEST", 3, 28], ["confirmation", "TEST", 122, 134]]], ["Our results suggest that there is no major role for the human collectins in colorectal cancer.", [["colorectal cancer", "ANATOMY", 76, 93], ["colorectal cancer", "DISEASE", 76, 93], ["human", "ORGANISM", 56, 61], ["collectins", "CELL", 62, 72], ["colorectal cancer", "CANCER", 76, 93], ["human collectins", "PROTEIN", 56, 72], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["colorectal cancer", "PROBLEM", 76, 93], ["no major", "UNCERTAINTY", 34, 42], ["colorectal", "ANATOMY", 76, 86], ["cancer", "OBSERVATION", 87, 93]]]], "9b8fc086d5e8f7a3599048738bd39a1794b2d5af": [["investigate how the diversity of hosts influences infectious disease ecology.", [["infectious disease", "DISEASE", 50, 68]]], ["For multi-host diseases, a change in host species richness or abundance can modify the dynamics of local infectious diseases by either reducing (\"dilution effect\") or increasing (\"amplification effect\") the risk of transmission to the targeted host species.", [["infectious diseases", "DISEASE", 105, 124], ["multi-host diseases", "PROBLEM", 4, 23], ["a change in host species richness", "PROBLEM", 25, 58], ["local infectious diseases", "PROBLEM", 99, 124], ["increasing (\"amplification effect", "PROBLEM", 167, 200], ["host diseases", "OBSERVATION", 10, 23], ["host species", "OBSERVATION", 37, 49], ["local", "OBSERVATION_MODIFIER", 99, 104], ["infectious", "OBSERVATION", 105, 115], ["increasing", "OBSERVATION_MODIFIER", 167, 177]]], ["The underlying hypothesis is that, the competence of reservoirs varies according to the host species.", [["hypothesis", "OBSERVATION", 15, 25], ["host species", "OBSERVATION", 88, 100]]], ["The dilution effect has been demonstrated mainly through theoretical work and there have been only few case studies.", [["The dilution effect", "PROBLEM", 0, 19], ["dilution effect", "OBSERVATION", 4, 19]]], ["Regarding the genetic diversity of host, an important issue is: to what extent does a reduction of this diversity impact the ability of the host population to response to infectious diseases?", [["infectious diseases", "DISEASE", 171, 190], ["infectious diseases", "PROBLEM", 171, 190]]], ["Third, we rapidly examine the role of biodiversity in the treatment of infectious diseases.", [["infectious diseases", "DISEASE", 71, 90], ["infectious diseases", "PROBLEM", 71, 90], ["infectious", "OBSERVATION", 71, 81]]], ["To conclude, we consider that the consequences of the loss of species biodiversity on infectious diseases is still largely unknown, notably due to the lack of knowledge on the dynamics of host-pathogen relationships, especially at the population and at the community level..", [["infectious diseases", "DISEASE", 86, 105], ["the loss of species biodiversity", "PROBLEM", 50, 82], ["infectious diseases", "PROBLEM", 86, 105], ["species", "OBSERVATION_MODIFIER", 62, 69], ["biodiversity", "OBSERVATION_MODIFIER", 70, 82]]], ["We highlight that work on multi-host/ ulti-pathogen systems should be fostered and that new approaches, such as metagenomic investigations that does not require a priori assumptions, are promising to describe a community of pathogens and their interactions.IntroductionOver the past 50 years, human activity has altered habitats and reduced biodiversity on an unprecedented scale that comes close to mass extinction (MEA 2005) .", [["human", "ORGANISM", 293, 298], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 293, 298], ["multi-host/ ulti-pathogen systems", "TREATMENT", 26, 59], ["metagenomic investigations", "TEST", 112, 138], ["altered habitats", "PROBLEM", 312, 328], ["reduced biodiversity", "PROBLEM", 333, 353], ["an unprecedented scale", "TREATMENT", 357, 379], ["reduced", "OBSERVATION_MODIFIER", 333, 340], ["biodiversity", "OBSERVATION_MODIFIER", 341, 353]]], ["At the same time, new infectious diseases seem to be emerging at an increasing rate (Wilcox and Gubler 2005) .", [["infectious diseases", "DISEASE", 22, 41], ["new infectious diseases", "PROBLEM", 18, 41], ["new", "OBSERVATION_MODIFIER", 18, 21], ["infectious", "OBSERVATION", 22, 32]]], ["During this period, there has been a dramatic spread of highly pathogenic diseases such as AIDS and multi-drug resistant bacterial infections, and in more recent years SARS, West Nile in North America, and highly pathogenic influenza viruses (Jones et al. 2008) .IntroductionHabitat loss, largely a result of the conversion of forests and savannas into agricultural land, cities, and industrial sites, is the major cause of change in biodiversity.", [["AIDS", "DISEASE", 91, 95], ["bacterial infections", "DISEASE", 121, 141], ["SARS", "DISEASE", 168, 172], ["influenza viruses", "DISEASE", 224, 241], ["Habitat loss", "DISEASE", 275, 287], ["highly pathogenic diseases", "PROBLEM", 56, 82], ["AIDS", "PROBLEM", 91, 95], ["multi-drug resistant bacterial infections", "PROBLEM", 100, 141], ["highly pathogenic influenza viruses", "PROBLEM", 206, 241], ["IntroductionHabitat loss", "PROBLEM", 263, 287], ["the conversion of forests", "TREATMENT", 309, 334], ["dramatic", "OBSERVATION_MODIFIER", 37, 45], ["spread", "OBSERVATION_MODIFIER", 46, 52], ["highly", "OBSERVATION_MODIFIER", 56, 62], ["pathogenic", "OBSERVATION_MODIFIER", 63, 73], ["diseases", "OBSERVATION", 74, 82], ["drug resistant", "OBSERVATION_MODIFIER", 106, 120], ["bacterial", "OBSERVATION_MODIFIER", 121, 130], ["infections", "OBSERVATION", 131, 141], ["pathogenic", "OBSERVATION_MODIFIER", 213, 223], ["influenza viruses", "OBSERVATION", 224, 241], ["Habitat loss", "OBSERVATION", 275, 287], ["change", "OBSERVATION", 424, 430], ["biodiversity", "OBSERVATION", 434, 446]]], ["Biodiversity represents the diversity of life at all levels of biological organization, from the genes within populations, the species that compose a community, to the communities that compose ecosystems.", [["diversity", "OBSERVATION_MODIFIER", 28, 37]]], ["Intuitively, one might assume that greater overall biodiversity would lead to a greater diversity of pathogens and hosts, and thereby increase the incidence of infectious diseases (Dunn et al. 2010 ).", [["infectious diseases", "DISEASE", 160, 179], ["a greater diversity of pathogens", "PROBLEM", 78, 110], ["infectious diseases", "PROBLEM", 160, 179], ["biodiversity", "OBSERVATION", 51, 63], ["infectious", "OBSERVATION_MODIFIER", 160, 170]]], ["Yet disease regulation is said to be one of the services provided by biodiversity because a high level of species diversity creates a buffer that reduces the risk of transmission (MEA 2005; Walpole et al. 2009 ).", [["disease regulation", "PROBLEM", 4, 22], ["a high level of species diversity", "PROBLEM", 90, 123], ["a buffer", "TREATMENT", 132, 140], ["disease", "OBSERVATION", 4, 11], ["species diversity", "OBSERVATION", 106, 123]]], ["Scientific evidence supporting both of these views is beginning to emerge, but the core question remains: how is biodiversity linked to infectious disease?", [["infectious disease", "DISEASE", 136, 154], ["infectious disease", "PROBLEM", 136, 154], ["infectious", "OBSERVATION", 136, 146]]], ["This is the question addressed in this chapter.IntroductionPathogens are organisms that have a negative impact on the fitness of their host(s), often, if now always, by producing visible symptoms (e.g. a disease).", [["IntroductionPathogens", "PROBLEM", 47, 68], ["visible symptoms", "PROBLEM", 179, 195], ["a disease)", "PROBLEM", 202, 212]]], ["Such trophic interaction between two organisms, a host and a parasite, is just one of several interactions that take place within communities and ecosystems, others being those of prey-predator and plant-phytophagous for instance (Begon et al. 2006) .", [["trophic interaction", "OBSERVATION", 5, 24]]], ["Studies incorporating pathogens are scarce (Hudson et al. 2006) , probably due to the difficulties of surveying pathogens (using intrusive or even destructive sampling methods\u2026).", [["pathogens", "PROBLEM", 22, 31], ["surveying pathogens", "PROBLEM", 102, 121], ["probably due to", "UNCERTAINTY", 66, 81]]], ["However, although numerous species of pathogens still need to be described (Dobson et al. 2008) , there is no doubt that pathogens represent a large part of biodiversity on earth.", [["earth", "ORGANISM_SUBDIVISION", 173, 178], ["numerous species of pathogens", "PROBLEM", 18, 47], ["pathogens", "PROBLEM", 121, 130], ["numerous", "OBSERVATION_MODIFIER", 18, 26], ["species", "OBSERVATION_MODIFIER", 27, 34], ["no doubt", "UNCERTAINTY", 107, 115], ["pathogens", "OBSERVATION", 121, 130], ["large", "OBSERVATION_MODIFIER", 143, 148], ["biodiversity", "OBSERVATION", 157, 169]]], ["Given that each free living species is host to numerous pathogens, and that pathogens of pathogens also exist (consider, for example, phages that are virus affecting bacteria), several authors believe that pathogens may be the most diverse living group on earth (Windsor 1998) .IntroductionThe link between biodiversity and the ecology of infectious diseases is not simple.", [["infectious diseases", "DISEASE", 339, 358], ["earth", "ORGANISM_SUBDIVISION", 256, 261], ["each free living species", "PROBLEM", 11, 35], ["numerous pathogens", "PROBLEM", 47, 65], ["pathogens", "PROBLEM", 89, 98], ["phages", "PROBLEM", 134, 140], ["virus affecting bacteria", "PROBLEM", 150, 174], ["pathogens", "PROBLEM", 206, 215], ["infectious diseases", "PROBLEM", 339, 358], ["biodiversity", "OBSERVATION_MODIFIER", 307, 319], ["infectious", "OBSERVATION", 339, 349]]], ["In this chapter, we investigate how biodiversity influences the ecology of infectious diseases at the intraspecific level (genetic variability of pathogens and hosts) and at the level of communities (species composition).", [["infectious diseases", "DISEASE", 75, 94], ["infectious diseases", "PROBLEM", 75, 94], ["pathogens", "PROBLEM", 146, 155], ["infectious", "OBSERVATION", 75, 85]]], ["Although we mainly provide examples from human and animal diseases, we also use some illustrations from plants.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["animal diseases", "PROBLEM", 51, 66]]], ["We describe patterns of biodiversity and the consequences of changes in biodiversity on the ecology of infectious diseases.", [["infectious diseases", "DISEASE", 103, 122], ["infectious diseases", "PROBLEM", 103, 122], ["biodiversity", "OBSERVATION", 24, 36], ["infectious", "OBSERVATION", 103, 113]]], ["Lastly, we rapidly examine the role of biodiversity in the treatment of infectious diseases.How Does the Diversity of Pathogens InfluenceInfectious Disease Ecology?How Many Pathogens Are There?We shall consider infectious diseases caused by bacteria, virus, fungi, protozoa and endo-parasites, and exclude from our analysis ecto-parasites that are considered here as disease vectors.", [["infectious diseases", "DISEASE", 72, 91], ["infectious diseases", "DISEASE", 211, 230], ["infectious diseases", "PROBLEM", 72, 91], ["infectious diseases", "PROBLEM", 211, 230], ["bacteria", "PROBLEM", 241, 249], ["virus", "PROBLEM", 251, 256], ["fungi", "PROBLEM", 258, 263], ["protozoa", "PROBLEM", 265, 273], ["endo-parasites", "PROBLEM", 278, 292], ["our analysis ecto-parasites", "TEST", 311, 338], ["infectious", "OBSERVATION", 72, 82], ["Pathogens", "OBSERVATION", 173, 182], ["infectious", "OBSERVATION", 211, 221], ["bacteria", "OBSERVATION", 241, 249]]], ["In the light of the discussion above, the pathogen status of a given living organism clearly is not a straightforward question (consider, for example, the case of some Rickettsia species that are considered to be not only blood vertebrate pathogens, but also tick symbionts, Perlman et al. 2006 ).", [["blood", "ANATOMY", 222, 227], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["some Rickettsia species", "PROBLEM", 163, 186], ["blood vertebrate pathogens", "PROBLEM", 222, 248]]], ["When pathogens have complex life-cycles, some stages may have a different biology (such as biotrophic or necrotrophic plant pathogens, Morris et al. 2009 ).", [["biotrophic or necrotrophic plant pathogens", "PROBLEM", 91, 133]]], ["Furthermore, horizontal gene transfer is so extensive in bacteria that many microbio logists question the existence of species in bacteria, preferring to consider bacteria as populations that exchange genes.", [["extensive in bacteria", "PROBLEM", 44, 65], ["species in bacteria", "PROBLEM", 119, 138], ["bacteria", "PROBLEM", 163, 171]]], ["However, the existence of core genes responsible for the maintenance of species-specific phenotypic clusters is an argument supporting the identification of bacterial species (Riley and Lizotte-Waniewski 2009) .", [["core genes", "DNA", 26, 36], ["specific phenotypic clusters", "PROBLEM", 80, 108], ["bacterial species", "PROBLEM", 157, 174], ["bacterial species", "OBSERVATION", 157, 174]]], ["For these reasons, combined with the limited knowledge available of the systematics of many pathogens (Brooks and Hoberg 2001) , it is difficult to accurately estimate the number of pathogen species.", [["many pathogens", "PROBLEM", 87, 101], ["pathogen species", "PROBLEM", 182, 198], ["many", "OBSERVATION_MODIFIER", 87, 91], ["pathogens", "OBSERVATION", 92, 101], ["pathogen species", "OBSERVATION", 182, 198]]], ["Estimations of pathogen species richness vary from 10% to 50% of living beings (de Mee\u00fbs et al. 1998; Poulin and Morand 2004) .", [["pathogen species richness", "PROBLEM", 15, 40], ["pathogen species", "OBSERVATION", 15, 31]]], ["In estuaries, the biomass of macro and micro-parasites has been estimated as exceeding that of top predators .", [["biomass", "OBSERVATION_MODIFIER", 18, 25]]], ["Although the existence of pathogens has been known for a long time, lists of species only were compiled recently for human and animals (Ashford and Crewe 1998; Cleaveland et al. 2001; Taylor et al. 2001) , with an update on human pathogens completed in 2007 (Woolhouse and Gaunt 2007) .", [["human", "ORGANISM", 117, 122], ["human", "ORGANISM", 224, 229], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 224, 229], ["pathogens", "PROBLEM", 26, 35], ["pathogens", "OBSERVATION", 26, 35]]], ["Approximately 1,400 human pathogens were reported, 616 livestock pathogens (cattle, sheep, goats, pigs and horses), and 374 domestic carnivore pathogens (dogs and cats).", [["human", "ORGANISM", 20, 25], ["cattle", "ORGANISM", 76, 82], ["sheep", "ORGANISM_SUBDIVISION", 84, 89], ["goats", "ORGANISM", 91, 96], ["pigs", "ORGANISM", 98, 102], ["horses", "ORGANISM", 107, 113], ["dogs", "ORGANISM", 154, 158], ["cats", "ORGANISM", 163, 167], ["human", "SPECIES", 20, 25], ["cattle", "SPECIES", 76, 82], ["sheep", "SPECIES", 84, 89], ["goats", "SPECIES", 91, 96], ["pigs", "SPECIES", 98, 102], ["horses", "SPECIES", 107, 113], ["dogs", "SPECIES", 154, 158], ["cats", "SPECIES", 163, 167], ["human", "SPECIES", 20, 25], ["cattle", "SPECIES", 76, 82], ["sheep", "SPECIES", 84, 89], ["goats", "SPECIES", 91, 96], ["pigs", "SPECIES", 98, 102]]], ["No clear figure was given for wildlife (but see the Global Mammal Parasite Database at http://www.mammalparasites.org/).", [["clear figure", "PROBLEM", 3, 15], ["clear", "OBSERVATION_MODIFIER", 3, 8], ["figure", "OBSERVATION", 9, 15]]], ["On average, over two new species of human viruses also are discovered each year (Woolhouse et al. 2008) .", [["human", "ORGANISM", 36, 41], ["human", "SPECIES", 36, 41], ["human viruses", "SPECIES", 36, 49], ["human viruses", "PROBLEM", 36, 49], ["average", "OBSERVATION_MODIFIER", 3, 10], ["human viruses", "OBSERVATION", 36, 49]]], ["Pathogens affecting humans have received more attention than those affecting other species.", [["humans", "ORGANISM", 20, 26], ["humans", "SPECIES", 20, 26], ["humans", "SPECIES", 20, 26]]], ["If one assumes that other animal species are affected in a proportional manner, huge numbers of pathogens remain to be discovered.", [["other animal species", "PROBLEM", 20, 40], ["pathogens", "PROBLEM", 96, 105], ["pathogens", "OBSERVATION", 96, 105]]], ["Altogether, 70,000, 5,000 and 4,000 of fungi, viruses and bacteria respectively have been described, which represent only 5%, 1%, and 0-1% of the total estimated number of species of fungal, viral and bacterial species.", [["fungi", "PROBLEM", 39, 44], ["viruses", "PROBLEM", 46, 53], ["bacteria", "PROBLEM", 58, 66], ["fungal", "PROBLEM", 183, 189], ["viral and bacterial species", "PROBLEM", 191, 218], ["fungal", "OBSERVATION", 183, 189], ["bacterial species", "OBSERVATION", 201, 218]]], ["It is difficult to know the number of plant pathogens, but a significantly proportion of the fungal, viral and bacterial species are likely to be plant pathogens (Ingram 1999) .How Many Pathogens Are There?Until recently, many new pathogen discoveries relied on the investigation of atypical symptoms.", [["plant pathogens", "PROBLEM", 38, 53], ["the fungal, viral and bacterial species", "PROBLEM", 89, 128], ["plant pathogens", "PROBLEM", 146, 161], ["atypical symptoms", "PROBLEM", 283, 300], ["plant", "OBSERVATION_MODIFIER", 38, 43], ["pathogens", "OBSERVATION", 44, 53], ["fungal", "OBSERVATION", 93, 99], ["bacterial species", "OBSERVATION", 111, 128], ["new", "OBSERVATION_MODIFIER", 227, 230], ["pathogen", "OBSERVATION", 231, 239]]], ["Today, new findings are facilitated by molecular techniques that render it possible to detect and characterise unculturable pathogens and to investigate the presence of genes and genomes independently of individuals (metagenomics).", [["characterise unculturable pathogens", "PROBLEM", 98, 133]]], ["Although multi-host pathogens are more numerous than single hosts, interactions between pathogens and hosts can evolve towards the specialisation of pathogens on a given host species (Cleaveland et al. 2001; Huyse et al. 2005; Pedersen et al. 2005) .", [["multi-host pathogens", "PROBLEM", 9, 29], ["pathogens", "PROBLEM", 88, 97], ["pathogens", "PROBLEM", 149, 158], ["pathogens", "OBSERVATION", 20, 29], ["more", "OBSERVATION_MODIFIER", 34, 38], ["numerous", "OBSERVATION_MODIFIER", 39, 47]]], ["Such a specialisation can lead to speciation, id est the birth of a new pathogen species.", [["a new pathogen species", "PROBLEM", 66, 88]]], ["Co-cladogenesis, a process of parallel diversification in hosts and pathogens, also can give birth to numerous pathogen species (Page 2003) .", [["Co-cladogenesis", "DISEASE", 0, 15], ["Co-cladogenesis", "PROBLEM", 0, 15], ["parallel diversification in hosts", "PROBLEM", 30, 63], ["pathogens", "PROBLEM", 68, 77], ["parallel", "OBSERVATION_MODIFIER", 30, 38], ["diversification", "OBSERVATION", 39, 54]]], ["Until the development of molecular tools, these species were very difficult to distinguish (cryptic species).", [["these species", "PROBLEM", 42, 55]]], ["Systematic investigations using molecular tools have made it possible, however, to reveal a high diversity of pathogens.", [["Systematic investigations", "TEST", 0, 25], ["molecular tools", "TEST", 32, 47], ["a high diversity of pathogens", "PROBLEM", 90, 119], ["high diversity", "OBSERVATION_MODIFIER", 92, 106], ["pathogens", "OBSERVATION", 110, 119]]], ["For instance, in a systematic inventory of viruses in various vertebrate hosts conducted over a 20 year period in the Central African Republic, 919 different viruses were isolated, including 39 new ones (Saluzzo et al. 2004) .", [["viruses", "PROBLEM", 43, 50], ["different viruses", "PROBLEM", 148, 165], ["viruses", "OBSERVATION", 43, 50], ["Central", "ANATOMY_MODIFIER", 118, 125]]], ["Two species of Plasmodium, P. falciparum, infecting humans, and P. reichenowi, infecting chimpanzees, were long considered to be within the clade that includes humans and the great apes.", [["Plasmodium, P. falciparum", "DISEASE", 15, 40], ["Plasmodium", "ORGANISM", 15, 25], ["P. falciparum", "ORGANISM", 27, 40], ["humans", "ORGANISM", 52, 58], ["P. reichenowi", "ORGANISM", 64, 77], ["chimpanzees", "ORGANISM", 89, 100], ["humans", "ORGANISM", 160, 166], ["P. falciparum", "SPECIES", 27, 40], ["humans", "SPECIES", 52, 58], ["P. reichenowi", "SPECIES", 64, 77], ["humans", "SPECIES", 160, 166], ["P. falciparum", "SPECIES", 27, 40], ["humans", "SPECIES", 52, 58], ["P. reichenowi", "SPECIES", 64, 77], ["humans", "SPECIES", 160, 166], ["Plasmodium", "PROBLEM", 15, 25], ["P. falciparum", "PROBLEM", 27, 40], ["P. reichenowi", "TREATMENT", 64, 77], ["Plasmodium", "OBSERVATION_MODIFIER", 15, 25], ["falciparum", "OBSERVATION_MODIFIER", 30, 40]]], ["However, recent studies of apes in their natural habitat have revealed a much higher diversity of species infecting great apes; in addition, it has been found that P. falciparum also infect gorillas (Liu et al. 2010; Prugnolle et al. 2010 ) and are at the origin of human malaria.How Many Pathogens Are There?Metagenomic studies in ecosystems such as human faeces (Zhang et al. 2006 ) and marine sediments (Breitbart et al. 2004 ) also have revealed that the majority of viral sequences found did not match in the databanks.", [["P. falciparum", "DISEASE", 164, 177], ["malaria", "DISEASE", 272, 279], ["P. falciparum", "ORGANISM", 164, 177], ["gorillas", "ORGANISM", 190, 198], ["human", "ORGANISM", 266, 271], ["human", "ORGANISM", 351, 356], ["viral sequences", "DNA", 471, 486], ["P. falciparum", "SPECIES", 164, 177], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 351, 356], ["P. falciparum", "SPECIES", 164, 177], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 351, 356], ["recent studies", "TEST", 9, 23], ["P. falciparum", "PROBLEM", 164, 177], ["human malaria", "PROBLEM", 266, 279], ["Metagenomic studies", "TEST", 309, 328], ["human faeces", "PROBLEM", 351, 363], ["viral sequences", "PROBLEM", 471, 486], ["species", "OBSERVATION_MODIFIER", 98, 105], ["infecting", "OBSERVATION_MODIFIER", 106, 115], ["great apes", "OBSERVATION_MODIFIER", 116, 126], ["human", "ANATOMY", 266, 271], ["malaria", "OBSERVATION", 272, 279], ["Pathogens", "OBSERVATION", 289, 298]]], ["Finally, new investigations have been launched to monitor people, animals and animal die-offs in areas where people have a high exposure to wildlife.", [["people", "ORGANISM", 58, 64], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 58, 64], ["people", "SPECIES", 109, 115]]], ["Generic, broad screening tools will be used to detect pathogen species (Wolfe et al. 2007 ).", [["broad screening tools", "TEST", 9, 30], ["pathogen species", "PROBLEM", 54, 70]]], ["To our knowledge, a similar approach has not yet been implemented for pathogens of animals or plants.Does the Worldwide Distribution of Pathogen Species Diversity Mirror That of Other Organisms?In addition to the inventories of pathogen biodiversity, scientists have investigated which part of the world holds the highest diversity of pathogen species.", [["Pathogen Species Diversity", "PROBLEM", 136, 162], ["Other Organisms", "PROBLEM", 178, 193], ["pathogen biodiversity", "TREATMENT", 228, 249], ["pathogen species", "PROBLEM", 335, 351], ["Pathogen Species", "OBSERVATION", 136, 152], ["pathogen biodiversity", "OBSERVATION", 228, 249], ["pathogen species", "OBSERVATION", 335, 351]]], ["Many studies on plants and animals have shown that species richness decreases the further one moves away from the equator.", [["Many studies", "TEST", 0, 12], ["species richness", "PROBLEM", 51, 67], ["species richness", "OBSERVATION", 51, 67]]], ["Comparative studies exploring pathogen species richness in the tropics compared to temperate zones are scarce and have produced discrepant results.", [["Comparative studies", "TEST", 0, 19], ["pathogen species richness", "PROBLEM", 30, 55]]], ["Guernier et al (2004) studied the worldwide distribution of 229 human pathogens (bacteria, virus, fungi, protozoa, and helminths) according to environmental, demographic and economical factors.", [["helminths", "DISEASE", 119, 128], ["human", "ORGANISM", 64, 69], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["human pathogens", "PROBLEM", 64, 79], ["bacteria", "PROBLEM", 81, 89], ["virus", "PROBLEM", 91, 96], ["fungi", "PROBLEM", 98, 103], ["protozoa", "PROBLEM", 105, 113]]], ["They found that parasite species richness decreased with latitude and had a spatially nested organization; i.e. some species are widely distributed and occur in many communities while others have more restricted distributions and occur only in a subset of locations.", [["parasite species richness", "PROBLEM", 16, 41], ["a spatially nested organization", "PROBLEM", 74, 105], ["some species", "PROBLEM", 112, 124], ["parasite", "OBSERVATION_MODIFIER", 16, 24], ["species", "OBSERVATION_MODIFIER", 25, 32], ["richness", "OBSERVATION_MODIFIER", 33, 41], ["decreased", "OBSERVATION_MODIFIER", 42, 51], ["widely", "OBSERVATION_MODIFIER", 129, 135], ["distributed", "OBSERVATION_MODIFIER", 136, 147], ["restricted distributions", "OBSERVATION_MODIFIER", 201, 225]]], ["Such findings were confirmed by the analysis of Dunn et al. (2010) , who showed that human pathogen diversity was strongly related to both mammal and bird species richness.", [["human", "ORGANISM", 85, 90], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["the analysis", "TEST", 32, 44], ["human pathogen diversity", "PROBLEM", 85, 109], ["bird species", "OBSERVATION", 150, 162]]], ["Diseases that occur in temperate zones also tend to occur in the tropics, while some tropical diseases are restricted only to the tropics.", [["Diseases", "PROBLEM", 0, 8], ["some tropical diseases", "PROBLEM", 80, 102], ["diseases", "OBSERVATION", 94, 102]]], ["In primates, the number of protozoa species, which primarily are vector-borne transmitted, increase as one approaches the equator, however, the same trend was not found for viruses and helminths (Nunn et al. 2005 ).", [["helminths", "DISEASE", 185, 194], ["primates", "ORGANISM", 3, 11], ["protozoa species", "PROBLEM", 27, 43], ["viruses", "PROBLEM", 173, 180], ["protozoa species", "OBSERVATION", 27, 43]]], ["Lindenfors et al (2007), who examined the parasite richness of 980 parasite species and 146 terrestrial carnivore species, found that helminth parasite species richness increased the further away one moved from the equator.", [["parasite species", "PROBLEM", 67, 83], ["146 terrestrial carnivore species", "PROBLEM", 88, 121], ["helminth parasite species richness", "PROBLEM", 134, 168], ["terrestrial carnivore species", "OBSERVATION", 92, 121], ["helminth", "OBSERVATION_MODIFIER", 134, 142], ["parasite", "OBSERVATION_MODIFIER", 143, 151], ["species", "OBSERVATION_MODIFIER", 152, 159], ["richness", "OBSERVATION_MODIFIER", 160, 168], ["increased", "OBSERVATION_MODIFIER", 169, 178]]], ["The reason for this finding is unknown and may be related to a bias in sampling because carnivores inhabiting areas of industrialized countries in the Northern Hemisphere may have been sampled more intensely.", [["a bias in sampling", "PROBLEM", 61, 79], ["Northern Hemisphere", "ANATOMY", 151, 170]]], ["Some studies have shown higher tick species richness at lower latitudes (Cumming 2000) .", [["Some studies", "TEST", 0, 12], ["higher tick species richness", "PROBLEM", 24, 52], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["tick", "OBSERVATION_MODIFIER", 31, 35], ["species", "OBSERVATION_MODIFIER", 36, 43], ["richness", "OBSERVATION_MODIFIER", 44, 52], ["lower latitudes", "OBSERVATION_MODIFIER", 56, 71]]], ["However, this is not the case for flea species, which have been found to have low richness at lower latitudes (Krasnov et al. 2004) .", [["flea species", "PROBLEM", 34, 46], ["low richness at lower latitudes", "PROBLEM", 78, 109], ["low", "OBSERVATION_MODIFIER", 78, 81], ["richness", "OBSERVATION", 82, 90]]], ["A final example is Ichneumonid parasitoid hymenoptera.", [["parasitoid hymenoptera", "OBSERVATION", 31, 53]]], ["Although a higher specific host diversity is found in the tropics, the number of species of this parasitoid group is similar in both tropical and temperate regions.", [["a higher specific host diversity", "PROBLEM", 9, 41], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["specific", "OBSERVATION_MODIFIER", 18, 26], ["host", "OBSERVATION_MODIFIER", 27, 31], ["diversity", "OBSERVATION", 32, 41], ["species", "OBSERVATION_MODIFIER", 81, 88], ["similar", "OBSERVATION_MODIFIER", 117, 124], ["both", "OBSERVATION_MODIFIER", 128, 132], ["tropical", "OBSERVATION_MODIFIER", 133, 141]]], ["It has been hypothesised that this is due to habitat fragmentation (leading to a lower density of hosts); lack of seasonality (and thus of a host population dynamics with peaks and high density of hosts), or the higher content in toxic compounds of tropical plants and thus in phytophagous insects (the \"nasty hypothesis\") (Gauld et al. 1992) .", [["habitat fragmentation", "PROBLEM", 45, 66], ["a lower density of hosts", "PROBLEM", 79, 103], ["high density of hosts", "PROBLEM", 181, 202], ["tropical plants", "PROBLEM", 249, 264], ["due to", "UNCERTAINTY", 38, 44], ["habitat fragmentation", "OBSERVATION", 45, 66], ["lower density", "OBSERVATION_MODIFIER", 81, 94], ["high density", "OBSERVATION_MODIFIER", 181, 193], ["higher content", "OBSERVATION_MODIFIER", 212, 226], ["toxic compounds", "OBSERVATION_MODIFIER", 230, 245], ["tropical plants", "OBSERVATION", 249, 264]]], ["A meta-analysis of parasite-associated host mortality (Robar et al. 2010 ) revealed that host mortality risk declined as one moves away from the equator, indicating that, in addition to parasitic load, the effect of parasites on host mortality might be determined by some abiotic factors.", [["abiotic factors", "PROTEIN", 272, 287], ["parasite", "PROBLEM", 19, 27], ["host mortality risk", "PROBLEM", 89, 108], ["parasitic load", "PROBLEM", 186, 200], ["parasites", "PROBLEM", 216, 225], ["some abiotic factors", "PROBLEM", 267, 287], ["parasitic load", "OBSERVATION", 186, 200], ["abiotic factors", "OBSERVATION", 272, 287]]], ["Thus, although there is a trend to find higher pathogen richness as we move toward the equator, it is thus challenging to identify a global pattern between the richness of all pathogen species and their latitudinal distribution.", [["higher pathogen richness", "PROBLEM", 40, 64], ["all pathogen species", "PROBLEM", 172, 192], ["global", "OBSERVATION_MODIFIER", 133, 139], ["all", "OBSERVATION_MODIFIER", 172, 175], ["pathogen species", "OBSERVATION", 176, 192], ["latitudinal", "OBSERVATION_MODIFIER", 203, 214], ["distribution", "OBSERVATION_MODIFIER", 215, 227]]], ["However, it should be noted that of the 87 pathogens that have been discovered since 1980, most have a global distribution (Woolhouse and Gaunt 2007) .Pathogen Intraspecific Diversity Is One Factor Favouring Disease EmergencePathogens generally are characterised as having higher mutation rates and generation times than those of their hosts (Hamilton et al. 1990 ).", [["the 87 pathogens", "PROBLEM", 36, 52], ["higher mutation rates", "PROBLEM", 273, 294], ["global", "OBSERVATION_MODIFIER", 103, 109], ["distribution", "OBSERVATION_MODIFIER", 110, 122], ["Intraspecific", "OBSERVATION_MODIFIER", 160, 173], ["Diversity", "OBSERVATION_MODIFIER", 174, 183]]], ["Genetic variability also results from recombination during sexual reproduction of eukaryotic pathogens, and any other genetic exchange mechanisms such as bacterial conjugation or viral recombination.", [["Genetic variability", "PROBLEM", 0, 19], ["eukaryotic pathogens", "PROBLEM", 82, 102], ["any other genetic exchange mechanisms", "PROBLEM", 108, 145], ["bacterial conjugation", "PROBLEM", 154, 175], ["viral recombination", "PROBLEM", 179, 198], ["viral recombination", "OBSERVATION", 179, 198]]], ["In addition, many animal and plant pathogens use a vector to increase gene flow among populations and to reach a new individual host.", [["a vector", "TREATMENT", 49, 57], ["pathogens", "OBSERVATION", 35, 44]]], ["This genetic diversity is a crucial factor in disease emergence (Cleaveland et al. 2001 ) and allows pathogens to adapt to the main selective pressures they face: hosts' immune systems, the need to be transmitted, and treatments or vaccines used to counter infections.", [["infections", "DISEASE", 257, 267], ["a crucial factor in disease emergence", "PROBLEM", 26, 63], ["treatments", "TREATMENT", 218, 228], ["vaccines", "TREATMENT", 232, 240], ["infections", "PROBLEM", 257, 267], ["crucial", "OBSERVATION_MODIFIER", 28, 35]]], ["The capacity of some pathogens to genetically diversify facilitates their ability to evade host immune systems.", [["some pathogens", "PROBLEM", 16, 30]]], ["One of the best examples is the Human Immunodeficiency Virus (HIV), which is able to change its appearance faster than the time its takes for the immune system to reply (Drosopoulos et al. 1998 ).", [["Human Immunodeficiency Virus (HIV)", "DISEASE", 32, 66], ["Human Immunodeficiency Virus", "ORGANISM", 32, 60], ["HIV", "ORGANISM", 62, 65], ["Human", "SPECIES", 32, 37], ["Immunodeficiency Virus", "SPECIES", 38, 60], ["HIV", "SPECIES", 62, 65], ["Human Immunodeficiency Virus", "SPECIES", 32, 60], ["HIV", "SPECIES", 62, 65], ["the Human Immunodeficiency Virus (HIV)", "PROBLEM", 28, 66]]], ["Another example is P. falciparum, which generates high levels of variability in genes involved in antigenic variability and virulence (var genes) by producing frequent recombination events between heterologous chromosomes (Freitas-Junior et al. 2000) .", [["chromosomes", "ANATOMY", 210, 221], ["P. falciparum", "DISEASE", 19, 32], ["P. falciparum", "ORGANISM", 19, 32], ["chromosomes", "CELLULAR_COMPONENT", 210, 221], ["var genes", "DNA", 135, 144], ["heterologous chromosomes", "DNA", 197, 221], ["P. falciparum", "SPECIES", 19, 32], ["P. falciparum", "SPECIES", 19, 32], ["P. falciparum", "PROBLEM", 19, 32], ["antigenic variability", "PROBLEM", 98, 119], ["virulence (var genes)", "PROBLEM", 124, 145], ["heterologous chromosomes", "TREATMENT", 197, 221], ["falciparum", "OBSERVATION", 22, 32]]], ["High genetic variation of pathogens also is involved in the interspecies infection process as it facilitates the infection of a broader range of host species, which is another characteristic of emerging pathogens (Cleaveland et al. 2001; Woolhouse and Gowtage-Sequeria 2005) .", [["infection", "DISEASE", 73, 82], ["infection", "DISEASE", 113, 122], ["High genetic variation of pathogens", "PROBLEM", 0, 35], ["the interspecies infection process", "PROBLEM", 56, 90], ["the infection", "PROBLEM", 109, 122], ["host species", "PROBLEM", 145, 157], ["emerging pathogens", "PROBLEM", 194, 212], ["pathogens", "OBSERVATION", 26, 35], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 113, 122], ["host species", "OBSERVATION", 145, 157], ["another characteristic of", "UNCERTAINTY", 168, 193], ["pathogens", "OBSERVATION", 203, 212]]], ["The evolutionary potential of pathogens allows them to respond quickly to the directional selective pressure provided by the massive use of drugs (Palumbi 2001) .", [["pathogens", "PROBLEM", 30, 39], ["the directional selective pressure", "TREATMENT", 74, 108], ["drugs", "TREATMENT", 140, 145], ["pathogens", "OBSERVATION", 30, 39], ["massive", "OBSERVATION_MODIFIER", 125, 132]]], ["In areas where selective pressure is important, such as in hospitals, multiresistant bacteria are very frequent (Levy and Marshall 2004) .", [["selective pressure", "TREATMENT", 15, 33], ["multiresistant bacteria", "PROBLEM", 70, 93], ["selective", "OBSERVATION_MODIFIER", 15, 24], ["pressure", "OBSERVATION", 25, 33]]], ["For bacteria, resistant genes probably originated from environmental organisms with which they shared their ecological niche (Aminov and Mackie 2007) .", [["resistant genes", "DNA", 14, 29], ["bacteria", "PROBLEM", 4, 12], ["resistant genes", "PROBLEM", 14, 29], ["resistant genes", "OBSERVATION", 14, 29]]], ["These genes can be transferred between different species of bacteria and even between species that colonize different hosts (Nikolich et al. 1994) .Pathogen Intraspecific Diversity Is One Factor Favouring Disease EmergenceAlthough vaccination is a major advance of modern medicine, it thus far has contributed to the eradication of only one infectious disease in humans (small pox, www.who.int/mediacentre/factsheets/smallpox/en) and one in cattle, buffalo and wildebeest (rinderpest, Normile 2008) .", [["infectious disease", "DISEASE", 341, 359], ["humans", "ORGANISM", 363, 369], ["cattle", "ORGANISM", 441, 447], ["buffalo", "ORGANISM", 449, 456], ["humans", "SPECIES", 363, 369], ["cattle", "SPECIES", 441, 447], ["humans", "SPECIES", 363, 369], ["cattle", "SPECIES", 441, 447], ["buffalo", "SPECIES", 449, 456], ["bacteria", "PROBLEM", 60, 68], ["modern medicine", "TREATMENT", 265, 280], ["one infectious disease in humans", "PROBLEM", 337, 369], ["bacteria", "OBSERVATION", 60, 68], ["one", "OBSERVATION_MODIFIER", 337, 340], ["infectious", "OBSERVATION", 341, 351], ["small", "OBSERVATION_MODIFIER", 371, 376], ["pox", "OBSERVATION", 377, 380]]], ["As many vaccines do not totally block transmission, vaccination modifies the selective pressure on pathogens.", [["many vaccines", "TREATMENT", 3, 16], ["vaccination", "TREATMENT", 52, 63], ["pathogens", "PROBLEM", 99, 108]]], ["For instance, theoretical work has shown that vaccines that reduce the growth rate or toxicity of pathogens also reduce selection pressure against virulent pathogens, leading to higher intrinsic virulence (Gandon et al. 2001 ).", [["toxicity", "DISEASE", 86, 94], ["vaccines", "TREATMENT", 46, 54], ["the growth rate", "PROBLEM", 67, 82], ["toxicity of pathogens", "PROBLEM", 86, 107], ["selection pressure", "TREATMENT", 120, 138], ["virulent pathogens", "PROBLEM", 147, 165]]], ["In the poultry industry, an increase in virulence of avian tumour viruses has followed the use of vaccines that reduce virus growth rates (Witter 1997) .Pathogen Diversity to Which Hosts Are Exposed Influences Host Susceptibility to DiseaseAlthough plants lack an adaptive immune system, through evolution they have developed various strategies to stop plant pathogen infections.", [["tumour", "ANATOMY", 59, 65], ["avian tumour", "DISEASE", 53, 65], ["pathogen infections", "DISEASE", 359, 378], ["avian tumour viruses", "ORGANISM", 53, 73], ["an increase in virulence of avian tumour viruses", "PROBLEM", 25, 73], ["vaccines", "TREATMENT", 98, 106], ["virus growth rates", "PROBLEM", 119, 137], ["an adaptive immune system", "TREATMENT", 261, 286], ["various strategies", "TREATMENT", 326, 344], ["plant pathogen infections", "PROBLEM", 353, 378], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["avian tumour viruses", "OBSERVATION", 53, 73], ["pathogen", "OBSERVATION_MODIFIER", 359, 367], ["infections", "OBSERVATION", 368, 378]]], ["An induced or acquired systemic resistance occurs following host recognition of a pathogen, which triggers the production of a hypersensitive reaction (Jones and Dangl 2006) .", [["acquired systemic resistance", "PROBLEM", 14, 42], ["a pathogen", "PROBLEM", 80, 90], ["a hypersensitive reaction", "PROBLEM", 125, 150], ["systemic resistance", "OBSERVATION", 23, 42], ["hypersensitive reaction", "OBSERVATION", 127, 150]]], ["Through this mechanism, the plant provides itself protection from secondary infection in distal tissues, even if the plant faces a pathogen for which it does not have the resistance gene (Durrant and Dong 2004 ).Pathogen Diversity to Which Hosts Are Exposed Influences Host Susceptibility to DiseaseThe immune system of vertebrates acquires its efficiency by being exposed to a diverse array of pathogens.", [["distal tissues", "ANATOMY", 89, 103], ["immune system", "ANATOMY", 303, 316], ["infection", "DISEASE", 76, 85], ["tissues", "TISSUE", 96, 103], ["itself protection", "TREATMENT", 43, 60], ["secondary infection in distal tissues", "PROBLEM", 66, 103], ["a pathogen", "PROBLEM", 129, 139], ["pathogens", "PROBLEM", 395, 404], ["secondary", "OBSERVATION_MODIFIER", 66, 75], ["infection", "OBSERVATION", 76, 85], ["distal tissues", "OBSERVATION", 89, 103], ["pathogen", "OBSERVATION", 131, 139], ["diverse", "OBSERVATION_MODIFIER", 378, 385], ["pathogens", "OBSERVATION", 395, 404]]], ["The striking increase in hygiene standards that began in the early twentieth century has considerably lowered humans' exposure to pathogens, at least in developed countries.", [["humans", "ORGANISM", 110, 116], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 110, 116], ["hygiene standards", "TREATMENT", 25, 42], ["pathogens", "PROBLEM", 130, 139], ["striking", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["hygiene standards", "OBSERVATION", 25, 42]]], ["The immune response triggered by a pathogen can provide some cross protection against other pathogens (e.g. Huang et al. 2008) .", [["a pathogen", "PROBLEM", 33, 43], ["other pathogens", "PROBLEM", 86, 101]]], ["A low exposure to a diversity of pathogens has had immediate consequences in decreasing the risk of disease.", [["A low exposure", "PROBLEM", 0, 14], ["pathogens", "PROBLEM", 33, 42], ["disease", "PROBLEM", 100, 107], ["low exposure", "OBSERVATION_MODIFIER", 2, 14], ["pathogens", "OBSERVATION", 33, 42], ["disease", "OBSERVATION", 100, 107]]], ["But could this low exposure also induce evolutionary change in the ability of a host to respond to infection?", [["infection", "DISEASE", 99, 108], ["evolutionary change", "PROBLEM", 40, 59], ["infection", "PROBLEM", 99, 108], ["change", "OBSERVATION_MODIFIER", 53, 59], ["infection", "OBSERVATION", 99, 108]]], ["Due to a trade off between investment in disease resistance and other traits linked to fitness, low exposure could decrease the frequency of resistance down through the generations, setting the stage for a potentially devastating outbreak (Altizer et al. 2003; Graham et al. 2010) .", [["disease resistance", "PROBLEM", 41, 59], ["low exposure", "PROBLEM", 96, 108], ["disease resistance", "OBSERVATION", 41, 59], ["devastating", "OBSERVATION_MODIFIER", 218, 229]]], ["Domestic species that are bred to be protected from pathogens might be more susceptible to infectious diseases (Lyles and Dobson 1993) .", [["infectious diseases", "DISEASE", 91, 110], ["Domestic species", "PROBLEM", 0, 16], ["pathogens", "PROBLEM", 52, 61], ["infectious diseases", "PROBLEM", 91, 110]]], ["Furthermore, it has been suggested that on islands, where some pathogens may be absent, hosts may have lower immune response abilities (island syndrome) (Lee and Klasing 2004) .Pathogen Diversity to Which Hosts Are Exposed Influences Host Susceptibility to DiseaseHowever, studies that have tested this hypothesis, both using experimental and theoretical approaches, have had contrasting results (Beadell et al. 2007; Hochberg and M\u00f8ller 2001; Matson 2006) .Pathogen Diversity to Which Hosts Are Exposed Influences Host Susceptibility to DiseaseInfections by different species of pathogens or by different strains of the same species within the same individual host or vector are common (Abbot et al. 2007; Cox 2001) .", [["some pathogens", "PROBLEM", 58, 72], ["lower immune response abilities (island syndrome", "PROBLEM", 103, 151], ["studies", "TEST", 273, 280], ["different species of pathogens", "PROBLEM", 559, 589], ["different strains of the same species", "PROBLEM", 596, 633]]], ["In fact, parasite diversity in hosts seems to be a major evolutionary and ecological force for hosts (Bordes and Morand 2009 ).", [["parasite diversity in hosts", "PROBLEM", 9, 36], ["parasite diversity", "OBSERVATION", 9, 27]]], ["These concomitant infections can trigger cross-effective immune responses between pathogens that are antigenically similar, having thus an impact on the issue of the infection (Lee et al. 2010 ).", [["infections", "DISEASE", 18, 28], ["infection", "DISEASE", 166, 175], ["These concomitant infections", "PROBLEM", 0, 28], ["pathogens", "PROBLEM", 82, 91], ["the infection", "PROBLEM", 162, 175], ["infections", "OBSERVATION", 18, 28], ["infection", "OBSERVATION", 166, 175]]], ["An infection also can enhance susceptibility to subsequent infection (Cattadori et al. 2007 ).", [["infection", "DISEASE", 3, 12], ["infection", "DISEASE", 59, 68], ["An infection", "PROBLEM", 0, 12], ["subsequent infection", "PROBLEM", 48, 68], ["infection", "OBSERVATION", 3, 12], ["infection", "OBSERVATION", 59, 68]]], ["In particular, individuals with already are in poor physical condition may be more susceptible to multiple infections (Beldomenico and Begon 2009; Telfer et al. 2008) .", [["infections", "DISEASE", 107, 117], ["poor physical condition", "PROBLEM", 47, 70], ["multiple infections", "PROBLEM", 98, 117], ["multiple", "OBSERVATION_MODIFIER", 98, 106], ["infections", "OBSERVATION", 107, 117]]], ["Furthermore, concomitant infection may allow the exchange of genetic material between strains of a given pathogen species or even between species through horizontal gene transfer (see Sect.", [["infection", "DISEASE", 25, 34], ["concomitant infection", "PROBLEM", 13, 34], ["genetic material", "TREATMENT", 61, 77], ["pathogen species", "PROBLEM", 105, 121], ["concomitant", "OBSERVATION_MODIFIER", 13, 24], ["infection", "OBSERVATION", 25, 34]]], ["13.2.2 above), allowing the emergence of new virulent strains.", [["strains", "ANATOMY", 54, 61], ["new virulent strains", "PROBLEM", 41, 61]]], ["An extreme case is one in which a pathogen drives the extinction of a population or species.", [["a pathogen", "PROBLEM", 32, 42], ["extreme", "OBSERVATION_MODIFIER", 3, 10], ["case", "OBSERVATION", 11, 15]]], ["Such scenarios are rare but do occur, generally due to a conjunction of pathogens and other causes.", [["Such scenarios", "PROBLEM", 0, 14], ["pathogens", "PROBLEM", 72, 81], ["pathogens", "OBSERVATION", 72, 81]]], ["For instance, the decline of amphibian populations around the world is thought to be linked to a fungal pathogen Batrachochytrium dendrobatidis causing Chytridiomycosis (Crawford et al. 2010 ).", [["Batrachochytrium dendrobatidis", "DISEASE", 113, 143], ["Chytridiomycosis", "DISEASE", 152, 168], ["Batrachochytrium dendrobatidis", "ORGANISM", 113, 143], ["Batrachochytrium dendrobatidis", "SPECIES", 113, 143], ["Batrachochytrium dendrobatidis", "SPECIES", 113, 143], ["amphibian populations", "PROBLEM", 29, 50], ["a fungal pathogen Batrachochytrium dendrobatidis", "PROBLEM", 95, 143], ["Chytridiomycosis", "PROBLEM", 152, 168], ["amphibian populations", "OBSERVATION", 29, 50], ["fungal", "OBSERVATION_MODIFIER", 97, 103]]], ["Amphibians could have an increased susceptibility to the fungus due to changes in temperature variability (Rohr and Raffel 2010) .", [["an increased susceptibility to the fungus", "PROBLEM", 22, 63], ["changes in temperature variability", "PROBLEM", 71, 105], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["susceptibility", "OBSERVATION", 35, 49], ["fungus", "OBSERVATION", 57, 63]]], ["Another example is the dramatic decline of the native red squirrel in the UK that has been attributed to a combination of direct competition with the grey squirrel and disease-mediated competition because the grey squirrel is a reservoir host of the squirrelpox virus that causes disease in the red squirrel (Tompkins et al. 2002) .", [["red squirrel", "ORGANISM", 54, 66], ["UK", "GENE_OR_GENE_PRODUCT", 74, 76], ["squirrel", "ORGANISM", 155, 163], ["grey squirrel", "ORGANISM", 209, 222], ["squirrelpox virus", "ORGANISM", 250, 267], ["squirrel", "ORGANISM", 299, 307], ["red squirrel", "SPECIES", 54, 66], ["grey squirrel", "SPECIES", 150, 163], ["grey squirrel", "SPECIES", 209, 222], ["squirrelpox virus", "SPECIES", 250, 267], ["red squirrel", "SPECIES", 295, 307], ["disease", "PROBLEM", 168, 175], ["the squirrelpox virus", "PROBLEM", 246, 267], ["disease in the red squirrel", "PROBLEM", 280, 307], ["dramatic", "OBSERVATION_MODIFIER", 23, 31], ["decline", "OBSERVATION_MODIFIER", 32, 39], ["native", "OBSERVATION_MODIFIER", 47, 53], ["red", "OBSERVATION", 54, 57], ["squirrel", "OBSERVATION_MODIFIER", 58, 66]]], ["The local extinction of a host also may have tremendous consequences on an entire ecosystem (see for example the case of the wildebeest /rinderpest interactions in the Serengeti, Holdo et al. 2009 ).How Does the Diversity of Hosts Influence InfectiousDisease Ecology?Change in Host Species Richness Modifies Infectious Disease RiskA change in species richness or abundance can modify the dynamics of local infectious diseases by either reducing or increasing the risk of transmission to the targeted species.", [["InfectiousDisease", "DISEASE", 241, 258], ["infectious diseases", "DISEASE", 406, 425], ["RiskA change in species richness", "PROBLEM", 327, 359], ["local infectious diseases", "PROBLEM", 400, 425], ["local", "OBSERVATION_MODIFIER", 4, 9], ["extinction", "OBSERVATION", 10, 20], ["Host Species Richness", "OBSERVATION", 277, 298], ["Infectious", "OBSERVATION_MODIFIER", 308, 318], ["local", "OBSERVATION_MODIFIER", 400, 405], ["infectious", "OBSERVATION", 406, 416]]], ["The term \"dilution effect\" has conveyed different meanings since its first use in disease ecology literature (see Box 2 in the paper Keesing et al. 2006) .", [["The term \"dilution effect", "PROBLEM", 0, 25]]], ["The broad definition of the dilution effect refers to \"the phenomenon -the net effect -when increased species diversity reduces disease risk\" that is produced by a variety of mechanisms (\"amplification effect\" refers to the opposite phenomenon) (Keesing et al. 2006) .", [["the dilution effect", "PROBLEM", 24, 43], ["the phenomenon", "PROBLEM", 55, 69], ["the net effect", "PROBLEM", 71, 85], ["increased species diversity", "PROBLEM", 92, 119], ["disease risk", "PROBLEM", 128, 140], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["dilution effect", "OBSERVATION", 28, 43]]], ["This applies to vector-borne and directly transmitted diseases, although the concept of dilution has been developed most with regards to the tick-borne Lyme disease (Allan et al. 2003; LoGiudice et al. 2003 LoGiudice et al. , 2008 .", [["vector-borne and directly transmitted diseases", "DISEASE", 16, 62], ["Lyme disease", "DISEASE", 152, 164], ["directly transmitted diseases", "PROBLEM", 33, 62], ["the tick-borne Lyme disease", "PROBLEM", 137, 164], ["diseases", "OBSERVATION", 54, 62]]], ["The hypothesis underlying the amplification and dilution effect is that for many diseases, the competence of reservoirs, i.e. the ability to become infected and retransmit the pathogen, varies according to the host species (Haydon et al. 2002) .", [["the amplification", "TREATMENT", 26, 43], ["many diseases", "PROBLEM", 76, 89], ["reservoirs", "TREATMENT", 109, 119], ["infected", "PROBLEM", 148, 156], ["the pathogen", "PROBLEM", 172, 184], ["infected", "OBSERVATION", 148, 156]]], ["The composition of the host community thus can influence the transmission dynamic of the disease.", [["community", "ANATOMY", 28, 37], ["the disease", "PROBLEM", 85, 96], ["disease", "OBSERVATION", 89, 96]]], ["Similarly, since vectors have different competence to transmit pathogens, the composition of the vector community likely influences transmission dynamics.", [["transmit pathogens", "PROBLEM", 54, 72]]], ["Different mechanisms are thought to be involved, but they are difficult to differentiate (Begon 2008; Keesing et al. 2006) .", [["thought to be", "UNCERTAINTY", 25, 38]]], ["One is the modification of the encounter rate (when reduced, this corresponds to the \"dilution effect\" sensu stricto).Change in Host Species Richness Modifies Infectious Disease RiskIn the presence of species that are poorly competent, the transmission event that should link an infectious individual to a susceptible individual instead links infectious individuals to non-competent individuals.", [["the \"dilution effect", "PROBLEM", 81, 101], ["Host Species Richness", "OBSERVATION", 128, 149], ["Infectious", "OBSERVATION_MODIFIER", 159, 169], ["species", "OBSERVATION", 201, 208], ["infectious", "OBSERVATION", 279, 289]]], ["For vector-borne diseases, the increased diversity of a poorly competent host species on which the vector feeds increases the proportion of vector bites that are wasted.", [["vector-borne diseases", "DISEASE", 4, 25], ["vector-borne diseases", "PROBLEM", 4, 25], ["the increased diversity", "PROBLEM", 27, 50], ["a poorly competent host species", "PROBLEM", 54, 85], ["the vector feeds", "TREATMENT", 95, 111], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["diversity", "OBSERVATION_MODIFIER", 41, 50], ["poorly competent", "OBSERVATION_MODIFIER", 56, 72], ["host species", "OBSERVATION", 73, 85]]], ["For direct transmission, the addition of non competent hosts can decrease transmission if these hosts remove infectious particles (Begon 2008) .", [["infectious particles", "PROBLEM", 109, 129]]], ["A second mechanism at work is that a high diversity of host species regulates the abundance of the competent host population.", [["a high diversity of host species", "PROBLEM", 35, 67], ["high diversity", "OBSERVATION_MODIFIER", 37, 51], ["host species", "OBSERVATION", 55, 67], ["host population", "OBSERVATION", 109, 124]]], ["A third mechanism is based on the link between species richness and host mortality.", [["A third mechanism", "PROBLEM", 0, 17], ["host mortality", "OBSERVATION", 68, 82]]], ["This is the case when predators modify the mortality rate of a host and lower pathogen transmission by feeding on a heavily diseased individual (Packer et al. 2003) .", [["lower pathogen transmission", "TREATMENT", 72, 99]]], ["Two other mechanisms are cited by Keesing et al (2006) , but they are difficult to demonstrate: (i) the modification of recovery when species added to a community facilitate the recovery of infected individuals by, for instance, providing resources, and (ii) the modification of transmission once the contact has occurred, for instance, when adding a species modifies the pathogen load within the host.Change in Host Species Richness Modifies Infectious Disease RiskThe dilution effect has been demonstrated mainly through theoretical work; there have been few case studies.", [["Infectious Disease", "DISEASE", 443, 461], ["a species", "PROBLEM", 349, 358], ["The dilution effect", "PROBLEM", 466, 485], ["few case studies", "TEST", 557, 573], ["Host Species Richness", "OBSERVATION", 412, 433], ["Infectious", "OBSERVATION_MODIFIER", 443, 453], ["dilution effect", "OBSERVATION", 470, 485], ["few", "OBSERVATION_MODIFIER", 557, 560]]], ["One of the main examples is Lyme disease in the USA that is caused by pathogenic bacteria transmitted by ticks.", [["Lyme disease", "DISEASE", 28, 40], ["Lyme disease in the USA", "PROBLEM", 28, 51], ["pathogenic bacteria", "PROBLEM", 70, 89], ["main", "OBSERVATION_MODIFIER", 11, 15], ["Lyme", "OBSERVATION_MODIFIER", 28, 32], ["disease", "OBSERVATION", 33, 40], ["caused by", "UNCERTAINTY", 60, 69], ["pathogenic", "OBSERVATION_MODIFIER", 70, 80], ["bacteria", "OBSERVATION", 81, 89]]], ["These ticks feed readily on many species of vertebrates and these species vary in their degrees of reservoir competence.", [["these species", "PROBLEM", 60, 73], ["reservoir competence", "OBSERVATION", 99, 119]]], ["The white-footed mouse (Peromyscus leucopus) is thought to be the most competent host and dominates in fragmented forests.", [["mouse", "ORGANISM", 17, 22], ["Peromyscus leucopus", "ORGANISM", 24, 43], ["mouse", "SPECIES", 17, 22], ["Peromyscus leucopus", "SPECIES", 24, 43], ["white-footed mouse", "SPECIES", 4, 22], ["Peromyscus leucopus", "SPECIES", 24, 43], ["The white-footed mouse (Peromyscus leucopus", "PROBLEM", 0, 43], ["white", "OBSERVATION_MODIFIER", 4, 9], ["thought to be", "UNCERTAINTY", 48, 61], ["fragmented", "OBSERVATION_MODIFIER", 103, 113], ["forests", "OBSERVATION", 114, 121]]], ["In native forests, which harbour a higher diversity of species than fragmented forests, ticks have a higher probability to dilute their bite by feeding on a less competent host (Allan et al. 2003; LoGiudice et al. 2003 LoGiudice et al. , 2008 .", [["native", "OBSERVATION_MODIFIER", 3, 9], ["forests", "OBSERVATION", 10, 17], ["higher diversity", "OBSERVATION_MODIFIER", 35, 51]]], ["However, such a dilution effect has not been demonstrated in Europe, probably because of the complexity of the disease ecology which involves numerous reservoir host and bacteria species (Halos et al. 2010) .", [["a dilution effect", "PROBLEM", 14, 31], ["the disease ecology", "PROBLEM", 107, 126], ["bacteria species", "PROBLEM", 170, 186], ["disease", "OBSERVATION", 111, 118], ["numerous", "OBSERVATION_MODIFIER", 142, 150], ["reservoir host", "OBSERVATION", 151, 165]]], ["Another example is the West Nile virus, where an increased diversity of non passerine birds, which are less competent reservoir hosts compared to passerines, was associated with decreased West Nile virus infection in mosquitoes and humans (Ezenwa et al. 2006; Swaddle and Calos 2008) .", [["West Nile virus infection", "DISEASE", 188, 213], ["West Nile virus", "ORGANISM", 23, 38], ["non passerine birds", "ORGANISM", 72, 91], ["West Nile virus", "ORGANISM", 188, 203], ["humans", "ORGANISM", 232, 238], ["Nile virus", "SPECIES", 193, 203], ["humans", "SPECIES", 232, 238], ["West Nile virus", "SPECIES", 23, 38], ["West Nile virus", "SPECIES", 188, 203], ["humans", "SPECIES", 232, 238], ["the West Nile virus", "PROBLEM", 19, 38], ["an increased diversity of non passerine birds", "PROBLEM", 46, 91], ["decreased West Nile virus infection", "PROBLEM", 178, 213], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["diversity", "OBSERVATION_MODIFIER", 59, 68], ["non passerine birds", "OBSERVATION_MODIFIER", 72, 91], ["less competent", "OBSERVATION_MODIFIER", 103, 117], ["reservoir hosts", "OBSERVATION", 118, 133]]], ["To date, there have been few examples of directly transmitted diseases, but studies on hantaviruses have shown that higher diversity of small mammals appears to regulate reservoir host populations through competition or predation.", [["directly transmitted diseases", "PROBLEM", 41, 70], ["studies on hantaviruses", "TEST", 76, 99], ["small mammals", "PROBLEM", 136, 149], ["few", "OBSERVATION_MODIFIER", 25, 28], ["diseases", "OBSERVATION", 62, 70], ["higher", "OBSERVATION_MODIFIER", 116, 122], ["diversity", "OBSERVATION_MODIFIER", 123, 132], ["small mammals", "OBSERVATION", 136, 149]]], ["High small-mammal diversity also might inhibit intraspecific aggressive encounters between reservoir hosts that result in hantavirus transmission (Suz\u00e1n et al. 2009 ).Change in Host Species Richness Modifies Infectious Disease RiskIn plants, crop diversity can reduce the total burden of disease in agricultural systems.", [["hantavirus transmission", "DISEASE", 122, 145], ["High small-mammal diversity", "PROBLEM", 0, 27], ["reservoir hosts", "TREATMENT", 91, 106], ["RiskIn plants", "TREATMENT", 227, 240], ["crop diversity", "PROBLEM", 242, 256], ["the total burden of disease in agricultural systems", "PROBLEM", 268, 319], ["small", "OBSERVATION_MODIFIER", 5, 10], ["mammal diversity", "OBSERVATION", 11, 27], ["intraspecific", "OBSERVATION_MODIFIER", 47, 60], ["aggressive", "OBSERVATION_MODIFIER", 61, 71], ["hantavirus", "OBSERVATION", 122, 132], ["Host Species Richness", "OBSERVATION", 177, 198], ["Infectious", "OBSERVATION_MODIFIER", 208, 218], ["total", "OBSERVATION_MODIFIER", 272, 277], ["burden", "OBSERVATION_MODIFIER", 278, 284], ["disease", "OBSERVATION", 288, 295]]], ["This results from the combined effects of (i) the limitation of pathogen dispersal thanks to the physical barriers provided by the presence of non-host plants (Burdon and Chilvers 1982) , (ii) induced systemic resistance, and (iii) competition among pathogens.", [["systemic resistance", "PROBLEM", 201, 220], ["systemic resistance", "OBSERVATION", 201, 220]]], ["The efficiency of crop mixtures is linked to the size of the area on which this method is used: a high level of success has been observed in a field trial with susceptible and resistant varieties of rice conducted on a large scale (3,342 ha) in China (Zhu et al. 2000) .Change in Host Species Richness Modifies Infectious Disease RiskIllustrations of amplification effects are typically the consequences of species introduction that radically modifies encounter rates.", [["rice", "SPECIES", 199, 203], ["rice", "SPECIES", 199, 203], ["crop mixtures", "TREATMENT", 18, 31], ["a large scale", "TREATMENT", 217, 230], ["amplification effects", "PROBLEM", 351, 372], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["crop mixtures", "OBSERVATION", 18, 31], ["size", "OBSERVATION_MODIFIER", 49, 53], ["area", "OBSERVATION_MODIFIER", 61, 65], ["Host Species Richness", "OBSERVATION", 280, 301], ["Infectious", "OBSERVATION_MODIFIER", 311, 321]]], ["The added species can introduce new pathogens that infect native hosts (spillover) (Bruemmer et al. 2010) or amplify the circulation of local pathogens (spillback) (Kelly et al. 2009 ).", [["The added species", "PROBLEM", 0, 17], ["new pathogens", "PROBLEM", 32, 45], ["local pathogens", "PROBLEM", 136, 151]]], ["The introduction of additional species also can provide sources of vector meals and increase vector numbers or activity (Saul 2003) .", [["additional species", "TREATMENT", 20, 38], ["vector meals", "TREATMENT", 67, 79]]], ["For instance, the introduction of Siberian chipmunks (Tamias sibiricus) in suburban forests could increase the risk of Lyme disease because this host seems to be more competent than native hosts (Vourc'h et al. 2007 ).", [["Lyme disease", "DISEASE", 119, 131], ["Siberian chipmunks", "ORGANISM", 34, 52], ["Tamias sibiricus", "ORGANISM", 54, 70], ["Tamias sibiricus", "SPECIES", 54, 70], ["Siberian chipmunks", "SPECIES", 34, 52], ["Tamias sibiricus", "SPECIES", 54, 70], ["Siberian chipmunks (Tamias sibiricus)", "TREATMENT", 34, 71], ["Lyme disease", "PROBLEM", 119, 131], ["Lyme disease", "OBSERVATION", 119, 131]]], ["The introduction of the mosquito Aedes albopictus in many parts of the world has facilitated the transmission of the chikungunya virus (Benedict et al. 2007; Charrel et al. 2007) .Change in Host Species Richness Modifies Infectious Disease RiskTheoretical works based on deterministic modelling have looked at the conditions in disease transmission dynamics that are needed for the amplification or the dilution effect to occur (Begon 2008; Dobson 2004) .", [["chikungunya", "DISEASE", 117, 128], ["mosquito Aedes albopictus", "ORGANISM", 24, 49], ["chikungunya virus", "ORGANISM", 117, 134], ["Aedes albopictus", "SPECIES", 33, 49], ["Aedes albopictus", "SPECIES", 33, 49], ["chikungunya virus", "SPECIES", 117, 134], ["the mosquito Aedes albopictus", "TREATMENT", 20, 49], ["the chikungunya virus", "PROBLEM", 113, 134], ["Host Species Richness", "OBSERVATION", 190, 211]]], ["When there is a relationship between the risk of a disease, the abundance of the reservoir host, and the abundance of an additional host, the addition of a species does not necessarily decrease the risk.", [["a disease", "PROBLEM", 49, 58], ["a species", "PROBLEM", 154, 163], ["disease", "OBSERVATION", 51, 58]]], ["In the case of Lyme disease, for example, tick abundance mainly is determined by the abundance of deer, which are in fact a non competent reservoir.", [["Lyme disease", "DISEASE", 15, 27], ["deer", "ORGANISM", 98, 102], ["deer", "SPECIES", 98, 102], ["Lyme disease", "PROBLEM", 15, 27], ["tick abundance", "PROBLEM", 42, 56], ["Lyme disease", "OBSERVATION", 15, 27]]], ["An increased abundance of deer may reduce infection prevalence when immature ticks are feeding on the deer.", [["infection", "DISEASE", 42, 51], ["deer", "ORGANISM", 26, 30], ["ticks", "ORGANISM", 77, 82], ["deer", "ORGANISM_SUBDIVISION", 102, 106], ["deer", "SPECIES", 26, 30], ["infection prevalence", "PROBLEM", 42, 62], ["immature ticks", "PROBLEM", 68, 82], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["abundance", "OBSERVATION_MODIFIER", 13, 22], ["may", "UNCERTAINTY", 31, 34], ["reduce", "OBSERVATION_MODIFIER", 35, 41], ["infection", "OBSERVATION", 42, 51]]], ["At the same time, however, the overall number of adult ticks increase proportionally with the number of deer (Begon 2008) .", [["deer", "SPECIES", 104, 108], ["adult ticks", "PROBLEM", 49, 60], ["adult", "OBSERVATION_MODIFIER", 49, 54], ["ticks", "OBSERVATION", 55, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["proportionally", "OBSERVATION_MODIFIER", 70, 84]]], ["Further research in this field are relying on the modelling of the global community competence of hosts and vectors (Roche 2008) .Change in Host Species Richness Modifies Infectious Disease RiskScientists and societies are increasingly interested in the dilution effect (MEA 2005) due to the link between habitat disturbance, generalist host characteristics, and their competence in disease transmission.", [["Infectious Disease", "DISEASE", 171, 189], ["habitat disturbance", "PROBLEM", 305, 324], ["Host Species Richness", "OBSERVATION", 140, 161]]], ["Disturbance seems to favour generalist hosts (hosts that use different types of habitats) (Devictor et al. 2008; Marvier et al. 2004) , and these hosts often have a broad geographical distribution (McKinney and Lockwood 1999; Smart et al. 2006 ).", [["broad", "OBSERVATION_MODIFIER", 165, 170]]], ["Crucially, these species also seem to have a higher competence reservoir or vector reservoir than species that are not favoured by disturbance (Mills 2006; Molyneux et al. 2008; Vittor et al. 2006) .", [["not favoured", "UNCERTAINTY", 115, 127]]], ["For example, many murid rodents that are recognized hosts of hemorrhagic fever viruses are opportunistic species that seem to be favoured in disturbed environments.", [["hemorrhagic fever", "DISEASE", 61, 78], ["murid rodents", "ORGANISM", 18, 31], ["hemorrhagic fever viruses", "ORGANISM", 61, 86], ["hemorrhagic fever viruses", "SPECIES", 61, 86], ["many murid rodents", "PROBLEM", 13, 31], ["hemorrhagic fever viruses", "PROBLEM", 61, 86], ["opportunistic species", "PROBLEM", 91, 112], ["hemorrhagic", "OBSERVATION_MODIFIER", 61, 72], ["seem to be", "UNCERTAINTY", 118, 128]]], ["The question is whether there is a causal link between a species' generalist and opportunist character and its disease competence.", [["its disease competence", "PROBLEM", 107, 129]]], ["Why are murid species associated with hemorrhagic fever more generalist than those which are not?", [["hemorrhagic fever", "DISEASE", 38, 55], ["murid species", "PROBLEM", 8, 21], ["hemorrhagic fever", "PROBLEM", 38, 55], ["hemorrhagic", "OBSERVATION_MODIFIER", 38, 49], ["fever", "OBSERVATION", 50, 55]]], ["Could it be possible that specialist species also carry hemorrhagic fever viruses, only these viruses have not yet been identified?", [["hemorrhagic fever", "DISEASE", 56, 73], ["hemorrhagic fever viruses", "ORGANISM", 56, 81], ["hemorrhagic fever viruses", "PROBLEM", 56, 81], ["these viruses", "PROBLEM", 88, 101], ["hemorrhagic", "OBSERVATION_MODIFIER", 56, 67]]], ["Or is there something intrinsic in opportunistic species that makes them more likely to evolve and maintain hemorrhagic fever viruses (Mills 2006)?Does a Loss in a Host's Genetic Diversity Weaken Its Ability to Respond to Infectious Diseases?Only a very small subset of plant and animal species have been domesticated (Diamond 2002) .", [["hemorrhagic fever", "DISEASE", 108, 125], ["Infectious Diseases", "DISEASE", 222, 241], ["something intrinsic in opportunistic species", "PROBLEM", 12, 56], ["hemorrhagic fever viruses", "PROBLEM", 108, 133], ["a Loss", "PROBLEM", 152, 158], ["a very small subset of plant and animal species", "PROBLEM", 247, 294], ["opportunistic species", "OBSERVATION", 35, 56], ["hemorrhagic", "OBSERVATION_MODIFIER", 108, 119], ["very", "OBSERVATION_MODIFIER", 249, 253], ["small", "OBSERVATION_MODIFIER", 254, 259], ["subset", "OBSERVATION_MODIFIER", 260, 266], ["plant", "OBSERVATION", 270, 275], ["animal species", "OBSERVATION", 280, 294]]], ["Many species of that small subset, for example, cattle (in animals) and maize (in plants), have seen their genetic diversity considerably reduced for the purpose of intensive production (The Bovine Hapmap Consortium, Matsuoka et al. 2002) .", [["maize", "ORGANISM_SUBDIVISION", 72, 77], ["Bovine", "ORGANISM", 191, 197], ["cattle", "SPECIES", 48, 54], ["maize", "SPECIES", 72, 77], ["Bovine", "SPECIES", 191, 197], ["cattle", "SPECIES", 48, 54], ["maize", "SPECIES", 72, 77], ["Bovine", "SPECIES", 191, 197], ["The Bovine Hapmap Consortium", "TREATMENT", 187, 215], ["small", "OBSERVATION_MODIFIER", 21, 26], ["subset", "OBSERVATION", 27, 33]]], ["In the wild, small populations of endangered species often have a very reduced genetic diversity (Keller and Waller 2002) .", [["endangered species", "PROBLEM", 34, 52], ["small", "OBSERVATION_MODIFIER", 13, 18], ["populations", "OBSERVATION_MODIFIER", 19, 30], ["endangered species", "OBSERVATION", 34, 52], ["very", "OBSERVATION_MODIFIER", 66, 70], ["reduced", "OBSERVATION_MODIFIER", 71, 78]]], ["This then raises the following question: to what extent does a reduction of the genetic diversity in a host species impact the ability of the host population to response to infectious diseases (May 1995) ?", [["infectious diseases", "DISEASE", 173, 192], ["infectious diseases", "PROBLEM", 173, 192]]], ["Genetic loci associated with the major histocompatibility complex (MHC) plays a key role in the acquired immune response of vertebrates (Altizer et al. 2003) .", [["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 33, 65], ["major histocompatibility complex", "PROTEIN", 33, 65], ["MHC", "PROTEIN", 67, 70], ["Genetic loci", "PROBLEM", 0, 12]]], ["MHC genes code for molecules that recognize foreign peptides (antigens) and display them on the cell surface.", [["cell surface", "ANATOMY", 96, 108], ["cell surface", "CELLULAR_COMPONENT", 96, 108], ["MHC genes", "DNA", 0, 9], ["antigens", "PROTEIN", 62, 70], ["foreign peptides", "PROBLEM", 44, 60]]], ["When the MHC-protein is displayed, it can be presented to immune cells, such as T lymphocytes or Natural Killer cells, which subsequently can trigger an adaptive immune response.", [["immune cells", "ANATOMY", 58, 70], ["T lymphocytes", "ANATOMY", 80, 93], ["Natural Killer cells", "ANATOMY", 97, 117], ["immune cells", "CELL", 58, 70], ["T lymphocytes", "CELL", 80, 93], ["Natural Killer cells", "CELL", 97, 117], ["MHC", "PROTEIN", 9, 12], ["immune cells", "CELL_TYPE", 58, 70], ["T lymphocytes", "CELL_TYPE", 80, 93], ["Natural Killer cells", "CELL_TYPE", 97, 117], ["the MHC-protein", "TEST", 5, 20], ["immune cells", "PROBLEM", 58, 70], ["Natural Killer cells", "TREATMENT", 97, 117], ["immune cells", "OBSERVATION", 58, 70], ["Natural Killer cells", "OBSERVATION", 97, 117]]], ["Because MHC genes are faced with an important diversity of antigens, they must themselves be diverse.", [["MHC", "GENE_OR_GENE_PRODUCT", 8, 11], ["MHC genes", "DNA", 8, 17], ["antigens", "PROTEIN", 59, 67]]], ["The measure of the genetic diversity of MHC based on an analysis of polymorphism sequences of MHC among individuals in populations has been widely used in conservation biology as a proxy to estimate the fitness of populations confronted by pathogens (Alcaide et al. 2010; Bernatchez and Landry 2003; Sommer 2005) .", [["MHC", "PROTEIN", 40, 43], ["MHC", "PROTEIN", 94, 97], ["an analysis", "TEST", 53, 64], ["polymorphism sequences", "PROBLEM", 68, 90]]], ["However, the level of genetic variation at MHC loci results from different evolutionary forces (selection, gene flow, mutation) varying both in space and time in co-evolutionary systems involving both hosts and pathogens, making conservation genetics of non-model organism a challenging task (Stockwell et al. 2003) .", [["MHC loci", "DNA", 43, 51], ["gene flow", "TEST", 107, 116], ["mutation", "PROBLEM", 118, 126], ["pathogens", "PROBLEM", 211, 220], ["non-model organism", "PROBLEM", 254, 272], ["different", "OBSERVATION_MODIFIER", 65, 74], ["evolutionary forces", "OBSERVATION", 75, 94]]], ["We already have many examples where low genetic diversity of species has favoured the diffusion of, and/or susceptibility to, pathogens.", [["low genetic diversity of species", "PROBLEM", 36, 68], ["pathogens", "PROBLEM", 126, 135]]], ["For example, the low genetic diversity of the Tasmanian devil could be involved in its susceptibility to facial tumor disease (McCallum 2008) .", [["facial tumor", "ANATOMY", 105, 117], ["facial tumor", "DISEASE", 105, 117], ["facial tumor", "CANCER", 105, 117], ["facial tumor disease", "PROBLEM", 105, 125], ["low genetic", "OBSERVATION_MODIFIER", 17, 28], ["diversity", "OBSERVATION_MODIFIER", 29, 38], ["facial", "ANATOMY", 105, 111], ["tumor", "OBSERVATION", 112, 117]]], ["The low genetic diversity found in commercially traded bee queens has been hypothesised as being one of the factors explaining colony collapse disorder (Le Conte and Navajas 2008).", [["colony", "ANATOMY", 127, 133], ["collapse disorder", "DISEASE", 134, 151], ["The low genetic diversity", "PROBLEM", 0, 25], ["colony collapse disorder", "PROBLEM", 127, 151], ["low genetic", "OBSERVATION_MODIFIER", 4, 15], ["diversity", "OBSERVATION_MODIFIER", 16, 25], ["collapse", "OBSERVATION", 134, 142]]], ["The problem is even more critical in intensive crops in which disease resistance has relied on the use of a very small number of genes.", [["more critical", "OBSERVATION_MODIFIER", 20, 33], ["disease resistance", "OBSERVATION", 62, 80], ["small", "OBSERVATION_MODIFIER", 113, 118]]], ["This selection strategy has proven to be ineffective as pathogens manage to overcome the resistance.", [["This selection strategy", "TREATMENT", 0, 23], ["pathogens", "PROBLEM", 56, 65], ["the resistance", "PROBLEM", 85, 99]]], ["For example, the resistance of Brassica napus (canola, oilseed rape and colza) to Leptosphaeria maculans (causing the blackleg disease) due to a major resistance gene was overcome in an area covering approximately 50,000 ha in South Australia in a period of 3 years (Sprague et al. 2006 ).The Importance of Biodiversity as a Source of Treatment for Infectious DiseasesEven with advances in synthetic chemistry, which provides many biologically active molecules, pharmaceuticals derived from nature remain an important part of pharmaceutical practice today (Newman et al. 2008 ).", [["Brassica napus (canola, oilseed rape", "CHEMICAL", 31, 67], ["Leptosphaeria maculans", "CHEMICAL", 82, 104], ["blackleg disease", "DISEASE", 118, 134], ["Infectious Diseases", "DISEASE", 349, 368], ["Brassica napus", "ORGANISM", 31, 45], ["canola", "ORGANISM_SUBDIVISION", 47, 53], ["oilseed rape", "ORGANISM", 55, 67], ["colza", "ORGANISM_SUBDIVISION", 72, 77], ["Leptosphaeria maculans", "ORGANISM", 82, 104], ["major resistance gene", "DNA", 145, 166], ["Brassica napus", "SPECIES", 31, 45], ["canola", "SPECIES", 47, 53], ["oilseed", "SPECIES", 55, 62], ["Leptosphaeria maculans", "SPECIES", 82, 104], ["Brassica napus", "SPECIES", 31, 45], ["canola", "SPECIES", 47, 53], ["oilseed", "SPECIES", 55, 62], ["Leptosphaeria maculans", "SPECIES", 82, 104], ["Brassica napus", "PROBLEM", 31, 45], ["Leptosphaeria maculans", "PROBLEM", 82, 104], ["the blackleg disease", "PROBLEM", 114, 134], ["a major resistance gene", "PROBLEM", 143, 166], ["Treatment", "TREATMENT", 335, 344], ["Infectious Diseases", "PROBLEM", 349, 368], ["synthetic chemistry", "TEST", 390, 409], ["resistance", "OBSERVATION_MODIFIER", 17, 27], ["Brassica napus", "OBSERVATION", 31, 45]]], ["All organisms have developed compounds to protect themselves against infectious diseases and to interact with individuals of their own species or other species (e.g. Rogerio et al. 2010 ).", [["infectious diseases", "DISEASE", 69, 88], ["All organisms", "PROBLEM", 0, 13], ["infectious diseases", "PROBLEM", 69, 88]]], ["These molecules, coming from all organisms (bacteria, fungus, animals, plants) in terrestrial, marine and extreme ecosystems, represent an amazing diversity that has been tested in the field for millions of years by involving millions of individuals.", [["These molecules", "PROBLEM", 0, 15], ["all organisms", "PROBLEM", 29, 42], ["bacteria", "PROBLEM", 44, 52], ["fungus", "PROBLEM", 54, 60], ["extreme ecosystems", "PROBLEM", 106, 124], ["amazing diversity", "OBSERVATION", 139, 156]]], ["However, only a very small subset of plants and marine organisms has been investigated for novel bioactive compounds.", [["a very small subset of plants and marine organisms", "PROBLEM", 14, 64], ["novel bioactive compounds", "PROBLEM", 91, 116], ["very", "OBSERVATION_MODIFIER", 16, 20], ["small", "OBSERVATION_MODIFIER", 21, 26], ["subset", "OBSERVATION_MODIFIER", 27, 33], ["plants", "OBSERVATION", 37, 43], ["marine organisms", "OBSERVATION", 48, 64], ["bioactive compounds", "OBSERVATION", 97, 116]]], ["Furthermore, it is estimated that less that 1% of bacterial species and only 5% of fungal species are known.", [["bacterial species", "PROBLEM", 50, 67], ["fungal species", "PROBLEM", 83, 97], ["bacterial species", "OBSERVATION", 50, 67], ["fungal species", "OBSERVATION", 83, 97]]], ["Those which have not yet been identified could be sources of novel molecules (Cragg and Newman 2005) .The Importance of Biodiversity as a Source of Treatment for Infectious DiseasesObservations of natural medicine practices used by indigenous people have led to the discovery of many drugs.", [["people", "ORGANISM", 243, 249], ["people", "SPECIES", 243, 249], ["novel molecules", "PROBLEM", 61, 76], ["Treatment", "TREATMENT", 148, 157], ["natural medicine practices", "TREATMENT", 197, 223], ["many drugs", "TREATMENT", 279, 289]]], ["The most well known and widely used pharmaceuticals are quinine, used as a model to synthesize anti-malarial drugs (chloroquine and mefloquine), and artemisinin, indentified as a potent anti-malarial drug by Chinese scientists (Newman et al. 2008) .", [["quinine", "CHEMICAL", 56, 63], ["chloroquine", "CHEMICAL", 116, 127], ["mefloquine", "CHEMICAL", 132, 142], ["artemisinin", "CHEMICAL", 149, 160], ["quinine", "CHEMICAL", 56, 63], ["chloroquine", "CHEMICAL", 116, 127], ["mefloquine", "CHEMICAL", 132, 142], ["artemisinin", "CHEMICAL", 149, 160], ["quinine", "SIMPLE_CHEMICAL", 56, 63], ["chloroquine", "SIMPLE_CHEMICAL", 116, 127], ["mefloquine", "SIMPLE_CHEMICAL", 132, 142], ["artemisinin", "SIMPLE_CHEMICAL", 149, 160], ["quinine", "TREATMENT", 56, 63], ["a model to synthesize anti-malarial drugs", "TREATMENT", 73, 114], ["chloroquine", "TREATMENT", 116, 127], ["mefloquine", "TREATMENT", 132, 142], ["artemisinin", "TREATMENT", 149, 160]]], ["Animals also are a source of inspiration for drugs against infectious diseases.", [["infectious diseases", "DISEASE", 59, 78], ["Animals", "ORGANISM", 0, 7], ["drugs", "TREATMENT", 45, 50], ["infectious diseases", "PROBLEM", 59, 78]]], ["For instance, compounds of the sponge Cryptotethya crypta inspired the elaboration of antiviral medication such as AZT used in the treatment of HIV/AIDS (Cragg and Newman 2005) .", [["AZT", "CHEMICAL", 115, 118], ["HIV/AIDS", "DISEASE", 144, 152], ["AZT", "CHEMICAL", 115, 118], ["Cryptotethya crypta", "ORGANISM", 38, 57], ["AZT", "SIMPLE_CHEMICAL", 115, 118], ["HIV", "ORGANISM", 144, 147], ["Cryptotethya crypta", "SPECIES", 38, 57], ["HIV", "SPECIES", 144, 147], ["the sponge Cryptotethya crypta", "TREATMENT", 27, 57], ["antiviral medication", "TREATMENT", 86, 106], ["AZT", "TREATMENT", 115, 118], ["HIV/AIDS", "PROBLEM", 144, 152]]], ["Observing great apes medicate themselves through the plants they eat also could help to reveal new active compounds (Krief et al. 2004 ).ConclusionPathogens constitute a large part of biodiversity on earth and are present in all ecosystems and at all trophic levels, where they have a large impact on ecosystem functioning and on the population dynamics and evolution of their hosts.", [["new active compounds", "PROBLEM", 95, 115], ["the population dynamics", "TEST", 330, 353], ["large", "OBSERVATION_MODIFIER", 170, 175], ["biodiversity", "OBSERVATION", 184, 196], ["large", "OBSERVATION_MODIFIER", 285, 290], ["impact", "OBSERVATION_MODIFIER", 291, 297], ["ecosystem functioning", "OBSERVATION", 301, 322]]], ["The recent acceleration of biodiversity loss due to human activities deeply impacts host-pathogen dynamics.", [["biodiversity loss", "DISEASE", 27, 44], ["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["biodiversity loss", "PROBLEM", 27, 44], ["human activities", "PROBLEM", 52, 68], ["acceleration", "OBSERVATION_MODIFIER", 11, 23], ["biodiversity loss", "OBSERVATION", 27, 44]]], ["Pathogens and hosts form co-evolving systems exercising major selective pressures on each other.", [["Pathogens", "PROBLEM", 0, 9]]], ["Furthermore, the virulence or pathogenicity of a given species depends on its environment -which includes the hosts -that is highly variable in space and time.", [["the virulence", "PROBLEM", 13, 26], ["highly", "OBSERVATION_MODIFIER", 125, 131], ["variable", "OBSERVATION_MODIFIER", 132, 140]]], ["In such a context, human beings will never be able to completely control or eradicate every pathogen species; rather, we should accept that we must coexist with pathogens.", [["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["every pathogen species", "PROBLEM", 86, 108], ["pathogens", "PROBLEM", 161, 170]]], ["To better understand and predict the evolution of pathogens and the impact of human activities on them, more in-depth studies are needed on how pathogens interact with host communities within different ecosystems.ConclusionTo understand human, animal, and plant epidemics, two-species systems involving only a single host and a single pathogen species are no longer appropriate.", [["human", "ORGANISM", 78, 83], ["human", "ORGANISM", 237, 242], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 237, 242], ["pathogens", "PROBLEM", 50, 59], ["plant epidemics", "PROBLEM", 256, 271], ["a single pathogen species", "PROBLEM", 326, 351], ["no longer", "UNCERTAINTY", 356, 365]]], ["The approach considering multi-host/multi-pathogen systems in their environment is the framework that now needs to be used to deepen our understanding of disease dynamics Woolhouse et al. 2001) (Fig. 13.1) .", [["multi-host/multi-pathogen systems", "TREATMENT", 25, 58]]], ["However, these dynamics are very complex and difficult to study because precise knowledge regarding the diversity of pathogens and of interactions taking place on several scales is lacking (Lloyd-Smith et al. 2009 ).", [["pathogens", "PROBLEM", 117, 126]]], ["In addition to intensive fieldwork to collect adequate data and modeling to understand the main processes, the use of molecular tools in a multi-host/multi-pathogen framework will facilitate investigations into pathogen-host community interactions.", [["community", "ANATOMY", 225, 234]]], ["In particular, new generation sequencing techniques render it easier to characterize the genetic diversity of pathogens and hosts.", [["new generation sequencing techniques", "TREATMENT", 15, 51], ["pathogens", "PROBLEM", 110, 119], ["pathogens", "OBSERVATION", 110, 119]]], ["For instance, metagenomic investigations allow an approach that does not require a priori assumptions that is useful to describe a community of pathogens and their interactions.", [["metagenomic investigations", "TEST", 14, 40], ["pathogens", "PROBLEM", 144, 153]]], ["Molecular techniques also may be used to clarify the taxonomic status of pathogens, revealing cryptic species or host races.", [["Molecular techniques", "TREATMENT", 0, 20], ["pathogens", "PROBLEM", 73, 82], ["cryptic species", "PROBLEM", 94, 109], ["cryptic species", "OBSERVATION", 94, 109], ["host races", "OBSERVATION", 113, 123]]], ["With suitable molecular Fig. 13 .1 Schematic representation of the link between biodiversity and the ecology of infectious diseases.", [["infectious diseases", "DISEASE", 112, 131], ["infectious diseases", "PROBLEM", 112, 131], ["infectious", "OBSERVATION", 112, 122]]], ["Diseases results from the complex interactions between the three compartments corresponding to pathogens, hosts and vectors (in the case of vector-borne diseases).", [["vector-borne diseases", "DISEASE", 140, 161], ["Diseases", "PROBLEM", 0, 8], ["pathogens", "PROBLEM", 95, 104]]], ["The biodiversity of these three compartments can be considered at the community level (each circle corresponding to a species) or at the intraspecific level (each circle corresponding to a population or an individual within a population).", [["biodiversity", "OBSERVATION_MODIFIER", 4, 16]]], ["The gray shading off of each unit considered (species, population or individual) illustrates its genetic or phenotypic variability in space and time, while variations in size illustrate frequency or density differences within the ecosystem.", [["density differences within the ecosystem", "PROBLEM", 199, 239], ["phenotypic variability", "OBSERVATION", 108, 130], ["size", "OBSERVATION_MODIFIER", 170, 174], ["density", "OBSERVATION", 199, 206]]], ["Interactions within each compartment can be direct (competition) or indirect (apparent competition\u2026), synergic or antagonistic as illustrated by the different arrows markers (producing a high level of polymorphism), the analysis of genetic variability within a spatially explicit framework renders it possible to identify the routes followed by a given pathogen.", [["the analysis", "TEST", 216, 228], ["genetic variability", "PROBLEM", 232, 251], ["pathogen", "PROBLEM", 353, 361]]], ["Moreover, molecular techniques can be used to identify genes involved in important life history traits of a pathogen such as virulence and transmission.", [["a pathogen", "PROBLEM", 106, 116]]], ["Better knowledge of the mechanisms involved in host-pathogen interactions, and the extent of their variability, will significantly advance our understanding of outbreaks.ConclusionAlthough our knowledge of the number and variety of pathogens is not complete, it appears that their diversity, like that of their hosts and vectors, is greater in tropical areas than in temperate ones, and in undisturbed habitats than disturbed ones (Chaisiri et al. 2010; Friggens and Beier 2010) .", [["pathogens", "PROBLEM", 232, 241], ["greater", "OBSERVATION_MODIFIER", 333, 340]]], ["The reason we are so concerned by the loss of species biodiversity is because a reduction of biodiversity seems to favour opportunistic species that are highly competent as pathogen reservoirs and vectors.", [["the loss of species biodiversity", "PROBLEM", 34, 66], ["a reduction of biodiversity", "PROBLEM", 78, 105], ["opportunistic species", "PROBLEM", 122, 143]]], ["However, this observation was derived from only a few studies and theoretical works, mainly undertaken in the temperate zones.", [["a few studies", "TEST", 48, 61], ["zones", "ANATOMY_MODIFIER", 120, 125]]], ["Further investigations should be launched to verify the link between, and understand the process involved in, biodiversity loss and disease dynamics.", [["biodiversity loss", "DISEASE", 110, 127], ["Further investigations", "TEST", 0, 22], ["biodiversity loss and disease dynamics", "PROBLEM", 110, 148], ["biodiversity loss", "OBSERVATION", 110, 127]]], ["This especially should be done in the tropics to understand whether high levels of biodiversity create a buffer reducing the risk of disease transmission, and to understand the consequences of biodiversity loss in high biodiversity regions.", [["biodiversity loss", "DISEASE", 193, 210], ["a buffer", "TREATMENT", 103, 111], ["disease transmission", "PROBLEM", 133, 153], ["biodiversity loss in high biodiversity regions", "PROBLEM", 193, 239], ["disease", "OBSERVATION", 133, 140], ["high biodiversity", "OBSERVATION", 214, 231]]], ["With global changes, there is a high risk that diseases currently circulating in the tropics will reach temperate zones where species diversity is reduced and the availability of alternate hosts is limited.", [["global changes", "PROBLEM", 5, 19], ["a high risk that diseases", "PROBLEM", 30, 55], ["species diversity", "PROBLEM", 126, 143], ["global", "OBSERVATION_MODIFIER", 5, 11], ["changes", "OBSERVATION", 12, 19], ["diseases", "OBSERVATION", 47, 55], ["species diversity", "OBSERVATION", 126, 143], ["reduced", "OBSERVATION_MODIFIER", 147, 154]]], ["What may happen in a world where increased movements of hosts and pathogens, high population densities, and rapidly changing environments increase contact rates, spread, and selective pressures on pathogens and hosts while at the same time a combination of low exposure to pathogen biodiversity and decreased genetic variability in some animals increases susceptibility to new diseases?", [["increased movements of hosts", "PROBLEM", 33, 61], ["pathogens", "PROBLEM", 66, 75], ["high population densities", "PROBLEM", 77, 102], ["selective pressures on pathogens", "PROBLEM", 174, 206], ["low exposure", "PROBLEM", 257, 269], ["pathogen biodiversity", "TREATMENT", 273, 294], ["decreased genetic variability", "PROBLEM", 299, 328], ["new diseases", "PROBLEM", 373, 385], ["pressures", "OBSERVATION_MODIFIER", 184, 193], ["low exposure", "OBSERVATION_MODIFIER", 257, 269], ["decreased", "OBSERVATION_MODIFIER", 299, 308], ["genetic variability", "OBSERVATION", 309, 328], ["new", "OBSERVATION_MODIFIER", 373, 376], ["diseases", "OBSERVATION", 377, 385]]]], "PMC7472968": [["IntroductionSince December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as the cause of a severe respiratory disease and is causing a worldwide pandemic.", [["respiratory", "ANATOMY", 152, 163], ["coronavirus", "DISEASE", 41, 52], ["acute respiratory syndrome coronavirus", "DISEASE", 65, 103], ["respiratory disease", "DISEASE", 152, 171], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 58, 105], ["SARS-CoV-2", "ORGANISM", 107, 117], ["severe acute respiratory syndrome coronavirus", "SPECIES", 58, 103], ["SARS-CoV-2", "SPECIES", 107, 117], ["a novel coronavirus", "PROBLEM", 33, 52], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 54, 103], ["SARS-CoV", "TEST", 107, 115], ["a severe respiratory disease", "PROBLEM", 143, 171], ["a worldwide pandemic", "PROBLEM", 187, 207], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["respiratory disease", "OBSERVATION", 152, 171]]], ["Tests based on reverse transcription-polymerase chain reaction (RT-PCR) are the most suitable mode of rapid diagnosis of acute SARS-CoV-2 infections which is essential for patient management and contact tracing [1].", [["infections", "DISEASE", 138, 148], ["CoV-2", "ORGANISM", 132, 137], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["SARS-CoV-2", "SPECIES", 127, 137], ["Tests", "TEST", 0, 5], ["reverse transcription", "TEST", 15, 36], ["polymerase chain reaction", "TEST", 37, 62], ["RT-PCR", "TEST", 64, 70], ["acute SARS", "PROBLEM", 121, 131], ["CoV-2 infections", "PROBLEM", 132, 148], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["SARS", "OBSERVATION", 127, 131]]], ["Several commercial and laboratory developed (LD) assays are available but few manufacture-independent evaluations and few comparisons between assays have been published up to now [1].", [["LD) assays", "TEST", 45, 55], ["independent evaluations", "TEST", 90, 113], ["assays", "TEST", 142, 148]]], ["Moreover, the comparison between assays is hampered by the absence of accepted gold standard test as well as our incomplete knowledge of the natural history of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 160, 180], ["SARS-CoV-2", "ORGANISM", 160, 170], ["SARS-CoV-2", "SPECIES", 160, 170], ["gold standard test", "TEST", 79, 97], ["SARS", "PROBLEM", 160, 164], ["CoV-2 infection", "PROBLEM", 165, 180], ["infection", "OBSERVATION", 171, 180]]], ["Studies evaluating the concordance between assays are thus needed at this point in the pandemic.IntroductionWe evaluated the concordance between the two-target cobas SARS-CoV-2 test (Roche Molecular Diagnostics, Laval, Canada) on the fully automated cobas 8800 platform authorized by Health Canada and a laboratory-developed (LD) standardized RT-PCR test using widely used primer set and probe [2,3] in samples submitted at the diagnostic laboratory for patient care at the Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al.Materials and methodsA subset of combined nasopharyngeal/oropharyngeal swabs routinely collected in Hanks media from 377 individuals between 21 April 2020 and 11 June 2020 were transported to the laboratory the same day and tested in parallel as part of routine clinical care using the cobas SARS-CoV-2 assay and the LD RT-PCR test.", [["nasopharyngeal", "ANATOMY", 563, 577], ["oropharyngeal swabs", "ANATOMY", 578, 597], ["patient", "ORGANISM", 454, 461], ["nasopharyngeal", "CANCER", 563, 577], ["patient", "SPECIES", 454, 461], ["Studies evaluating", "TEST", 0, 18], ["assays", "TEST", 43, 49], ["standardized RT", "TEST", 330, 345], ["PCR test", "TEST", 346, 354], ["combined nasopharyngeal/oropharyngeal swabs", "TREATMENT", 554, 597], ["routine clinical care", "TREATMENT", 775, 796], ["the cobas SARS", "TEST", 803, 817], ["CoV", "TEST", 818, 821], ["the LD RT-PCR test", "TEST", 834, 852], ["nasopharyngeal", "ANATOMY", 563, 577], ["oropharyngeal swabs", "ANATOMY", 578, 597]]], ["Testing was requested for investigation of symptomatic individuals, follow-up of positive individuals or investigation of outbreaks or contact with a positive source.", [["symptomatic individuals", "PROBLEM", 43, 66], ["positive individuals", "PROBLEM", 81, 101], ["outbreaks", "PROBLEM", 122, 131], ["a positive source", "PROBLEM", 148, 165]]], ["According to information provided in the request form for SARS-CoV-2 detection, 121 individuals had no symptoms, 132 were symptomatic and information was not provided for 124 individuals.", [["SARS", "DISEASE", 58, 62], ["individuals", "ORGANISM", 84, 95], ["SARS-CoV", "SPECIES", 58, 66], ["SARS", "PROBLEM", 58, 62], ["symptoms", "PROBLEM", 103, 111], ["symptomatic", "PROBLEM", 122, 133]]], ["Both assays had been previously validated against a panel of samples with known results including negative and positive samples from the reference laboratory of the Province of Quebec, the Laboratoire de Sant\u00e9 Publique du Qu\u00e9bec (LSPQ).Materials and methodsThe validation study and publication of results was permitted without obtaining formal written consent from patients by the Directeur des Affaires M\u00e9dicales Universitaires du CHUM as part of l\u2019Urgence sanitaire de la Sant\u00e9 Publique du Qu\u00e9bec, since results are published without identification of participants and as part of diagnostic purposes and assay validation.Materials and methodsThe LD RT-PCR test developed by the LSPQ uses a standardized protocol consisting of automated RNA extraction followed by RT-PCR targeting the envelope (E) gene with widely utilized primers and probe [2].", [["samples", "ANATOMY", 61, 68], ["samples", "CANCER", 61, 68], ["patients", "ORGANISM", 365, 373], ["LSPQ", "DNA", 680, 684], ["envelope (E) gene", "DNA", 786, 803], ["patients", "SPECIES", 365, 373], ["participants", "SPECIES", 554, 566], ["The validation study", "TEST", 257, 277], ["diagnostic purposes", "TEST", 582, 601], ["assay validation", "TEST", 606, 622], ["The LD RT-PCR test", "TEST", 644, 662], ["a standardized protocol", "TREATMENT", 690, 713], ["automated RNA extraction", "TREATMENT", 728, 752], ["RT-PCR targeting the envelope (E) gene", "TREATMENT", 765, 803]]], ["Briefly, nucleic acid from 200 \u00b5L of specimen suspended in Hanks medium was extracted on a NucliSens\u00ae easyMAG \u2122 instrument (Biom\u00e9rieux) using the Easy Mag extraction kit as suggested by the manufacturer\u2019s instructions.", [["specimen", "ANATOMY", 37, 45], ["nucleic acid", "CHEMICAL", 9, 21], ["nucleic acid", "SIMPLE_CHEMICAL", 9, 21], ["nucleic acid", "TEST", 9, 21], ["a NucliSens\u00ae easyMAG \u2122 instrument", "TREATMENT", 89, 122], ["the Easy Mag extraction kit", "TREATMENT", 142, 169]]], ["Five of the 25 \u00b5L elution volume was amplified with real-time RT-PCR using the TaqPath 1-step multiplex no ROX mastermix and E gene specific primers at 0.4 \u00b5M and 6-carboxyfluorescein (FAM)-labeled hydrolysis probe at 0.2 \u00b5M [2].", [["ROX", "CHEMICAL", 107, 110], ["6-carboxyfluorescein", "CHEMICAL", 163, 183], ["FAM", "CHEMICAL", 185, 188], ["6-carboxyfluorescein", "CHEMICAL", 163, 183], ["FAM", "CHEMICAL", 185, 188], ["6-carboxyfluorescein", "SIMPLE_CHEMICAL", 163, 183], ["FAM", "SIMPLE_CHEMICAL", 185, 188], ["ROX mastermix", "DNA", 107, 120], ["E gene specific primers", "DNA", 125, 148], ["the 25 \u00b5L elution volume", "TREATMENT", 8, 32], ["the TaqPath", "TEST", 75, 86], ["carboxyfluorescein (FAM)-labeled hydrolysis probe", "TREATMENT", 165, 214]]], ["Due to the limited availability of reagents, only one SARS-CoV-2 target was tested with the LD RT-PCR.", [["SARS-CoV-2 target", "DNA", 54, 71], ["the LD RT-PCR", "TEST", 88, 101]]], ["The reaction mixture was heated at 53 \u00b0C for 10 min, at 95 \u00b0C for 2 min and then amplified for 45 cycles at 95 \u00b0C for 3 s and 60 \u00b0C for 30 s.", [["The reaction mixture", "TREATMENT", 0, 20]]], ["RT-PCR was performed on a Light Cycler 480 II (Roche Molecular systems, Laval, Canada).", [["RT-PCR", "TEST", 0, 6], ["a Light Cycler", "TEST", 24, 38]]], ["One negative control and one positive control were included in each batch of testing.", [["testing", "TEST", 77, 84], ["negative", "OBSERVATION", 4, 12]]], ["Samples were considered positive in the presence of an amplification curve below a Ct of 40.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["an amplification curve", "TEST", 52, 74], ["a Ct", "TEST", 81, 85]]], ["The limit of detection of the assay was 300 viral RNA copies per mL of medium (data not shown).Materials and methodsPrior to testing on the cobas 8800, each specimen was treated to inactivate potential infectious viruses: 400 \u00b5L of specimen in Hanks was added to 200 \u00b5L of cobas 8800 lysis buffer, followed by an incubation at room temperature for 10 min.", [["specimen", "ANATOMY", 157, 165], ["specimen", "ANATOMY", 232, 240], ["cobas 8800", "CHEMICAL", 140, 150], ["infectious viruses", "DISEASE", 202, 220], ["cobas 8800", "CHEMICAL", 273, 283], ["the assay", "TEST", 26, 35], ["testing", "TEST", 125, 132], ["the cobas", "TEST", 136, 145], ["potential infectious viruses", "PROBLEM", 192, 220], ["specimen in Hanks", "TREATMENT", 232, 249], ["cobas 8800 lysis buffer", "TREATMENT", 273, 296], ["infectious", "OBSERVATION_MODIFIER", 202, 212]]], ["The detection of SARS-CoV-2 RNA was then performed on the inactivated 600 \u00b5L-aliquot with the cobas 8800 instrument, as suggested by the manufacturer.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 17, 27], ["SARS-CoV-2 RNA", "RNA", 17, 31], ["SARS-CoV", "SPECIES", 17, 25], ["SARS-CoV-2 RNA", "TEST", 17, 31], ["the cobas", "TEST", 90, 99]]], ["A two-target RT-PCR was used on this instrument: one targeting Orf1, a non-structural region that is unique to SARS-CoV-2 coding for the RdRp activity of the virus, and the second targeting a conserved region in the structural protein envelope E gene for pan-sabercovirus detection.", [["Orf1", "GENE_OR_GENE_PRODUCT", 63, 67], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["envelope E", "GENE_OR_GENE_PRODUCT", 235, 245], ["Orf1", "DNA", 63, 67], ["SARS-CoV-2", "DNA", 111, 121], ["structural protein envelope E gene", "DNA", 216, 250], ["SARS-CoV", "SPECIES", 111, 119], ["target RT-PCR", "TREATMENT", 6, 19], ["a non-structural region", "PROBLEM", 69, 92], ["CoV", "TEST", 116, 119], ["the RdRp activity of the virus", "PROBLEM", 133, 163], ["pan-sabercovirus detection", "TEST", 255, 281], ["virus", "OBSERVATION", 158, 163]]], ["An internal RNA control was detected in each sample to control for amplification efficiency and RNA extraction from sample.", [["sample", "ANATOMY", 45, 51], ["An internal RNA control", "TREATMENT", 0, 23], ["amplification efficiency", "PROBLEM", 67, 91], ["RNA extraction", "TREATMENT", 96, 110], ["internal", "OBSERVATION_MODIFIER", 3, 11], ["RNA control", "OBSERVATION", 12, 23]]], ["Uracil-N-glycosylase is also included in the master mix to catalyze contaminating amplicons.", [["Uracil-N", "CHEMICAL", 0, 8], ["Uracil", "CHEMICAL", 0, 6], ["Uracil-N-glycosylase", "GENE_OR_GENE_PRODUCT", 0, 20], ["Uracil-N-glycosylase", "PROTEIN", 0, 20], ["Uracil", "TEST", 0, 6], ["glycosylase", "PROBLEM", 9, 20]]], ["A sample was considered positive if a positive result was obtained for the Orf1 gene only or for both Orf1 and E genes, as suggested by the manufacturer\u2019s instructions.", [["sample", "ANATOMY", 2, 8], ["Orf1", "GENE_OR_GENE_PRODUCT", 75, 79], ["Orf1", "GENE_OR_GENE_PRODUCT", 102, 106], ["E", "GENE_OR_GENE_PRODUCT", 111, 112], ["Orf1 gene", "DNA", 75, 84], ["Orf1", "DNA", 102, 106], ["E genes", "DNA", 111, 118], ["A sample", "TEST", 0, 8]]], ["Samples testing positive only for the E gene were considered as SARS-CoV-2 presumptive positive.", [["Samples", "ANATOMY", 0, 7], ["E", "GENE_OR_GENE_PRODUCT", 38, 39], ["SARS-CoV-2", "ORGANISM", 64, 74], ["E gene", "DNA", 38, 44], ["SARS-CoV", "SPECIES", 64, 72], ["Samples testing", "TEST", 0, 15], ["the E gene", "TEST", 34, 44], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72]]], ["Testing was performed in 96 samples batches, including one positive control and one negative control.", [["samples", "ANATOMY", 28, 35], ["Testing", "TEST", 0, 7]]], ["The Limit of detection of the assay was 20 viral RNA copies per mL of medium (data not shown).", [["the assay", "TEST", 26, 35]]], ["Samples with discrepant results between the cobas and LDT assays were tested, when enough sample left was available, in the Abbott RealTime SARS-CoV-2 test on the Abbott m2000 system (Abbott Molecular Inc., Des Plaines, IL), as suggested by the manufacturer [4].Materials and methodsIn the absence of gold standard for SARS-CoV-2 RNA detection, data was analyzed using a contingency table to assess the overall, positive and negative agreement with 95 % confidence intervals (95 % CI) calculated.", [["Samples", "ANATOMY", 0, 7], ["cobas", "ORGANISM", 44, 49], ["SARS-CoV", "SPECIES", 319, 327], ["Samples", "TEST", 0, 7], ["the cobas", "TEST", 40, 49], ["LDT assays", "TEST", 54, 64], ["CoV", "TEST", 145, 148], ["SARS", "PROBLEM", 319, 323], ["CoV", "TEST", 324, 327], ["RNA detection", "TEST", 330, 343], ["a contingency table", "TEST", 369, 388]]], ["The level of agreement was also assessed using kappa statistics.", [["kappa statistics", "TEST", 47, 63]]], ["By definition, Kappa values above 0.75 indicate excellent agreement, values between 0.40 and 0.75 indicate fair to good agreement, and values below 0.40 represent poor agreement beyond chance [5].", [["Kappa values", "TEST", 15, 27]]], ["A McNemar\u2019s test was applied to assess differences between matched proportions.", [["A McNemar\u2019s test", "TEST", 0, 16]]], ["The distributions of Ct values between assays were compared using the non-parametric Wilcoxon pair test.", [["Ct values", "TEST", 21, 30], ["assays", "TEST", 39, 45], ["the non-parametric Wilcoxon pair test", "TEST", 66, 103]]], ["Linear regression analysis was performed to compare Cycle thresholds (Ct) values between gene targets and assays.", [["Linear regression analysis", "TEST", 0, 26], ["Cycle thresholds", "TEST", 52, 68], ["Ct) values", "TEST", 70, 80], ["gene targets", "TEST", 89, 101], ["assays", "TEST", 106, 112]]], ["Statistical analysis was done using the Statistica software (Statsoft Inc, OK, USA).ResultsThe results of the comparison of the cobas SARS-CoV-2 and LD RT-PCR on 377 routinely collected nasopharyngeal/oropharyngeal swabs are summarized in Table 1.", [["nasopharyngeal", "ANATOMY", 186, 200], ["oropharyngeal swabs", "ANATOMY", 201, 220], ["nasopharyngeal", "CANCER", 186, 200], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 201, 220], ["cobas SARS-CoV", "SPECIES", 128, 142], ["Statistical analysis", "TEST", 0, 20], ["the cobas SARS", "TEST", 124, 138], ["CoV", "TEST", 139, 142], ["LD RT-PCR", "TEST", 149, 158], ["nasopharyngeal/oropharyngeal swabs", "TREATMENT", 186, 220], ["nasopharyngeal", "ANATOMY", 186, 200], ["oropharyngeal swabs", "ANATOMY", 201, 220]]], ["The LD RT-PCR assay reported 281 samples as \u2018detected\u2019 and 96 as \u2018not detected\u2019.", [["samples", "ANATOMY", 33, 40], ["The LD RT-PCR assay", "TEST", 0, 19]]], ["The cobas SARS-CoV-2 test reported 301 samples as \u2018detected\u2019 and 76 as \u2018not detected\u2019.", [["samples", "ANATOMY", 39, 46], ["samples", "CANCER", 39, 46], ["cobas SARS-CoV", "SPECIES", 4, 18], ["The cobas SARS", "TEST", 0, 14], ["CoV-2 test", "TEST", 15, 25]]], ["PCR inhibition was not encountered in these specimens.", [["specimens", "ANATOMY", 44, 53], ["PCR inhibition", "TEST", 0, 14], ["these specimens", "TEST", 38, 53]]], ["The positive and negative agreement between assays between the cobas SARS-CoV-2 and the LD RT-PCR assays were 99.3 % (95 % CI, 97.3\u201399.9) and 77.1 % (95 % CI, 67.7\u201384.4), respectively.", [["cobas SARS-CoV-2", "ORGANISM", 63, 79], ["SARS-CoV", "SPECIES", 69, 77], ["assays", "TEST", 44, 50], ["the cobas SARS", "TEST", 59, 73], ["CoV", "TEST", 74, 77], ["the LD RT", "TEST", 84, 93], ["PCR assays", "TEST", 94, 104], ["CI", "TEST", 123, 125], ["CI", "TEST", 155, 157], ["positive", "OBSERVATION", 4, 12]]], ["The overall percent agreement between the two tests was 93.6 %, 95 % CI 90.7\u201395.7.", [["the two tests", "TEST", 38, 51], ["CI", "TEST", 69, 71]]], ["The calculated kappa coefficient of 0.82 (95 % CI, 0.75\u22120.85) indicated an excellent agreement between tests.ResultsOf the 22 samples positive by cobas SARS-CoV-2 and negative by LD RT-PCR, 9 were positive only for the Orf1 gene and all had a Ct above 35.1, 5 were positive for both Orf1 and E genes and all had a Ct above 33.9 while 8 were positive only for the E gene and all had a Ct above 35.5.", [["samples", "ANATOMY", 126, 133], ["CoV-2", "ORGANISM", 157, 162], ["Orf1", "GENE_OR_GENE_PRODUCT", 219, 223], ["Orf1", "GENE_OR_GENE_PRODUCT", 283, 287], ["E", "GENE_OR_GENE_PRODUCT", 292, 293], ["E", "GENE_OR_GENE_PRODUCT", 363, 364], ["cobas SARS-CoV-2", "DNA", 146, 162], ["Orf1 gene", "DNA", 219, 228], ["Orf1", "DNA", 283, 287], ["E genes", "DNA", 292, 299], ["E gene", "DNA", 363, 369], ["SARS-CoV", "SPECIES", 152, 160], ["The calculated kappa coefficient", "TEST", 0, 32], ["CI", "TEST", 47, 49], ["tests", "TEST", 103, 108], ["the 22 samples", "TEST", 119, 133], ["cobas SARS", "TEST", 146, 156], ["CoV", "TEST", 157, 160], ["LD RT-PCR", "TEST", 179, 188], ["the Orf1 gene", "TEST", 215, 228], ["a Ct", "TEST", 241, 245], ["both Orf1 and E genes", "PROBLEM", 278, 299], ["a Ct", "TEST", 312, 316], ["a Ct", "TEST", 382, 386]]], ["The later 8 samples were reported as presumptive positives as per the manufacturer\u2019s recommendation.", [["samples", "ANATOMY", 12, 19]]], ["If these were excluded from the analysis, 74 of 88 samples were negative in the LD RT-PCR and cobas assays for a negative agreement between assays of 84.1 % (95 % CI 74.4\u201393.7).", [["samples", "ANATOMY", 51, 58], ["samples", "CANCER", 51, 58], ["the analysis", "TEST", 28, 40], ["the LD RT-PCR", "TEST", 76, 89], ["cobas assays", "TEST", 94, 106], ["assays", "TEST", 140, 146], ["CI", "TEST", 163, 165]]], ["Moreover, samples that were found to be positive only with the cobas SARS-CoV-2 assay were more often positive for only one target [17 of the 22 (77.3 %)] than samples also positive in the LD RT-PCR assay [47 of 279 (16.9 %), p < 0.0001].", [["samples", "ANATOMY", 10, 17], ["samples", "ANATOMY", 160, 167], ["samples", "CANCER", 160, 167], ["samples", "TEST", 10, 17], ["the cobas SARS", "TEST", 59, 73], ["CoV", "TEST", 74, 77], ["samples", "TEST", 160, 167], ["the LD RT", "TEST", 185, 194], ["PCR assay", "TEST", 195, 204]]], ["The two samples negative for both targets in the cobas SARS-CoV-2 assay yet positive in the LD RT-PCR test, had both Ct values above 35 (35.3, 35.6).", [["samples", "ANATOMY", 8, 15], ["cobas SARS-CoV", "SPECIES", 49, 63], ["The two samples", "TEST", 0, 15], ["the cobas SARS", "TEST", 45, 59], ["CoV", "TEST", 60, 63], ["the LD RT", "TEST", 88, 97], ["PCR test", "TEST", 98, 106], ["Ct values", "TEST", 117, 126]]], ["Thus, discordant samples between assays all had high Ct values, suggesting a low SARS-CoV-2 load.", [["samples", "ANATOMY", 17, 24], ["CoV-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["assays", "TEST", 33, 39], ["high Ct values", "PROBLEM", 48, 62], ["a low SARS", "PROBLEM", 75, 85], ["CoV", "TEST", 86, 89], ["low SARS", "OBSERVATION", 77, 85]]], ["The Ct values obtained in the cobas SARS-CoV-2 assay were significantly lower (p = 0.0009) in the 279 samples testing positive in both assays (32.9 \u00b1 5.4 (95 % CI, 32.3\u201333.6), median of 34.7, range 15.4\u201339.1) compared to the 22 samples with discordant results between tests (36.6 \u00b1 1.0 (95 % CI, 36.2\u201337.1), median of 36.5, range 35.3\u201338.1).", [["samples", "ANATOMY", 102, 109], ["samples", "ANATOMY", 228, 235], ["cobas SARS-CoV", "SPECIES", 30, 44], ["The Ct values", "TEST", 0, 13], ["the cobas SARS", "TEST", 26, 40], ["CoV-2 assay", "TEST", 41, 52], ["samples testing", "TEST", 102, 117], ["assays", "TEST", 135, 141], ["CI", "TEST", 160, 162], ["median", "TEST", 176, 182], ["range", "TEST", 192, 197], ["tests", "TEST", 268, 273], ["CI", "TEST", 292, 294], ["median", "TEST", 308, 314], ["range", "TEST", 324, 329]]], ["Of the 22 samples positive only in the cobas SARS-CoV-2 assay, 20 could be tested in the Abbott RealTime SARS-CoV-2 test: one showed inhibition, 8 were \u2018detected\u2019 with low cycle number (CN) values between 26.7 and 31.5, and 11 were \u2018not detected\u2019.", [["samples", "ANATOMY", 10, 17], ["cobas SARS-CoV", "SPECIES", 39, 53], ["the 22 samples", "TEST", 3, 17], ["the cobas SARS", "TEST", 35, 49], ["CoV", "TEST", 50, 53], ["CoV", "TEST", 110, 113]]], ["Since these latter samples were weakly reactive initially in the cobas assay, had been frozen for 6\u20139 weeks and thawed, the 11 negative samples in the Abbott RealTime test yet initially positive in the cobas assay were retested in the cobas assay : only one out of 10 then scored positive in the cobas test.ResultsAn excellent correlation (r2 = 0.98, p < 0.0001) was obtained between Ct values for SARS-CoV-2 ORF-1 target and E target in the cobas SARS-CoV-2 assays (Fig. 1).", [["samples", "ANATOMY", 19, 26], ["samples", "ANATOMY", 136, 143], ["samples", "CANCER", 19, 26], ["ORF-1", "GENE_OR_GENE_PRODUCT", 409, 414], ["SARS-CoV-2 ORF-1 target", "DNA", 398, 421], ["E target", "DNA", 426, 434], ["weakly reactive", "PROBLEM", 32, 47], ["the cobas assay", "TEST", 61, 76], ["the Abbott RealTime test", "TEST", 147, 171], ["the cobas assay", "TEST", 198, 213], ["the cobas assay", "TEST", 231, 246], ["the cobas test", "TEST", 292, 306], ["r2", "TEST", 340, 342], ["p", "TEST", 351, 352], ["Ct values", "TEST", 384, 393], ["SARS", "TEST", 398, 402], ["CoV", "TEST", 403, 406], ["ORF", "TEST", 409, 412], ["the cobas SARS", "TEST", 438, 452], ["CoV", "TEST", 453, 456], ["weakly", "OBSERVATION_MODIFIER", 32, 38], ["reactive", "OBSERVATION_MODIFIER", 39, 47]]], ["The correlation between Ct values obtained in the LD RT-PCR test and cobas SARS CoV-2 ORF-1 target for positive samples in both assays was good (r2 = 0.82, data not shown).DiscussionAutomated assays for detection of SARS-CoV-2 RNA have the advantage over LD RT-PCR protocols of requiring minimal hands-on time thus facilitating mass screening for public health and patient management purposes.", [["samples", "ANATOMY", 112, 119], ["CoV-2 ORF-1", "GENE_OR_GENE_PRODUCT", 80, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 216, 226], ["patient", "ORGANISM", 365, 372], ["cobas SARS CoV-2 ORF-1 target", "DNA", 69, 98], ["SARS-CoV-2 RNA", "RNA", 216, 230], ["patient", "SPECIES", 365, 372], ["SARS CoV", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 216, 224], ["Ct values", "TEST", 24, 33], ["the LD RT-PCR test", "TEST", 46, 64], ["cobas SARS CoV", "TEST", 69, 83], ["ORF", "TEST", 86, 89], ["positive samples", "PROBLEM", 103, 119], ["both assays", "TEST", 123, 134], ["r2", "TEST", 145, 147], ["SARS", "PROBLEM", 216, 220], ["CoV", "TEST", 221, 224], ["LD RT-PCR protocols", "TREATMENT", 255, 274], ["facilitating mass screening", "TEST", 315, 342], ["public health", "TREATMENT", 347, 360], ["patient management purposes", "TREATMENT", 365, 392], ["mass", "OBSERVATION", 328, 332]]], ["Automated assays also generate consistent results between testing sites.", [["Automated assays", "TEST", 0, 16]]], ["On the other hand, LD RT-PCR tests do not rely on availability of commercial reagents and thus offer more flexibility.", [["LD RT-PCR tests", "TEST", 19, 34], ["commercial reagents", "TREATMENT", 66, 85]]], ["Moreover, they do not require high volume of samples to be cost effective.", [["high volume of samples", "PROBLEM", 30, 52]]], ["Despite the advantages of automated platforms, few manufacture-independent evaluations of these assays have been reported and few comparisons between commercial assays and LD RT-PCR tests have been published up to now.", [["these assays", "TEST", 90, 102], ["commercial assays", "TEST", 150, 167], ["LD RT-PCR tests", "TEST", 172, 187]]], ["The cobas 8800 instrument is a fully automated platform performing extraction, PCR amplification, signal detection and reporting of results.", [["PCR amplification", "TEST", 79, 96], ["signal detection", "TEST", 98, 114]]], ["This assay has been shown to have good clinical performance in one report [3] and excellent linearity over seven logs of viral load [6].", [["This assay", "TEST", 0, 10]]], ["There is currently no gold standard for the diagnosis of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 57, 77], ["SARS-CoV-2", "ORGANISM", 57, 67], ["SARS-CoV-2", "SPECIES", 57, 67], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 infection", "PROBLEM", 66, 77], ["no", "UNCERTAINTY", 19, 21], ["gold standard", "OBSERVATION_MODIFIER", 22, 35], ["SARS", "OBSERVATION", 57, 61], ["infection", "OBSERVATION", 68, 77]]], ["Therefore, we assessed the agreement between the cobas SARS-CoV-2 test and a LD RT-PCR that had been validated with a provincial panel and is performed by several laboratories in the province of Quebec, although its clinical performance is unknown.", [["cobas SARS-CoV", "SPECIES", 49, 63], ["the cobas SARS", "TEST", 45, 59], ["CoV", "TEST", 60, 63], ["a LD RT-PCR", "TEST", 75, 86], ["a provincial panel", "TEST", 116, 134]]], ["The limit of detection of the LD RT-PCR assay is 300 SARS-CoV-2 RNA copies per mL of sample, as reported by the LSPQ (personal communication).", [["the LD RT-PCR assay", "TEST", 26, 45], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61]]], ["The LD RT-PCR in the current report was using primers and probe described by Corman et al. against the E gene, reagents that have been confirmed to be sensitive in work comparing several primer-probe sets [2,7].DiscussionWe found an excellent overall and positive agreement between assays.", [["LD RT-PCR", "DNA", 4, 13], ["E gene", "DNA", 103, 109], ["The LD RT-PCR", "TEST", 0, 13], ["primers and probe", "TREATMENT", 46, 63], ["assays", "TEST", 282, 288]]], ["The negative agreement was lower because of samples positive in the cobas SARS-CoV-2 test but negative in the LD RT-PCR test.", [["samples", "ANATOMY", 44, 51], ["cobas SARS-CoV", "SPECIES", 68, 82], ["samples positive", "PROBLEM", 44, 60], ["the cobas SARS", "TEST", 64, 78], ["CoV-2 test", "TEST", 79, 89], ["the LD RT", "TEST", 106, 115], ["PCR test", "TEST", 116, 124]]], ["Samples yielding discordant results were tested in a third assay approved for SARS-CoV-2 diagnosis.", [["Samples", "ANATOMY", 0, 7], ["SARS-CoV", "SPECIES", 78, 86], ["Samples", "TEST", 0, 7], ["a third assay", "TEST", 51, 64], ["SARS", "PROBLEM", 78, 82]]], ["Nearly half of these samples tested positive with the Abbott RealTime SARS-CoV-2 test.", [["samples", "ANATOMY", 21, 28], ["samples", "CANCER", 21, 28], ["these samples", "TEST", 15, 28], ["CoV", "TEST", 75, 78]]], ["Retesting the Abbott RealTime SARS-CoV-2-negative sample in the cobas assay yielded negative results in all but one sample, suggesting loss of a SARS-CoV-2 RNA in the process of freezing and thawing and transportation of specimens.", [["sample", "ANATOMY", 50, 56], ["sample", "ANATOMY", 116, 122], ["specimens", "ANATOMY", 221, 230], ["SARS", "DISEASE", 145, 149], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["cobas", "ORGANISM", 64, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 145, 155], ["SARS-CoV-2 RNA", "RNA", 145, 159], ["CoV", "TEST", 35, 38], ["the cobas assay", "TEST", 60, 75], ["a SARS", "PROBLEM", 143, 149], ["CoV", "TEST", 150, 153], ["transportation of specimens", "TEST", 203, 230]]], ["The reactivity of discordant samples was low compared to that of concordant samples, suggesting low SARS-CoV-2 viral load infections.", [["samples", "ANATOMY", 29, 36], ["samples", "ANATOMY", 76, 83], ["infections", "DISEASE", 122, 132], ["CoV-2", "ORGANISM", 105, 110], ["discordant samples", "TEST", 18, 36], ["low SARS", "PROBLEM", 96, 104], ["CoV", "TEST", 105, 108], ["2 viral load infections", "PROBLEM", 109, 132], ["suggesting", "UNCERTAINTY", 85, 95], ["low SARS", "OBSERVATION", 96, 104], ["viral load infections", "OBSERVATION", 111, 132]]], ["None of these samples had Ct values lower than 35.", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["these samples", "TEST", 8, 21], ["Ct values", "TEST", 26, 35]]], ["Moreover, most of the discordant samples positive in the cobas 8880 but negative in the LD RT-PCR were reactive in only one out of two targets in the automated assay.", [["samples", "ANATOMY", 33, 40], ["cobas 8880", "CHEMICAL", 57, 67], ["samples", "CANCER", 33, 40], ["cobas 8880", "DNA", 57, 67], ["cobas 8880", "SPECIES", 57, 67], ["the discordant samples", "TEST", 18, 40], ["the cobas", "TEST", 53, 62], ["the LD RT-PCR", "TEST", 84, 97], ["reactive", "OBSERVATION_MODIFIER", 103, 111]]], ["These discordances may reflect differences in primer and probe sequences, detection of several gene targets in the 8800 test, assays limit of detection or sample processing differences [2].DiscussionOur study has limitations.", [["sample", "ANATOMY", 155, 161], ["primer and probe sequences", "DNA", 46, 72], ["probe sequences", "TEST", 57, 72], ["DiscussionOur study", "TEST", 189, 208], ["may reflect", "UNCERTAINTY", 19, 30]]], ["This evaluation was conducted on samples from individual with symptoms or during follow-up of a confirmed infection.", [["samples", "ANATOMY", 33, 40], ["infection", "DISEASE", 106, 115], ["This evaluation", "TEST", 0, 15], ["symptoms", "PROBLEM", 62, 70], ["infection", "PROBLEM", 106, 115], ["infection", "OBSERVATION", 106, 115]]], ["The level of agreement in individuals without symptoms at the beginning of infection was not evaluated here.", [["infection", "DISEASE", 75, 84], ["individuals", "ORGANISM", 26, 37], ["symptoms", "PROBLEM", 46, 54], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["The comparison was performed at a time in the pandemic with fewer individuals with low Ct results and an important proportion of specimens with high Ct values indicating low viral loads (140 (45.3 %) of 301 samples positive with cobas SARS-CoV-2 had Ct values >34.9).", [["specimens", "ANATOMY", 129, 138], ["samples", "ANATOMY", 207, 214], ["specimens", "CANCER", 129, 138], ["samples", "CANCER", 207, 214], ["specimens", "TEST", 129, 138], ["high Ct values", "TEST", 144, 158], ["low viral loads", "PROBLEM", 170, 185], ["samples", "TEST", 207, 214], ["cobas SARS", "TEST", 229, 239], ["CoV", "TEST", 240, 243], ["Ct values", "TEST", 250, 259], ["low viral", "OBSERVATION_MODIFIER", 170, 179]]], ["Because of the limited availability of reagents for the LD RT-PCR test, it was impossible to test in parallel all samples sent to our laboratory with both assays and impossible to test more than one gene target in the LD RT-PCR test.", [["samples", "ANATOMY", 114, 121], ["the LD RT-PCR test", "TEST", 52, 70], ["the LD RT-PCR test", "TEST", 214, 232]]], ["Only discordant samples were tested in a third assay, we could thus not calculate the performance of the cobas test with an expanded gold standard.ConclusionIn conclusion, this study demonstrated an excellent agreement between the cobas SARS-CoV-2 test in the 8800 platform and a LD RT-PCR test, although the cobas assay detected a greater number of samples with low viral load infections.", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 350, 357], ["viral load infections", "DISEASE", 367, 388], ["samples", "CANCER", 16, 23], ["the cobas test", "TEST", 101, 115], ["this study", "TEST", 172, 182], ["the cobas SARS", "TEST", 227, 241], ["CoV", "TEST", 242, 245], ["a LD RT-PCR test", "TEST", 278, 294], ["the cobas assay", "TEST", 305, 320], ["low viral load infections", "PROBLEM", 363, 388], ["greater", "OBSERVATION_MODIFIER", 332, 339], ["low", "OBSERVATION_MODIFIER", 363, 366], ["viral load infections", "OBSERVATION", 367, 388]]], ["Further studies comparing different platforms in parallel, as well as using clinical information will allow establishing a gold standard and determine the true performance of automated high throughput platforms.Source of supportThis work was supported by the laboratory budget under the sanitary emergency of the Province of Quebec without funding from commercial sources.Declaration of Competing InterestThe authors report no declarations of interest.", [["Further studies", "TEST", 0, 15]]]], "fe8a996e0d1fd7e189d9b81ede4308a556c03b9e": [["IntroductionMixing materials in the right amount is a common problem in many industries.", [["IntroductionMixing materials", "TREATMENT", 0, 28], ["right", "ANATOMY_MODIFIER", 36, 41], ["common", "OBSERVATION_MODIFIER", 54, 60], ["problem", "OBSERVATION", 61, 68]]], ["This problem can be encountered in several applications; when refining crude-oil into useful petroleum products, one has to manage the mixture of different hydrocarbon products; when recycling plastic, the portion of some material type should not exceed some thresholds; when producing different types of wood paneling, each type of paneling is made by gluing and pressing together a different mixture of pine and oak chips; etc. The work presented in this paper is motivated by the problem of plastic sorting for recycling purposes, that will serve as a running and illustrative example of our proposal.", [["hydrocarbon", "CHEMICAL", 156, 167], ["oil", "ORGANISM_SUBSTANCE", 77, 80], ["pine", "ORGANISM_SUBDIVISION", 405, 409], ["petroleum products", "TREATMENT", 93, 111], ["different hydrocarbon products", "TREATMENT", 146, 176], ["pine and oak chips", "TREATMENT", 405, 423], ["wood paneling", "OBSERVATION", 305, 318], ["oak chips", "OBSERVATION", 414, 423]]], ["Our goal is then to find the sorting optimizing the recycling process.IntroductionAs sorting plastic manually is time and cost-consuming, automatic processing machines are now put in place, with several sensors (e.g., infra-red cameras) installed to recognize the material of a plastic piece.", [["automatic processing machines", "TREATMENT", 138, 167], ["a plastic piece", "TREATMENT", 276, 291]]], ["In our setting, we consider that such classifiers returns mass functions modelling our knowledge about the material type.IntroductionA classical tool to perform optimization under uncertainty is stochastic optimization.", [["mass functions", "PROBLEM", 58, 72], ["stochastic optimization", "TREATMENT", 195, 218]]], ["As we add pieces to a given container, we will also have to compute the global uncertainty of a container by adding mass functions of different weights.", [["mass functions of different weights", "PROBLEM", 116, 151], ["mass", "OBSERVATION", 116, 120]]], ["To do so, we will adapt the technique proposed in [7] for general intervals to the case of discrete proportions.IntroductionThe paper is organised as follows.", [["the technique", "TREATMENT", 24, 37]]], ["Section 3 gives some reminders about belief functions, summing operation of mass functions, cautious prediction, and Choquet integral.", [["mass functions", "PROBLEM", 76, 90], ["mass", "OBSERVATION", 76, 80]]], ["The illustration concerning plastic sorting is presented in Sect.", [["plastic sorting", "OBSERVATION", 28, 43]]], ["5.Stochastic Optimisation Problem FormalisationWe consider a deposit of scrap plastic, crude-oil, wood, etc., with a total physical weight W .", [["oil", "ANATOMY", 93, 96], ["wood", "ANATOMY", 98, 102], ["oil", "ORGANISM_SUBSTANCE", 93, 96], ["wood", "ORGANISM_SUBDIVISION", 98, 102], ["a total physical weight W", "TREATMENT", 115, 140]]], ["This weight represent a set of pieces that will be put in C containers depending on the composition of each piece.", [["a set of pieces", "TREATMENT", 22, 37], ["C containers", "TREATMENT", 58, 70]]], ["Remark then that p(.|f ) can be converted to a pmf over the discrete subset of proportions {(1, 0, . . . , 0), . . . , (0, . . . , 1)} of [0, 1] n .", [["[0, 1] n", "SIMPLE_CHEMICAL", 138, 146]]], ["The constraints (1b) are then replaced by chance constraintsStochastic Optimisation Problem Formalisationwhere P f,c is the measure induced from p c \u2295 p(.|f ), and \u03b7 is typically close to 1.", [["\u03b7", "PROTEIN", 164, 165]]], ["Finally the stochastic optimisation problem is the following max c\u2208{1,...,C}Stochastic Optimisation Problem FormalisationHowever, it may be the case that pieces uncertainty is too severe to be modelled by probabilities, in which case more general models, such as belief functions, should be used.", [["the stochastic optimisation problem", "PROBLEM", 8, 43]]], ["In the next sections, we discuss an extension of Eqs.", [["sections", "ANATOMY", 12, 20]]], ["(2)-(3) for such uncertainty models.Belief FunctionsBelief functions [12, 14] are uncertainty models that combine probabilistic and set-valued uncertainty representations, therefore providing an expressive and flexible framework to represent different kinds of uncertainty.", [["such uncertainty models", "PROBLEM", 12, 35], ["an expressive and flexible framework", "PROBLEM", 192, 228], ["different kinds", "OBSERVATION_MODIFIER", 242, 257]]], ["Beyond probabilities and sets, they also extend possibility theory [5] .Belief FunctionsGiven a space X with elements x, the basic tools used within belief function theory is the mass function, also called basic belief assignment (bba), is a set function m : 2 X \u2192 [0, 1] satisfyingBelief FunctionsThe elements A \u2208 2 X such that m(A) > 0 are called focal elements and they form a set denoted F. (m, F) is called body of evidence.Belief FunctionsThe belief function Bel : 2 X \u2192 [0, 1] is a set function that measures how much an event A is implied by our information such thatBelief FunctionsThe plausibility function P l : 2 X \u2192 [0, 1] is a set function that measures how much an event A is consistent with our information such thatBelief FunctionsNote that when focal elements are singletons x, we have Bel = P l and retrieve probabilities.Sum Operation on Imprecise ProportionLet us denote the unit simplex bySum Operation on Imprecise ProportionLet us consider two sets of pieces sf 1 and sf 2 made of materials among S = {s 1 , . . . , s n } with physical masses w 1 and w 2 .", [["focal elements", "DNA", 349, 363], ["a space X with elements", "TREATMENT", 94, 117], ["the mass function", "PROBLEM", 175, 192], ["the unit simplex bySum Operation", "TREATMENT", 892, 924], ["physical masses", "PROBLEM", 1051, 1066], ["mass", "OBSERVATION", 179, 183], ["masses", "OBSERVATION", 1060, 1066]]], ["The information about the material type proportions in sf 1 and sf 2 are given respectively by the bodies of evidence (m 1 , F 1 ) and (m 2 , F 2 ) defined over U, with discrete focal elements in a finite number.", [["discrete focal elements", "PROBLEM", 169, 192], ["discrete", "OBSERVATION_MODIFIER", 169, 177], ["focal", "OBSERVATION_MODIFIER", 178, 183], ["elements", "OBSERVATION", 184, 192]]], ["A focal element inSum Operation on Imprecise ProportionThe information resulting from adding sf 2 with sf 1 is a mass function denoted m 1\u22952 and defined as follows for I \u2282 U [7] :Sum Operation on Imprecise Proportionwhere F 1\u22952 is a finite set made of discrete subsets of U resulting from summing proportion in F 1 and F 2 ; the total weight associated to the mixture is w 1 + w 2 and is defined for two focal elements J \u2208 F 1 and K \u2208 F 2 as follows:Sum Operation on Imprecise ProportionNote that in case where imprecise information are convex sets, e.g. intervals, only the lower and the upper bounds of the intervals are involved in the determination of J K [7] .", [["A focal element", "PROBLEM", 0, 15], ["a mass function", "PROBLEM", 111, 126], ["the total weight", "TEST", 325, 341], ["focal", "OBSERVATION_MODIFIER", 2, 7], ["element", "OBSERVATION_MODIFIER", 8, 15], ["mass", "OBSERVATION", 113, 117], ["discrete", "OBSERVATION_MODIFIER", 252, 260], ["subsets", "OBSERVATION", 261, 268], ["lower", "ANATOMY_MODIFIER", 575, 580], ["upper", "ANATOMY_MODIFIER", 589, 594]]], ["Let us consider the case where S = {s 1 , s 2 , s 3 , s 4 } and sf 1 and sf 2 are both composed of a single piece each with weight 1 kg.", [["Let us", "TEST", 0, 6], ["S", "TEST", 31, 32], ["weight", "TEST", 124, 130]]], ["The focal elements presented in Table 1 have the following meaning: J 1 means that sf 1 is a pure material of type s 1 or s 2 , and J 2 means that sf 1 is a pure material of type s 2 , and similarly for K 1 , K 2 .Sum Operation on Imprecise ProportionThe obtained mass function when mixing sf 1 and sf 2 is given by its body of evidence ({I 1 , I 2 , I 3 , I 4 }, m 1\u22952 ) as follows:Inference from Imprecise ProportionsThe set A \u03b1 of vector proportions that satisfy i\u2208A \u03b8 i \u2264 \u03b1 is of interest in our problem because it allows expressing constraints containers must respect, as indicate Eq.", [["K", "CHEMICAL", 203, 204], ["The focal elements", "PROBLEM", 0, 18], ["K", "TEST", 203, 204], ["K", "TEST", 209, 210], ["focal", "OBSERVATION_MODIFIER", 4, 9], ["mass", "OBSERVATION", 264, 268]]], ["Given focal elementsInference from Imprecise ProportionsIn the discrete case whereCautious PredictionsIn our case, belief functions will be produced by classifiers that will be learned from a set of examples/pieces f 1 , . . . , f l having m features X 1 , . . . , X m having received a label in S. Given a new object f , this classifier will output a mass m(.|f ) as a prediction.", [["focal elements", "DNA", 6, 20], ["focal elements", "PROBLEM", 6, 20], ["a mass m", "PROBLEM", 350, 358], ["focal elements", "OBSERVATION", 6, 20], ["mass", "OBSERVATION", 352, 356]]], ["Such classifiers are indeed useful in our application, as they provide more reliable information, and can account for many defects, such as the missingness of some feature X j for f (due to a broken sensor), or the fact that measurements are done by industrial on line machine device instead of laboratory measurements, meaning that variability in measurement due to atmospheric disturbances, ageing of plastics, black or dark-coloured materials, etc. lead to reducing the quality of the spectrum obtained from plastic pieces.", [["many defects", "PROBLEM", 118, 130], ["line machine device", "TREATMENT", 264, 283], ["laboratory measurements", "TEST", 295, 318], ["atmospheric disturbances", "PROBLEM", 367, 391], ["black or dark-coloured materials", "PROBLEM", 413, 445], ["defects", "OBSERVATION", 123, 130], ["atmospheric disturbances", "OBSERVATION", 367, 391], ["plastic pieces", "OBSERVATION", 511, 525]]], ["Instead of point prediction classifiers, we will use classifiers providing cautious predictions in form of a posterior mass function over S [8] , but the approach could apply to other such classifiers [3, 4, 11] .", [["a posterior mass function", "PROBLEM", 107, 132], ["posterior", "ANATOMY_MODIFIER", 109, 118], ["mass", "OBSERVATION", 119, 123]]], ["It should be stressed that in our case, one could prefer to put a good plastic in a low price container rather than ruining a high price container by violating constraints (1b), so being cautious by accounting for imperfectness of information is essential.Choquet IntegralThe Choquet integral [9] is an integral that applies to non-additive measures, often referred as fuzzy measures [10] .", [["a low price container", "TREATMENT", 82, 103], ["a high price container", "TREATMENT", 124, 146], ["Choquet IntegralThe Choquet integral", "TREATMENT", 256, 292], ["non-additive measures", "TREATMENT", 328, 349]]], ["Since a Belief function defined over a space S is such a fuzzy measure 1 , we can apply the Choquet integral to it in the following way: given a vector of real positive values y = (y 1 , ..., y n ) \u2208 R +n , its Choquet integral w.r.t.", [["the Choquet integral", "TREATMENT", 88, 108]]], ["Bel is defined asChoquet Integralwhere 0 = y \u03c3(0) \u2264 y \u03c3(1) \u2264 y \u03c3(2) \u2264 ... \u2264 y \u03c3(n) (\u03c3 is a permutation over {1, . . . , n}).Choquet IntegralIf Bel = P l, then Eq.", [["Choquet", "TEST", 17, 24], ["Integralwhere", "TEST", 25, 38], ["\u03c3", "TEST", 54, 55], ["\u2264", "TEST", 68, 69], ["\u03c3", "TEST", 84, 85], ["a permutation over {", "TEST", 89, 109]]], ["We consider all the previous ingredients, except that now the information about a new piece to add to a container is given by a mass function m(.|f ) defined over S = {s 1 , . . . , s n }, and our information about the proportions of materials in a given container c is also given by a mass function m c bearing on U. As before, one can easily go from a mass m(.|f ) on S to a mass on U (see Example 1 for an illustration).The Objective FunctionThe expected value in the objective function (2) can be replaced by the Choquet integral based on the belief function Bel(.|f ).", [["a mass m", "PROBLEM", 352, 360], ["a mass", "PROBLEM", 375, 381], ["the Choquet integral", "TREATMENT", 513, 533], ["mass", "OBSERVATION", 286, 290], ["mass", "OBSERVATION", 354, 358], ["mass", "OBSERVATION", 377, 381], ["value", "OBSERVATION_MODIFIER", 458, 463]]], ["2, we will only be interested to model in the objective function the potential gain of adding the new piece f to one of the container, without bothering about the container current proportions, as those will be treated in the constraints.", [["the new piece f", "TREATMENT", 94, 109]]], ["If g is the overall gain of a container containing materials of a specified kind A, where elements A \u2282 S are considered as impurities whose percentage should not exceed \u03b1 c , we simply consider the function g c (s) = g(s) for s \u2208 A, and g c (s) = \u03b1 c \u00b7 g(s).Example 2.Consider four material types S = {s 1 , . . . , s 4 } and three containers.", [["\u03b1 c", "GENE_OR_GENE_PRODUCT", 169, 172], ["\u03b1 c", "PROTEIN", 169, 172], ["a container containing materials", "TREATMENT", 28, 60], ["four material types S", "TEST", 277, 298]]], ["The example of Table 2 shows that the larger the threshold, the higher the gain when adding impurities to a container.", [["larger", "OBSERVATION_MODIFIER", 38, 44], ["higher", "OBSERVATION_MODIFIER", 64, 70]]], ["(2) becomes: max c\u2208{1,...,C} C Bel(.|f ) (g c (s 1 ), . . . , g c (s n ))Example 2.The objective function (7) is an expected value based on Choquet integral where gains are weighted related to our belief on the material type of the new piece including imprecise information.", [["c\u2208{1,...,C} C", "CHEMICAL", 17, 30], ["c\u2208", "TEST", 17, 19]]], ["Let denotes x (1)then this expectedvalue guarantee x (1) surely and adds to it the gaps x (i) \u2212 x (i\u22121) weighted by Bel({s (i) , . . . , s (n) }|f ). , {s 1 , s 2 }}, (0.2, 0.8) ).", [["this expectedvalue guarantee", "TREATMENT", 22, 50], ["{s", "TEST", 152, 154]]], ["The formula (5) gives us the new mass function m f \u2295c when adding the piece f to the container c.", [["mass", "OBSERVATION", 33, 37]]], ["However, we must now replace he probability measure P f \u2295c in this constraint is by the pair (Bel f \u2295c , P l f \u2295c ).", [["P f \u2295c", "DNA", 52, 58]]], ["Such a reasoning can be applied by replacing the constraint (3) by two constraints:The Constraintswhere \u03b7 c \u2208]0, 1] are enough large.", [["large", "OBSERVATION", 127, 132]]], ["Note that such ideas are not new, and have been for instance recently applied to the travelling salesman problem [6] .The ConstraintsExample 4.", [["new", "OBSERVATION_MODIFIER", 29, 32]]], ["3.3 we give the way to determine Bel(A \u03b1 ) and P l(A \u03b1 ) that are required to check the constraints (8a) and (8b).", [["P l", "DNA", 47, 50]]], ["Complexity issues arise when the number of pieces is very large.", [["Complexity issues", "PROBLEM", 0, 17], ["very large", "PROBLEM", 53, 63], ["very", "OBSERVATION_MODIFIER", 53, 57], ["large", "OBSERVATION", 58, 63]]], ["Indeed, the number of focal elements involved when determining Bel f \u2295c (9b) and P l f \u2295c (9c) become exponential, yet one can easily solve this issue by considering approximations (e.g., deleting focal elements of very small mass).IllustrationIn this section we present an application concerning plastic sorting where the pieces of a deposit should be separated by types of materials in different containers prior to recycling due to some physico-chemical reasons related to nonmiscibility.", [["nonmiscibility", "DISEASE", 476, 490], ["very small mass", "PROBLEM", 215, 230], ["an application", "TREATMENT", 271, 285], ["a deposit", "PROBLEM", 333, 342], ["focal", "OBSERVATION_MODIFIER", 22, 27], ["focal", "OBSERVATION_MODIFIER", 197, 202], ["very", "OBSERVATION_MODIFIER", 215, 219], ["small", "OBSERVATION_MODIFIER", 220, 225], ["mass", "OBSERVATION", 226, 230]]], ["Optical sorting devices are used to automatically sort the pieces.", [["Optical sorting devices", "TREATMENT", 0, 23]]], ["As it is shown in Fig. 1 borrowed from [1] , pieces of plastics arrive continuously on a conveyor belt before being recorded by an infra-red camera.", [["plastics", "TREATMENT", 55, 63], ["a conveyor belt", "TREATMENT", 87, 102], ["Fig", "OBSERVATION", 18, 21]]], ["However, the on line acquired information is subject to several issues inducing the presence of imprecision on one hand, i.e. some features information are not precise enough to draw clear distinctions between the materials type, and uncertainty on the other hand, i.e. due to the reliability of information caused by atmospheric disturbance, etc (please refer to [8] for more details).", [["hand", "ORGANISM_SUBDIVISION", 259, 263], ["atmospheric disturbance", "PROBLEM", 318, 341], ["atmospheric disturbance", "OBSERVATION", 318, 341]]], ["The second source is the optical device which provides spectra of lesser quality.", [["the optical device", "TREATMENT", 21, 39], ["optical device", "OBSERVATION", 25, 39], ["lesser", "OBSERVATION_MODIFIER", 66, 72]]], ["Since small quantity of badly sorted plastics can lead to high decreases of impact resistance [13] and of monetary value, impurities should be limited.", [["badly sorted plastics", "PROBLEM", 24, 45], ["high decreases of impact resistance", "PROBLEM", 58, 93], ["monetary value", "TEST", 106, 120], ["small", "OBSERVATION_MODIFIER", 6, 11], ["quantity", "OBSERVATION_MODIFIER", 12, 20], ["high", "OBSERVATION_MODIFIER", 58, 62], ["decreases", "OBSERVATION_MODIFIER", 63, 72]]], ["Thus, experts have defined tolerance threshold on the proportions of impurities.IllustrationIn this illustration we propose a sorting procedure based on the optimisation problem in (9a)-(9d).", [["(9a)-(9d", "SIMPLE_CHEMICAL", 181, 189], ["defined tolerance threshold", "PROBLEM", 19, 46], ["a sorting procedure", "TREATMENT", 124, 143]]], ["The cautious classification is provided using the evidential classifier proposed in [8] .IllustrationLet us recap the procedure performed to sort each fragment f : -Estimate the resulting composition of each container c if we add f to it as a mass function m f \u2295c using the sum operation defined in Sect.", [["the procedure", "TREATMENT", 114, 127], ["a mass function", "PROBLEM", 241, 256], ["the sum operation", "TREATMENT", 270, 287]]], ["3.2. -Select the containers verifying the constraints (9b) and (9c).Illustration-Compare the objective function (9a) for the selected container.Illustration-Update the evidence about the chosen container.Data PresentationLet us consider a plastic waste deposit composed of 25 pieces of four material types s 1 , s 2 , s 3 , s 4 .", [["a plastic waste deposit", "TREATMENT", 237, 260], ["waste deposit", "OBSERVATION", 247, 260]]], ["The first container is dedicated to plastic types s 1 , s 2 and the proportions of impurities, i.e s 3 , s 4 , should not exceed \u03b1 1 = 0.05.", [["impurities", "OBSERVATION", 83, 93]]], ["The second container is dedicated to plastic types s 3 , s 4 , and the proportions of impurities, i.e s 1 , s 2 , should not exceed \u03b1 2 = 0.05.", [["impurities", "OBSERVATION", 86, 96]]], ["The third container is actually the reject option, thus all types of plastics are considered as impurities (or considered as valid materials), but there is no need to control them, thereby \u03b1 3 = 1.", [["plastics", "TREATMENT", 69, 77], ["no need", "UNCERTAINTY", 156, 163]]], ["Each example of the database is composed of its 154-dimension features and its ATR label.SimulationsThe evidential classifier proposed in [8] has been trained on the 11747 examples and applied on the testing set, i.e., 11618 other examples.", [["the testing set", "TEST", 196, 211], ["154-dimension", "OBSERVATION_MODIFIER", 48, 61]]], ["We obtained 11618 mass functions m(.|f 1 ), . . . , m(.|f 11618 ).", [["mass", "OBSERVATION", 18, 22]]], ["In order to evaluate the sorting procedure, we tested the performances on 40 simulations of fragment streams.", [["the sorting procedure", "TREATMENT", 21, 42], ["fragment streams", "PROBLEM", 92, 108]]], ["For computational reasons, we stopped the sorting procedure at the 25th fragment for each simulation.", [["25th fragment", "DNA", 67, 80], ["the sorting procedure", "TREATMENT", 38, 59]]], ["Note that the complexity of the sorting procedure is exponential, i.e., O((2 |S| ) nb of pieces ) [7] .", [["O", "CHEMICAL", 72, 73], ["the sorting procedure", "TREATMENT", 28, 49]]], ["Figure 2 , 3 and 4 show respectively the evolution of the weight of materials in the two first containers, the belief that the constraints are respected and the real proportions of impurities.", [["Figure", "TEST", 0, 6]]], ["The thresholds are set to \u03b7 1 = \u03b7 2 = 0.6.", [["The thresholds", "TEST", 0, 14]]], ["Using the testing labels we can evaluate the real proportions of impurities.", [["the testing labels", "TEST", 6, 24], ["impurities", "OBSERVATION", 65, 75]]], ["In Fig. 4 , we observe that the proportion of impurities are most of the times below the required threshold except for a few simulations where mistakes are made for the first pieces added in container 1 and 2.", [["the first pieces", "TREATMENT", 165, 181]]], ["Since at the beginning of the sorting, there are only few pieces, the mistakes have a high impact on the proportions.", [["few", "OBSERVATION_MODIFIER", 54, 57], ["pieces", "OBSERVATION", 58, 64], ["high", "OBSERVATION_MODIFIER", 86, 90], ["impact", "OBSERVATION_MODIFIER", 91, 97]]], ["After checking, it turned out that the mass functions provided for these examples were not accurate.", [["the mass functions", "PROBLEM", 35, 53], ["mass", "OBSERVATION", 39, 43]]], ["In order to evaluate the quality of the resulting sorted material, we introduce the score q c as the percentage of simulations respecting impurities proportions constraints at the end of the sorting in the container c.", [["simulations respecting impurities", "TREATMENT", 115, 148]]], ["This is significantly higher than the required levels 60%, which is in-line with the fact that we are acting cautiously.", [["significantly", "OBSERVATION_MODIFIER", 8, 21], ["higher", "OBSERVATION_MODIFIER", 22, 28]]], ["However, this would only have been possible if we had perfect classification results, something that is unlikely.DiscussionIn order to verify the benefit of the proposed sorting procedure based on the optimisation problem (9a)-(9d), named here evidential procedure, we compare it to the stochastic procedure based on the stochastic optimisation problem (4a)-(4c) and to the deterministic procedure based on optimisation problem (1a)-(1c).", [["the proposed sorting procedure", "TREATMENT", 157, 187], ["evidential procedure", "TREATMENT", 244, 264], ["the stochastic procedure", "TREATMENT", 283, 307], ["the deterministic procedure", "TREATMENT", 370, 397]]], ["We consider stochastic procedure based on the Pignistic probability derived from m(.|f ) while the deterministic procedure is based on a classifier producing point prediction.", [["stochastic procedure", "TREATMENT", 12, 32], ["the deterministic procedure", "TREATMENT", 95, 122]]], ["Two criteria are used to perform this comparison: the quality of the resulting materials in the two containers q 1 , q 2 ; the rate of average gain obtained on all simulations, denoted Rag.DiscussionWhat we see here is that not accounting for uncertainty, or considering a less expressive model (i.e., probabilities) do indeed bring a better average gain, but fails to meet the constraints imposed to the containers for them to be usable at all.", [["Rag", "GENE_OR_GENE_PRODUCT", 185, 188], ["Rag", "PROTEIN", 185, 188]]], ["Indeed, the evidential procedure achieves high quality of the sorting material while the two other procedures do not respect the required constraints on the containers composition.", [["the evidential procedure", "TREATMENT", 8, 32]]], ["This could be solved by considering more penalizing gains in case of bad sorting for the deterministic procedure and stochastic procedure, yet this would complexify the procedure.", [["bad sorting", "PROBLEM", 69, 80], ["the deterministic procedure", "TREATMENT", 85, 112], ["stochastic procedure", "TREATMENT", 117, 137], ["the procedure", "TREATMENT", 165, 178]]], ["Thus the evidential procedure seems preferable for applications where constraints on impurities are strong, i.e. very small \u03b1 or when the confidence level required for the application is high, i.e., \u03b7 closer to 1.", [["the evidential procedure", "TREATMENT", 5, 29]]], ["When such requirements are not necessary, we would advice the use of an alternative procedure less computationally demanding.ConclusionWe proposed in this paper a formulation of the mixture problem of material types in the framework of belief functions.", [["an alternative procedure", "TREATMENT", 69, 93]]], ["The usefulness of this work is illustrated using the sorting procedure of plastic material.", [["the sorting procedure of plastic material", "TREATMENT", 49, 90]]], ["A stepwise approach is proposed to avoid the complicated complete resolution.", [["A stepwise approach", "TREATMENT", 0, 19], ["resolution", "OBSERVATION_MODIFIER", 66, 76]]], ["As perspectives for this work, one should optimise the stepwise summing of mass functions in on line sorting procedure by controlling the focal elements generated at each step in order to overcome the exponential complexity.", [["focal elements", "DNA", 138, 152], ["mass functions", "PROBLEM", 75, 89], ["line sorting procedure", "TREATMENT", 96, 118], ["mass", "OBSERVATION", 75, 79], ["focal", "OBSERVATION_MODIFIER", 138, 143]]], ["Furthermore, one may relax the constraints on impurities at each step by requiring them only at the end of the sorting procedure.", [["the sorting procedure", "TREATMENT", 107, 128]]]], "PMC6702729": [["BackgroundRecently, the World Small Animal Veterinary Association Renal Standardization Study Group (WSAVA-RSSG) has provided criteria to diagnose glomerular diseases in dogs based on light microscopy (LM) and transmission electron microscopy (TEM), as well as immunofluorescence [1].", [["Renal", "ANATOMY", 66, 71], ["glomerular", "ANATOMY", 147, 157], ["glomerular diseases", "DISEASE", 147, 166], ["glomerular", "TISSUE", 147, 157], ["dogs", "ORGANISM", 170, 174], ["dogs", "SPECIES", 170, 174], ["glomerular diseases in dogs", "PROBLEM", 147, 174], ["light microscopy", "TEST", 184, 200], ["transmission electron microscopy", "TEST", 210, 242], ["Renal", "ANATOMY", 66, 71], ["glomerular", "ANATOMY", 147, 157], ["diseases", "OBSERVATION", 158, 166]]], ["According to the WSAVA-RSSG, two broad diagnostic categories have been identified, namely immune-complex glomerulonephritis (ICGN) and non-immune-complex glomerulonephritis (non-ICGN) [1].", [["glomerulonephritis", "DISEASE", 105, 123], ["ICGN", "DISEASE", 125, 129], ["non-immune-complex glomerulonephritis", "DISEASE", 135, 172], ["ICGN", "CANCER", 125, 129], ["WSAVA", "DNA", 17, 22], ["RSSG", "DNA", 23, 27], ["two broad diagnostic categories", "PROBLEM", 29, 60], ["complex glomerulonephritis", "PROBLEM", 97, 123], ["non-immune-complex glomerulonephritis", "PROBLEM", 135, 172], ["complex", "OBSERVATION_MODIFIER", 97, 104], ["glomerulonephritis", "OBSERVATION", 105, 123], ["complex", "OBSERVATION_MODIFIER", 146, 153], ["glomerulonephritis", "OBSERVATION", 154, 172]]], ["Because specific morphological criteria for glomerular diseases have not been reported in cats, the above classification scheme is commonly adopted in the feline species.", [["glomerular", "ANATOMY", 44, 54], ["glomerular diseases", "DISEASE", 44, 63], ["glomerular", "MULTI-TISSUE_STRUCTURE", 44, 54], ["cats", "ORGANISM", 90, 94], ["feline", "ORGANISM", 155, 161], ["cats", "SPECIES", 90, 94], ["glomerular diseases", "PROBLEM", 44, 63], ["glomerular", "ANATOMY", 44, 54], ["diseases", "OBSERVATION", 55, 63], ["feline species", "OBSERVATION", 155, 169]]], ["However, to date only few reports of ICGN in cats have been published and membranous glomerulonephropathy (MGN) was reported most frequently [2\u20136], often associated with feline leukemia virus (FeLV) infection [4, 6\u20138].", [["membranous glomerulonephropathy", "ANATOMY", 74, 105], ["ICGN", "DISEASE", 37, 41], ["membranous glomerulonephropathy", "DISEASE", 74, 105], ["MGN", "DISEASE", 107, 110], ["feline leukemia virus (FeLV) infection", "DISEASE", 170, 208], ["ICGN", "CANCER", 37, 41], ["cats", "ORGANISM", 45, 49], ["membranous glomerulonephropathy", "CANCER", 74, 105], ["MGN", "CANCER", 107, 110], ["feline leukemia virus", "ORGANISM", 170, 191], ["FeLV", "ORGANISM", 193, 197], ["ICGN", "PROTEIN", 37, 41], ["cats", "SPECIES", 45, 49], ["feline leukemia virus", "SPECIES", 170, 191], ["feline leukemia virus", "SPECIES", 170, 191], ["FeLV", "SPECIES", 193, 197], ["ICGN in cats", "PROBLEM", 37, 49], ["membranous glomerulonephropathy (MGN)", "PROBLEM", 74, 111], ["feline leukemia virus (FeLV) infection", "PROBLEM", 170, 208], ["membranous", "OBSERVATION_MODIFIER", 74, 84], ["glomerulonephropathy", "OBSERVATION", 85, 105], ["leukemia virus", "OBSERVATION", 177, 191]]], ["ICGN has also been described in feline immunodeficiency virus (FIV) positive cats and mesangioproliferative glomerulonephritis (MeGN) was the most common lesion [9].", [["lesion", "ANATOMY", 154, 160], ["ICGN", "CHEMICAL", 0, 4], ["feline immunodeficiency virus (FIV) positive", "DISEASE", 32, 76], ["glomerulonephritis", "DISEASE", 108, 126], ["MeGN", "DISEASE", 128, 132], ["ICGN", "GENE_OR_GENE_PRODUCT", 0, 4], ["feline immunodeficiency virus", "ORGANISM", 32, 61], ["FIV", "ORGANISM", 63, 66], ["cats", "ORGANISM", 77, 81], ["mesangioproliferative glomerulonephritis", "CANCER", 86, 126], ["MeGN", "CANCER", 128, 132], ["ICGN", "PROTEIN", 0, 4], ["feline immunodeficiency virus", "SPECIES", 32, 61], ["cats", "SPECIES", 77, 81], ["feline immunodeficiency virus", "SPECIES", 32, 61], ["FIV", "SPECIES", 63, 66], ["feline immunodeficiency virus", "PROBLEM", 32, 61], ["mesangioproliferative glomerulonephritis", "PROBLEM", 86, 126], ["the most common lesion", "PROBLEM", 138, 160], ["mesangioproliferative", "OBSERVATION_MODIFIER", 86, 107], ["glomerulonephritis", "OBSERVATION", 108, 126], ["most common", "OBSERVATION_MODIFIER", 142, 153], ["lesion", "OBSERVATION", 154, 160]]], ["Further, MeGN has been reported in a cat with cyanotic congenital heart disease, as observed in humans who developed transient proteinuria and edema [10, 11].", [["heart", "ANATOMY", 66, 71], ["MeGN", "CHEMICAL", 9, 13], ["cyanotic", "DISEASE", 46, 54], ["congenital heart disease", "DISEASE", 55, 79], ["proteinuria", "DISEASE", 127, 138], ["edema", "DISEASE", 143, 148], ["MeGN", "GENE_OR_GENE_PRODUCT", 9, 13], ["cat", "ORGANISM", 37, 40], ["heart", "ORGAN", 66, 71], ["humans", "ORGANISM", 96, 102], ["edema", "PATHOLOGICAL_FORMATION", 143, 148], ["MeGN", "PROTEIN", 9, 13], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["cyanotic congenital heart disease", "PROBLEM", 46, 79], ["transient proteinuria", "PROBLEM", 117, 138], ["edema", "PROBLEM", 143, 148], ["cyanotic", "OBSERVATION_MODIFIER", 46, 54], ["congenital", "OBSERVATION", 55, 65], ["heart", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79], ["transient", "OBSERVATION_MODIFIER", 117, 126], ["proteinuria", "OBSERVATION", 127, 138], ["edema", "OBSERVATION", 143, 148]]], ["In addition, feline coronavirus leading to feline infectious peritonitis (FIP) has been associated with various types of ICGN, including MGN, MeGN and membranoproliferative glomerulonephritis (MPGN) [12].", [["ICGN", "ANATOMY", 121, 125], ["feline coronavirus", "DISEASE", 13, 31], ["feline infectious peritonitis", "DISEASE", 43, 72], ["FIP", "DISEASE", 74, 77], ["ICGN", "DISEASE", 121, 125], ["membranoproliferative glomerulonephritis", "DISEASE", 151, 191], ["MPGN", "DISEASE", 193, 197], ["feline coronavirus", "ORGANISM", 13, 31], ["feline", "ORGANISM", 43, 49], ["ICGN", "CANCER", 121, 125], ["MGN", "CANCER", 137, 140], ["feline coronavirus", "SPECIES", 13, 31], ["feline", "SPECIES", 43, 49], ["feline coronavirus", "SPECIES", 13, 31], ["feline coronavirus", "PROBLEM", 13, 31], ["feline infectious peritonitis", "PROBLEM", 43, 72], ["FIP", "PROBLEM", 74, 77], ["ICGN", "PROBLEM", 121, 125], ["MGN", "PROBLEM", 137, 140], ["MeGN", "PROBLEM", 142, 146], ["membranoproliferative glomerulonephritis", "PROBLEM", 151, 191], ["feline coronavirus", "OBSERVATION", 13, 31], ["feline", "OBSERVATION_MODIFIER", 43, 49], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["peritonitis", "OBSERVATION", 61, 72], ["membranoproliferative", "OBSERVATION_MODIFIER", 151, 172], ["glomerulonephritis", "OBSERVATION", 173, 191]]], ["Finally, MPGNs resembling human type I and III have been described in two cats [3, 13], as well as proliferative, necrotizing and crescentic ICGN in a cat [14].BackgroundChronic kidney disease (CKD) secondary to non-ICGN is much more frequent than ICGN, with the majority of cats having non-specific renal lesions [15, 16].", [["MPGNs", "ANATOMY", 9, 14], ["ICGN", "ANATOMY", 141, 145], ["kidney", "ANATOMY", 178, 184], ["renal lesions", "ANATOMY", 300, 313], ["necrotizing", "DISEASE", 114, 125], ["ICGN", "DISEASE", 141, 145], ["BackgroundChronic kidney disease", "DISEASE", 160, 192], ["CKD", "DISEASE", 194, 197], ["non-ICGN", "DISEASE", 212, 220], ["renal lesions", "DISEASE", 300, 313], ["human", "ORGANISM", 26, 31], ["type I and III", "GENE_OR_GENE_PRODUCT", 32, 46], ["cats", "ORGANISM", 74, 78], ["ICGN", "CANCER", 141, 145], ["kidney", "ORGAN", 178, 184], ["ICGN", "CANCER", 248, 252], ["cats", "ORGANISM", 275, 279], ["renal lesions", "PATHOLOGICAL_FORMATION", 300, 313], ["MPGNs", "PROTEIN", 9, 14], ["human", "SPECIES", 26, 31], ["human type I", "SPECIES", 26, 38], ["necrotizing and crescentic ICGN", "PROBLEM", 114, 145], ["BackgroundChronic kidney disease", "PROBLEM", 160, 192], ["CKD)", "PROBLEM", 194, 198], ["non-ICGN", "PROBLEM", 212, 220], ["non-specific renal lesions", "PROBLEM", 287, 313], ["necrotizing", "OBSERVATION_MODIFIER", 114, 125], ["crescentic", "OBSERVATION_MODIFIER", 130, 140], ["kidney", "ANATOMY", 178, 184], ["disease", "OBSERVATION", 185, 192], ["CKD", "OBSERVATION", 194, 197], ["much more frequent", "OBSERVATION_MODIFIER", 224, 242], ["non-specific", "OBSERVATION_MODIFIER", 287, 299], ["renal", "ANATOMY", 300, 305], ["lesions", "OBSERVATION", 306, 313]]], ["It is usually documented in aged cats and chronic interstitial nephritis (CIN) associated with secondary glomerular involvement is the predominant morphologic diagnosis [15\u201317].", [["glomerular", "ANATOMY", 105, 115], ["interstitial nephritis", "DISEASE", 50, 72], ["CIN", "DISEASE", 74, 77], ["cats", "ORGANISM", 33, 37], ["interstitial nephritis", "PATHOLOGICAL_FORMATION", 50, 72], ["CIN", "CANCER", 74, 77], ["glomerular", "TISSUE", 105, 115], ["cats", "SPECIES", 33, 37], ["chronic interstitial nephritis", "PROBLEM", 42, 72], ["secondary glomerular involvement", "PROBLEM", 95, 127], ["chronic", "OBSERVATION_MODIFIER", 42, 49], ["interstitial", "ANATOMY_MODIFIER", 50, 62], ["nephritis", "OBSERVATION", 63, 72], ["secondary", "OBSERVATION_MODIFIER", 95, 104], ["glomerular", "OBSERVATION", 105, 115], ["predominant", "OBSERVATION_MODIFIER", 135, 146], ["morphologic", "OBSERVATION_MODIFIER", 147, 158]]], ["However, no studies have detailed the ultrastructural lesions in the glomeruli of these cats, thereby reducing diagnostic specificity and sensibility.", [["lesions", "ANATOMY", 54, 61], ["glomeruli", "ANATOMY", 69, 78], ["lesions", "PATHOLOGICAL_FORMATION", 54, 61], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 69, 78], ["cats", "ORGANISM", 88, 92], ["cats", "SPECIES", 88, 92], ["studies", "TEST", 12, 19], ["the ultrastructural lesions", "PROBLEM", 34, 61], ["diagnostic specificity", "TEST", 111, 133], ["lesions", "OBSERVATION", 54, 61], ["glomeruli", "ANATOMY", 69, 78]]], ["Based on the severity of interstitial fibrosis and inflammatory infiltration, CIN is currently histologically classified according to a scale that ranges from 0 to 3, in ascending order of severity [17].", [["interstitial", "ANATOMY", 25, 37], ["fibrosis", "DISEASE", 38, 46], ["CIN", "DISEASE", 78, 81], ["interstitial fibrosis", "PROBLEM", 25, 46], ["inflammatory infiltration", "PROBLEM", 51, 76], ["CIN", "PROBLEM", 78, 81], ["a scale", "TEST", 134, 141], ["interstitial", "ANATOMY_MODIFIER", 25, 37], ["fibrosis", "OBSERVATION", 38, 46], ["inflammatory", "OBSERVATION_MODIFIER", 51, 63], ["infiltration", "OBSERVATION", 64, 76]]], ["The amount of fibrosis represents the lesion that best correlates with the severity of azotemia, hyperphosphatemia and anemia, while glomerular hypertrophy correlates best with the severity of proteinuria [17].BackgroundLarge cohort studies describing ICGN in cats are still lacking because cases with primary glomerular lesions are seldom encountered and the use of renal biopsy is yet very limited in clinical practice.", [["lesion", "ANATOMY", 38, 44], ["glomerular", "ANATOMY", 133, 143], ["primary glomerular lesions", "ANATOMY", 302, 328], ["renal", "ANATOMY", 367, 372], ["fibrosis", "DISEASE", 14, 22], ["azotemia", "DISEASE", 87, 95], ["hyperphosphatemia", "DISEASE", 97, 114], ["anemia", "DISEASE", 119, 125], ["glomerular hypertrophy", "DISEASE", 133, 155], ["proteinuria", "DISEASE", 193, 204], ["primary glomerular lesions", "DISEASE", 302, 328], ["glomerular", "TISSUE", 133, 143], ["ICGN", "CANCER", 252, 256], ["cats", "ORGANISM", 260, 264], ["glomerular lesions", "PATHOLOGICAL_FORMATION", 310, 328], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 367, 379], ["cats", "SPECIES", 260, 264], ["fibrosis", "PROBLEM", 14, 22], ["the lesion", "PROBLEM", 34, 44], ["azotemia", "PROBLEM", 87, 95], ["hyperphosphatemia", "PROBLEM", 97, 114], ["anemia", "PROBLEM", 119, 125], ["glomerular hypertrophy", "PROBLEM", 133, 155], ["proteinuria", "PROBLEM", 193, 204], ["BackgroundLarge cohort studies", "TEST", 210, 240], ["primary glomerular lesions", "PROBLEM", 302, 328], ["renal biopsy", "TEST", 367, 379], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["fibrosis", "OBSERVATION", 14, 22], ["lesion", "OBSERVATION", 38, 44], ["azotemia", "OBSERVATION", 87, 95], ["hyperphosphatemia", "OBSERVATION", 97, 114], ["anemia", "OBSERVATION", 119, 125], ["glomerular", "OBSERVATION_MODIFIER", 133, 143], ["hypertrophy", "OBSERVATION", 144, 155], ["proteinuria", "OBSERVATION", 193, 204], ["glomerular", "ANATOMY", 310, 320], ["lesions", "OBSERVATION", 321, 328], ["renal", "ANATOMY", 367, 372], ["biopsy", "OBSERVATION", 373, 379]]], ["Therefore, the aims of this study were first to characterize morphological diagnosis of ICGN with LM and TEM in a large group of cats and to identify associations with clinical and laboratory findings.", [["ICGN", "ANATOMY", 88, 92], ["ICGN", "CANCER", 88, 92], ["cats", "ORGANISM", 129, 133], ["this study", "TEST", 23, 33]]], ["Secondly, a group of non-ICGN cats were used for comparison to highlight the need of histopathology and electron microscopy to obtain a final diagnosis.Cats with ICGN and clinical features associated with morphological diagnoses ::: ResultsOf 37 cats diagnosed with ICGN, breed was known for 36; 34 (94.4%) were DSH and 2 (5.6%) purebred, including 1 each of Norwegian Forest and Abyssinian.Cats with ICGN and clinical features associated with morphological diagnoses ::: ResultsConcerning FIV and FeLV status, all cats had been tested and 13 (35.1%) cats were positive for retroviral infection, including 10 FIV-positive cats and 3 FeLV-positive; none was concurrently infected with both viruses.", [["ICGN", "DISEASE", 162, 166], ["ICGN", "DISEASE", 266, 270], ["DSH", "DISEASE", 312, 315], ["ICGN", "DISEASE", 401, 405], ["retroviral infection", "DISEASE", 574, 594], ["cats", "ORGANISM", 30, 34], ["ICGN", "CANCER", 162, 166], ["cats", "ORGANISM", 246, 250], ["FIV", "ORGANISM", 490, 493], ["FeLV", "ORGANISM", 498, 502], ["cats", "ORGANISM", 515, 519], ["cats", "ORGANISM", 551, 555], ["retroviral", "ORGANISM", 574, 584], ["FIV", "ORGANISM", 609, 612], ["cats", "ORGANISM", 622, 626], ["FeLV", "ORGANISM", 633, 637], ["cats", "SPECIES", 246, 250], ["cats", "SPECIES", 515, 519], ["cats", "SPECIES", 551, 555], ["cats", "SPECIES", 622, 626], ["FIV", "SPECIES", 490, 493], ["retroviral", "SPECIES", 574, 584], ["FIV", "SPECIES", 609, 612], ["non-ICGN cats", "TREATMENT", 21, 34], ["histopathology", "TEST", 85, 99], ["electron microscopy", "TEST", 104, 123], ["ICGN", "PROBLEM", 266, 270], ["DSH", "TEST", 312, 315], ["Abyssinian", "TREATMENT", 380, 390], ["all cats", "TEST", 511, 519], ["cats", "TEST", 551, 555], ["retroviral infection", "PROBLEM", 574, 594], ["10 FIV", "TEST", 606, 612], ["positive cats", "PROBLEM", 613, 626], ["3 FeLV-positive", "PROBLEM", 631, 646], ["FeLV status", "OBSERVATION", 498, 509], ["positive for", "UNCERTAINTY", 561, 573], ["retroviral infection", "OBSERVATION", 574, 594], ["viruses", "OBSERVATION", 689, 696]]], ["The mean serum creatinine concentration was 3.3 \u00b1 2.3 mg/dL (median: 2.6 mg/dL; min-max: 0.6\u201311.1 mg/dL).", [["serum", "ANATOMY", 9, 14], ["creatinine", "CHEMICAL", 15, 25], ["creatinine", "CHEMICAL", 15, 25], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["creatinine", "SIMPLE_CHEMICAL", 15, 25], ["The mean serum creatinine concentration", "TEST", 0, 39], ["min-max", "TEST", 80, 87]]], ["Mean UPC ratio at diagnosis was 7 \u00b1 3.2 (median: 2.6; min-max 2.4\u201318.6).", [["UPC", "GENE_OR_GENE_PRODUCT", 5, 8], ["Mean UPC ratio", "TEST", 0, 14], ["diagnosis", "TEST", 18, 27], ["min-max", "TEST", 54, 61]]], ["The mean SBP value was 154 \u00b1 25 mmHg (median: 160 mmHg; min-max 110\u2013200 mmHg); SBP was not available in 10 cats.", [["cats", "ORGANISM", 107, 111], ["The mean SBP value", "TEST", 0, 18], ["min-max", "TEST", 56, 63], ["SBP", "TEST", 79, 82]]], ["Five (13.5%) cats were in IRIS stage 1, 15 (40.5%) in stage 2, 11 (29.7%) in stage 3 and 6 (16.2%) in stage 4.Cats with ICGN and clinical features associated with morphological diagnoses ::: ResultsMorphological diagnoses of cats affected by ICGN were MGN (Fig. 1A, B) in 18 (48.6%), MPGN (Fig. 1C, D) in 14 (37.8%), and MeGN in 5 (13.5%).", [["IRIS", "DISEASE", 26, 30], ["ICGN", "DISEASE", 120, 124], ["MPGN", "DISEASE", 284, 288], ["cats", "ORGANISM", 13, 17], ["cats", "ORGANISM", 225, 229], ["B", "GENE_OR_GENE_PRODUCT", 266, 267], ["MeGN", "CANCER", 321, 325], ["cats", "SPECIES", 13, 17], ["cats", "SPECIES", 225, 229], ["cats", "TEST", 13, 17], ["IRIS stage", "TEST", 26, 36], ["stage", "TEST", 54, 59], ["stage", "TEST", 77, 82], ["cats", "PROBLEM", 225, 229], ["MPGN (Fig", "TEST", 284, 293], ["MeGN", "TEST", 321, 325], ["IRIS", "ANATOMY", 26, 30]]], ["Of the 10 FIV-positive cats, 5 had MGN, 4 MPGN, and 1 MeGN; of the 3 FeLV-positive cats, 1 each had MGN, MPGN and MeGN.", [["MPGN", "DISEASE", 42, 46], ["MPGN", "DISEASE", 105, 109], ["FIV", "ORGANISM", 10, 13], ["cats", "ORGANISM", 23, 27], ["MGN", "CANCER", 35, 38], ["MeGN", "CANCER", 54, 58], ["FeLV", "ORGANISM", 69, 73], ["cats", "ORGANISM", 83, 87], ["MGN", "SIMPLE_CHEMICAL", 100, 103], ["cats", "SPECIES", 23, 27], ["cats", "SPECIES", 83, 87], ["MGN", "TEST", 35, 38], ["MPGN", "TEST", 42, 46], ["MGN", "TREATMENT", 100, 103], ["MPGN", "TREATMENT", 105, 109], ["MeGN", "TREATMENT", 114, 118], ["MPGN", "OBSERVATION", 105, 109]]]], "d806b5203cfba5a87c9a39a25d953572eacf9ab9": [["Development of Research Facilities for the Study of Viral Hemorrhagic FeversThe International Centre for Medical Researches of Franceville (CIRMF) was founded in 1974 by His Excellency El Hadj Omar Bongo Ondimba, President of the Gabonese Republic, and Mr. Pierre Guillaumat, the chairman of the petroleum company, Total Gabon.", [["Viral Hemorrhagic Fevers", "DISEASE", 52, 76], ["the Study", "TEST", 39, 48], ["Viral Hemorrhagic Fevers", "PROBLEM", 52, 76], ["Hemorrhagic", "OBSERVATION_MODIFIER", 58, 69], ["petroleum", "ANATOMY", 296, 305]]], ["In the 1990s, viral hemorrhagic fevers became a focus of attention in Equatorial.", [["viral hemorrhagic fevers", "DISEASE", 14, 38], ["viral hemorrhagic fevers", "PROBLEM", 14, 38], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["hemorrhagic", "OBSERVATION_MODIFIER", 20, 31], ["fevers", "OBSERVATION", 32, 38], ["Equatorial", "ANATOMY_MODIFIER", 70, 80]]], ["The decision to develop a high security laboratory for the study of Ebola virus disease came after a 1996 Ebola virus disease outbreak in Mayibout area, Gabon.", [["Ebola virus disease", "DISEASE", 68, 87], ["Ebola virus disease", "DISEASE", 106, 125], ["Ebola virus", "ORGANISM", 68, 79], ["Ebola virus", "SPECIES", 68, 79], ["Ebola virus", "SPECIES", 106, 117], ["Ebola virus", "SPECIES", 68, 79], ["Ebola virus", "SPECIES", 106, 117], ["the study", "TEST", 55, 64], ["Ebola virus disease", "PROBLEM", 68, 87], ["a 1996 Ebola virus disease outbreak", "PROBLEM", 99, 134], ["Ebola virus", "OBSERVATION", 68, 79], ["Ebola virus", "OBSERVATION", 106, 117]]], ["The main objective was to develop the potential for rapid and specific diagnosis on viral hemorrhagic fevers and to have a backup for field investigation of severe viral hemorrhagic fever epidemics.", [["viral hemorrhagic fevers", "DISEASE", 84, 108], ["viral hemorrhagic fever", "DISEASE", 164, 187], ["viral hemorrhagic fevers", "PROBLEM", 84, 108], ["a backup", "TREATMENT", 121, 129], ["field investigation", "TEST", 134, 153], ["severe viral hemorrhagic fever epidemics", "PROBLEM", 157, 197], ["main", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["viral", "OBSERVATION_MODIFIER", 164, 169], ["hemorrhagic", "OBSERVATION_MODIFIER", 170, 181], ["fever", "OBSERVATION", 182, 187]]], ["Because the unique expertise and interaction of the CIRMF team along with the international World Health Organization (WHO) teams for Ebola virus disease, the Gabonese government agreed to such a project.", [["Ebola virus disease", "DISEASE", 134, 153], ["Ebola virus", "ORGANISM", 134, 145], ["Ebola virus", "SPECIES", 134, 145], ["Ebola virus", "SPECIES", 134, 145], ["Ebola virus disease", "PROBLEM", 134, 153]]], ["The first BSL3+ (including negative pressure and glove box) laboratory was built in 1997, mostly financed by the Foreign Ministry of France ( Figure 2 ).", [["BSL3", "PROTEIN", 10, 14], ["The first BSL3", "TEST", 0, 14], ["glove box", "TEST", 49, 58]]], ["This laboratory was built in a period of quasi \"emergence\" of successive Ebola virus disease outbreaks in Gabon, and the plans to upgrade the BSL3+ laboratory were not efficient.", [["Ebola virus disease", "DISEASE", 73, 92], ["Ebola virus", "ORGANISM", 73, 84], ["BSL3", "PROTEIN", 142, 146], ["Ebola virus", "SPECIES", 73, 84], ["Ebola virus", "SPECIES", 73, 84], ["successive Ebola virus disease outbreaks", "PROBLEM", 62, 102], ["Ebola virus disease", "OBSERVATION", 73, 92]]], ["A specific research unit was founded in 1998 to study emerging infectious diseases: The Emerging Viral Disease Unit (UMVE).", [["infectious diseases", "DISEASE", 63, 82], ["Viral Disease", "DISEASE", 97, 110], ["infectious", "OBSERVATION", 63, 73], ["Viral Disease", "OBSERVATION", 97, 110]]], ["Thanks to work done between 1996 and 1998, both in the field and in research, CIRMF became a National Reference Laboratory and a WHO Collaborating Center in the Equatorial African region.", [["Equatorial", "ANATOMY_MODIFIER", 161, 171]]], ["The present high containment and high security laboratory, operated by the Emerging Viral Diseases Unit (UMVE), is one of 2 laboratories in Africa that can manipulate Risk Group 3/4 Agents (i.e., Ebola, Marburg, and Crimean-Congo hemorrhagic fever viruses).", [["Viral Diseases", "DISEASE", 84, 98], ["Ebola, Marburg", "DISEASE", 196, 210], ["Crimean-Congo hemorrhagic fever", "DISEASE", 216, 247], ["Ebola", "ORGANISM", 196, 201], ["Crimean-Congo hemorrhagic fever viruses", "ORGANISM", 216, 255], ["Congo hemorrhagic fever", "SPECIES", 224, 247], ["Crimean-Congo hemorrhagic fever viruses", "SPECIES", 216, 255], ["Crimean", "TEST", 216, 223], ["Congo hemorrhagic fever viruses", "PROBLEM", 224, 255], ["high", "OBSERVATION_MODIFIER", 12, 16], ["containment", "OBSERVATION_MODIFIER", 17, 28], ["Viral Diseases", "OBSERVATION", 84, 98]]], ["Research, including isolation and characterization of these highly pathogenic viruses is performed in accordance with international rules defined by WHO on the handling Risk Group 3/4 Agents Updated equipment includes a double door autoclave, thermo regulated cabinet, a high security centrifuge system, a conventional photonic microscope, a virus isolation unit, and two independent rooms the can be shut down alternatively after decontamination when necessary.", [["isolation", "TREATMENT", 20, 29], ["these highly pathogenic viruses", "PROBLEM", 54, 85], ["a double door autoclave", "TREATMENT", 218, 241], ["a conventional photonic microscope", "TREATMENT", 304, 338], ["a virus isolation unit", "TREATMENT", 340, 362], ["decontamination", "TREATMENT", 431, 446], ["pathogenic", "OBSERVATION_MODIFIER", 67, 77], ["viruses", "OBSERVATION", 78, 85]]], ["An uninterruptable controlled electrical supply for refrigeration, computer systems, and other systems is ensured by two back-up power plants.", [["electrical supply", "OBSERVATION", 30, 47]]], ["Investigators from this observatory conduct field studies on the prevalence of viral and parasitic diseases and their implications for public health [1] Dedicated to medical research, the Primate Center houses more than 450 primates belonging to ten different African species (e.g., chimpanzees (Pan troglodytes), gorillas (Gorilla sp), mandrills (Mandrillus sphinx), guenons (Cercopithecus sp.), collared mangabeys (Cercocebus torquatus), greater spot-nosed monkeys (Cercopithecus nictitans), vervet monkeys (Chlorocebus pygerythrus) and an Asian macaque (Macaca sp.) colony.", [["colony", "ANATOMY", 569, 575], ["viral and parasitic diseases", "DISEASE", 79, 107], ["chimpanzees", "ORGANISM", 283, 294], ["Pan troglodytes", "ORGANISM", 296, 311], ["gorillas", "ORGANISM", 314, 322], ["Gorilla sp", "ORGANISM", 324, 334], ["Mandrillus sphinx", "ORGANISM", 348, 365], ["guenons", "ORGANISM", 368, 375], ["Cercopithecus sp.", "ORGANISM", 377, 394], ["collared mangabeys", "ORGANISM", 397, 415], ["Cercocebus torquatus", "ORGANISM", 417, 437], ["monkeys", "ORGANISM", 459, 466], ["Cercopithecus nictitans", "ORGANISM", 468, 491], ["vervet monkeys", "ORGANISM", 494, 508], ["Chlorocebus pygerythrus", "ORGANISM", 510, 533], ["macaque", "ORGANISM", 548, 555], ["Macaca sp.", "ORGANISM", 557, 567], ["chimpanzees", "SPECIES", 283, 294], ["Pan troglodytes", "SPECIES", 296, 311], ["gorillas", "SPECIES", 314, 322], ["Gorilla sp", "SPECIES", 324, 334], ["mandrills", "SPECIES", 337, 346], ["Mandrillus sphinx", "SPECIES", 348, 365], ["guenons", "SPECIES", 368, 375], ["Cercopithecus sp", "SPECIES", 377, 393], ["mangabeys", "SPECIES", 406, 415], ["Cercocebus torquatus", "SPECIES", 417, 437], ["monkeys", "SPECIES", 459, 466], ["Cercopithecus nictitans", "SPECIES", 468, 491], ["vervet monkeys", "SPECIES", 494, 508], ["Chlorocebus pygerythrus", "SPECIES", 510, 533], ["Asian macaque", "SPECIES", 542, 555], ["Macaca sp.", "SPECIES", 557, 567], ["Pan troglodytes", "SPECIES", 296, 311], ["Gorilla sp)", "SPECIES", 324, 335], ["Mandrillus sphinx", "SPECIES", 348, 365], ["Cercopithecus sp.)", "SPECIES", 377, 395], ["collared mangabeys", "SPECIES", 397, 415], ["Cercocebus torquatus", "SPECIES", 417, 437], ["Cercopithecus nictitans", "SPECIES", 468, 491], ["vervet monkeys", "SPECIES", 494, 508], ["Chlorocebus pygerythrus", "SPECIES", 510, 533], ["Asian macaque", "SPECIES", 542, 555], ["this observatory conduct field studies", "TEST", 19, 57], ["viral and parasitic diseases", "PROBLEM", 79, 107], ["chimpanzees (Pan troglodytes)", "TREATMENT", 283, 312], ["gorillas (Gorilla sp", "TREATMENT", 314, 334], ["mandrills (Mandrillus sphinx)", "TREATMENT", 337, 366], ["vervet monkeys (Chlorocebus pygerythrus", "TREATMENT", 494, 533], ["an Asian macaque (Macaca sp.", "TREATMENT", 539, 567], ["parasitic diseases", "OBSERVATION", 89, 107]]], ["One of the largest primate centers in Africa, the Primate Center is equipped with level A2 and A3 animal facilities for scientific research protocols.", [["scientific research protocols", "TREATMENT", 120, 149], ["largest", "OBSERVATION_MODIFIER", 11, 18], ["primate", "OBSERVATION_MODIFIER", 19, 26], ["centers", "OBSERVATION_MODIFIER", 27, 34]]], ["The Great Apes are housed in large open-air facilities.", [["Great", "OBSERVATION_MODIFIER", 4, 9], ["Apes", "OBSERVATION_MODIFIER", 10, 14], ["large", "OBSERVATION_MODIFIER", 29, 34], ["open", "OBSERVATION_MODIFIER", 35, 39], ["air facilities", "OBSERVATION", 40, 54]]], ["Semi-free living colony of twelve forested hectares harbor about half of the primates at the Primate center.", [["colony", "ANATOMY", 17, 23], ["primates", "ORGANISM", 77, 85]]], ["At the Gorillas and Chimpanzee Study Station, researchers study ecological approaches to the emergence of zoonotic diseases, inter-species transmission of pathogens, and disease outbreaks in humans and wild animals [2] .FundingRunning costs are funded by the Ministry of Economy, Gabon, the national petroleum company of Total-Gabon, and the Ministry of Foreign and European Affairs, France.", [["zoonotic diseases", "DISEASE", 106, 123], ["humans", "ORGANISM", 191, 197], ["humans", "SPECIES", 191, 197], ["humans", "SPECIES", 191, 197], ["researchers study", "TEST", 46, 63], ["zoonotic diseases", "PROBLEM", 106, 123], ["pathogens", "PROBLEM", 155, 164], ["disease outbreaks in humans", "PROBLEM", 170, 197], ["pathogens", "OBSERVATION_MODIFIER", 155, 164], ["Foreign", "OBSERVATION", 354, 361]]], ["Several international agencies participate in a variety of financial supports including scientists' salaries, equipment, research projects, and academic grants (e.g., IRD, WHO, United States Agency for International Development, National Center for Scientific Research, France).TrainingTechnical laboratory training support of Gabonese teams and other African countries has been one of the major aims of CIRMF.", [["CIRMF", "CANCER", 404, 409]]], ["The UMVE actively participates in the academic training at the Regional Graduate School and the different State universities of Equatorial Africa.", [["Equatorial Africa", "PROBLEM", 128, 145], ["Equatorial Africa", "OBSERVATION", 128, 145]]], ["Continuing medical education in the form of post-doctoral workshops are held at the CIRMF for discussion and demonstration of modern techniques.National PartnershipsAs a National reference laboratory, CIRMF has the following roles: diagnosis of suspected cases during outbreaks of viral hemorrhagic fevers or severe clinical infectious syndromes; development of new methods for diagnosing such infections; surveillance of animal fatalities in reservoir or intermediate hosts; and intervention during outbreaks of unknown etiology.", [["viral hemorrhagic fevers", "DISEASE", 281, 305], ["infectious syndromes", "DISEASE", 325, 345], ["infections", "DISEASE", 394, 404], ["fatalities", "DISEASE", 429, 439], ["Continuing medical education", "TREATMENT", 0, 28], ["post-doctoral workshops", "TREATMENT", 44, 67], ["modern techniques", "TREATMENT", 126, 143], ["viral hemorrhagic fevers", "PROBLEM", 281, 305], ["severe clinical infectious syndromes", "PROBLEM", 309, 345], ["such infections", "PROBLEM", 389, 404], ["intervention", "TREATMENT", 480, 492], ["viral", "OBSERVATION_MODIFIER", 281, 286], ["hemorrhagic", "OBSERVATION_MODIFIER", 287, 298], ["severe", "OBSERVATION_MODIFIER", 309, 315], ["infectious", "OBSERVATION", 325, 335], ["new", "OBSERVATION_MODIFIER", 362, 365]]], ["CIRMF diagnosed infections of more than 70 pathogens that could not be identified in other biology laboratories throughout the country.", [["CIRMF", "CHEMICAL", 0, 5], ["infections", "DISEASE", 16, 26], ["infections", "PROBLEM", 16, 26], ["70 pathogens", "PROBLEM", 40, 52], ["infections", "OBSERVATION", 16, 26], ["could not be", "UNCERTAINTY", 58, 70]]], ["Tight connections with other scientific teams in Libreville are under development (i.e.,: Military Hospital, Libreville; General Hospital, Libreville; A. Schweitzer Lambarene Foundation).Regional PartnershipsThe Emerging Viral Diseases Unit, CIRMF, proposes forming a research partnership to study infectious diseases transmitted by animals of the tropical rain forests regions of Equatorial Africa.", [["Viral Diseases", "DISEASE", 221, 235], ["infectious diseases", "DISEASE", 298, 317], ["infectious diseases", "PROBLEM", 298, 317], ["Equatorial Africa", "PROBLEM", 381, 398], ["Viral Diseases", "OBSERVATION", 221, 235], ["tropical", "OBSERVATION_MODIFIER", 348, 356], ["Equatorial Africa", "OBSERVATION", 381, 398]]], ["An international partnership with the IRD, Marseille, France, and the Institute of Virology, Bonn, Germany, will assist in the development of this regional partnership.International PartnershipsWith the WHO Regional Office, Brazzaville, Republic of the Congo, the UMVE-CIRMF field team participates along with other international partners (e.g., Centers for Disease Control and Prevention, USA; Laboratory Centre for Disease Control and National Microbiology Laboratory, Winnipeg, Canada; P4 Laboratory of the National Institute for Communicable Diseases, South Africa) to respond to all Ebola virus disease epidemics in Africa.", [["Ebola virus disease epidemics", "DISEASE", 588, 617], ["Ebola virus", "ORGANISM", 588, 599], ["Ebola virus", "SPECIES", 588, 599], ["Ebola virus", "SPECIES", 588, 599], ["Disease Control", "TREATMENT", 358, 373], ["Communicable Diseases", "PROBLEM", 533, 554], ["all Ebola virus disease epidemics", "PROBLEM", 584, 617], ["Ebola virus", "OBSERVATION", 588, 599]]], ["CIRMF aims to use laboratory and field expertise be a regional focal resource in conjunction with local health authorities to organize epidemic responses.", [["focal", "OBSERVATION_MODIFIER", 63, 68]]], ["Also, an informal international laboratory network for the diagnosis and surveillance of severe infectious clinical syndromes includes: the Institut National de Recherche Biom\u00e9dicale, Democratic Republic of the Congo; Laboratoire National de Sant\u00e9 Publique de Brazzaville, Republic of the Congo; Metabiota/Laboratoire des Maladies Emergentes, Yaound\u00e9, Cameroon; Pasteur Institute, Bangui, Central African Republic; Institute of Virology, Bonn University, Germany; and P4 Jean M\u00e9rieux Lyon, France.", [["severe infectious clinical syndromes", "PROBLEM", 89, 125], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["infectious", "OBSERVATION", 96, 106]]], ["The UVME assists the National Public Health System in consolidating and formalizing microbiological monitoring of the Equatorial African sub-region.", [["microbiological monitoring", "TEST", 84, 110], ["Equatorial", "ANATOMY_MODIFIER", 118, 128]]], ["Ultimately, CIRMF will be positioned as a Center of Excellence for microbiological surveillance and research in a global network.Developing Tools and Methods for Virus DetectionDeveloping diagnostic tools and strategies is the main driver to improve surveillance and research of emerging viral diseases.", [["viral diseases", "DISEASE", 288, 302], ["microbiological surveillance", "TEST", 67, 95], ["Virus", "PROBLEM", 162, 167], ["diagnostic tools", "TEST", 188, 204], ["surveillance", "TEST", 250, 262], ["emerging viral diseases", "PROBLEM", 279, 302], ["viral diseases", "OBSERVATION", 288, 302]]], ["A strategic choice was made to link syndromes to an etiological agent, including hemorrhagic syndromes.", [["hemorrhagic syndromes", "DISEASE", 81, 102], ["hemorrhagic syndromes", "PROBLEM", 81, 102], ["hemorrhagic syndromes", "OBSERVATION", 81, 102]]], ["To isolate and diagnose highly pathogenic viruses, a progressive and diversified methodology was applied.", [["highly pathogenic viruses", "PROBLEM", 24, 49], ["diversified methodology", "TREATMENT", 69, 92], ["highly", "OBSERVATION_MODIFIER", 24, 30], ["pathogenic", "OBSERVATION_MODIFIER", 31, 41], ["viruses", "OBSERVATION", 42, 49], ["progressive", "OBSERVATION_MODIFIER", 53, 64], ["diversified", "OBSERVATION_MODIFIER", 69, 80]]], ["The first approach used real-time virus-specific PCR (qRT-PCR).", [["real-time virus", "TEST", 24, 39], ["specific PCR", "TEST", 40, 52], ["qRT", "TEST", 54, 57], ["PCR", "TEST", 58, 61]]], ["If the first approach was not successful, conventional RT-PCR was implemented using degenerate consensus primers targeting conserved regions of the genome.", [["genome", "CELLULAR_COMPONENT", 148, 154], ["degenerate consensus primers", "DNA", 84, 112], ["conventional RT-PCR", "TEST", 42, 61], ["degenerate consensus primers", "PROBLEM", 84, 112], ["genome", "ANATOMY", 148, 154]]], ["Ultimately, random amplification of nucleotide sequences was directly applied to the original biological material (DNA chip re-sequencing, meta-genomic pyrosequencing (454 Life Sciences, Branford, CT)).Understanding Filovirus Natural HistoryUMVE studied the factors implicated in the three steps that led to Ebola virus and Marburg virus diseases emergence in humans.", [["nucleotide", "CHEMICAL", 36, 46], ["Ebola virus", "DISEASE", 308, 319], ["Marburg virus diseases", "DISEASE", 324, 346], ["nucleotide", "CHEMICAL", 36, 46], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["Ebola virus", "ORGANISM", 308, 319], ["Marburg virus", "ORGANISM", 324, 337], ["humans", "ORGANISM", 360, 366], ["Ebola virus", "SPECIES", 308, 319], ["Marburg virus", "SPECIES", 324, 337], ["humans", "SPECIES", 360, 366], ["Ebola virus", "SPECIES", 308, 319], ["Marburg virus", "SPECIES", 324, 337], ["humans", "SPECIES", 360, 366], ["nucleotide sequences", "TREATMENT", 36, 56], ["DNA chip re-sequencing", "TREATMENT", 115, 137], ["CT", "TEST", 197, 199], ["Ebola virus", "PROBLEM", 308, 319], ["Marburg virus diseases", "PROBLEM", 324, 346], ["Ebola virus", "OBSERVATION", 308, 319]]], ["These steps include: the identification of reservoir species, the circulation within the natural host, the crossing to intermediary animal species, and finally the direct transmission to humans from great apes and fruit bats.", [["humans", "ORGANISM", 187, 193], ["humans", "SPECIES", 187, 193], ["humans", "SPECIES", 187, 193], ["reservoir species", "PROBLEM", 43, 60], ["reservoir species", "OBSERVATION", 43, 60], ["animal species", "OBSERVATION", 132, 146], ["great apes", "ANATOMY", 199, 209], ["fruit bats", "OBSERVATION", 214, 224]]], ["Antibodies and nucleotide sequences specific for Ebola virus were detected in the liver and spleen of fruit bat belonging to three species (Hypsignathus monstrosus, Epomops franqueti, Myonycteris torquata) in Gabon and Republic of the Congo (Figure 4 ).", [["liver", "ANATOMY", 82, 87], ["spleen", "ANATOMY", 92, 98], ["nucleotide", "CHEMICAL", 15, 25], ["Ebola virus", "DISEASE", 49, 60], ["nucleotide", "CHEMICAL", 15, 25], ["Ebola virus", "ORGANISM", 49, 60], ["liver", "ORGAN", 82, 87], ["spleen", "ORGAN", 92, 98], ["Hypsignathus monstrosus", "ORGANISM", 140, 163], ["Epomops franqueti", "ORGANISM", 165, 182], ["Myonycteris torquata", "ORGANISM", 184, 204], ["Ebola virus", "SPECIES", 49, 60], ["fruit bat", "SPECIES", 102, 111], ["Hypsignathus monstrosus", "SPECIES", 140, 163], ["Epomops franqueti", "SPECIES", 165, 182], ["Myonycteris torquata", "SPECIES", 184, 204], ["Ebola virus", "SPECIES", 49, 60], ["Hypsignathus monstrosus", "SPECIES", 140, 163], ["Epomops franqueti", "SPECIES", 165, 182], ["Myonycteris torquata", "SPECIES", 184, 204], ["Antibodies", "TEST", 0, 10], ["nucleotide sequences", "TEST", 15, 35], ["Ebola virus", "PROBLEM", 49, 60], ["liver", "ANATOMY", 82, 87], ["spleen", "ANATOMY", 92, 98], ["fruit bat", "OBSERVATION", 102, 111]]], ["Antibodies and nucleotide sequences specific for Marburg virus were found in the Egyptian fruit bat (Rousettus aegyptiacus) in Gabon, suggesting that bats might be reservoirs for filoviruses [3] [4] [5] .", [["nucleotide", "CHEMICAL", 15, 25], ["nucleotide", "CHEMICAL", 15, 25], ["Marburg virus", "ORGANISM", 49, 62], ["fruit bat", "ORGANISM", 90, 99], ["Rousettus aegyptiacus", "ORGANISM", 101, 122], ["bats", "ORGANISM", 150, 154], ["filoviruses [3] [4]", "SIMPLE_CHEMICAL", 179, 198], ["Marburg virus", "SPECIES", 49, 62], ["fruit bat", "SPECIES", 90, 99], ["Rousettus aegyptiacus", "SPECIES", 101, 122], ["Marburg virus", "SPECIES", 49, 62], ["Egyptian fruit bat", "SPECIES", 81, 99], ["Rousettus aegyptiacus", "SPECIES", 101, 122], ["Antibodies", "TEST", 0, 10], ["nucleotide sequences", "TEST", 15, 35], ["Marburg virus", "PROBLEM", 49, 62], ["filoviruses", "PROBLEM", 179, 190]]], ["We showed that Ebola virus caused extensive epizootics among gorillas and chimpanzees, killing thousands of animals during the last decade in parts of Gabon and Republic of the Congo [4] .", [["Ebola virus", "DISEASE", 15, 26], ["epizootics", "DISEASE", 44, 54], ["Ebola virus", "ORGANISM", 15, 26], ["gorillas", "ORGANISM", 61, 69], ["Ebola virus", "SPECIES", 15, 26], ["Ebola virus", "SPECIES", 15, 26], ["Ebola virus", "PROBLEM", 15, 26], ["Ebola virus", "OBSERVATION", 15, 26], ["extensive", "OBSERVATION_MODIFIER", 34, 43], ["epizootics", "OBSERVATION_MODIFIER", 44, 54]]], ["We characterized the viral variants associated with all Ebola virus disease outbreaks that occurred between 1996 and 2008 and developed new epidemiological models of Ebola virus disease epidemics, based on the identification of several independent epidemic chains.", [["Ebola virus disease", "DISEASE", 56, 75], ["Ebola virus disease epidemics", "DISEASE", 166, 195], ["Ebola virus", "ORGANISM", 56, 67], ["Ebola virus", "ORGANISM", 166, 177], ["Ebola virus", "SPECIES", 56, 67], ["Ebola virus", "SPECIES", 166, 177], ["Ebola virus", "SPECIES", 56, 67], ["Ebola virus", "SPECIES", 166, 177], ["the viral variants", "PROBLEM", 17, 35], ["all Ebola virus disease outbreaks", "PROBLEM", 52, 85], ["Ebola virus disease epidemics", "PROBLEM", 166, 195], ["several independent epidemic chains", "PROBLEM", 228, 263], ["viral variants", "OBSERVATION", 21, 35], ["all", "OBSERVATION_MODIFIER", 52, 55], ["Ebola virus disease", "OBSERVATION", 56, 75], ["new", "OBSERVATION_MODIFIER", 136, 139], ["Ebola virus disease", "OBSERVATION", 166, 185], ["epidemic chains", "OBSERVATION", 248, 263]]], ["The identification of multiple variants during the 2001 Gabon/Republic of Congo outbreak and two phylogenetically divergent lineages suggest independent introductions into great ape and human populations following multiple viral spillovers from a reservoir host [6] [7] .", [["ape", "ORGANISM", 178, 181], ["human", "ORGANISM", 186, 191], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["multiple variants", "PROBLEM", 22, 39], ["Congo outbreak", "PROBLEM", 74, 88], ["multiple viral spillovers", "PROBLEM", 214, 239], ["a reservoir host", "TREATMENT", 245, 261], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["viral spillovers", "OBSERVATION", 223, 239]]], ["In this \"multi-emergence\" hypothesis, Ebola virus disease outbreaks would occur episodically during certain ecological conditions caused by habitat disturbances or climatic phenomena.", [["Ebola virus disease", "DISEASE", 38, 57], ["Ebola virus", "ORGANISM", 38, 49], ["Ebola virus", "SPECIES", 38, 49], ["Ebola virus", "SPECIES", 38, 49], ["Ebola virus disease outbreaks", "PROBLEM", 38, 67], ["habitat disturbances", "PROBLEM", 140, 160], ["climatic phenomena", "PROBLEM", 164, 182], ["Ebola virus", "OBSERVATION", 38, 49], ["climatic phenomena", "OBSERVATION", 164, 182]]], ["This hypothesis also implicitly assumes that Ebola virus was present in Equatorial Africa long before the first documented disease outbreak in 1976, as supported by various serological surveys.", [["Ebola virus", "DISEASE", 45, 56], ["Ebola virus", "ORGANISM", 45, 56], ["Ebola virus", "SPECIES", 45, 56], ["Ebola virus", "SPECIES", 45, 56], ["Ebola virus", "PROBLEM", 45, 56], ["Ebola virus", "OBSERVATION", 45, 56], ["disease", "OBSERVATION", 123, 130]]], ["Furthermore, we recently showed that the 2007 Luebo outbreak in the Democratic Republic of the Congo was linked to massive fruit bat migration, strongly suggesting that humans could be infected directly by bats or by consumption of bats [8] .Ebola Virus Disease PathogenesisIn the study of immunological mechanisms of Ebola virus disease humans, we showed that fatal infection is associated with aberrant innate immunity and global suppression of adaptive immunity [, [9] [10] [11] [12] .", [["Ebola Virus", "DISEASE", 242, 253], ["Ebola virus disease", "DISEASE", 318, 337], ["infection", "DISEASE", 367, 376], ["humans", "ORGANISM", 169, 175], ["Ebola Virus", "ORGANISM", 242, 253], ["Ebola virus", "ORGANISM", 318, 329], ["humans", "ORGANISM", 338, 344], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 468, 486], ["humans", "SPECIES", 169, 175], ["Ebola Virus", "SPECIES", 242, 253], ["Ebola virus", "SPECIES", 318, 329], ["humans", "SPECIES", 338, 344], ["humans", "SPECIES", 169, 175], ["Ebola Virus", "SPECIES", 242, 253], ["Ebola virus", "SPECIES", 318, 329], ["humans", "SPECIES", 338, 344], ["massive fruit bat migration", "PROBLEM", 115, 142], ["Ebola Virus Disease", "PROBLEM", 242, 261], ["the study", "TEST", 277, 286], ["Ebola virus disease humans", "PROBLEM", 318, 344], ["fatal infection", "PROBLEM", 361, 376], ["aberrant innate immunity", "PROBLEM", 396, 420], ["massive", "OBSERVATION_MODIFIER", 115, 122], ["fruit bat migration", "OBSERVATION", 123, 142], ["Ebola virus", "OBSERVATION", 318, 329], ["fatal", "OBSERVATION_MODIFIER", 361, 366], ["infection", "OBSERVATION", 367, 376]]], ["The innate immune reaction is characterized by a 'cytokine storm', with a hyper secretion of numerous pro-inflammatory cytokines, chemokines and growth factors, and by the noteworthy absence of antiviral interferon (IFN)-\u03b1 [9, 13, 14] .", [["interferon (IFN)-\u03b1", "GENE_OR_GENE_PRODUCT", 204, 222], ["cytokine", "PROTEIN", 50, 58], ["pro-inflammatory cytokines", "PROTEIN", 102, 128], ["chemokines", "PROTEIN", 130, 140], ["growth factors", "PROTEIN", 145, 159], ["antiviral interferon (IFN)-\u03b1", "PROTEIN", 194, 222], ["The innate immune reaction", "PROBLEM", 0, 26], ["a 'cytokine storm'", "TREATMENT", 47, 65], ["a hyper secretion", "PROBLEM", 72, 89], ["numerous pro-inflammatory cytokines", "PROBLEM", 93, 128], ["chemokines and growth factors", "PROBLEM", 130, 159], ["antiviral interferon", "TREATMENT", 194, 214], ["innate immune reaction", "OBSERVATION", 4, 26], ["numerous", "OBSERVATION_MODIFIER", 93, 101], ["pro-inflammatory cytokines", "OBSERVATION", 102, 128], ["antiviral interferon", "OBSERVATION", 194, 214]]], ["Immunosuppression of adaptive immunity is characterized by very low levels of circulating cytokines produced by T lymphocytes and by massive loss of peripheral CD4 and CD8 lymphocytes, probably through Fas/FasL-mediated apoptosis.", [["T lymphocytes", "ANATOMY", 112, 125], ["peripheral CD4", "ANATOMY", 149, 163], ["CD8 lymphocytes", "ANATOMY", 168, 183], ["T lymphocytes", "CELL", 112, 125], ["CD4", "GENE_OR_GENE_PRODUCT", 160, 163], ["CD8", "GENE_OR_GENE_PRODUCT", 168, 171], ["Fas", "GENE_OR_GENE_PRODUCT", 202, 205], ["FasL", "GENE_OR_GENE_PRODUCT", 206, 210], ["circulating cytokines", "PROTEIN", 78, 99], ["T lymphocytes", "CELL_TYPE", 112, 125], ["peripheral CD4 and CD8 lymphocytes", "CELL_TYPE", 149, 183], ["Fas", "PROTEIN", 202, 205], ["FasL", "PROTEIN", 206, 210], ["Immunosuppression of adaptive immunity", "TREATMENT", 0, 38], ["very low levels of circulating cytokines", "PROBLEM", 59, 99], ["massive loss of peripheral CD4 and CD8 lymphocytes", "PROBLEM", 133, 183], ["Fas", "TEST", 202, 205], ["apoptosis", "PROBLEM", 220, 229], ["very", "OBSERVATION_MODIFIER", 59, 63], ["low levels", "OBSERVATION_MODIFIER", 64, 74], ["massive", "OBSERVATION_MODIFIER", 133, 140], ["loss", "OBSERVATION_MODIFIER", 141, 145], ["peripheral", "ANATOMY_MODIFIER", 149, 159], ["CD4", "ANATOMY", 160, 163], ["CD8 lymphocytes", "OBSERVATION", 168, 183], ["FasL", "OBSERVATION", 206, 210], ["apoptosis", "OBSERVATION", 220, 229]]], ["Finally, we hypothesized that a viral protein with super-antigen activity might be involved in the massive T cell apoptosis [15] .", [["T cell", "ANATOMY", 107, 113], ["super-antigen", "GENE_OR_GENE_PRODUCT", 51, 64], ["T cell", "CELL", 107, 113], ["viral protein", "PROTEIN", 32, 45], ["a viral protein", "PROBLEM", 30, 45], ["the massive T cell apoptosis", "PROBLEM", 95, 123], ["massive", "OBSERVATION_MODIFIER", 99, 106], ["T cell apoptosis", "OBSERVATION", 107, 123]]], ["In striking contrast with fatal outcome, effective control of Ebola virus infection is associated with balanced immune responses in survivors.", [["Ebola virus infection", "DISEASE", 62, 83], ["Ebola virus", "ORGANISM", 62, 73], ["Ebola virus", "SPECIES", 62, 73], ["Ebola virus", "SPECIES", 62, 73], ["fatal outcome", "PROBLEM", 26, 39], ["Ebola virus infection", "PROBLEM", 62, 83], ["Ebola virus", "OBSERVATION", 62, 73]]], ["Asymptomatic Ebola virus infection was demonstrated in humans during the 1996-97 disease outbreak in Gabon [16] .", [["Ebola virus infection", "DISEASE", 13, 34], ["Ebola virus", "ORGANISM", 13, 24], ["humans", "ORGANISM", 55, 61], ["Ebola virus", "SPECIES", 13, 24], ["humans", "SPECIES", 55, 61], ["Ebola virus", "SPECIES", 13, 24], ["humans", "SPECIES", 55, 61], ["Asymptomatic Ebola virus infection", "PROBLEM", 0, 34], ["Ebola virus", "OBSERVATION", 13, 24]]], ["Asymptomatic infection was associated with an early strong inflammatory response that may be involved in the early inhibition of viral replication [16, 17] .", [["infection", "DISEASE", 13, 22], ["Asymptomatic infection", "PROBLEM", 0, 22], ["an early strong inflammatory response", "PROBLEM", 43, 80], ["viral replication", "TREATMENT", 129, 146], ["infection", "OBSERVATION", 13, 22], ["early", "OBSERVATION_MODIFIER", 46, 51], ["strong", "OBSERVATION_MODIFIER", 52, 58], ["inflammatory", "OBSERVATION", 59, 71], ["viral replication", "OBSERVATION", 129, 146]]], ["Consistent with this discovery, we showed a decade later that a large fraction of the human population living in forested areas of Gabon has both humoral and cellular immunity to Ebola virus [18] .", [["cellular", "ANATOMY", 158, 166], ["Ebola virus", "DISEASE", 179, 190], ["human", "ORGANISM", 86, 91], ["cellular", "CELL", 158, 166], ["Ebola virus", "ORGANISM", 179, 190], ["human", "SPECIES", 86, 91], ["Ebola virus", "SPECIES", 179, 190], ["human", "SPECIES", 86, 91], ["Ebola virus", "SPECIES", 179, 190], ["the human population", "TREATMENT", 82, 102], ["Ebola virus", "PROBLEM", 179, 190], ["large", "OBSERVATION_MODIFIER", 64, 69], ["fraction", "OBSERVATION_MODIFIER", 70, 78], ["humoral", "ANATOMY", 146, 153]]], ["In the absence of identified risk factors, the high prevalence of 'immune' individuals suggests a common source of human exposure such as fruits contaminated by bat saliva.Ebola Virus Disease PathogenesisInitially focused on Ebola virus disease, UMVE science policy was redirected since 2007 by expanding the main research themes to other emerging viral diseases that could threaten public health in the Congo basin (Table 1) [19] [20] [21] [22] .Challenges of Conducting Filovirus Research in GabonCIRMF is geographically isolated from the capital of Gabon, Libreville.", [["fruits", "ANATOMY", 138, 144], ["Ebola Virus Disease", "DISEASE", 172, 191], ["Ebola virus disease", "DISEASE", 225, 244], ["viral diseases", "DISEASE", 348, 362], ["human", "ORGANISM", 115, 120], ["fruits", "ORGANISM_SUBDIVISION", 138, 144], ["bat", "ORGANISM", 161, 164], ["saliva", "ORGANISM_SUBSTANCE", 165, 171], ["Ebola Virus", "ORGANISM", 172, 183], ["Ebola virus", "ORGANISM", 225, 236], ["human", "SPECIES", 115, 120], ["Ebola Virus", "SPECIES", 172, 183], ["Ebola virus", "SPECIES", 225, 236], ["human", "SPECIES", 115, 120], ["Ebola virus", "SPECIES", 225, 236], ["'immune' individuals", "PROBLEM", 66, 86], ["human exposure", "PROBLEM", 115, 129], ["Ebola Virus Disease", "PROBLEM", 172, 191], ["Ebola virus disease", "PROBLEM", 225, 244], ["emerging viral diseases", "PROBLEM", 339, 362], ["Conducting Filovirus", "PROBLEM", 461, 481], ["Ebola virus disease", "OBSERVATION", 225, 244], ["viral diseases", "OBSERVATION", 348, 362], ["Filovirus", "OBSERVATION", 472, 481], ["geographically", "OBSERVATION_MODIFIER", 508, 522], ["capital", "OBSERVATION_MODIFIER", 541, 548]]], ["The capital is accessible by a 12-hour ride in a four-wheel drive vehicle or in a train (three times/week schedule) covering 641 km.", [["capital", "OBSERVATION_MODIFIER", 4, 11]]], ["Due to tropical weather, four weekly domestic plane rotations often fly on an inconsistent schedule.", [["an inconsistent schedule", "TREATMENT", 75, 99]]], ["Ultimately CIRMF needs to be largely autonomous in term of electrical power (i.e.,: unexpected fuel supply disruption), cold chain with the necessity to maintain in situ a unit of liquid nitrogen production (repository), and purified water supply.ConclusionsCIRMF is uniquely suited to study infectious diseases of the Congolese tropical rain forest, the second world's largest rain forest.", [["nitrogen", "CHEMICAL", 187, 195], ["cold chain", "PROBLEM", 120, 130], ["liquid nitrogen production", "TREATMENT", 180, 206], ["autonomous", "OBSERVATION", 37, 47]]], ["As a central point of a North-South transect of the rain forest, the Center is able to study the biodiversity of Africa including animal species, microbes, and parasites.ConclusionsCIRMF is dedicated to conduct medical research of the highest standard, and is the only facility of its type in Equatorial Africa.", [["parasites", "PROBLEM", 160, 169], ["central", "ANATOMY_MODIFIER", 5, 12], ["rain forest", "OBSERVATION", 52, 63], ["Equatorial Africa", "OBSERVATION", 293, 310]]], ["With unrivalled infrastructure, multiple sites, and multidisciplinary teams, the Center promotes a modern healthcare system in Gabon.", [["infrastructure", "OBSERVATION", 16, 30], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["sites", "OBSERVATION_MODIFIER", 41, 46]]], ["CIRMF teams are engaged in trans-disciplinary projects bringing together specialists from the health sciences, biological sciences, veterinary medicine, conservation, the humanities, and environmental sciences.", [["veterinary medicine", "TREATMENT", 132, 151]]], ["The Center welcomes partnerships from around the world to work on global human health issues.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78]]]]}